

DOCUMENT MADE AVAILABLE UNDER THE PATENT COOPERATION TREATY (PCT)

International application number:	PCT/EP2016/082662
International filing date:	23 December 2016 (23.12.2016)
Document type:	Certified copy of priority document
Document details:	Country/Office: EP
	Number: 16182845.4
	Filing date: 04 August 2016 (04.08.2016)
Date of receipt at the International Bureau:	31 January 2017 (31.01.2017)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a),(b) or (b-bis)

Bescheinigung

Die angehefteten Unterlagen stimmen mit der als ursprünglich eingereicht geltenden Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

Certificate

The attached documents are exact copies of the text in which the European patent application described on the following page is deemed to have been filed.

Attestation

Les documents joints à la présente attestation sont conformes au texte, considéré comme initialement déposé, de la demande de brevet européen qui est spécifiée à la page suivante.

Patentanmeldung Nr.

Patent application No.

Demande de brevet n°

16182845.4 / EP16182845

The organization code and number of your priority application, to be used for filing abroad under the Paris Convention, is EP16182845.

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.



V. Joseph

Anmeldung Nr:
Application no.: 16182845.4
Demande no :

Anmeldetag:
Date of filing: 04.08.16
Date de dépôt :

Anmelder / Applicant(s) / Demandeur(s):

Valneva SE
World Trade Center Lyon, Tour Oxygène
10-12 Boulevard Marius Vivier Merle
69003 Lyon/FR

Bezeichnung der Erfindung / Title of the invention / Titre de l'invention:

(Falls die Bezeichnung der Erfindung nicht angegeben ist, oder falls die Anmeldung in einer Nicht-Amtssprache des EPA eingereicht wurde, siehe Beschreibung bezüglich ursprünglicher Bezeichnung.

If no title is shown, or if the application has been filed in a non-EPO language, please refer to the description for the original title.

Si aucun titre n'est indiqué, ou si la demande a été déposée dans une langue autre qu'une langue officielle de l'OEB, se référer à la description pour le titre original.)

VIRUS PURIFICATION

In Anspruch genommene Priorität(en) / Priority(Priorities) claimed / Priorité(s) revendiquée(s)

Staat/Tag/Aktenzeichen / State/Date/File no. / Pays/Date/Numéro de dépôt:

Am Anmeldetag benannte Vertragsstaaten / Contracting States designated at date of filing / Etats contractants désignés lors du dépôt:

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL
PT RO RS SE SI SK SM TR

VIRUS PURIFICATION

FIELD OF INVENTION

The disclosure relates to methods for the purification of viruses for use in vaccines
5 and in particular relates to an improved sucrose gradient process step allowing the separation of impurities such as protamine sulphate.

The disclosure also relates to Zika virus vaccines and compositions and methods for producing said vaccines and administering the vaccines to subjects for the generation of an anti-Zika virus immune response.
10

BACKGROUND OF THE INVENTION

Adverse responses to protamine sulfate have been known for many years. Previous exposure to protamine can induce a humoral immune response and predispose susceptible individuals to the development of untoward reactions from the subsequent use of this drug.
15 Patients exposed to protamine through the use of protamine-containing insulin or during heparin neutralization may experience life-threatening reactions and fatal anaphylaxis upon receiving large doses of protamine intravenously. Severe reactions to intravenous protamine can occur in the absence of local or systemic allergic reactions to subcutaneous injection of protamine-containing insulin. Although there is no clear evidence for hypersensitivity
20 reactions of protamine sulphate linked to vaccination, vaccines containing protamine impurities have a precaution and contraindication warning in their labels stating that a serious allergic reaction after a previous dose of such a protamine containing vaccine (e.g. IXIARO®, see CDC site <http://www.cdc.gov/japaneseencephalitis/vaccine/>) is a contraindication to further doses. Thus elimination of said impurity is a medical request for
25 an improved safety profile. On the other hand protamine sulphate is an excellent tool (and often better than other tools such as benzonase) to purify crude harvests of viruses grown on cell substrates.

In 2007, Zika virus was detected for the first time outside of the endemic regions of Asia and Africa since its discovery in a Rhesus monkey in Uganda in 1947. Since then, the
30 virus has caused a large epidemic in French Polynesia, spreading through islands in the Pacific and into South and Central America by 2015 (WHO “Zika Situation Report” February 5, 2016). Evidence suggests that in addition to being transmitted by *Aedes* species

PAT018/EP/PR3

mosquitos, other vectors may exist, and the virus may be transmitted by blood transfusion, transplacentally, and through sexual transmission (WHO Zika Virus Fact Sheet, Feb. 2016). Though the symptoms of Zika virus infection include mild fever, rash, and conjunctivitis, there is a likely correlation between infection and neurological disorders, including Guillain-
5 Barré syndrome and microcephaly in fetuses/neonates subsequent to infection during pregnancy. There is currently no specific treatment or vaccine for Zika virus and the only preventative measurements involve control of the mosquito vector. Zika virus presents a substantial public health threat due to the wide circulation of the *Aedes* mosquito, multiple routes of transmission, and potentially severe neurological effects of infection.

10

SUMMARY OF THE INVENTION

During the course of virus purification, it was observed that addition of protamine sulfate to a virus harvest produced on a cell substrate removed not only contaminating DNA
15 derived from host cells, as expected, but surprisingly also virtually eliminated immature and otherwise non-infectious virus particles from the preparation. This finding provided a streamlined, gentle, reproducible and broadly-applicable process for obtaining highly-purified infectious virus particles for applications such as vaccine preparation. In addition, it was surprisingly found that said protamine sulfate can very efficiently be separated from the virus
20 fraction allowing for a safer vaccine produced at high yields.

Disclosed herein are virus vaccines and compositions comprising an inactivated virus, and related methods of producing said vaccines and compositions. Also provided are methods of administering said virus vaccines for the prevention of virus infection and/or for the production of an anti-virus immune response in subjects, for example subjects at risk of
25 being exposed to virus. In particular, the invention is directed to a virus vaccine comprising an optimally inactivated virus particle, wherein the virus particle in an appropriate dose is able to seroconvert a subject that is administered the virus vaccine with at least a 70% probability, preferably an 80% probability. Another advantage of the invention is that related methods of producing said vaccines and compositions are very efficient and provide
30 pure compositions largely void of impurities, in particular protamine sulphate, allowing for high volume production of vaccines. Examples to the above are provided for Zika virus and Chikungunya virus.

Each of the limitations of the invention can encompass various embodiments of the invention. It is, therefore, anticipated that each of the limitations of the invention involving any one element or combinations of elements can be included in each aspect of the invention. This invention is not limited in its application to the details of construction and the
5 arrangement of components set forth in the following description or illustrated in the drawings. The invention is capable of other embodiments and of being practiced or of being carried out in various ways.

BRIEF DESCRIPTION OF THE DRAWINGS

10 The accompanying drawings are not intended to be drawn to scale. The figures are illustrative only and are not required for enablement of the disclosure. For purposes of clarity, not every component may be labeled in every drawing, alignments were performed with the multi alignment package Jalview (Waterhouse et al., 2009, Bioinformatics 25 (9) 1189-1191). In the drawings:

15

Figure 1: Average distance tree (by % identity, nt), complete genomes.

Figure 2: Neighbor joining tree (by % identity, nt), complete genomes.

Figure 3: Pairwise alignment-Jalview (% identity, nt), complete genomes.

Figure 4: Average distance tree (by % identity, aa), E-protein.

20

Figure 5: Neighbor joining tree (by % identity, aa), E-protein.

Figure 6: Pairwise alignment-Jalview (% identity, aa), E-protein.

Figure 7: Alignment (blue shading: % identity, aa), E-protein.

Figure 8a: Overview of an efficient Zika virus purification process.

Figure 8b: Overview of an efficient inactivation step.

25

Figure 9: SEC-HPLC of individual 30x concentrated Zika harvest prior PS treatment

Figure 10: SEC-HPLC of individual 30x concentrated Zika harvest post PS treatment

Figure 11: Preparation of the sucrose gradient.

Figure 12: Representative SDS-PAGE from the sucrose gradient harvest of a Zika purification is shown.

30

Figure 13: Schematic separation of Virus (ChikV as an example) and PS/HPC using the optimized 3-layer sucrose gradient centrifugation process.

Figure 14: Correlation between JEV Antigen content in NIV analysed by ELISA and SEC-HPLC (Dionex Ultimate 3000, Supcrose 6 column).

Figure 15: A silver-stained SDS-PAGE gel showing the protein content of the virus preparation following different steps of the process of the invention (defined in the table next to the figure). The SGC purified pool consisting of SGC fractions F7-F11 is shown in lane 12.

Figure 16: The SEC area (mAU*min; right axis) and TCID₅₀ results (log TCID₅₀/mL; left axis) of ChikV production harvests before and after PS treatment is shown. The grey portions of the bars indicate large losses in SEC area following PS treatment, but no corresponding change in the total number of infectious particles (indicated by black portions of the bars) (A); SEC profile of virus preparation before and after PS addition, showing a complete removal of large size virus aggregates by PS treatment as well as a reduction in host cell proteins (HCP) and LMW impurities (B).

Figure 17: Relative amounts of ChikV particles and other components by SEC-HPLC analysis at the different steps of the process of the invention including, from top to bottom: crude harvest (a) are shown; 10X concentrated harvest; diafiltrated harvest; PS treated material; CC700-treated material and SGC purified pool.

Figure 18: Comparison of different sucrose gradients (a: gradient 1: 50%, 10% sucrose, b gradient 2: 50%, 35%, 10% sucrose, c: gradient 3: 50%, 25%, 10% sucrose, d: gradient 4: 50%, 35%, 15%, 10% sucrose) with ChikV particles.

Figure 19: Comparison of two different ZikaV harvest schedules.

Figure 20: SEC-HPLC elution profile of ZikaV NIV. Data were processed on Dionex Ultimate 3000 / Superose 6 Increase column.

Figure 21: SEC-MALLS analysis of inactivated ZikaV.

Figure 22: Cumulative particle size distribution of Zika NIV.

Figure 23: Graphical representation of the neutralization of the Zika virus H/PF/2013 with pooled mouse serum. The number of plaques without serum is set to 100%. The EC₅₀ is calculated with the 3-parameter method.

Figure 24: Graphical representation of the neutralization of the Zika virus MR766 with pooled mouse serum. The number of plaques without serum is set to 100%. The EC₅₀ is calculated with the 3-parameter method.

DETAILED DESCRIPTION OF THE INVENTION

Disclosed herein are virus vaccines and compositions comprising an inactivated virus, and related methods of producing said vaccines and compositions. Also provided are
5 methods of administering said virus vaccines for the prevention of virus infection and/or for the production of an anti-virus immune response in subjects, for example subjects at risk of being exposed to virus. In particular, the invention is directed to a virus vaccine comprising an optimally inactivated virus particle, wherein the virus particle in an appropriate dose is able to seroconvert a subject that is administered the virus vaccine with at least a 70%
10 probability, preferably an 80% probability. Another advantage of the invention is that related methods of producing said vaccines and compositions are very efficient and provide pure compositions largely void of impurities, in particular protamine sulphate, allowing for high volume production of vaccines. Examples to the above are provided for Zika virus and Chikungunya virus.

15 Disclosed herein are downstream processes for purifying virus particles from a crude preparation. The downstream process can be applied to either a virus which has not adapted for propagation on a particular cell substrate or for a partial / fully cell substrate adapted virus particle.

Aspects of the invention provide processes for the purification of infectious virus
20 particles comprising the steps of (a) providing a crude harvest (a) comprising virus particles and impurities, wherein the impurities are generated from growing said virus particles on a cell substrate; (b) reducing impurities from the crude harvest (a) by precipitation with an agent comprising a protamine salt, preferably a protamine sulphate, to obtain a virus preparation (b); and further purifying the virus preparation (b) by an optimized sucrose
25 density gradient centrifugation to obtain a virus preparation (c) comprising the infectious virus particles.

In some embodiments, the concentration of protamine sulphate in step (b) is about 1 to 10 mg/ml, more preferably about 1 to 5 mg/ml, more preferably about 1 to 2 mg/ml. In one embodiment, the concentration of protamine sulphate in step (b) is about 2 mg/mL. In one
30 embodiment, the concentration of protamine sulphate is 1.2 to 1.8 mg/ml, more preferably 1.4 to 1.6 mg/ml. In a preferred embodiment, the concentration of protamine sulphate in step (b) is about 1.6 mg/ml (for e.g. Chikungunya) or about 2 mg/ml (for e.g. Zika).

In some embodiments, the residual host cell DNA of the virus preparation (c) is less than 1 µg/mL, especially less than 900, 800, 700, 600, 500, 400, 300 or 200 ng/mL, preferably less than 100 ng/mL. In a preferred embodiment, the residual host cell DNA of the virus preparation (c) is less than 10 ng/mL. In some embodiments, the residual host cell protein of the final virus preparation (c) is less than 10 µg/mL, especially less than 9, 8, 7, 6, 5, 4, 3 or 2 µg/mL, preferably less than 1 µg/mL. In a preferred embodiment, the residual host cell protein of the virus preparation (c) is less than 100 ng/mL. In some embodiments, the residual non-infectious virus particles of the final virus preparation (c) is less than 10 µg/mL, especially less than 9, 8, 7, 6, 5, 4, 3 or 2 µg/mL, preferably less than 1 µg/mL. In a preferred embodiment, the residual non-infectious virus particles of the virus preparation (c) is less than 100 ng/mL. In some embodiments, the residual protamine is less than 1 µg/mL, especially less than 900, 800, 700, 600, 500, 400, 300 or 200 ng/mL, preferably less than 100 ng/mL, more preferably is below the detection limit in particular below the detection limit in the final drug substance.

In some embodiments, the crude harvest (a) comprising the virus particles and impurities is subjected to one or more pre-purification step(s) prior to step (b). In some embodiments, the one or more pre-purification step(s) comprises digesting host cell genomic DNA in the crude harvest (a) comprising the virus particles and impurities by enzymatic treatment. In some embodiments, the one or more pre-purification step(s) comprises filtration, ultrafiltration, concentration, buffer exchange and/or diafiltration. In some embodiments, the one or more pre-purification steps is filtration using a filter having a pore size equal to or less than 1 µm. In some embodiments, the filter has a pore size equal to or less than 0.2 µm. In a preferred embodiment, the filter has a pore size of 0.2 µm. In some embodiments, the concentration and/or ultra/diafiltration and/or buffer exchange is performed by tangential flow filtration (TFF). In some embodiments, ultra/diafiltration of the crude harvest (a) comprising the virus particles and impurities is performed using a hollow fiber membrane having a cut-off of equal to or less than 300 kDa. In a preferred embodiment, the hollow fiber membrane has a cut-off of 100 kDa.

In some embodiments, the virus particle is a live virus, a chimeric virus, an attenuated live virus, a modified live virus, or a recombinant live virus. In a further step, the virus particles of the invention may be optionally inactivated. In some embodiments, the virus particle is an attenuated form of the virus particle. For example, the virus may have

reduced infectivity, virulence, and/or replication in a host, as compared to a wild-type virus. In some embodiments, the virus is a mutated or modified virus, for example the nucleic acid of the virus may contain at least one mutation relative to the wild-type virus. In some embodiments, the virus is a recombinant live virus, meaning a virus that is generated
5 recombinantly and may contain nucleic acid from different sources.

In some embodiments, the virus particle is a live virus, an attenuated live virus, a modified live virus, or a recombinant live virus. In some embodiments, the virus belongs to a virus family selected from the group consisting of Paramyxoviridae, Orthomyxoviridae, Flaviviridae, Filoviridae, Arenaviridae, Rhabdoviridae, and Coronaviridae. In some
10 embodiments, the virus belongs to a virus family selected from the group consisting of Togaviridae (being live or inactivated), such as alphaviruses, or Flaviviridae (being live or inactivated). In some embodiments, the virus is a virus of the family Flaviviridae, i.e. a flavivirus. In other embodiments, the virus is a Zika virus or Yellow Fever virus. In preferred embodiments, the virus is a Zika virus. In a most preferred embodiment, the Zika
15 virus is a Zika virus from the Asian lineage.

In some embodiments, the relative reduction of impurity of the final virus preparation relative to the liquid medium (a) comprising the virus particles and impurities is in a range from 60 to 95%. In some embodiments, the residual impurity of the final virus preparation is less than 1%.

20 In some embodiments, the filtration of step in (b)(ii) of claim 1 is performed using a filter having a pore size equal to or greater than 1 μm . In some embodiments, the filter has a pore size equal to or greater than 0.2 μm . In a preferred embodiment, the filter has a pore size of 0.2 μm .

In some embodiments, the virus is propagated in a cell line selected from the group
25 consisting of an EB66 cell line, a Vero cell line, a Vero- α His cell line, a HeLa cell line, a HeLa-S3 cell line, a 293 cell line, a PC12 cell line, a CHO cell line, a 3T3 cell line, a PerC6 cell line, a MDSK cell line, a chicken embryonic fibroblast cell line, a duck cell line, and a diploid avian cell line. In some embodiments, said cell line is a duck cell line. In some embodiments, said cell line is a diploid avian cell line. In some embodiments, said cell line is
30 EB66 cell line. In a preferred embodiment, said cell line is a Vero cell line.

Aspects of the invention provide a use of any of the processes described herein for manufacturing a composition for immunization against a viral infection. In a preferred

embodiment, the composition is a vaccine. In one embodiment, the composition or vaccine is directed against Chikungunya virus. In one embodiment, the composition or vaccine is directed against a flavivirus. In one embodiment, the composition or vaccine is directed against Yellow Fever virus. In one embodiment, the composition or vaccine is directed against Zika virus such as e.g. a Zika virus of the Asian lineage.

Other aspects provide compositions comprising the virus particles obtainable by any of the processes described herein for treating and/or preventing a viral infection. In one embodiment, the viral infection is caused by Chikungunya virus. In one embodiment, the viral infection is caused by a flavivirus. In one embodiment, the viral infection is caused by Yellow Fever virus. In one embodiment, the viral infection is caused by Zika virus such as e.g. a Zika virus of the Asian lineage.

Furthermore, disclosed herein are Zika virus vaccines and compositions comprising an inactivated Zika virus, and related methods of producing said vaccines and compositions. Also provided are methods of administering the Zika virus vaccines for the prevention of Zika virus infection and/or for the production of an anti-Zika virus immune response in subjects, for example subjects at risk of being exposed to Zika virus.

Zika virus is a flavivirus closely related to Dengue virus and is similarly transmitted by the *Aedes* species mosquito, although other arthropod vectors for Zika virus are possible. Since it was first isolated from a Rhesus monkey in the Zika forest of Uganda in 1947, there were very few reported incidents of human infection, especially outside of the endemic regions of Africa and Asia until a large outbreak in French Polynesia in 2007 (Haddow *et al. PLoS Neglected Tropical Diseases* (2012) 6(2), Malone *et al. PLoS Neglected Tropical Diseases* (2016) 10(3),). The virus has since spread through islands of the Pacific, including Oceania, and into South and Central America (WHO “Zika Situation Report” February 5, 2016).

In addition to being spread by the bite of an infected mosquito, evidence also suggests transmission may occur between individuals, such as from the blood of an infected individual, *in utero*/transplacental transmission from an infected mother to the fetus, sexual transmission between sexual partners, and possibly by other local transmission routes. There is a possible association between Zika virus infection during pregnancy and microcephaly in the fetus/neonate. Microcephaly is a rare condition in which a baby’s head circumference is significantly less than expected based on the average for their age, sex, and ethnicity. This is

PAT018/EP/PR3

a result of the brain failing to undergo proper embryonic development, and in 90% of cases is associated with mental retardation (Rocha *et al.* (2016) *Bull World Health Organ* 8 Feb. 2016).

There is a probable association between individuals having had a prior Zika virus infection and the incidence of Guillain-Barré syndrome, a neurological disorder in which the individual's immune system destroys the myelin sheath surrounding axons of the peripheral nervous system (WHO "Zika Situation Report" February 5, 2016).

No specific treatments or vaccines for Zika virus currently exist, and the only measures at this time to prevent infection are through vector control and avoiding travel to regions experiencing outbreaks.

Described herein are Zika virus vaccines and compositions comprising inactivated Zika virus that provide a safe method for generating an immune response to Zika virus, including virus-neutralizing antibodies, that may help prevent against Zika virus infection.

Any strain of Zika virus may be used in the methods and compositions described herein. In some embodiments, the Zika virus is an isolate from an infected subject during a Zika virus outbreak. In some embodiments, the Zika virus is a strain isolated from Africa or from the African virus lineage. In some embodiments, the Zika virus is a strain isolated from Asia or from the Asian lineage (includes also strains from French Polynesia). In some embodiments, the Zika virus is a strain isolated from the Americas (South America, Central America, or North America), such as a Suriname Zika virus strain. In some embodiments, the Zika virus has a RNA genome corresponding (but not limited) to the DNA sequence provided by GenBank Accession No. AY632535.2, KU321639.1, KU497555.1, KU501215.1, KU509998.1, KU527068.1, KU681081.3, KU681082.3, KU707826.1, KU744693.1, or LC002520.1 or RNA genome disclosed partially or fully herein (SEQ ID NO: 2 to 69).

In some embodiments, the attenuated form of ChikV is derived from the LR2006-OPY1 ChikV infectious clone (La Reunion isolate). In some embodiments, the attenuated form of ChikV is the $\Delta 5\text{nsP3}$ mutant as described by Hallengård *et al.* (Novel Attenuated Chikungunya Vaccine Candidates Elicit Protective Immunity in C57BL/6 mice (2014) *Journal of Virology* 88(5):2858–2866) or an immunogenic variant thereof. The immunogenic variant of the $\Delta 5\text{nsP3}$ ChikV mutant is herein defined as having at least 80% sequence identity to the nucleotide sequence of the $\Delta 5\text{nsP3}$ mutant sequence, especially at least 81%,

PAT018/EP/PR3

82%, 83%, 84%, 85%, 86%, 87%, 88% 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% sequence identity.

In some embodiments, the process of the invention results in an enrichment of infectious virus particles from the crude harvest comprising infectious virus particles and non-infectious virus particles and other virus products such that the enrichment of the infectious virus particles is at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, preferably at least 80%, especially 85% relative to the total virus particle content of the crude harvest (a) comprising the virus particles and impurities.

In some embodiments, the residual impurity of the final virus preparation with respect to all impurities in the crude harvest is less than 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, preferably less than 5% as determined by SEC-HPLC (Size Exclusion Chromatography – HPLC).

Another aspect of this invention is the realization that by using an approach of a type of vaccine (i.e. the Japanese Encephalitis Vaccine (JEV) with tradename IXIARO®, see Srivastava A.K. et al., 2001, Vaccine 19, 4557-4565, WO99/11762) which the regulatory agencies have seen and licensed before, it may be possible to very quickly develop a Zika or Chikungunya vaccine and provide it to the subjects in need as soon as possible. The industrial process as disclosed for IXIARO®, providing a very effective vaccine against JEV, had to be complemented by further inventions disclosed herein in order to provide a more efficient (higher yield) and safer (less or no protamine sulphate with its allergic potential) Zika vaccine compared to the available JEV vaccine. A particular innovation of the herein disclosed vaccines are their avoidance of any protamine salt (SEQ ID NO: 1) in the final drug substance by introducing an improved sucrose gradient. Said sucrose gradient not only allowed the separation of protamine sulphate but also allowed for a very effective inactivation by formaldehyde and resulted in the case of Zika with over 90% yield with the improved process disclosed herein vs about 35% yield with the published JEV process, see experimental part for comparison).

Aspects of the disclosure relate to methods of producing a virus in Vero tissue culture cells. Vero cells are a commonly used tissue culture cell line derived from the kidney of an African green monkey. The Vero cells used in the methods described herein are the VERO (WHO) cell line, obtained from the Health Protection Agency general cell collection under catalogue number 88020401.

Vero cells can be grown to confluent monolayers, for example in tissue culture flasks; in suspension (on microcarriers), for example in roller bottles; or in any other cell culture system for viral production. In some embodiments, the Vero cells are grown in a bioreactor for viral production. For plaque assays or plaque reduction neutralization test (PRNT), Vero
5 cells are grown in monolayers in tissue culture flasks, dishes, or wells of a plate. To infect the Vero cells with the virus, the culture medium is inoculated with virus and the cells are incubated with the virus for a period of time. The cells may be washed after inoculation to remove any virus that did not adsorb to the cells in a given amount of time.

The methods provided herein involve passaging the virus in Vero cells. As used
10 herein, the terms “passage” or “passaging” refer to infecting a population of Vero cells with virus and subsequently inoculating a second population of Vero cells with virus produced by infection of the first Vero cell population. In some embodiments, a portion of the culture medium from the infected Vero cells (containing virus that was released from the infected cells) is used to inoculate a second population of Vero cells. This is referred to as one
15 passage or one round of passaging. The passaging may be performed serially, for example, a portion of the culture medium from the infected second population of Vero cells is used to inoculate a third population of Vero cells, and so on. In some embodiments, virus obtained from a single plaque is used to inoculate another population of cells.

In some embodiments, the virus is passaged in Vero cells several times, such as at
20 least 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 times. In some embodiments, the virus is passaged in Vero cells at least 4 times or 5 times. In some embodiments, the virus is passaged in Vero cells at least 30 times. It is important that the virus population, i.e. the virus sequences, stays as much as possible constant over said passaging. If adaption of the virus
25 occurs (i.e. appearance of mutated viruses in the original virus population), it is preferred that said passages are not used in the context of manufacturing of said virus, e.g. for Zika it was found that up to passage 3 and culturing to day 7 can be used without major shifts in virus population, i.e. introduction of virus population with mutations. However this observation need to be done for each virus strain and may be different.

30 In some embodiments, the Vero cells are incubated for at least 2 days after inoculation with the virus at e.g. a typical 0,01 MOI (multiplicity of infection), to allow for viral production, prior to passaging. In some embodiments, the Vero cells are incubated for

PAT018/EP/PR3

at least 3, 4, 5, 6, 7, 8, 9, 10 or more than 10 days e.g. at least 7 days after inoculation with the virus prior to passaging. The number of days the Vero cells are incubated after viral inoculation may depend on factors such as the multiplicity of infection used to inoculate the cells and the viral titer desired in the culture medium. Serial passaging of the virus in Vero
5 cells may result in generation of a Vero cell adapted virus strain.

The culture medium from the infected Vero cells may be harvested (collected) to obtain the virus. In some embodiments, the culture medium is harvested from infected Vero cells and is replaced with fresh culture medium, which is then harvested after another period of time. In some embodiments, the culture medium harvested from infected Vero cells is
10 pooled from independent Vero cell cultures and/or from independent days. Harvesting can be repeated up to 4 times by 7 or 9 days post infection, for example, and result in a high yield of virus per unit cell culture. In order to minimize the adoption of Zika virus strain to Vero cells, it was found that Vero cell could be incubated for at least 7 days, more preferably 5 days, prior to passaging and subsequently supernatants could be harvested at days 2, 3, 5 and 7 or
15 2, 3, and 5 (see also experimental part). The harvested culture medium can be stored at +4°C prior to purification of the virus from the culture medium up to 2 weeks.

In some embodiments, debris from infected and lysed Vero cells may be removed from the harvested culture medium, referred to as a “clarification” of the culture medium. The harvested culture medium may be clarified by common methods known in the art, such
20 as low-speed centrifugation, for example, at 1500 g for 10 min, and/or by filtration through a filter of pore size of 0.45 µm. The harvested culture medium can be stored at +4°C prior to concentration.

To concentrate the titer of the virus in the harvested culture medium, it may be subjected to concentration by any method known in the art. For example, the harvested
25 culture medium may be concentrated by methods including, without limitation, ultrafiltration, ultracentrifugation, centrifugal concentrator, vacuum centrifugation, and lyophilization. In some embodiments, the harvested culture medium is concentrated by ultrafiltration and the retentate containing the Zika virus is collected. In some embodiments, the harvested culture medium is concentrated by precipitation in which polyethylene glycol (PEG) 8000 is
30 dissolved in the culture medium (up to 10%) and the precipitate is dissolved in a buffer, for example phosphate-buffered saline (PBS, pH 7.0).

The harvested culture medium may be precipitated to produce a virus supernatant. In some embodiments, the harvested culture medium is precipitated to remove Vero cell DNA and other undesired material, such as Vero cell debris, from the harvested culture medium. In some embodiments, the harvested culture medium is concentrated prior to precipitation. In
5 some embodiments, the harvested culture medium is precipitated by adding protamine sulfate (c.g. SEQ ID NO: 1) to the harvested culture medium and incubating the mixture, for example at +4°C or on ice. In some embodiments, the harvested culture medium is treated with benzonase to remove Vero cell DNA and other undesired material, such as Vero cell debris, from the harvested culture medium. However, it was found that the treatment with
10 protamine sulfate is preferred (see experimental part). In some embodiments, the precipitated culture medium is centrifuged to collect precipitated material and the supernatant containing the virus, referred to as a “virus supernatant,” is collected.

The virus supernatant may be further purified after precipitation, for example density gradient ultracentrifugation. In some embodiments, the virus supernatant is further purified
15 by sucrose gradient. Fractions may be collected from the sucrose gradients and assayed for presence of the virus. Methods for assaying for virus positive fractions include plaque assay, hemagglutination assay, polyacrylamide gel electrophoresis, and antigen assays such as Western blotting and ELISA's. The fractions containing virus may be pooled based on titer of the virus and level of other impurities. The level or amount of impurities present in the
20 virus supernatant can be estimated by testing for Vero cell DNA, virus aggregates and/or Vero cell protein (see experimental part). A particular embodiment of the invention is the improved sucrose gradient that allows for an efficient protamine separation as shown in experimental part. It was surprisingly found that addition of a 10% sucrose virus containing fraction to a simple three layer sucrose density gradient (e.g. a gradient comprising a 15%
25 (w/w) sucrose solution, a 35% (w/w) sucrose solution, and a 50% (w/w) sucrose solution) was able to efficiently separate protamine sulphate without much loss of virus. Thus a particularly preferred embodiment of the invention is the use of a sucrose density gradient that is able to efficiently separate protamine sulphate, wherein said sucrose density gradient is used in the purification of virus such as the viruses described herein, e.g. a Zika virus, Yellow
30 Fever virus or Chikungunya virus.

To achieve a safe vaccine or composition for the administration to subjects, the virus supernatant may be inactivated (see experimental part for Zika virus). As used herein, the

terms “inactivated” and “optimally inactivated” may be used interchangeably and refer to a process (or its result) by which the virus is rendered unable to infect a host cell (non-infectious), but that does not affect or substantially affect the antigenicity of the virus, for example, the immunogenic antigens exposed on the surface of the virus are able to stimulate an immune response in a subject (*e.g.*, antigen-specific antibodies). By “does not affect or substantially affect the antigenicity of the virus” is meant that the inactivated virus retains at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or even essentially 100% of the antigenicity of a virus that is not subjected to inactivation.

A variety of methods are known in the art for inactivating viruses. In some embodiments, the virus is inactivated by chemical inactivation, thermal inactivation, pH inactivation, or UV inactivation.

In some embodiments, the inactivating is by chemical inactivation and involves contacting the virus with one or more chemical inactivation agent for a period of time under conditions such that the virus is inactivated but the antigenic epitopes are substantially intact. In some embodiments, the virus is inactivated for a period of time that is longer than is required to completely inactivate the virus. In some embodiments, the virus supernatant is inactivated for the number of days required to inactivate the virus plus at least one additional day. Samples of the virus supernatant may be taken at one or more times throughout the inactivation process and assessed for viral viability (infectivity) by any method known in the art, such as by infecting a monolayer of host cells (*i.e.*, plaque assay). Using such a procedure, the period of time that is required to completely inactivate the virus can be determined, and a longer period of time is selected to ensure complete inactivation.

In some embodiments, the virus is contacted with a chemical inactivation agent for between 1 day and 50 days, between 2 days and 40 days, between 2 days and 30 days, between 2 days and 20 days, between 2 days and 10 days, between 3 days and 9 days, between 4 days and 8 days, between 5 days and 7 days, between 2 days and 5 days, or between 5 and 10 days. In some embodiments, the virus is contacted with one or more chemical inactivation agents for at least 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days, 31 days, 32 days, 33 days, 34 days, 35 days, 36 days, 37 days, 38

PAT018/EP/PR3

days, 39 days, 40 days, 41 days, 42 days, 43 days, 44 days, 45 days, 46 days, 47 days, 48 days, 49 days, or at least 50 days.

In some embodiments, the chemical inactivation is performed at about +5°C, +10°C, +15°C, +20°C, +25°C, +30°C, +35°C, +40°C, or about +45°C. In some embodiments, the chemical inactivation is performed at about +4°C. In some embodiments, the chemical inactivation is performed at about +22°C.

Any chemical inactivation agent known in the art may be suitable for inactivating the virus in the methods described herein. It will be appreciated by one of skill in the art that factors such as the chemical inactivation agent and the temperature at which inactivation is performed may affect the length of time (number of days) required to completely inactivate the virus. Examples of chemical inactivation agents include, without limitation, formaldehyde, enzymes, β -propiolactone, ethanol, trifluoroacetic acid, acetonitrile, bleach, urea, guanidine hydrochloride, tri-n-butyl phosphate, ethylene-imine or a derivatives thereof, and organic solvents such as Tween, Triton, sodium deoxycholate, and sulphohetain. A preferred inactivation is the inactivation with formaldehyde at 22°C $\pm$ 2°C for about 10 days.

In some embodiments, the inactivating agent is neutralized after chemical inactivation of the virus. In some embodiments, the inactivating agent is formaldehyde and is neutralized after chemical inactivation using sodium thiosulphate or sodium metabisulfite.

In some embodiments, the virus is inactivated by thermal inactivation. In some embodiments, the thermal inactivation involves exposing the virus to heat, such as dry heat or vapor heat, for a period of time. In some embodiments, the thermal inactivation involves exposing the virus to temperatures of about +40°C, +45°C, +50°C, +55°C, +60°C, +65°C, +70°C, +75°C, +80°C, +85°C, +90°C, +95°C, or about +100°C. In some embodiments, the virus is exposed to heat for at least 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 24 hours, 36 hours, 48 hours, 60 hours, 72 hours, 84 hours, about 96 hours, or longer. A preferred thermal inactivation involves exposing the virus to temperatures of about +56°C for 60 minutes.

In some embodiments, the virus is inactivated by exposing the virus to acidic or alkaline conditions for a period of time such that the virus is completely inactivated. The pH of a virus preparation may be adjusted to a desired pH, for example by the addition of an acid, a base, or a buffer with a particular pH to the virus preparation. In some embodiments,

PAT018/EP/PR3

the virus is inactivated at an acidic pH of about 2, 2.5, 3, 3.5, 4, 4.5, 5 or about 5.5. In other embodiments, the virus is inactivated at an alkaline pH of about 8, 8.5, 9, 9.5, 10, or about 10.5.

In some embodiments, the virus is inactivated using UV inactivation. UV inactivation involves exposing the virus to energy-rich radiation, such as UV-A, UV-B, or UV-C light for a period of time.

It will be appreciated that any two or more methods of inactivation may be combined and performed concurrently or serially.

The inactivated virus may be subsequently dialyzed to remove any undesired material, including the inactivating agent and any neutralizing agent, and/or to replace the buffer with a buffer that is pharmaceutically acceptable for administration to subjects. In some embodiments, the inactivated virus is dialyzed with PBS. In addition or alternatively, the inactivated virus may be filtered, such as sterile filtered, through a 0.22 μm filter.

It is believed that the herein described improved process (comprising the PS treatment in combination with the optimized sucrose gradient) is applicable and efficient to any virus purification and in particular efficient for any RNA type virus (such as the herein described Zika and Chikungunya and yellow fever viruses) of similar size (i.e. about 50 to 100 nm). Furthermore, it is believed that the combination of the PS treatment with the optimized sucrose gradient (allowing for a complete (or almost complete) separation of PS provides a very efficient virus purification in the very high range, e.g. above 70%, more preferably 75%, 80% or 90%, even more preferably 95%. It is believed that the complete reduction of PS in the virus fraction through the process of the invention allows a very efficient inactivation with almost no or very low viral loss e.g. below 30%, more preferably less than 25%, 20% or 10% loss, even more preferably less than 15% loss.

Any of the methods or uses described herein may be for the prevention of a virus infection in a subject. As used herein, the terms "prevent," and "preventing," include the administration of a virus vaccine or composition to a subject to reduce, or delay the onset of the manifestation of clinical or subclinical symptoms, complications, pathologies or biochemical indicia of a disease or infection, or to reduce or inhibit the spread/transmission of the virus. As used herein, antigen(s), such as an inactivated virus, that is administered to a subject prophylactically (e.g., prior to infection) may be referred to as a vaccine.

Zika Vaccine

As described herein Zika virus may cause any of a variety of symptoms upon infection of a subject, and is generally characterized by mild fever; rash (exanthema) on face, neck trunk, upper arms; headache; sensitivity to light; non-inflammatory joint pain; conjunctivitis; lack of appetite; diarrhea; abdominal pain; and/or dizziness. Zika virus infection during pregnancy is likely associated with microcephaly in the fetus/neonate. There is also a probable association between the onset of Guillain-Barré syndrome or symptoms thereof. Diagnosis of Zika virus infection in subjects exposed to Zika virus or suspected of being exposed to Zika virus involves detecting the presence of virus-specific antibodies and/or molecular testing, such as PCR or real-time PCR detection of Zika virus.

Provided herein are methods for administering a dose of a therapeutically effective amount of a Zika virus vaccine to a subject in need thereof. In some embodiments, the subject is a mammalian subject, such as a human, non-human primate, rodent, rabbit, sheep, dog, cat, horse, or cow. In some embodiments, the subject is a mouse. In some embodiments, the subject is a human subject, such as a child, an adult, or an elderly adult. In some embodiments, the subject is a female subject. In some embodiments, the subject is pregnant or planning on becoming pregnant. In some embodiments, the subject is at risk of being exposed to Zika virus. In some embodiments, the subject is living in or traveling to an area where Zika virus is present or is thought to be present. In some embodiments, the subject is living in or traveling to an area that is experiencing a Zika virus infection outbreak. In some embodiments, the subject is living in or traveling to an area where an arthropod vector capable of transmitting the Zika virus vector is present or is thought to be present.

Any of the Zika virus vaccines or compositions described herein may be administered to a subject in a therapeutically effective amount or a dose of a therapeutically effective amount. As used herein, a “therapeutically effective amount” of vaccine is any amount that results in a desired response or outcome in a subject, such as those described herein, including but not limited to prevention of infection, an immune response or an enhanced immune response to Zika virus, or prevention or reduction of symptoms associated with Zika disease.

In some embodiments, the therapeutically effective amount of a Zika virus vaccine or composition described herein is an amount sufficient to generate antigen-specific antibodies (*e.g.*, anti-Zika virus antibodies). In some embodiments, the therapeutically effective amount

is sufficient to seroconvert a subject with at least 70% probability. In some embodiments, the therapeutically effective amount is sufficient to seroconvert a subject with at least 75%, 80%, 85% 90%, 95%, 96%, 97%, 98%, or at least 99% probability. Whether a subject has been seroconverted can be assessed by any method known in the art, such as obtaining a serum
5 sample from the subject and performing an assay to detect anti-Zika virus antibodies. In some embodiments, a subject is seroconverted if a serum sample from the subject contains an amount of anti-Zika virus antibodies that surpasses a threshold or predetermined baseline. A subject is generally considered seroconverted if there is at least a 4-fold increase in anti-Zika virus antibodies (*i.e.*, anti-Zika E protein IgG antibodies) present in a serum sample from the
10 subject as compared to a serum sample previously taken from the same subject.

In some embodiments, seroconversion of a subject is assessed by performing a plaque reduction neutralization test (PRNT). Briefly, PRNT is used to determine the serum titer required to reduce the number of Zika virus plaques by 50% (PRNT50) as compared to a control serum/antibody. The PRNT50 may be carried out using monolayers of Vero cells or
15 any other cell type/line that can be infected with Zika virus. Sera from subjects are diluted and incubated with live, non-inactivated Zika virus. The serum/virus mixture may be applied to the Vero cells and incubated for a period of time. Plaques formed on the Vero cell monolayers are counted and compared to the number of plaques formed by the Zika virus in the absence of serum or a control antibody. A threshold of neutralizing antibodies of 1:10
20 dilution of serum in a PRNT50 is generally accepted as evidence of protection (Hombach *et al.* Vaccine (2005) 23:5205-5211).

In some embodiments, the Zika virus may be formulated for administration in a composition, such as a pharmaceutical composition. The term “pharmaceutical composition” as used herein means a product that results from the mixing or combining of at least one
25 active ingredient, such as an inactivated Zika virus, and one or more inactive ingredients, which may include one or more pharmaceutically acceptable excipient.

Pharmaceutical compositions of the invention, including vaccines, can be prepared in accordance with methods well known and routinely practiced in the art (see *e.g.*, Remington: The Science and Practice of Pharmacy, Mack Publishing Co. 20th ed. 2000; and Ingredients
30 of Vaccines – Fact Sheet from the Centers for Disease Control and Prevention, *e.g.*, adjuvants and enhancers such as alum to help the vaccine improve its work, preservatives and stabilizers to help the vaccine remain unchanged (*e.g.*, albumin, phenols, glycine)).

Pharmaceutical compositions are preferably manufactured under GMP conditions. Typically a therapeutically effective dose of the inactivated Zika virus preparation is employed in the pharmaceutical composition of the invention. The inactivated Zika virus is formulated into pharmaceutically acceptable dosage forms by conventional methods known to those of skill
5 in the art. Dosage regimens are adjusted to provide the optimum desired response (*e.g.*, the prophylactic response).

Dosages of the active ingredients in the pharmaceutical compositions of the present invention can be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired pharmaceutical response for a particular subject, composition, and
10 mode of administration, without being toxic to the subject. The selected dosage level depends upon a variety of pharmacokinetic factors including the activity of the particular compositions of the present invention employed, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the
15 particular compositions employed, the age, sex, weight, condition, general health and prior medical history of the subject being treated, and like factors.

A physician, veterinarian or other trained practitioner, can start doses of the inactivated Zika virus vaccine employed in the pharmaceutical composition at levels lower than that required to achieve the desired therapeutic effect and gradually increase the dosage
20 until the desired effect (*e.g.*, production of anti-Zika virus antibodies) is achieved. In general, effective doses of the compositions of the present invention, for the prophylactic treatment of groups of people as described herein vary depending upon many different factors, including means of administration, target site, physiological state of the patient, whether the patient is human or an animal, other medications administered, and the titer of anti-Zika virus
25 antibodies desired. Dosages need to be titrated to optimize safety and efficacy. In some embodiments, the dosing regimen entails subcutaneous or intramuscular administration of a dose of inactivated Zika virus twice, once at day 0 and once at about day 7. In some embodiments, the dosing regimen entails subcutaneous administration of a dose of inactivated Zika virus twice, once at day 0 and once at about day 14. In some embodiments,
30 the dosing regimen entails subcutaneous administration of a dose of inactivated Zika virus twice, once at day 0 and once at about day 28. In some embodiments, the inactivated Zika virus is administered to the subject once.

Any of the Zika virus vaccines or compositions described herein may be administered to a subject with, prior to, or after administration of one or more adjuvants. An adjuvant is a molecule that enhances a response in a subject, such as an immune response, to an antigen or other molecule. In some embodiments, an adjuvant may stabilize an antigen or other molecule. Determining whether a Zika virus vaccine or compositions thereof are administered with an adjuvant depends on various factors (e.g., type and extent of response desired) and will be evident to one of skill in the art. In some embodiments, administering any of the Zika virus vaccines or compositions described herein with, prior to, or after administration of an adjuvant may enhance the production of virus neutralizing (anti-Zika virus) antibodies. In some embodiments, a subject that is administered any of the Zika virus vaccines or compositions described herein with, prior to, or after administration of an adjuvant may only require a single administration of the Zika virus vaccine or composition to be seroconverted (produce a level of anti-Zika virus antibodies). Examples of adjuvants may include, without limitation, aluminium salt (aluminium hydroxide or aluminium phosphate), calcium phosphate hydroxide, paraffin oil, killed bacteria, bacterial toxins, toxoids, subunits of bacteria, squalene, thimerosal, detergents, IL-1, IL-2, IL-12, 2-component adjuvants, such as 2-component adjuvants containing an antibacterial peptide and a TLR9 agonist (e.g., IC31®), and combinations such as Freund's complete adjuvant and Freund's incomplete adjuvant. In some embodiments, the Zika virus vaccines or compositions is administered with aluminium hydroxide. In some embodiments, the inactivated Zika virus vaccine or composition is administered with aluminium phosphate salt. A preferred aluminium salt is the aluminium hydroxide with reduced Cu content, e.g. lower than 1,25ppb based on the weight of the Zika composition, an adjuvant described in detail in WO 2013/083726 or Schlegl et al., Vaccine 33 (2015) 5989-5996.

In some embodiments, the adjuvant is comprised of two components. In some embodiments, the 2-component adjuvant comprises an antibacterial peptide and a TLR9 agonist. In some embodiments, the antibacterial peptide is provided by the amino acid sequence KLKL₅KLK (SEQ ID NO: 70). In some embodiments, the TLR9 agonist is a deoxyinosine-containing immunostimulatory oligodeoxynucleic acid molecule (I-ODN). In some embodiments, the I-ODN comprises the nucleic acid sequence (dIdC)₁₃ (SEQ ID NO: 69). In some embodiments, the adjuvant is IC31®. In some embodiments, the adjuvant is in nanoparticle form (See, e.g., US Patent No. 8,765,148 B2, incorporated by reference in its

PAT018/EP/PR3

entirety). In some embodiments, the adjuvant is IC31®, i.e. KLKL₅KLK (SEQ ID NO: 71) and the nucleic acid sequence (dIdC)₁₃ (SEQ ID NO: 72), in combination with an aluminium salt such as aluminium hydroxide.

5 The Zika virus vaccines or compositions described herein may be administered to a subject concomitantly with one or more vaccine to another infectious agent, such as another infectious agent is that present or thought to be present in the same geographic area as Zika virus. In some embodiments, the other infectious agent is one that the subject is also at risk of being in contact with. In some embodiments, the other infectious agent is transmitted by the same arthropod vector as Zika virus. In some embodiments, the other infectious agent is
10 Japanese Encephalitis virus, Yellow Fever virus, Dengue virus and/or Chikungunya virus.

Also within the scope of the present disclosure are kits for use in prophylactically administering to a subject, for example to prevent or reduce the severity of Zika virus infection. Such kits can include one or more containers comprising a composition containing inactivated Zika virus, such as an inactivated Zika virus vaccine. In some embodiments, the
15 kit may further include one or more additional containing comprising a second composition, such as a second vaccine. In some embodiments, the second vaccine is a vaccine for another arbovirus. In some embodiments, the second vaccine is a Dengue virus vaccine and/or a Chikungunya virus vaccine.

In some embodiments, the kit can comprise instructions for use in accordance with
20 any of the methods described herein. The included instructions can comprise a description of administration of the composition containing inactivated Zika virus to prevent, delay the onset, or reduce the severity of Zika virus infection. The kit may further comprise a description of selecting a subject suitable for administration based on identifying whether that subject is at risk for exposure to Zika virus or contracting a Zika virus infection. In still other
25 embodiments, the instructions comprise a description of administering a composition containing inactivated Zika virus to a subject at risk of exposure to Zika virus or contracting Zika virus infection.

The instructions relating to the use of the composition containing inactivated Zika virus generally include information as to the dosage, dosing schedule, and route of
30 administration for the intended treatment. The containers may be unit doses, bulk packages (e.g., multi-dose packages) or sub-unit doses. Instructions supplied in the kits of the

invention are typically written instructions on a label or package insert (*e.g.*, a paper sheet included in the kit), but machine readable instructions are also acceptable.

The kits of the present disclosure are in suitable packaging. Suitable packaging includes, but is not limited to, vials, bottles, jars, flexible packaging, and the like. Also contemplated are packages for use in combination with a specific device, such as a syringe or an infusion device. The container may have a sterile access port, for example the container may be a vial having a stopper pierceable by a hypodermic injection needle. At least one active agent in the composition is an inactivated Zika virus, as described herein.

This invention is not limited in its application to the details of construction and the arrangement of components set forth in the following description or illustrated in the drawings. The invention is capable of other embodiments and of being practiced or of being carried out in various ways. Also, the phraseology and terminology used herein is for the purpose of description and should not be regarded as limiting. The use of “including,” “comprising,” or “having,” “containing,” “involving,” and variations thereof herein, is meant to encompass the items listed thereafter and equivalents thereof as well as additional items.

Unless otherwise defined herein, scientific and technical terms used in connection with the present disclosure shall have the meanings that are commonly understood by those of ordinary skill in the art. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. The methods and techniques of the present disclosure are generally performed according to conventional methods well-known in the art. Generally, nomenclatures used in connection with, and techniques of biochemistry, enzymology, molecular and cellular biology, microbiology, virology, cell or tissue culture, genetics and protein and nucleic chemistry described herein are those well-known and commonly used in the art. The methods and techniques of the present disclosure are generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification unless otherwise indicated.

The present invention is further illustrated by the following examples, which in no way should be construed as further limiting. The entire contents of all of the references (including literature references, issued patents, published patent applications, and co-pending patent applications) cited throughout this application are hereby expressly incorporated by

PAT018/EP/PR3

reference, in particular for the teaching that is referenced hereinabove. However, the citation of any reference is not intended to be an admission that the reference is prior art.

SEQUENCES

- 5 The amino acid sequence of a typical form of protamine is provided by SEQ ID NO: 1:
PRRRRSSSRP VRRRRRPRVS RRRRRRGRR RR.

Provided below are examples of nucleic acid sequences of the genomes of Zika viruses that may be used in the methods, compositions, and/or vaccines described herein.

10

KU321639.1 Zika virus strain ZikaSPH2015, Brazil, complete genome (SEQ ID NO: 2)

GTGTGTTACTGTTGCTGACTCAGACTGCGACAGTTTCGAGTTTGAAGCGAAAGCTAGCAACAGTATCA
ACAGGTTTTATTTGGATTTGGAAACGAGAGTTTCTGGTCATGAAAAACCCAAAAAAGAAATCCGG
AGGATTCCGGATTGTCAATATGCTAAAACGCGGAGTAGCCCGTGTGAGCCCCCTTTGGGGGCTTGAA
15 GAGGCTGCCAGCCGACTTCTGCTGGGTCATGGGCCCATCAGGATGGTCTTGGCAATTCTAGCCTT
TTTGAGATTACGCGCAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTCAGTGGGGAAAA
AAGAGGCTATGGAAATAATAAAGAAGTTCAAGAAAGATCTGGCTGCCATGCTGAGAATAATCAAT
GCTAGGAAGGAGAAGAAGAGACGGGGCGCAGATACTAGTGTGCGGAATTGTTGGCCTCCTGCTGAC
CACAGCTATGGCAGCGGAGGTCCTAGACGTGGGAGTGCATACTATATGTACTTGGACAGAAACG
20 ATGCTGGGGAGGCCATATCTTTTCCAACCCACATTGGGGATGAATAAGTGTATATACAGATCATGG
ATCTTGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTATGCTGGATGAGGGGGTGGAA
CCAGATGACGTCGATTGTTGGTGCAACACGACGTCAACTTGGGTTGTGTACGGAACCTGCCATCAC
AAAAAAGGTGAAGCACGGAGATCTAGAAGAGCTGTGACGCTCCCCCTCCATTCCACTAGGAAGCT
GCAAACGCGGTCGCAAACCTGGTTGGAATCAAGAGAATACACAAAGCACTTGATTAGAGTCGAAA
25 ATTGGATATTCAGGAACCCTGGCTTCGCGTTAGCAGCAGCTGCCATCGCTTGGCTTTTGGGAAGCT
CAACGAGCCAAAAAGTCATATACTTGGTCATGATACTGCTGATTGCCCCGGCATAACAGCATCAGGT
GCATAGGATGAGCAATAGGGACTTTGTGGAAGGTATGTGTCAGGTGGGACTTGGGTTGATATTGCT
TGGAACATGGAGTTGTGTCAACCGTAATGGCACAGGACAAACCGACTGTCGACATAGAGCTGGTT
ACAACAACAGTCAGCAACATGGCGGAGGTAAGATCCTACTGCTATGAGGCATCAATATCAGACAT
30 GGCTTCGACAGCCGCTGCCCAACACAAGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAAT
ATGTCTGCAAAAGAACGTTAGTGGACAGAGGCTGGGGAAATGGATGTGGACTTTTGGCAAAGGG
AGTCTGGTGACATGCGCTAAGTTGCATGCTCCAAGAAAATGACCGGGAAGAGCATCCAGCCAGA
GAATCTGGAGTACCGGATAATGCTGTGCTAGTTTCATGGCTCCAGCACAGTGGGATGATCGTTAATGA
CACAGGACATGAACTGATGAGAATAGAGCGAAGGTTGAGATAACGCCCAATTCACCAAGAGCC
35 GAAGCCACCCTGGGGGGTTTTGGAAGCCTAGGACTTGATTGTGAACCGAGGACAGGCCTTGACTTT
TCAGATTTGTATTACTTGACTATGAATAACAAGCACTGGTTGGTTTACAAGGAGTGGTTCCACGAC
ATTCCATTACCTTGGCAGCTGGGGCAGACACCGGAATCCACACTGGAACAACAAGAAGCACT
GGTAGAGTTCAAGGACGCACATGCCAAAAAGGCAAACTGTCGTGGTTCTAGGGAGTCAAGAAGGAG
CAGTTCACACGGCCCTTGTCTGGAGCTCTGGAGGCTGAGATGGATGGTGCAAAGGGAAGGCTGTCC
40 TCTGGCCACTTGAAATGTGCGCTGAAAATGGATAAACTTAGATTGAAGGGCGTGTCTACTCCTTG
TGTACCGCAGCGTTACATTACCAAGATCCCGGCTGAAACACTGCACGGGACAGTCACAGTGGA
GGTACAGTACGCAGGGACAGATGGACCTTGCAAGGTTCCAGCTCAGATGGCGGTGGACATGCAAA
CTCTGACCCCACTTGGGAGGTTGATAACCCGTAACCCCGTAATCACTGAAAGCACTGAGAACTCTA
AGATGATGCTGGAACCTTGATCCACCTTTGGGGACTCTTACATTGTCATAGGAGTCGGGGGAGAAG
45 AAGATCACCCACCACTGGCACAGGAGTGGCAGCACCATTGGAAAAGCATTGTAAGCCACTGTGAG
AGGTGCCAAGAGAATGGCAGTCTTGGGAGACACAGCCTGGGACTTTGGATCAGTTGGAGGCGCTC
TCAACTCATTGGGCAAGGGCATCCATCAAATTTTTGGAGCAGCTTCAAATCATTGTTTGGAGGAA
TGTCTGGTTCTCACAATTCTCATTGGAACGTTGCTGATGTGGTTGGGTCTGAACACAAAGAATG

GATCTATTTCCCTTATGTGCTTGGCCTTAGGGGGAGTGTTGATCTTCTTATCCACAGCCGTCTCTGC
 TGATGTGGGGTGCTCGGTGGACTTCTCAAAGAAGGAGACGAGATGCGGTACAGGGGTGTTCTGTCT
 ATAACGACGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCCTGACTCCCCCGTAGATTGGCA
 GCAGCAGTCAAGCAAGCCTGGGAAGATGGTATCTGCGGGATCTCCTCTGTTTCAAGAATGGAAAA
 5 CATCATGTGGAGATCAGTAGAAGGGGAGCTCAACGCAATCCTGGAAGAGAATGGAGTTCAACTGA
 CGGTGCTTGTGGGATCTGTAAAAAACCCCATGTGGAGAGGTCCACAGAGATTGCCCGTGCCTGTG
 AACGAGCTGCCCCACGGCTGGAAGGCTTGGGGGAAATCGCACTTCGTGAGAGCAGCAAAGACAAA
 TAACAGCTTTGTCGTGGATGGTGACACACTGAAGGAATGCCCACTCAAACATAGAGCATGGAACA
 GCTTTCTTGTGGAGGATCATGGGTTCTGGGGTATTTACACTAGTGTCTGGCTCAAGGTTAGAGAAG
 10 ATTATTCATTAGAGTGTGATCCAGCCGTTATTGGAACAGCTGTAAAGGGAAAGGAGGCTGTACACA
 GTGATCTAGGCTACTGGATTGAGAGTGAGAAGAATGACACATGGAGGCTGAAGAGGGGCCATCTG
 ATCGAGATGAAAACATGTGAATGGCCAAAGTCCCACACATTGTGGACAGATGGAATAGAAGAGA
 GTGATCTGATCATACCAAGTCTTTAGCTGGGCCACTCAGCCATCACAATACCAGAGAGGGCTACA
 GGACCCAAATGAAAGGGCCATGGCACAGTGAAGAGCTTGAAATTCGGTTTGAGGAATGCCCAGGC
 15 ACTAAGGTCCACGTGGAGGAAACATGTGGAACAAGAGGACCATCTCTGAGATCAACCACTGCAAG
 CGGAAGGGTGATCGAGGAATGGTGCTGCAGGGAGTGCACAATGCCCCCACTGTCGTTCCGGGCTA
 AAGATGGCTGTTGGTATGGAATGGAGATAAGGCCCAGGAAAGAACAGAAAGCAACTTAGTAAG
 GTCAATGGTGACTGCAGGATCAACTGATCAGATGGATCACTTCTCCCTTGAGAGTGCTTGTGATTCT
 GCTCATGGTGCAGGAAGGGCTGAAGAAGAGAATGACCACAAAGATCATATAAGCACATCAATG
 20 GCAGTGCTGGTAGCTATGATCCTGGGAGGATTTTCAATGAGTGACCTGGCTAAGCTTGCAATTTTG
 ATGGGTGCCACCTTCGCGGAAATGAACACTGGAGGAGATGTAGCTCATCTGGCGCTGATAGCGGC
 ATTCAAAGTCAGACCAGCGTTGCTGGTATCTTTTCATCTTCAGAGCTAATTGGACACCCCGTGAAAG
 CATGCTGCTGGCCTTGGCCTCGTGTCTTTTGCAAACCTGCGATCTCCGCCTTGGAAGGCGACCTGAT
 GGTTCATCAATGGTTTTGCTTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCACGCACTGAT
 25 AACATCACCTTGGCAATCCTGGCTGCTCTGACACCACTGGCCCGGGGCACACTGCTTGTGGCGTGG
 AGAGCAGGCCTTGCTACTTGCGGGGGGTTTATGCTCCTCTCTCTGAAGGGAAAAGGCAGTGTGAA
 GAAGAACTTACCATTTGTCATGGCCCTGGGACTAACCGCTGTGAGGCTGGTCGACCCCATCAACGT
 GGTGGGGCTGCTGTTGCTCACAAGGAGTGGGAAGCGGAGCTGGCCCCCTAGCGAAGTACTCACAG
 CTGTTGGCCTGATATGCGCATTGGCTGGAGGGTTCGCCAAGGCAGATATAGAGATGGCTGGGCCC
 30 ATGGCCGCGGTGCTGCTAATTGTCAGTTACGTGGTCTCAGGAAAGAGTGTGGACATGTACATT
 GAAAGAGCAGGTGACATCACATGGGAAAAAGATGCGGAAGTCACTGGAAACAGTCCCCGGCTCG
 ATGTGGCGCTAGATGAGAGTGGTGATTTCTCCCTGGTGGAGGATGACGGTCCCCCATGAGAGAG
 ATCATACTCAAGGTGGTCTCTGATGACCATCTGTGGCATGAACCCAATAGCCATACCCTTTGCAGCT
 GGAGCGTGGTACGTATACGTGAAGACTGGAAAAAGGAGTGGTGCTCTATGGGATGTGCCTGCTCC
 35 CAAGGAAGTAAAAAAGGGGGAGACCACAGATGGAGTGTACAGAGTAATGACTCGTAGACTGCTA
 GGTTCACACAAGTTGGAGTGGGAGTTATGCAAGAGGGGGTCTTTACACTATGTGGCACGTGAC
 AAAAGGATCCGCGCTGAGAAGCGGTGAAGGGAGACTTGATCCATACTGGGGAGATGTCAAGCAG
 GATCTGGTGCATCTGTGGTCCATGGAGCTAGATGCCGCTGGGACGGGCACAGCGAGGTGCA
 GCTCTTGGCCGTGCCCCCGGAGAGAGAGCGAGGAACATCCAGACTCTGCCCGGAATATTTAAGA
 40 CAAAGGATGGGGACATTGGAGCGGTTGCGCTGGATTACCCAGCAGGAACCTCAGGATCTCCAATC
 CTAGACAAGTGTGGGAGAGTGATAGGACTTTATGGCAATGGGGTCTGTGATCAAAAATGGGAGTTA
 TGTTAGTGCCATCACCCAAAGGGAGGAGGGAGGAAGAGACTCCTGTTGAGTGCTTCGAGCCTTCGA
 TGCTGAAGAAGAAGCAGCTAACTGTCTTAGACTTGCATCCTGGAGCTGGGAAAAACAGGAGAGTT
 CTTCTGAAATAGTCCGTGAAGCCATAAAAAACAAGACTCCGTACTGTGATCTTAGCTCCAACCAGG
 45 GTTGTCGCTGTGAAATGGAGGAAGCCCTTAGAGGGCTTCCAGTGCGTTATATGACAACAGCAGTC
 AATGTCACCCACTCTGGAACAGAAATCGTCAGTTAATGTGCCATGCCACCTTCACTTACAGTCTA
 CTACAGCCAATCAGAGTCCCCAACTATAATCTGTATATTATGGATGAGGCCCCACTTCACAGATCCC
 TCAAGTATAGCAGCAAGAGGATACATTTCAACAAGGGTTGAGATGGGCGAGGCGGCTGCCATCTT
 CATGACCGCCACGCCACCAGGAACCCGTGACGCATTTCCGGACTCCAACCTACCAATTATGGACAC
 50 CGAAGTGGAAGTCCCAGAGAGAGCCTGGAGCTCAGGCTTTGATTGGGTGACGGATTATTCTGGAA
 AAACAGTTTGGTTTGTTCGAAGCGTGAGGAACGGCAATGAGATCGCAGCTTGTCTGACAAAGGCT
 GGAAAACGGGTCATACAGCTCAGCAGAAAGACTTTTGAGACAGAGTTCCAGAAAACAAAACATCA
 AGAGTGGGACTTTGTCTGTGACAACTGACATTTTCAGAGATGGGCGCCAACCTTTAAAGCTGACCGTGT
 CATAGATTCCAGGAGATGCCTAAAGCCGCTCATACTTGATGGCGAGAGAGTCACTTCTGGCTGGAC
 55 CCATGCCTGTACACATGCCAGCGCTGCCAGAGGAGGGGGCGCATAGGCAGGAATCCCAACAAA
 CCTGGAGATGAGTATCTGTATGGAGGTGGGTGCGCAGAGACTGACGAAGACCATGCACACTGGCT
 TGAAGCAAGAATGCTCCTTGACAATATTTACCTCCAAGATGGCCTCATAGCCTCGCTCTATCGACC

TGAGGCCGACAAAGTAGCAGCCATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAAGGAAGACC
 TTTGTGGAATCATGAAAAGAGGAGATCTTCTGTTTGGCTGGCCTATCAGGTTGCATCTGCCGGA
 ATAACCTACACAGATAGAAGATGGTGCTTTGATGGCACGACCAACAACACCATAATGGAAGACAG
 5 TGTGCCCGCAGAGGTGTGGACCAGACACGGAGAGAAAAGAGTGCTCAAACCGAGGTGGATGGAC
 GCCAGAGTTTGTTCAGATCATGCGGCCCTGAAGTCATTCAAGGAGTTTGGCGCTGGGAAAAGAGG
 AGCGGCTTTTGGAGTGATGGAAGCCCTGGGAACACTGCCAGGACACATGACAGAGAGATTCCAGG
 AAGCCATTGACAACCTCGCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAGCCGCG
 GCGGCCCAATTGCCGGAGACCCTAGAGACCATTATGCTTTTGGGGTTGCTGGGAACAGTCTCGCTG
 GGAATCTTTTTCGTCTTGATGAGGAACAAGGGCATAGGGAAGATGGGCTTTGGAATGGTGAATCTT
 10 GGGGCCAGCGCATGGCTCATGTGGCTCTCGGAAATTGAGCCAGCCAGAATTGCATGTGTCCCTATT
 GTTGTGTTCTATTGCTGGTGGTGTCTACCTGAGCCAGAAAAGCAAAGATCTCCCCAGGACAAC
 CAAATGGCAATCATCATCATGGTAGCAGTAGGTCTTCTGGGCTTGATTACCGCCAATGAACTCGGA
 TGGTTGGAGAGAAACAAAGAGTGACCTAAGCCATCTAATGGGAAGGAGAGAGGAGGGGGCAACCA
 TGGGATTCTCAATGGACATTGACCTGCGGCCAGCCTCAGCTTGGGCCATCTATGCTGCCTTGACAA
 15 CTTTCATTACCCCAGCCGTCCAACATGCAGTGACCACCTTCATACAACAACACTACTCCTTAATGGCGA
 TGGCCACGCAAGCTGGAGTGTTGTTTGGTATGGGCAAAGGGATGCCATTCTACGCATGGGACTTTG
 GAGTCCCCTGCTAATGATAGGTTGCTACTCACAATTAACGCCCTGACCCTAATAGTGGCCATCA
 TTTTGCTCGTGGCGCACTACATGTACTTGATCCAGGGCTGCAGGCAGCAGCTGCGCGTGCTGCC
 AGAAGAGAACGGCAGCTGGCATCATGAAGAACCCTGTTGTGGATGGAATAGTGGTGAATGACATT
 20 GACACAATGACAATTGACCCCCAAGTGGAGAAAAAGATGGGACAGGTGCTACTCATGGCAGTAGC
 CGTCTCCAGCGCCATACTGTGCGGACCGCCTGGGGGTGGGGGAGGCTGGGGCCCTGATCACAG
 CCGCAACTTCCACTTTGTGGGAAGGCTCTCCGAACAAGTACTGGAACCTCTACAGCCACTTCAC
 TGTGTAACATTTTATAGGGGAAGTTACTTGCTGGAGCTTCTCTAATCTACACAGTAACAAGAAACG
 CTGGCTTGGTCAAGAGACGTGGGGGTGGAACAGGAGAGACCCTGGGAGAGAAATGGAAGGCCCG
 25 CTTGAACCAGATGTGCGCCCTGGAGTTCTACTCCTACAAAAAGTCAGGCATCACCGAGGTGTGCAG
 AGAAGAGGCCCCGCGCGCCCTCAAGGACGGTGTGGCAACGGGAGGCCATGCTGTGTCCCGAGGAA
 GTGCAAAGCTGAGATGGTTGGTGGAGCGGGGATACCTGCAGCCCTATGGAAAGGTCATTGATCTT
 GGATGTGGCAGAGGGGGCTGGAGTTACTACGCCGCCACCATCCGCAAAGTTCAAGAAGTGAAAGG
 ATACACAAAAGGAGGGCCCTGGTCATGAAGAACCCTGGTGGTGGTGAAGCTATGGGTGGAACATAG
 30 TCCGTCTTAAGAGTGGGGTGGACGTCTTTCATATGGCGGCTGAGCCGTGTGACACGTTGCTGTGTG
 ACATAGGTGAGTCATCATCTAGTCCTGAAGTGGAAGAAGCACGGACGCTCAGAGTCCTCTCCATG
 GTGGGGGATTGGCTTGAAAAAAGACCAGGAGCCTTTTGTATAAAAGTGTTGTGCCATACACCAG
 CACTATGATGGAACCCCTGGAGCGACTGCAGCGTAGGTATGGGGGAGGACTGGTCAGAGTGCCAC
 TCTCCCGCAACTCTACACATGAGATGTACTGGGTCTCTGGAGCGAAAAGCAACACCATAAAAAGT
 35 GTGTCCACCACGAGCCAGCTCCTCTTGGGGCGCATGGACGGGCTAGGAGGCCAGTGAAATATGA
 GGAGGATGTGAATCTCGGCTCTGGCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATGA
 AGATCATTTGTTAACCGCATTGAAAGGATCCGCAAGTGAGCACGCGGAAACGTGGTTCTTTGACGAG
 AACCACCATATAGGACATGGGCTTACCATGGAAGCTATGAGGCCCCACACAAGGTCAGCGTC
 CTCTCTAATAAACGGGGTTGTCAGGCTCCTGTCAAAACCCTGGGATGTGGTGAATGAGTCACAGG
 40 AATAGCCATGACCGACACCACACCGTATGGTCAGCAAAGAGTTTTCAAGGAAAAAGTGACACTA
 GGGTGCCAGACCCCCAAGAAGGTACTCGTCAGGTTATGAGCATGGTCTCTTCTGTTGTGAAAAG
 AGCTAGGCAAAACACAAACGGCCACGAGTCTGTACCAAAGAAAGAGTTCATCAACAAGGTTCTGAGC
 AATGCAGCATTAGGGGCAATATTTGAAGAGGAAAAAGAGTGGAAGACTGCAGTGGAAGCTGTGA
 ACATCCAAGGTTCTGGGCTCTAGTGGACAAGGAAAAGAGAGCACCACTGAGAGGAGAGTGCCA
 45 GAGTTGTGTGTACAACATGATGGGAAAAAGAGAAAAAGAAACAAGGGGAATTTGAAAAGGCCAAG
 GGCAGCCGCGCCATCTGGTATATGTGGCTAGGGGCTAGATTCTAGAGTTTCAAGGCCCTTGATTCT
 TTGAACGAGGATCACTGGATGGGGAGAGAGAACTCAGGAGGTGGTGTGTAAGGGCTGGGATTACA
 AAGACTCGGATATGTCCTAGAAGAGATGAGTCGCATACCAGGAGGAAGGATGTATGCAGATGACA
 CTGCTGGCTGGGACACCCGCATCAGCAGGTTTGTATCTGGAGAATGAAGCTCTAATCACCACCAA
 50 ATGGAGAAAAGGACACAGGGCCTTGGCATTGGCCATAATCAAGTACACATACCAAAACAAAAGTGGT
 AAAGGTCCTTAGACCAGCTGAAAAAGGGAAAAACAGTTATGGACATTATTTTCGAGACAAGACCAAA
 GGGGGAGCGGACAAGTTGTCACTTACGCTCTTAACACATTTACCAACCTAGTGGTGCAACTCATTC
 GGAATATGGAGGCTGAGGAAGTCCTAGAGATGCAAGACTTGTGGCTGCTGCGGAGGTGAGAGAAA
 GTGACCAACTGGTTGCAAGAGCAACGGATGGGATAGGCTCAAACGAATGGCAGTCAGTGGAGATGA
 55 TTGCGTTGTGAAGCCAATTGATGATAGGTTTGCACATGCCCTCAGGTTCTTGAATGATATGGGAAA
 AGTTAGGAAGGACACACAAGAGTGGAACCCCTCAACTGGATGGGACAAGTGGGAAGAAGTTCCG
 TTTTGCTCCCACCACTTCAACAAGCTCCATCTCAAGGACGGGAGGTCCATTGTGGTTCCTGCCGC

PAT018/EP/PR3

CACCAAGATGAACTGATTGGCCGGGCCCCGCGTCTCTCCAGGGGCGGGATGGAGCATCCGGGAGAC
TGCTTGCCTAGCAAAATCATATGCGCAAATGTGGCAGCTCCTTTATTTCCACAGAAGGGACCTCCG
ACTGATGGCCAATGCCATTTGTTTCATCTGTGCCAGTTGACTGGGTTCCAAGTGGGAGAACTACCTG
5 GTCAATCCATGGAAAGGGAGAATGGATGACCACTGAAGACATGCTTGTGGTGTGGAAACAGAGTGT
GGATTGAGGAGAACGACCACATGGAAGACAAGACCCCAGTTACGAAATGGACAGACATTCCCTAT
TTGGGAAAAAAGGGAAGACTTGTGGTGTGGATCTCTCATAGGGCACAGACCCGCGCACCACCTGGGC
TGAGAACATTAAAAACACAGTCAACATGGTGCAGGATCATAGGTGATGAAGAAAAGTACATGG
ACTACCTATCCACCCAAGTTCGCTACTTGGGTGAAGAAGGGTCTACACCTGGAGTGTGTGAAGCAC
CAATCTTAATGTTGTGAGGCTGTAGTCAGCCACAGCTTGGGGAAAGCTGTGCAGCCTGTGACCC
10 CCCCAGGAGAAGCTGGGAAACCAAGCCTATAGTCAGGCCGAGAACGCCATGGCACGGAAGAAGC
CATGCTGCCTGTGAGCCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAGGCGCAGG
ATGGGAAAAGAAGGTGGCGACCTTCCCCACCTTCAATCTGGGGCCTGAACTGGAGATCAGCTGT
GGATCTCCAGAAGAGGGACTAGTGGTTAGAGGAGA

15 KU497555.1 Zika virus isolate Brazil-ZKV2015, Brazil, complete genome (SEQ ID NO: 3)

CCAATCTGTGAATCAGACTGCGACAGTTCGAGTTTGAAGCGAAAGCTAGCAACAGTATCAACAGG
TTTTATTTTGGATTTGGAAACGAGAGTTTCTGGTCATGAAAAACCCAAAAAAGAAATCCGGAGGAT
TCCGGATTGTCAATATGCTAAACGCGGAGTAGCCCGTGTGAGCCCCCTTGGGGGCTTGAAGAGG
CTGCCAGCCGACTTCTGCTGGGTTCATGGGCCCATCAGGATGGTCTTGGCGATTCTAGCCTTTTTG
20 AGATTCACGGCAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTCAGTGGGGAAAAAAGA
GGCTATGGAAATAATAAAGAAGTTCAAGAAAGATCTGGCTGCCATGCTGAGAATAATCAATGCCA
GGAAGGAGAAGAAGAGACGAGGCGCAGATACTAGTGTGCGGAATCGTTGGCCTCCTGCTGACCACA
GCTATGGCAGCGGAGGTCACTAGACGTGGGAGTGCATACTATATGTACTTGGACAGAAACGATGC
TGGGGAGGGCCATATCTTTTCCAACACATTTGGGGATGAATAAGTGTATATACAGATCATGGATCT
25 TGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTATGCTGGATGAGGGGGGTGGAACCAG
ATGACGTCGATTGTTGGTGCAACACGACGTCAACTTGGGTTGTGTACGGAACCTGCCATCAGAAAA
AAGGTGAAGCACGGAGATCTAGAAGAGCTGTGACGCTCCCTCCCTTCCACTAGGAAGCTGCAA
ACGCGGTCGCAACCTGGTTGGAATCAAGAGAATACACAAAGCACTTGATTAGAGTCGAAAATTG
GATATTCAGGAACCTGGCTTCGCGTTAGCAGCAGCTGCCATCGCTTGGCTTTTGGGAAGCTCAAC
30 GAGCCAAAAAGTCATATACTTGGTCATGATACTGCTGATTGCCCCGGCATAACAGCATCAGGTGCAT
AGGAGTCAGCAATAGGGACTTTGTGGAAGGTATGTCAGGTGGGACTTGGGTTGATGTTGTCTTGA
ACATGGGGGTTGTGTCACCGTAATGGCAGCAGGACAAACCGACTGTGACATAGAGCTGGTTACAA
CAACAGTCAGCAACATGGCGGAGGTAAGATCCTACTGCTATGAGGCATCAATATCAGACATGGCT
TCGGACAGCCGCTGCCCAACACAAGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAATATGT
35 CTGCAAAAGAACGTTAGTGGACAGAGGCTGGGGAAATGGATGTGGACTTTTTGGCAAAGGGAGCC
TGGTGACATGCGCTAAGTTTGCATGCTCCAAGAAAATGACCGGGAAGAGCATCCAGCCAGAGAAT
CTGGAGTACCGGATAATGCTGTCAAGTTTATGGCTCCAGCACAGTGGGATGATCGTTAATGACACA
GGACATGAACTGATGAGAATAGAGCGAAGGTTGAGATAACGCCCAATTCACCAAGAGCCGAAG
CCACCTGGGGGGTTTGGAAAGCTTAGGACTTGATTGTGAACCGAGGACAGGCCTTGACTTTTCAG
40 ATTTGTATTACTTGACTATGAATAACAAGCACTGGTTGGTTCACAAGGAGTGGTTCACGACATTC
CATTACCTTGGCAGCTGGGGCAGACACCGGAACCTCCACACTGGAACAACAAGAAGCACTGGTA
GAGTTCAAGGACGCACATGCCAAAAAGGCAAACTGTCGTGGTTCTAGGGACTCAAGAAGGAGCAGT
TCACACGGCCCTTGTGAGGCTCTGGAGGCTGAGATGGATGGTGCAAAGGGAAGGCTGTCTCTG
GCCACTTGAAATGTGCGCTGAAAATGGATAAACTTAGATTGAAGGGCGTGTCTACTCCTTGTGTA
45 CCGCAGCGTTACATTACCAAGATCCCGGCTGAAACACTGCACGGGACAGTCACAGTGGAGGTA
CAGTACGCAGGGACAGATGGACCTTGCAAGGTTCCAGCTCAGATGGCGGTGGACATGCAAACTCT
GACCCCAAGTTGGGAGGTTGATAACCGCTAACCCCGTAATCACTGAAAGCACTGAGAACTCTAAGA
TGATGCTGGAACCTTGATCCACCATTTGGGGACTCTTACATTGTCATAGGAGTCGGGGAGAAGAAG
ATCACCCACCACTGGCACAGGAGTGGCAGCACTTGGGAAAAGCAATTTGAAGCCACTGTGAGAGG
50 TGCCAAAGAGAATGGCAGTCTTGGGAGACACAGCCTGGGACTTTGGATCAGTTGGAGGCGCTCTCA
ACTCATTGGGCAAGGGCATCCATCAAATTTTTGGAGCAGCTTTCAAATCATTGTTTGGAGGAATGT
CCTGGTTCTCAGAAATCTCATTGGAACGTTGCTGATGTGGTTGGGTCTGAACACAAAGAATGGAT
CTATTTCCCTTATGTGCTTGGCCTTAGGGGGAGTGTGTGATCTTCTATCCACAGCCGTCTCTGCTGA
TGTGGGGTGTCTCGGTGGACTTCTCAAGAAGGAGACGAGATGTGGTACAGGGGTGTTCTGTCTATA
55 ACGACGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCCTGACTCTCCCGTAGATTGGCAGCA

GCAGTCAAGCAAGCCTGGGAAGATGGTATCTGCGGGATCTCCTCTGTTTCAAGAATGGAAAACAT
 CATGTGGAGATCAGTAGAAGGGGAGCTTAACGCAATCCTGGAAGAGAATGGAGTTCAACTGACGG
 TCGTTGTGGGATCTGTAAAAAACCCCATGTGGAGAGGTCCACAGAGATTGCCCCTGCCTGTGAAC
 5 GAGCTGCCCCACGGCTGGAAGGCTTGGGGGAAATCGTACTTCGTCAGAGCAGCAAAGACAAATAA
 CAGCTTTGTCGTGGATGGTGACACACTGAAGGAATGCCCACTCAAACATAGAGCATGGAACAGCT
 TTCTTGTGGAGGATCATGGGTTCGGGGTATTTACACTAGTGTCTGGCTCAAGGTTAGAGAAGATT
 ATTCATTAGAGTGTGATCCAGCCGTTATTGGAACAGCTGTTAAGGGAAAGGAGGCTGTACACAGT
 GATCTAGGCTACTGGATTGAGAGTGAGAAGAATGACACATGGAGGCTGAAGAGGGCCCATCTGAT
 10 CGAGATGAAAACATGTGAATGGCCAAAGTCCCACACATTGTGGACAGATGGAATAGAAGAGAGT
 GATCTGATCATACCCAAGTCTTTAGCTGGGCCACTCAGCCATCACAATACCAGAGAGGGCTACAG
 GACCCAAATGAAAAGGGCCATGGCACAGTGAAGAGCTTGAAATTCGGTTTGAGGAATGCCCAGGCA
 CTAAGGTCCACGTGGAGGAAACATGTGGAACAAGAGGACCATCTCTGAGATCAACCACTGCAAGC
 GGAAGGGTATCGAGGAATGGTGCTGCAGGGAGTGCACAATGCCCCCACTGTCGTTCCGGGCTAA
 AGATGGCTGTTGGTATGGAATGGAGATAAGGCCCAGGAAAGAACCAGAAAGCAACTTAGTAAGG
 15 TCAATGGTGACTGCAGGATCAACTGATCACATGGATCACTTCTCCCTTGAGTGCTTGTGATTCTG
 CTCATGGTGCAGGAAGGGCTGAAGAAGAGAATGACCACAAAGATCATCATAAGCACATCAATGGC
 AGTGCTGGTAGCTATGATCCTGGGAGGATTTTCAATGAGTGACCTGGCTAAGCTTGCAATTTTGAT
 GGGTGCCACCTTCGCGGAAATGAACACTGGAGGAGATGTAGCTCATCTGGCGCTGATAGCGGCAT
 TCAAAGTCAGACCAGCGTTGCTGGTATCTTTCATCTTCAGAGCTAATTGGACACCCCGTGAAAGCA
 20 TGCTGCTGGCCTTGGCCTCGTGTTTTTIGCAAATGCGATCTCCGCCCTTGAAGGCGACCTGATGGT
 TCTCATCAATGGTTTTGCTTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCACGCACTGACAA
 CATCACCTTGCCAATCTGGCTGCTCTGACACCACTGGCCCCGGGGCACACTGCTTGTGGCGTGGAG
 AGCAGGCCTTGCTACTTGCGGGGGGTTTATGCTCCTCTCTCTGAAGGGAAAAGGCAGTGTGAAGA
 AGAACTTACCATTTGTCATGGCCCTGGGACTAACCCTGTGAGGCTGGTCGACCCCATCAACGTGG
 25 TGGGACTGCTGTTGCTCACAAGGAGTGGGAAGCGGAGCTGGCCCCCTAGCGAAGTACTCACAGCT
 GTTGGCCTGATATGCGCATTGGCTGGAGGGTTCGCCAAGGCAGATATAGAGATGGCTGGGCCCCAT
 GGCCGCGGTCTGGTCTGCTAATTGTCAAGTACGTGGTCTCAGGAAAGAGTGTGGACATGTACATTGA
 AAGAGCAGGTGACATCACATGGGAAAAAGATGCGGAAGTCACTGGAAACAGTCCCCGGCTCGAT
 GTGGCGCTAGATGAGAGTGGTGACTTCTCCCTGGTGGAGGATGACGGTCCCCCATGAGAGAGAT
 30 CATACTCAAGGTGGTCTGATGACCATCTGTGGCATGAACCCAATAGCCATACCTTTGCAAGTGG
 AGCGTGGTACGTATACGTGAAGACTGGAAAAAGGAGTGGTGCTCTATGGGATGTGCCTGCTCCCA
 AGGAAGTAAAAAAGGGGGAGACCACAGATGGAGTGTAACAGAGTAATGACTCGTAGACTGCTAGG
 TTCAACACAAGTTGGAGTGGGAGTTATGCAAGAGGGGGTCTTTCACACTATGTGGCACGTCACAA
 AAGGATCCGCGCTGAGAAGCGGTGAAGGGAGACTTGATCCATACTGGGGAGATGTCAAGCAGGAT
 35 CTGGTGTCTACTGTGGTCCATGGAAGCTAGATGCCGCCTGGGACGGGCACAGCGAGGTGCAGCT
 CTTGGCCGTGCCCCCGGAGAGAGCGAGGAACATCCAGACTCTGCCCGGAATATTTAAGACAA
 AGGATGGGGACATTGGAGCGGTTGCGTGGATATCCAGCAGGAACCTTCAGGATCTCCAATCTCTA
 GACAAGTGTGGGAGAGTGATAGGACTTTATGGCAATGGGGTCTGTGATAAAAAAGGAGTTATGT
 TAGTGCCATCACCCAAGGGAGGAGGGAGGAAGAGACTCCTGTTGAGTGCTTCGAGCCTTCGATGC
 40 TGAAGAAGAAGCAGCTAACTGTCTTAGACTTGATCCTGGAGCTGGGAAAACCAGGAGAGTTCTT
 CCTGAAATAGTCCGTGAAGCCATAAAAAACAAGACTCCGTACTGTGATCTTAGCTCCAACCAGGGTT
 GTCGCTGCTGAAATGGAGGAAGCCCTTAGAGGGCTTCCAGTGCGTTATATGACAAACAGCAGTCAA
 TGTCACCCACTCTGGAACAGAAATCGTCGACTTAATGTGCCATGCCACCTTCACTTCACGTCTACT
 ACAGCCAATCAGAGTCCCCAACTATAATCTGTATATTATGGATGAGGCCCCACTTCACAGATCCCTC
 45 AAGCATAGCAGCAAGAGGATACATTTCAACAAGGTTGAGATGGGCGAGGCGGCTGCCATCTTCA
 TGACCGCCACGCCACCAGGAACCCGTGACGCATTTCCGGACTCCAACCTACCAATTATGGACACCG
 AAGTGGAAGTCCCAGAGAGAGCCTGGAGCTCAGGCTTTGATTGGGTGACGGATCATTCTGGAAAA
 ACAGTTTGGTTTGTTCGAAGCGTGAGGAACGGCAATGAGATCGCAGCTTGTCTGACAAAGGCTGG
 AAAACGGGTCATACAGCTCAGCAGAAAGACTTTTGAGACAGAGTTCCAGAAAACAAAACATCAAG
 50 AGTGGGACTTTGTCTGTGACAACTGACATTTTCAGAGATGGGCGCCAACCTTTAAAGCTGACCGTGTCA
 TAGATTCCAGGAGATGCCTAAAGCCGTCATACTTGATGGCGAGAGAGTCATTCTGGCTGGACCC
 ATGCCTGTCACACATGCCAGCGCTGCCAGAGGAGGGGGCGCATAGGCAGGAATCCCAACAAACC
 TGGAGATGAGTACCTGTATGGAGGTGGGTGCGCAGAGACTGACGAAGACCATGCACACTGGCTTG
 AAGCAAAGAATGCTCCTTGACAAATATTACCTCCAAGATGGCCTCATAGCCTCGCTATCGACCTG
 55 AGGCCGACAAAAGTAGCAGCCATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAAGGAAGACCTT
 TGTGGAACATCATGAAAAGAGGAGATCTTCTGTTTGGCTGGCCTATCAGGTTGCATCTGCCGGAAT
 AACCTACACAGATAGAAGATGGTGCTTTGATGGCACGACCAACAACACCATAATGGAAGACAGTG

TGCCGGCAGAGGTGTGGACCAGACACGGAGAGAAAAGAGTGCTCAAACCGAGGTGGATGGACGC
 CAGAGTTTGTTCAGATCATGCGGCCCTGAAGTCATTCAAGGAGTTTGCCGCTGGGAAAAGAGGAG
 CGGCTTTTGGAGTGATGGAAGCCCTGGGAACACTGCCAGGACACATGACAGAGAGATTCCAGGAA
 5 GCCATTGACAACCTCGCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAAGCCGCGGC
 GGCCCAATTGCCGGAGACCCTAGAGACCATTATGCTTTTGGGGTTGCTGGGAACAGTCTCGCTGGG
 AATCTTTTTCGTCTTGATGAGGAACAAGGGCATAGGGAAGATGGGCTTTGGAATGGTGACTCTTG
 GGCCAGCGCATGGCTCATGTGGCTCTCGGAAATTGAGCCAGCCAGAATTGCATGTGTCTCATTGT
 TGTGTTCTATTGCTGGTGGTGTCTACCTGAGCCAGAAAAGCAAAGATCTCCCCAGGACAACCA
 AATGGCAATCATCATCATGGTAGCAGTAGGTCTTCTGGGCTTGATTACCGCCAATGAACTCGGATG
 10 GTTGGAGAGAACAAAGAGTGACCTAAGCCATCTAATGGGAAGGAGAGAGAGGGGGCAACCATA
 GGATTCTCAATGGACATTGACCTGCGGCCAGCCTCAGCTTGGGCCATCTATGCTGCCTTGACAAC
 TTCATTACCCAGCCGTCCAACATGCAGTGACCACTTCATACAACTACTCCTTAATGGCGATG
 GCCACGCAAGCTGGAGTGTTGTTGGTATGGGCAAAGGGATGCCATTCTACGCATGGGACTTTGGA
 GTCCCGCTGCTAATGATAGGTTGCTACTCACAATTAACACCCCTGACCCTAATAGTGGCCATCATT
 15 TTGCTCGTGGCGCACTACATGTACTTGATCCAGGGCTGCAGGCAGCAGCTGCGCGTGTGCCAG
 AAGAGAACGGCAGCTGGCATCATGAAGAACCCTGTTGTGGATGGAATAGTGGTGAAGTGAACATTGA
 CACAATGACAATTGACCCCAAGTGGAGAAAAAGATGGGACAGGTGCTACTCATAGCAGTAGCCG
 TCTCCAGCGCCATACTGTGCGGGACCGCCTGGGGGTGGGGGGAGGCTGGGGCCCTGATCACAGCC
 GCAACTTCCACTTTGTGGGAAGGCTCTCCGAACAAGTACTGGAACCTCCTTACAGCCACTTCACTG
 20 TGTAACATTTTATAGGGGAAGTTACTTGGCTGGAGCTTCTCTAATCTACACAGTAACAAGAAACGCT
 GGCTTGGTCAAGAGACGTGGGGGTGGAACAGGAGAGACCCTGGGAGAGAAATGGAAGGCCCGCT
 TGAACCAAGATGTCGGCCCTGGAGTTCTACTCCTACAAAAAGTCAGGCATCACCGAGGTGTGCAGA
 GAAGAGGCCCGCCGCGCCCTCAAGGACGGTGTGGCAACGGGAGGCCATGCTGTGTCCCAGGAAAG
 TGCAAAGCTGAGATGGTTGGTGGAGCGGGGATACCTGCAGCCCTATGGAAGGTCATTGATCTTG
 25 GATGTGGCAGAGGGGGCTGGAGTTACTACGCCGCCACCATCCGCAAAGTCAAGAAGTGAAGGA
 TACACAAAAGGAGGCCCTGGTCATGAAGAACCCTGTTGGTGCAAAGCTATGGGTGGAACATAGT
 CCGTCTTAAGAGTGGGGTGGACGTCTTTCATATGGCGGCTGAGCCGTGTGACACGTTGCTGTGTGA
 CATAGGTGAGTCATCATCTAGTCCTGAAGTGGAAGAAGCACGGACGCTCAGAGTCCTCTCCATGGT
 GGGGGATTGGCTTGA AAAAAGACCAGGAGCCTTTTGCATAAAAGTGTGTGCCCATACACCAGCA
 30 CTATGATGGAACCCCTGGAGCGACTGCAGCGTAGGTATGGGGGAGGACTGGTCAGAGTGCCACTC
 TCCCGCAACTCTACACATGAGATGTACTGGGTCTCTGGAGCGAAAAGCAACACCATAAAAAGTGT
 GTCCACCACGAGCCAGCTCCTCTTGGGGCGCATGGACGGGCCTAGGAGGCCAGTGAAATATGAGG
 AGGATGTGAATCTCGGCTCTGGCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATGAAG
 ATCATTGGTAACCGCATTGAAAGGATCCGCAGTGAGCACGCGGAAACGTGGTCTTTGACGAAAA
 35 CCACCCATATAGGACATGGGCTTACCATGGAAGCTATGTGGCCCCACACAAGGGTCAGCGTCCTC
 TCTAATAAACGGGGTTGTGACGGCTCCTGTCAAAACCCCTGGGATGTGGTGAAGTGGAGTCAAGGAA
 TAGCCATGACCGACACACACCCGTATGGTCAGCAAAAGAGTTTCAAGGAAAAAGTGGACACTAGG
 GTGCCAGACCCCAAGAAAGGCACCTCGTAGTTATGAGCATGGTCTCTTCTGTGTGGAAGAG
 CTAGGCAACACAAAACGACCACGAGTCTGTACCAAGAAGAGTTTCATCAACAAGGTTTCGTAGCAA
 40 TGCAGCATTAGGGGCAATATTTGAAGAGGAAAAAGAGTGGAAGACTGCAGTGGAAGCTGTGAAC
 GATCCAAGGTTCTGGGCTCTAGTGGACAAGGAAAGAGAGCACACCTGAGAGGAGAGTGCCAGA
 GTTGTGTGTACAACATGATGGGAAAAAGAGAAAAAGAAACAAGGGGAATTTGGAAGGCCAAGGG
 CAGCCGCGCCATCTGGTATATGTGGCTAGGGGCTAGATTTCTAGAGTTCGAAGCCCTTGGATTCTT
 GAACGAGGATCACTGGATGGGGAGAGAGAACTCAGGAGGTGGTGTGAAGGGCTGGGATTACAA
 45 AGACTCGGATATGTCTAGAAGAGATGAGTCGCATACCAGGAGGAAGGATGTATGCAGATGACAC
 TGCTGGCTGGGACACCCGCATCAGCAGGTTTGATCTGGAGAATGAAGCTCTAATCAACCAACCAAA
 TGGAGAAAGGGCACAGGGCCTTGGCATTGGCCATAATCAAGTACACATACCAAAAACAAAGTGGA
 AAGGTCCTTAGACCAGCTGAAAAAGGGAAAAACAGTTATGGACATTATTTGAGACAAGACCAAG
 GGGGAGCGGACAAGTTGTCACTTACGCTCTTAACACATTTACCAACCTAGTGGTGCAACTCATTCTG
 50 GAATATGGAGGCTGAGGAAGTTCTAGAGATGCAAGACTTGTGGCTGCTGCGGAGGTCAGAGAAAA
 TGACCAACTGGTTGCAGAGCAACGGATGGGATAGGCTCAAACGAATGGCAGTCAGTGGAGATGAT
 TGC GTTGTGAAGCCAATTGATGATAGGTTTGCACATGCCCTCAGGTTCTTGAATGATATGGGAAA
 GTTAGGAAGGACACACAAGAGTGGAACCCCTCAACTGGATGGGACAACCTGGGAAGAAGTTCCGTT
 TTGCTCCCAACCTTCAACAAGCTCATCTCAAGGACGGGAGGTCCATTGTGGTTCCTGCCGCCA
 55 CCAAGATGAACTGATTGGCCGGGGCCGCGTCTCTCCAGGGGCGGGATGGAGCATCCGGGAGACTG
 CTTGCTAGCAAAATCATATGCGCAAATGTGGCAGCTCCTTTATTTCCACAGAAGGGACCTCCGAC
 TGATGGCCAATGCCATTTGTTTCATCTGTGCCAGTTGACTGGGTTCCAACTGGGAGAACTACCTGGT

PAT018/EP/PR3

CAATCCATGGAAAGGGAGAATGGATGACCACTGAAGACATGCTTGTGGTGTGGAACAGAGTGTGG
ATTGAGGAGAACGACCACATGGAAGACAAGACCCCAGTTACGAAATGGACAGACATTCCCTATTT
GGGAAAAAGGGAAGACTTGTGGTGTGGATCTCTCATAGGGCACAGACCGCGCACCACCTGGGCTG
5 AGAACATTAAAAATACAGTCAACATGGTGCAGGATCATAGGTGATGAAGAAAAGTACATGGAC
TACCTATCCACCCAAGTTCGCTACTTGGGTGAAGAAGGGTCTACACCTGGAGTGTGTGAGCACC
ATCTTAATGTTGTCAGGCCCTGTAGTCAGCCACAGCTTGGGGAAAAGCTGTGCAGCCTGTGACCCCT
CCAGGAGAAGCTGGGTAAACCAAGCCTATAGTCAGGCCGAGAACGCCATGGCACGGAAGAAGCCA
TGCTGCCTGTGAGCCCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAGGCGCAGGAT
GGGAAAAGAAGGTGGCGACCTTCCCCACCTTCAATCTGGGGCCTGAACTGGAGATCAGCTGTGG
10 ATCTCCAGAAGAGGGACTAGTGGTTAGAGGAGACCCCCGGAACGCAAAACAGCATATTGACG
CTGGGAAAGACCAGAGACTCCATGAGTTTCCACCACGCTGGCCGCCAGGCACAGATCGCCGAATA
GCGGCGGCCGGTGTGGGGAATCCA

KU501215.1 Zika virus strain PRVABC59, Puerto Rico, complete genome (SEQ ID NO: 4)

15 GTTGTGATCTGTGTGAATCAGACTGCGACAGTTCGAGTTTGAAGCGAAAGCTAGCAACAGTATCA
ACAGGTTTTATTTGGATTTGGAAACGAGAGTTTCTGGTCATGAAAAACCCAAAAAAGAAATCCG
GAGGATCCGATTGTCAATATGCTAAAACGCGGAGTAGCCCGTGTGAGCCCCCTTTGGGGCTTGA
AGAGGCTGCCAGCCGACTTCTGCTGGGTCTATGGGCCATCAGGATGGTCTTGGCGATTCTAGCCT
TTTTGAGATTCACGGCAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTCAGTGGGAAAA
20 AAGAGGCTATGGAACAATAAAGAAGTCAAGAAAGATCTGGCTGCCATGCTGAGAATAATCAAT
GCTAGGAAGGAGAAGAAGAGACGAGGCGCAGATACTAGTGTGCGAATTGTTGGCCTCCTGCTGAC
CACAGCTATGGCAGCGGAGGTCACTAGACGTGGGAGTGCATACTATATGTAATTGGACAGAAACG
ATGCTGGGGAGGCCATATCTTTTCCAACCACATTGGGGATGAATAAGTGTATATACAGATCATGG
ATCTTGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTATGCTGGATGAGGGGGTGGAA
25 CCAGATGACGTCGATTGTTGGTGCAACACGACGTCAACTTGGGTTGTGTACGGAACCTGCCATCAC
AAAAAAGGTGAAGCACGGAGATCTAGAAGAGCTGTGACGCTCCCCCTCCATTCCACCAGGAAGCT
GCAAACGCGGTCGCAAACCTGGTTGGAATCAAGAGAATACACAAAGCACTTGATTAGAGTCGAAA
ATTGGATATTCAGGAACCTGGCTTCGCGTTAGCAGCAGCTGCCATCGCTTGGCTTTTGGGAAGCT
CAACGAGCCAAAAAGTCATATACTTGGTCATGATACTGCTGATTGCCCGGCATACAGCATCAGGT
30 GCATAGGAGTCAGCAATAGGGACTTTGTGGAAGGTATGTGAGGTGGGACTTGGGTTGATGTTGTCT
TGGAACATGGAGGTTGTGTCAACGTAATGGCACAGGACAAACCGACTGTGACATAGAGCTGGTT
ACAACAACAGTCAGCAACATGGCGGAGGTAAGATCTTACTGCTATGAGGCATCAATATCAGACAT
GGCTTCTGACAGCCGCTGCCCCAACACAAGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAAT
ATGTCTGCAAAAGAACGTTAGTGGACAGAGGCTGGGGAAATGGATGTGGACTTTTGGCAAAGGG
35 AGCCTGGTGACATGCGCTAAGTTTGCATGCTCCAAGAAAATGACCGGGAAGAGCATCCAGCCAGA
GAATCTGGAGTACCGGATAATGCTGTCAGTTCATGGCTCCAGCACAGTGGGATGATCGTTAATGA
CACAGGACATGAAACTGATGAGAATAGAGCGAAAGTTGAGATAACGCCCAATTCACCGAGAGCC
GAAGCCACCCTGGGGGGTTTGGAAAGCCTAGGACTTGATTGTGAACCGAGGACAGGCCTTGACTTT
TCAGATTTGTATTACTTGACTATGAATAACAAGCACTGGTTGGTTTACAAGGAGTGGTTCCACGAC
40 ATTCCATTACCTTGGCAGCTGGGGCAGACACCGGAACTCCACACTGGAACAACAAGAAGCACT
GGTAGAGTTCAAGGACGCACATGCCAAAAGGCAAACTGTCGTGGTTCTAGGGAGTCAAGAAGGAG
CAGTTCACACGGCCCTTGTGAGGCTCTGGAGGCTGAGATGGATGGTGCAAAAGGGAAGGCTGTCC
TCTGGCCACTTGAAATGTGCGCTGAAAATGGATAAACTTAGATTGAAGGGCGTGTACTACTCTTG
TGTAATGACGCGTTACATTACCAAGATCCCGGCTGAAACACTGCACGGGACAGTCACAGTGGGA
45 GGTACAGTACGAGGGACAGATGGACCTTGCAAGGTTCCAGCTCAGATGGCGGTGGACATGCAAA
CTCTGACCCCAAGTTGGGAGGTTGATAAACCCTAACCCTGTAATCACTGAAAGCACTGAGAACTCTA
AGATGATGCTGGAACCTTGATCCACCATTTGGGGACTCTTACATTGTCATAGGAGTCGGGGAGAAG
AAGATCACCCACCACTGGCACAGGAGTGGCAGCACCATTGGAAAAGCATTGGAAGCCACTGTGAG
AGGTGCCAAGAGAATGGCAGTCTTGGGAGACACAGCCTGGGACTTTGGATCAGTTGGAGGCGCTC
50 TCAACTCATTGGGCAAGGGCATCCATCAAAATTTTGGAGCAGCTTTCAAAATCATTGTTTGGAGGAA
TGTCCTGGTTCTCACAAATTCTCATTGGAACGTTGCTGATGTGGTTGGGTCTGAACACAAAGAATG
GATCTATTTCCCTTATGTGCTTGGCCTTAGGGGGAGTGTGATCTTCTTATCCACAGCCGTCTCTGC
TGATGTGGGGTGTCTCGGTGGACTTCTCAAAGAAGGAGACGAGATGCGGTACAGGGGTGTTCTGTCT
ATAACGACGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCCTGACTCCCCCGTAGATTGGCA
55 GCAGCAGTCAAGCAAGCCTGGGAAGATGGTATCTGCGGGATCTCCTCTGTTTCAAGAATGGAAAA

CATCATGTGGAGATCAGTAGAAGGGGAGCTCAACGCAATCCTGGAAGAGAATGGAGTTCAACTGA
 CGGTCTGTTGTGGGATCTGTAAAAAACCCCATGTGGAGAGGTCCACAGAGATTGCCCGTGCCTGTG
 AACGAGCTGCCCCACGGCTGGAAGGCTTGGGGGAAATCGTATTTTCGTGAGAGCAGCAAAGACAAA
 5 TAACAGCTTTGTCTGGATGGTGACACACTGAAGGAATGCCCACTCAAACATAGAGCATGGAACA
 GCTTTCTTGTGGAGGATCATGGGTTTCGGGGTATTTACACTAGTGTCTGGCTCAAGGTTAGAGAAG
 ATTATTCATTAGAGTGTGATCCAGCCGTATTGGAACAGCTGTTAAGGGAAAGGAGGCTGTACACA
 GTGATCTAGGCTACTGGATTGAGAGTGAGAAGAATGACACATGGAGGCTGAAGAGGGCCCATCTG
 ATCGAGATGAAAACATGTGAATGGCCAAAGTCCCACACATTGTGGACAGATGGAATAGAAGAGA
 GTGATCTGATCATACCCAAGTCTTTAGCTGGGCCACTCAGCCATCACAATACCAGAGAGGGGCTACA
 10 GGACCCAAATGAAAGGGCCATGGCACAGTGAAGAGCTTGAAATTCGTTTGAGGAATGCCCAGGC
 ACTAAGGTCCACGTGGAGGAAACATGTGGAACAAGAGGACCATCTCTGAGATCAACCACTGCAAG
 CGGAAGGGTGATCGAGGAATGGTGCTGCAGGGAGTGCACAATGCCCCCACTGTCTGTTCCGGGCTA
 AAGATGGCTGTTGGTATGGAATGGAGATAAGGCCCAGGAAAGAACAGAAAGCAACTTAGTAAG
 GTCAATGGTGACTGCAGGATCAACTGATCAGATGGACCACTTCTCCCTGGAGTGCTTGTGATCCT
 15 GCTCATGGTGCAGGAAGGGCTGAAGAAGAGAATGACCACAAAGATCATATAAGCACATCAATG
 GCAGTGCTGGTAGCTATGATCCTGGGAGGATTTTCAATGAGTGACCTGGCTAAGCTTGCAATTTTG
 ATGGGTGCCACCTTCGCGGAAATGAACACTGGAGGAGATGTAGCTCATCTGGCGCTGATAGCGGC
 ATCAAAGTCAGACCAGCGTTGCTGGTATCTTTCATCTTCAGAGCTAATTGGACACCCCGTGAAAG
 CATGCTGCTGGCCTTGGCCTCGTGTCTTTTGCAAACTGCGATCTCCGCCTTGGAAGGCGACCTGAT
 20 GGTTCATCAATGGTTTTGCTTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCACGCACTGAT
 AACATCACCTTGGCAATCCTGGCTGCTCTGACACCCTGGCCCGGGGCACACTGCTTGTGGCGTGG
 AGAGCAGGCCTTGCTACTTGCGGGGGGTTTATGCTCCTCTCTGAAGGGAAAAGGCAGTGTGAA
 GAAGAACTTACCATTTGTCATGGCCCTGGGACTAACCGCTGTGAGGCTGGTCGACCCCATCAACGT
 GGTGGGACTGCTGTTGCTCACAAGGAGTGGGAAGCGGAGCTGGCCCCCTAGCGAAGTACTCACAG
 25 CTGTTGGCCTGATATGCGCATTGGCTGGAGGGTTCGCCAAGGCAGATATAGAGATGGCTGGGCCC
 ATGGCCGCGGTGCGTCTGCTAATTGTCAGTTACGTGGTCTCAGGAAAGAGTGTGGACATGTACATT
 GAAAGAGCAGGTGACATCACATGGGAAAAAGATGCGGAAGTCACTGGAAACAGTCCCCGGCTCG
 ATGTGGCGCTAGATGAGAGTGGTGATTTCTCCCTGGTGGAGGATGACGGTCCCCCATGAGAGAG
 ATCATACTCAAGGTGGTCTGATGACCATCTGTGGCATGAACCAATAGCCATACCCCTTTGCAGCT
 30 GGAGCGTGGTACGTATACGTGAAGACTGGAAGAGGAGTGGTGCTCTATGGGATGTGCCTGCTCC
 CAAGGAAGTAAAAAAGGGGGAGACCACAGATGGAGTGTACAGAGTAATGACTCGTAGACTGCTA
 GGTTCACACAAGTTGGAGTGGGAGTTATGCAAGAGGGGGTCTTTCACACTATGTGGCACGTCAC
 AAAAGGATCCGCGCTGAGAAGCGGTGAAGGGAGACTTGATCCATACTGGGGAGATGTCAAGCAG
 GATCTGGTGTCACTGTGGTCCATGGAAGCTAGATGCCGCTGGGATGGGCACAGCGAGGTGCA
 35 GCTCTTGGCCGTGCCCCCGGAGAGAGAGCGAGGAACATCCAGACTCTGCCCGGAATATTTAAGA
 CAAAGGATGGGGACATTGGAGCGGTGCGCTGGATTACCCAGCAGGAACCTCAGGATCTCCAATC
 CTAGACAAGTGTGGGAGAGTGATAGGACTTTATGGCAATGGGGTCTGTGATCAAAAACGGGAGTTA
 TGTAGAGTGCATACCCCAAGGGAGGAGGAGGAAGAGACTCCTGTTGAGTGTCTCGAGCCCTGA
 TGCTGAAGAAGAAGCAGCTAACTGTCTTAGACTTGCATCCTGGAGCTGGGAAAACAGGAGAGTT
 40 CTTCTGAAATAGTCCGTGAAGCCATAAAAACAAGACTCCGTACTGTGATCTTAGCTCCAACCAGG
 GTTGTGCTGCTGATAATGGAGGAGGCCCTTAGAGGGCTTCCAGTGCCTTATATGACAACAGCAGTC
 AATGTCACCCACTCTGGAACAGAAATCGTCGACTTAATGTGCCATGCCACCTTCACTTCACGTCTA
 CTACAGCCAATCAGAGTCCCCAACTATAATCTGTATATTATGGATGAGGCCCACTTCACAGATCCC
 TCAAGTATAGCAGCAAGAGGATACATTTCAACAAGGGTTGAGATGGGCGAGGCGGCTGCCATCTT
 45 CATGACCGCCACGCCACCAGGAACCCGTGAGCCTTTCCGGACTCCAACCTACCAATTATGGACAC
 CGAAGTGGAAGTCCCAAGAGAGAGCCTGGAGCTCAGGCTTTGATTGGGTGACGGATCATTCTGGAA
 AAACAGTTTGGTTTGTTCGAAGCGTGAGGAACGGCAATGAGATCGCAGCTTGTCTGACAAAGGCT
 GGAAAACGGGTCATACAGCTCAGCAGAAAGACTTTTGGAGACAGAGTTCCAGAAAACAAAACATCA
 AGAGTGGGACTTTGTCTGACAACTGACATTTTCAGAGATGGGCGCCAACCTTTAAAGCTGACCGTGT
 50 CATAGATTCCAGGAGATGCCTAAAGCCGGTCATACTTGATGGCGAGAGAGTCATTCTGGCTGGAC
 CCATGCCCTGTCACACATGCCAGCGCTGCCAGAGGAGGGGGCGCATAGGCAGGAATCCCAACAAA
 CCTGGAGATGAGTATCTGTATGGAGGTGGGTGCGCAGAGACTGACGAAGACCATGCACACTGGCT
 TGAAGCAAGAATGCTCCTTGACAATATTTACCTCCAAGATGGCCTCATAGCCTCGCTCTATCGACC
 TGAGGCCGACAAAAGTAGCAGCCATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAAAGGAAGACC
 55 TTTGTGGAACCTCATGAAAAGAGGAGATCTTCTGTTTGGCTGGCCTATCAGGTTGCATCTGCCGGA
 ATAACCTACACAGATAGAAGATGGTGCTTTGATGGCACGACCAACAACACCATAATGGAAGACAG
 TGTGCCCGCAGAGGTGTGGACCAGACACGGAGAGAAAAGAGTGCTCAAACCGAGGTGGATGGAC

GCCAGAGTTTGTTCAGATCATGCGGCCCTGAAGTCATTCAAGGAGTTTGCCGCTGGGAAAAAGAGG
 AGCGGCTTTTGGAGTGATGGAAGCCCTGGGAACACTGCCAGGACACATGACAGAGAGATTCCAGG
 AAGCCATTGACAACCTCGTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAGCCGCG
 GCGGCCCAATTGCCGGAGACCCTAGAGACCATAATGCTTTTGGGGTTGCTGGGAACAGTCTCGCTG
 5 GGAATCTTCTTCGTCTTGATGAGGAACAAGGGCATAGGGAAGATGGGCTTTGGAATGGTGACTCTT
 GGGGCCAGCGCATGGCTCATGTGGCTCTCGGAAATTGAGCCAGCCAGAATTGCATGTGCTCCTCATT
 GTTGTGTTCTATTGCTGGTGGTGTCTACCTGAGCCAGAAAAGCAAAGATCTCCCCAGGACAAC
 CAAATGGCAATCATCATCATGGTAGCAGTAGGTCTTCTGGGCTTGATTACCGCCAATGAACTCGGA
 TGGTTGGAGAGAAACAAAGAGTGACCTAAGCCATCTAATGGGAAGGAGAGAGGAGGGGGCAACCA
 10 TAGGATTCTCAATGGACATTGACCTGCGGCCAGCCTCAGCTTGGGCCATCTATGCTGCCTTGACAA
 CTTTCATTACCCAGCCGTCCAACATGCAGTGACCACCTCATACAACAACTACTCCTTAATGGCGA
 TGGCCACGCAAGCTGGAGTGTTGTTGGCATGGGCAAAGGGATGCCATTCTACGCATGGGACTTTG
 GAGTCCCGCTGCTAATGATAGGTTGCTACTCACAATTAACACCCCTGACCCTAATAGTGGCCATCA
 TTTTGCTCGTGGCGCACTACATGTACTTGATCCCAGGGCTGCAGGCAGCAGCTGCGCGTGTGCC
 15 AGAAGAGAACGGCAGCTGGCATCATGAAGAACCCTGTTGTGGATGGAATAGTGGTGACTGACATT
 GACACAATGACAATTGACCCCCAAGTGGAGAAAAAGATGGGACAGGTGCTACTCATAGCAGTAGC
 CGTCTCCAGCGCCATACTGTGCGGACCGCCTGGGGGTGGGGGGAGGCTGGGGCTCTGATCACAG
 CCGCAACTTCCACTTTGTGGGAAGGCTCTCCGAACAAGTACTGGAACCTCTACAGCCACTTCAC
 TGTGTAACATTTTATAGGGGAAGTTACTTGCTGGAGCTTCTCTAATCTACACAGTAACAAGAAACG
 20 CTGGCTTGGTCAAGAGACGTGGGGGTGGAACAGGAGAGACCCTGGGAGAGAAATGGAAGGCCCG
 CTTGAACCAGATGTCGGCCCTGGAGTTCTACTCCTACAAAAAGTCAGGCATCACCAGAGGTGTGCAG
 AGAAGAGGCCCCGCCGCCCTCAAGGACGGTGTGGCAACGGGAGGCCATGCTGTGTCCCGAGGAA
 GTGCAAAGCTGAGATGGTTGGTGGAGCGGGGATACCTGCAGCCCTATGGAAAGGTCATTGATCTT
 GGATGTGGCAGAGGGGGCTGGAGTTACTACGTCGCCACCATCCGCAAAGTTCAAGAAGTGAAAGG
 25 ATACACAAAAGGAGGGCCCTGGTCATGAAGAACCCGTGTTGGTGCAAAGCTATGGGTGGAACATAG
 TCCGTCTTAAGAGTGGGGTGGACGTCTTTCATATGGCGGTGAGCCGTGTGACACGTTGCTGTGTG
 ACATAGGTGAGTCATCATCTAGTCCTGAAGTGAAGAAGCACGGACGCTCAGAGTCCTCTCCATG
 GTGGGGGATTGGCTTGAAAAAAGACCAGGAGCCTTTTGTATAAAAGTGTTGTGCCCATACACCAG
 CACTATGATGGAACCCCTGGAGCGACTGCAGCGTAGGTATGGGGGAGGACTGGTCAGAGTGCCAC
 30 TCTCCCGCAACTCTACACATGAGATGACTGGGTCTCTGGAGCGAAAAGCAACACCATAAAAAAGT
 GTGTCCACCACGAGCCAGCTCCTCTTGGGGCGCATGGACGGGCCTAGGAGGCCAGTGAAATATGA
 GGAGGATGTGAATCTCGGCTCTGGCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATGA
 AGATCATTGGTAACCGCATTGAAAGGATCCGCAGTGAGCACGCGGAAACGTGGTTCTTTGACGAG
 AACCACCCATATAGGACATGGGCTTACCATGGAAGCTATGAGGCCCCACACAAGGGTCAGCGTC
 35 CTCTCTAATAAACGGGGTTGTCAGGCTCCTGTCAAAACCCTGGGATGTGGTGACTGGAGTCACAGG
 AATAGCCATGACCGACACCACACCGTATGGTCAGCAAAGAGTTTCAAGGAAAAAGTGGAACATA
 GGGTGCCAGACCCCCAAGAAGGCCTCGTCAGTTATGAGCATGGTCTCTTCTGGTTGTGGAAG
 AGCTAGCAAAACACAAACGGCCACGAGTCTGACCAAAAGAAGAGTTTCATCAACAAGGTTCTGATG
 AATGCAGCATTAGGGCAATATTTGAAGAGGAAAAAGAGTGGAAGACTGCAGTGGAAGCTGTGA
 40 ACGATCCAAGGTTCTGGGCTCTAGTGGAACAAGGAAAAGAGAGCACCACTGAGAGGAGAGTGCCA
 GAGCTGTGTGTACAACATGATGGGAAAAAGAGAAAAGAAACAAGGGGAATTTGGAAAGGCCAAG
 GGCAGCCGCGCCATCTGGTATATGTGGCTAGGGGCTAGATTCTAGAGTTTCAAGCCCTTGGATT
 TTGAACGAGGATCACTGGATGGGGAGAGAGAACTCAGGAGGTGGTGTGAAGGGCTGGGATTACA
 AAGACTCGGATATGTCTAGAAAGAGATGAGTCGTATACAGGAGGAAGGATGTATGCAGATGACA
 45 CTGCTGGCTGGGACACCCGCATTAGCAGGTTTGATCTGGAGAATGAAGCTCTAATCACCACCAA
 ATGGAGAAAAGGGCACAGGGCCTTGGCATTGGCCATAATCAAGTACACATACCAAAAACAAAGTGGT
 AAAGGTCCTTAGACCAGCTGAAAAAGGGAAAAACAGTTATGGACATTATTTTCGAGACAAGACCAAA
 GGGGGAGCGGACAAGTTGTCACTTACGCTCTTAACACATTTACCAACCTAGTGGTGCAACTCATTC
 GGAATATGGAGGCTGAGGAAGTTCTAGAGATGCAAGACTTGTGGCTGCTGCGGAGGTGAGAGAAA
 50 GTGACCAACTGGTTGCAGAGCAACGGATGGGATAGGCTCAAACGAATGGCAGTCAGTGAGATGA
 TTGCGTTGTGAAGCCAATTGATGATAGGTTTGCACATGCCCTCAGGTTCTTGAATGATATGGGAAA
 AGTTAGGAAGGACACACAAGAGTGGAACCCCTCAACTGGATGGGACAACCTGGGAAGAAGTTCCG
 TTTTGCTCCCACCACTTCAACAAGCTCCATCTCAAGGACGGGAGGTCCATTGTGGTTCCCTGCCGC
 CACCAAGATGAACCTGATTGGCCGGGCCCGCTCTCTCCAGGGGCGGGATGGAGCATCCGGGAGAC
 55 TGCTTGCTAGCAAAATCATATGCGCAAATGTGGCAGCTCCTTTATTTCCACAGAAGGGACCTCCG
 ACTGATGGCCAATGCCATTTGTTTCATCTGTGCCAGTTGACTGGGTTCCAACTGGGAGAACTACCTG
 GTCAATCCATGGAAAGGGAGAATGGATGACCCTGAAGACATGCTTGTGGTGTGGAACAGAGTGT

PAT018/EP/PR3

GGATTGAGGAGAACGACCACATGGAAGACAAGACCCCAGTTACGAAATGGACAGACATTCCCTAT
TTGGGAAAAAGGGAAGACTTGTGGTGTGGATCTCTCATAGGGCACAGACCGCGCACCACCTGGGC
TGAGAACATTAAAAACACAGTCAACATGGTGCGCAGGATCATAGGTGATGAAGAAAAAGTACATGG
ACTACCTATCCACCCAAGTTCGCTACTTGGGTGAAGAAGGGTCTACACCTGGAGTGTGTGAAGCAC
5 CAATCTTAATGTTGTCAGGCCTGCTAGTCAGCCACAGCTTGGGGAAAGCTGTGCAGCCTGTGACCC
CCCCAGGAGAAGCTGGGAAACCAAGCCTATAGTCAGGCCGAGAACGCCATGGCACGGAAGAAGC
CATGCTGCCTGTGAGCCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAGGCGCAGG
ATGGGAAAAGAAGGTGGCGACCTTCCCCACCTTCAATCTGGGGCCTGAACTGGAGATCAGCTGT
GGATCTCCAGAAGAGGGACTAGTGGTTAGAGGA

10

KU509998.1 Zika virus strain Haiti/1225/2014, Haiti, complete genome (SEQ ID NO: 5)

GTTGTTACTGTTGCTGACTCAGACTGCGACAGTTCGAGTTTGAAGCGAAAAGCTAGCAACAGTATCA
ACAGGTTTTATTGGATTGGAACGAGAGTTTCTGGTCATGAAAAACCCAAAAAGAAATCCGG
AGGATTCCGGATTGTCAATATGCTAAAACGCGGAGTAGCCCGTGTGAGCCCCTTTGGGGGCTTGAA
15 GAGGCTGCCAGCCGACTTCTGCTGGGTCATGGGCCCATCAGGATGGTCTTGGCAATTCTAGCCTT
TTTGAGATTCACGGCAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTTCAGTGGGGAAAA
AAGAGGCTATGGAATAATAAAGAAGTTCAAGAAAAGATCTGGCTGCCATGCTGAGAATAATCAAT
GCTAGGAAGGAGAAGAAGAGACGAGGCGCAGATACTAGTGTGGAATTGTTGGCCTCTGCTGAC
CACAGCTATGGCAGCGGAGGTCACTAGACGTGGGAGTGCATACTATATGTACTTGGACAGAAACG
20 ATGCTGGGGAGGCCATATCTTTTCCAACCACATTGGGGATGAATAAGTGTATATACAGATCATGG
ATCTTGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTATGCTGGATGAGGGGGTGGAA
CCAGATGACGTCGATTGTTGGTGCAACACGACGTCAACTTGGGTTGTGTACGGAACCTGCCATCAC
AAAAAAGGTGAAGCACGGAGATCTAGAAGAGCTGTGACGCTCCCCCTCCATTCCACTAGGAAGCT
GCAAACGCGGTGCAAAACCTGGTTGGAATCAAGAGAATACACAAAGCACTTGATTAGAGTCGAAA
25 ATTGGATATTCAGGAACCTGGCTTCGCGTTAGCAGCAGCTGCCATCGCTTTTGGGAAGCT
CAACGAGCCAAAAAGTCATATACTTGGTCATGATACTGCTGATTGCCCGGCATACAGCATCAGGT
GCATAGGAGTCAGCAATAGGGACTTTGTGGAAGGTATGTCAGGTGGGACTTGGGTTGATGTTGTCT
TGGAACATGGAGGTTGTGTCACCGTAATGGCACAGGACAAACCGACTGTCGACATAGAGCTGGTT
ACAACAACAGTCAGCAACATGGCGGAGGTAAAGATCCTACTGCTATGAGGCATCAATATCAGACAT
30 GGCTTCGGACAGCCGCTGCCCAACACAAGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAAT
ATGTCTGCAAAAGAACGTTAGTGGACAGAGGCTGGGGAAATGGATGTGGACTTTTGGCAAAGGG
AGTCTGGTGACATGCGCTAAGTTTGCATGTCTCAAGAAAATGACCGGGAAGAGCATCCAGCCAGA
GAATCTGGAGTACCGGATAATGCTGTGCTGCTCATGGCTCCAGCACAGTGGGATGATCGTTAATGA
CACAGGACATGAACTGATGAGAATAGAGCGAAGGTTGAGATAACGCCCAATTCACCAAGAGCC
35 GAAGCCACCCTGGGGGGTTTTGGAAGCCTAGGACTTGATTGTGAACCGAGGACAGGCCTTGACTTT
TCAGATTTGTATTACTTGACTATGAATAACAAGCACTGGTTGGTTTACAAGGAGTGGTTCCACGAC
ATTCCATTACCTTGGCAGCTGGGGCAGACACCGGAATCCCACTGGAACAACAAAGAAGCACT
GGTAGAGTTCAAGGACGCACATGCCAAAAGGCCAACTGTCGTGGTTCTAGGGAGTCAAGAAGGAG
CAGTTCACACGGCCCTTGTGAGCTCTGGAGGCTGAGATGGATGGTGCAAAGGGAAGGCTGTCC
40 TCTGGCCACTTGAAATGTCGCCTGAAAATGGATAAACTTAGATTGAAGGGCGTGTACACTCCTTG
TGACCGCAGCGTTCACATTACCAAGATCCCGGCTGAAACACTGCACGGGACAGTCAAGTGGGA
GGTACAGTACGCAGGGACAGATGGACCTTGCAAGGTTCCAGCTCAGATGGCGGTGGACATGCAAAA
CTCTGACCCAGTTGGGAGGTTGATAACCGCTAACCCCGTAATCACTGAAAGCACTGAGAACTCTA
AGATGATGCTGGAACCTGATCCACCATTGGGGACTCTTACATTGTCATAGGAGTCGGGGAGAAG
45 AAGATCACCCACCACTGGCACAGGAGTGGCAGCACCATTGGAAAAGCATTGGAAGCCACTGTGAG
AGGTGCCAAGAGAATGGCAGTCTTGGGAGACACAGCCTGGGACTTTGGATCAGTTGGAGGCGCTC
TCAACTCATTGGGCAAGGGCATCCATCAAATTTTTGGAGCAGCTTCAAATCATTGTTGGAGGAA
TGTCTGGTTCTCACAATTCTCATTGGAACGTTGCTGATGTGGTTGGGTCTGAACACAAAGAATG
GATCTATTTCCCTTATGTGCTTGGCCTTAGGGGAGGTGTTGATCTTCTTATCCACAGCCGTCTCTGC
50 TGATGTGGGGTGTCTCGGTGGACTTCTCAAAGAAGGAGACGAGATGCGGTACAGGGGTGTTCTGCT
ATAACGACGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCCTGACTCCCCCGTAGATTGGCA
GCAGCAGTCAAGCAAGCCTGGGAAGATGGTATCTGCGGGATCTCCTCTGTTTCAAGAATGGA
CATCATGTGGAGATCAGTAGAAGGGGAGCTCAACGCAATCCTGGAAGAGAATGGAGTTCAACTGA
CGGTCTGTTGTGGGATCTGTAAAAAACCCCATGTGGAGAGGTTCCACAGAGATTGCCCGTGCCTGTG
55 AACGAGCTGCCCCACGGCTGGAAGGCTTGGGGGAAATCGCACTTCGTGAGAGCAGCAAAAGACAAA

TAACAGCTTTGTCGTGGATGGTGACACACTGAAGGAATGCCCACTCAAACATAGAGCATGGAACA
 GCTTCTTGTGGAGGATCATGGGTTCGGGGTATTTACACTAGTGTCTGGCTCAAGGTTAGAGAAG
 ATTATTCATTAGAGTGTGATCCAGCCGTTATTGGAACAGCTGTAAAGGGAAAGGAGGCTGTACACA
 GTGATCTAGGCTACTGGATTGAGAGTGAGAAGAATGACACATGGAGGCTGAAGAGGGGCCATCTG
 5 ATCGAGATGAAAACATGTGAATGGCCAAAGTCCCACACATTGTGGACAGATGGAATAGAAGAGA
 GTGATCTGATCATACCCAAGTCTTTAGCTGGGCCACTCAGCCATCACAATACCAGAGAGGGCTACA
 GGACCCAAATGAAAGGGCCATGGCACAGTGAAGAGCTTGAAATTCGGTTTGAGGAATGCCAGGC
 ACTAAGGTCCACGTGGAGGAAACATGTGGAACAAGAGGACCATCTCTGAGATCAACCACTGCAAG
 CGGAAGGGTGATCGAGGAATGGTGCTGCAGGGAGTGCACAATGCCCCCACTGTCTGTTCCGGGCTA
 10 AAGATGGCTGTTGGTATGGAATGGAGATAAGGCCAGGAAAGAACAGAAAGCAACTTAGTAAG
 GTCAATGGTGACTGCAGGATCAACTGATCAGATGGATCACTTCTCCCTTGGAGTGCTTGTGATTCT
 GCTCATGGTGCAGGAAGGGCTGAAGAAGAGAATGACCACAAAGATCATCATAAGCACATCAATG
 GCAGTGCTGGTAGCTATGATCCTGGGAGGATTTTCAATGAGTGACCTGGCTAAGCTTGCAATTTTG
 ATGGGTGCCACCTTCGCGGAAATGAACACTGGAGGAGATGTAGCTCATCTGGCGCTGATAGCGGC
 15 ATTCAAAGTCAGACCAGCGTTGCTGGTATCTTTCATCTTCAGAGCTAATTGGACACCCCGTGAAAG
 CATGCTGCTGGCCTTGGCCTCGTGTCTTTTGCAAACTGCGATCTCCGCCTTGGAAAGGCGACCTGAT
 GGTCTCATCAATGGTTTTGCTTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCACGCACTGAT
 AACATCACCTTGGCAATCCTGGCTGCTCTGACACCACTGGCCCGGGGCACACTGCTTGTGGCGTGG
 AGAGCAGGCCTTGCTACTTGCGGGGGGTTTATGCTCCTCTCTCTGAAGGGAAAAGGCAGTGTGAA
 20 GAAGAACTTACCATTTGTCATGGCCCTGGGACTAACCCTGTGAGGCTGGTCGACCCCATCAACGT
 GGTGGGGCTGCTGTTGCTCACAAGGAGTGGGAAGCGGAGCTGGCCCCCTAGCGAAGTACTCACAG
 CTGTTGGCCTGATATGCGCATTGGCTGGAGGGTTCGCCAAGGCAGATATAGAGATGGCTGGGCCC
 ATGGCCGCGGTCTGCTAATTGTCAGTTACGTGGTCTCAGGAAAAGAGTGTGGACATGTACATT
 GAAAGAGCAGGTGACATCACATGGGAAAAAGATGCGGAAGTCACTGGAAACAGTCCCCGGCTCG
 25 ATGTGGCGCTAGATGAGAGTGGTGATTTCTCCCTGGTGGAGGATGACGGTCCCCCATGAGAGAG
 ATCATACTCAAGGTGGTCTGATGACCATCTGTGGCATGAACCCAATAGCCATACCCTTTGCAGCT
 GGAGCGTGGTACGTATACGTGAAGACTGGAAAAAGGAGTGGTGCTCTATGGGATGTGCCTGCTCC
 CAAGGAAGTAAAAAAGGGGGAGACCACAGATGGAGTGTACAGAGTAATGACTCGTAGACTGCTA
 GGTTC AACACAAGTTGGAGTGGGAGTTATGCAAGAGGGGGTCTTTCACACTATGTGGCACGTCAC
 30 AAAAGGATCCGCGCTGAGAAGCGGTGAAGGAGACTTGATCCATACTGGGGAGATGTCAAGCAG
 GATCTGGTGTCACTGTGGTCCATGGAAGCTAGATGCCGCTGGGACGGGCACAGCGAGGTGCA
 GCTCTTGCCCGTGCCCCCGGAGAGAGAGCGAGGAACATCCAGACTCTGCCCGGAATATTTAAGA
 CAAAGGATGGGGACATTGGAGCGGTTGCGCTGGATTACCCAGCAGGAACCTCAGGATCTCCAATC
 CTAGACAAGTGTGGGAGAGTGATAGGACTTTATGGCAATGGGGTCTGATCAAAAATGGGAGTTA
 35 TGTTAGTGCCATACCCAAGGGAGGAGGGAGGAAGAGACTCCTGTTGAGTGCTTCGAGCCTTCGA
 TGCTGAAGAAGAAGCAGCTAACTGTCTTAGACTTGCATCCTGGAGCTGGGAAAACAGGAGAGTT
 CTTCCTGAAATAGTCCGTGAAGCCATAAAAAACAAGACTCCGTACTGTGATCTTAGCTCCAACGAG
 GTTGCTCGCTGTGAAATGGAGGAAGCCCTTAGAGGGCTTCCAGTGCGTTATATGACAACAGCAGTC
 AATGTCACCCACTCTGGAACAGAAATCGTCGACTTAATGTGCCATGCCACCTTCACCTCACGTCTA
 40 CTACAGCCAATCAGAGTCCCCAACTATAATCTGTATATTATGGATGAGGCCCACTTCACAGATCCC
 TCAAGTATAGCAGCAAGAGGATACATTTCAACAAGGGTTGAGATGGGCGAGGCGGCTGCCATCTT
 CATGACCGCCACGCCACCAGGAACCCGTGACGCATTTCCGGACTCCAACCTACCAATTATGGACAC
 CGAAGTGGAAGTCCCAGAGAGAGCCTGGAGCTCAGGCTTTGATTGGGTGACGGATTATCTGGAA
 AAACAGTTTGGTTTGTTC AAGCGTGAGGAACGGCAATGAGATCGCAGCTTGTCTGACAAAGGCT
 45 GGAAAACGGGTCATACAGCTCAGCAGAAAGACTTTTGAGACAGAGTCCAGAAAAACAAACATCA
 AGAGTGGGACTTTGTCTGTGACAACTGACATTTACAGAGATGGGCGCCAACTTTAAAGCTGACCGTGT
 CATAGATTCCAGGAGATGCCTAAAGCCGGTCATACTTGATGGCGAGAGAGTCATTCTGGCTGGAC
 CCATGCCTGTCACACATGCCAGCGCTGCCAGAGGAGGGGGCGCATAGGCAGGAATCCCAACAAA
 CCTGGAGATGAGTATCTGTATGGAGGTGGGTGCGCAGAGACTGACGAAGACCATGCACACTGGCT
 50 TGAAGCAAGAATGCTCCTTGACAATATTTACCTCCAAGATGGCCTCATAGCCTCGCTCTATCGACC
 TGAGGCCGACAAAAGTAGCAGCCATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAAAGGAAGACC
 TTTGTGGAATCATGAAAAGAGGAGATCTTCTGTTTGGCTGGCCTATCAGGTTGCATCTGCCGGA
 ATAACCTACACAGATAGAAGATGGTGCTTTGATGGCACGACCAACAACACCATAATGGAAGACAG
 TGTGCCGCGCAGAGGTGTGGACCAGACACGGAGAGAAAAAGAGTGCTCAAACCGAGGTGGATGGAC
 55 GCCAGAGTTTGTTCAGATCATGCGGCCCTGAAGTCATTCAAGGAGTTTGGCGCTGGGAAAAAGAGG
 AGCGGCTTTTGGAGTGATGGAAGCCCTGGGAACACTGCCAGGACACATGACAGAGAGATTCCAGG
 AAGCCATTGACAACCTCGCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAGCCGCG

GCGGCCCAATTGCCGGAGACCCTAGAGACCATTATGCTTTTGGGGTTGCTGGGAACAGTCTCGCTG
 GGAATCTTTTTCGTCTTGATGAGGAACAAGGGCATAGGGAAGATGGGCTTTGGAATGGTGACTCTT
 GGGGCCAGCGCATGGCTCATGTGGCTCTCGGAAATTGAGCCAGCCAGAATTGCATGTGTCCCTCATT
 GTTGTGTTCTATTGCTGGTGGTGTCTACCTGAGCCAGAAAAGCAAAGATCTCCCCAGGACAAC
 5 CAAATGGCAATCATCATCATGGTAGCAGTAGGTCTTCTGGGCTTGATTACCGCCAATGAACTCGGA
 TGGTTGGAGAGAACAAAGAGTGACCTAAGCCATCTAATGGGAAGGAGAGAGGAGGGGGCAACCA
 TGGGATTCTCAATGGACATTGACCTGCGGCCAGCCTCAGCTTGGGCCATCTATGCTGCCTTGACAA
 CTTTCATTACCCCAGCCGTCCAACATGCAGTGACCACTTCATACAACAATACTCCTTAATGGCGA
 TGGCCACGCAAGCTGGAGTGTGTTTGGTATGGGCAAAGGGATGCCATTCTACGCATGGGACTTTG
 10 GAGTCCCCTGCTAATGATAGGTTGCTACTCACAATTAACGCCCTGACCCTAATAGTGGCCATCA
 TTTTGCTCGTGGCGCACTACATGTACTTGATCCAGGGCTGCAGGCAGCAGCTGCGCGTGTGCCC
 AGAAGAGAACGGCAGCTGGCATCATGAAGAACCCTGTTGTGGATGGAATAGTGGTGACTGACATT
 GACACAATGACAATTGACCCCCAAGTGGAGAAAAAGATGGGACAGGTGCTACTCATGGCAGTAGC
 CGTCTCCAGCGCCATACTGTCGCGGACCGCCTGGGGGTGGGGGGAGGCTGGGGCCCTGATCACAA
 15 CCGCAACTTCCACTTTGTGGGAAGGCTCTCCGAACAAGTACTGGAACCTCTACAGCCACTTCAC
 TGTGTAACATTTTTAGGGGAAGTTACTTGGCTGGAGCTTCTCTAATCTACACAGTAACAAGAAACG
 CTGGCTTGGTCAAGAGACGTGGGGGTGGAACAGGAGAGACCCTGGGAGAGAAATGGAAGGCCCG
 CTTGAACCAGATGTCGGCCCTGGAGTTCTACTCCTACAAAAAGTCAGGCATCACCGAGGTGTGCAG
 AGAAGAGGCCCCGCCGCCCTCAAGGACGGTGTGGCAACGGGAGGCCATGCTGTGTCCCAGGAA
 20 GTGCAAAGCTGAGATGGTTGGTGGAGCGGGGATACCTGCAGCCCTATGGAAAGGTCATTGATCTT
 GGATGTGGCAGAGGGGGCTGGAGTTACTACGCCGCCACCATCCGCAAAGTTCAAGAAGTGAAAGG
 ATACACAAAAGGAGGCCCTGGTCATGAAGAACCCTGTTGGTGCAAAGCTATGGGTGGAACATAG
 TCCGTCTTAAGAGTGGGGTGGACGTCTTTCATATGGCGGCTGAGCCGTGTGACACGTTGCTGTGTG
 ACATAGGTGAGTCATCATCTAGTCTGAAGTGGAAAGAACGACGGACGCTCAGAGTCTCTCCATG
 25 GTGGGGGATTGGCTTGAAAAAAGACCAGGAGCCTTTTGTATAAAAGTGTTGTGCCCATACACCAG
 CACTATGATGGAAAACCCTGGAGCGACTGCAGCGTAGGTATGGGGGAGGACTGGTCAGAGTGCCAC
 TCTCCCGCAACTCTACACATGAGATGTAAGTGGTCTCTGGAGCGAAAAGCAACACCATAAAAAAGT
 GTGTCCACCACGAGCCAGCTCCTCTTGGGGCGCATGGACGGGCCCTAGGAGGCCAGTGAAATATGA
 GGAGGATGTGAATCTCGGCTCTGGCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATGA
 30 AGATCATTGGTAACCGCATTGAAAGGATCCGAGTGAGCACGCGGAAACGTGGTCTTTGACGAG
 AACCACCCATATAGGACATGGGCTTACCATGGAAGCTATGAGGCCCCCACACAAGGGTCAGCGTC
 CTCTCTAATAAACGGGGTTGTCAGGCTCCTGTCAAAAACCCTGGGATGTGGTGACTGGAGTCACAGG
 AATAGCCATGACCGACACCACACCGTATGGTCAGCAAAGAGTTTTCAAGGAAAAAGTGACACTA
 GGGTGCCAGACCCCCAAGAAGGCACTCGTCAGGTTATGAGCATGGTCTCTTCTGTTGTGGAAAG
 35 AGCTAGGCAAAACAAACGGCCACGAGTCTGTACCAAAGAAGAGTTTCATCAACAAGGTTTCGTAGC
 AATGCAGCATTAGGGGCAATATTTGAAGAGGAAAAAGAGTGGAAGACTGCAGTGGAAGCTGTGA
 ACGATCCAAGGTTCTGGGCTCTAGTGGACAAGGAAAGAGAGCACCACCTGAGAGGAGAGTGCCA
 GAGTTGTGTACAAACATGATGGGAAAAAGAGAAAAAGAAACAAAGGGGAATTTGGAAAGGCCAA
 GGCAGCCGCGCCATCTGGTATATGTGGCTAGGGGCTAGATTTCTAGAGTTCGAAGCCCTTGGATT
 40 TTGAACGAGGATCACTGGATGGGGAGAGAGAACTCAGGAGGTGGTGTGTAAGGGCTGGGATTACA
 AAGACTCGGATATGTCCTAGAAGAGATGAGTCGCATACCAGGAGGAAGGATGTATGCAGATGACA
 CTGCTGGCTGGGACACCCGCATCAGCAGGTTTGATCTGGAGAATGAAGCTCTAATCACCACCAA
 ATGGAGAAAGGGCACAGGGCCTTGGCATTGGCCATAATCAAGTACACATACCAAAACAAAGTGGT
 AAAGGTCCTTAGACCAGCTGAAAAAGGGAAGACAGTTATGGACATTATTTTCGAGACAAGACCAAA
 45 GGGGGAGCGGACAAGTTGTCACTTACGCTCTTAACACATTTACCAACCTAGTGGTGCAACTCATTC
 GGAATATGGAGGCTGAGGAAGTTCTAGAGATGCAAGACTTGTGGCTGCTGCGGAGGTCAAGAGAAA
 GTGACCAACTGGTTGCAGAGCAACGGATGGGATAGGCTCAAACGAATGGCAGTCAGTGAGATGA
 TTGCGTTGTGAAGCCAATTGATGATAGGTTTGCACATGCCCTCAGGTTCTTGAATGATATGGGAAA
 AGTTAGGAAGGACACACAAGAGTGGAACCCTCAACTGGATGGGACAACCTGGGAAGAAGTTCCG
 50 TTTTGCTCCCACTTCAACAAGCTCCATCTCAAGGACGGGAGGTCCATTGTGGTTCCTGCCGC
 CACCAAGATGAACTGATTGGCCGGGGCCGCGTCTCTCCAGGGGCGGGATGGAGCATCCGGGAGAC
 TGCTTGCTAGCAAAATCATATGCGCAAATGTGGCAGCTCCTTTATTTCCACAGAAGGGACCTCCG
 ACTGATGGCCAATGCCATTTGTTTCATCTGTGCCAGTTGACTGGGTTCCAAGTGGGAGAACTACCTG
 GTCATCCATGGAAAAGGAGAAATGGATGACCACTGAAGACATGCTTGTGGTGTGGAACAGAGTGT
 55 GGATTGAGGAGAACGACCACATGGAAGACAAGACCCAGTTACGAAATGGACAGACATTCCCTAT
 TTGGGAAAAAGGGAAGACTTGTGGTGTGGATCTCTCATAGGGCACAGACCGCGCACCACTGGGC
 TGAGAACATTAAAAACACAGTCAACATGGTGCGCAGGATCATAGGTGATGAAGAAAAGTACATGG

PAT018/EP/PR3

ACTACCTATCCACCCAAGTTCGCTACTTGGGTGAAGAAGGGTCTACACCTGGAGTGCTGTAAGCAC
CAATCTTAATGTTGTCAGGCCTGCTAGTCAGCCACAGCTTGGGGAAAGCTGTGCAGCCTGTGACCC
CCCCAGGAGAAGCTGGGAAACCAAGCCTATAGTCAGGCCGAGAACGCCATGGCACGGAAGAAGC
CATGCTGCCGTGTGAGCCCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAGGGCGCAGG
5 ATGGGAAAAGAAGGTGGCGACCTTCCCCACCTTCAATCTGGGGCCTGAACTGGAGATCAGCTGT
GGATCTCCAGAAGAGGGACTAGTGGTTAGAGGAGA

KU527068.1 Zika virus strain Natal RGN, Brazil: Rio Grande do Norte, Natal, complete
genome (SEQ ID NO: 6)

10 AGTTGTTGATCTGTGTGAATCAGACTGCGACAGTTCGAGTTTGAAGCGAAAGCTAGCAACAGTATC
AACAGGTTTTATTTTGGATTTGGAAACGAGAGTTTCTGGTCATGAAAAACCCAAAAAAGAAATCC
GGAGGATTCCGGATTGTCAATATGCTAAAACGCGGAGTAGCCCGTGTGAGCCCCCTTTGGGGGCTTG
AAGAGGCTGCCAGCCGGACTTCTGCTGGGTCTATGGGCCCATCAGGATGGTCTTGGCAATTCTAGCC
TTTTTGAGATTCACGGCAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTCAGTGGGGAAA
15 AAAGAGGCTATGGAAATAATAAAGAAGTTCAAGAAAGATCTGGCTGCCATGCTGAGAATAATCAA
TGCTAGGAAGGAGAAGAAGAGACGAGGCGCAGATACTAGTGTGGAATTGTTGGCCTCCTGCTGA
CCACAGCTATGGCAGCGGAGGTCACTAGACGTGGGAGTGCATACTATATGTACTTGGACAGAAAC
GATGCTGGGGAGGCCATATCTTTCCAACCACATTGGGGATGAATAAGTGTATATACAGATCATG
GATCTTGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTATGCTGGATGAGGGGGTGA
20 ACCAGATGACGTGATTGTTGGTGCAACACGACGTCAACTTGGGTTGTGTACGGAACCTGCCATCA
CAAAAAAGGTGAAGCACGGAGATCTAGAAGAGCTGTGACGCTCCCCTCCATTCCACTAGGAAGC
TGCAACGCGGTGCGAAACCTGGTTGGAATCAAGAGAATACACAAAGCACTTGATTAGAGTCGAA
AATTGGATATTCAGGAACCTGGCTTCGCGTTAGCAGCAGCTGCCATCGCTTGGCTTTTGGGAAGC
TCAACGAGCCAAAAAGTCATATACTTGGTCATGATACTGCTGATTGCCCCGGCATAACAGCATCAGG
25 TGCATAGGAGTCAGCAATAGGGACTTTGTGGAAGGTATGTCAGGTGGGACTTGGGTTGATGTTGTC
TTGGAACATGGAGTTGTGTACCGTAATGGCACAGGACAAACCGACTGTGACATAGAGCTGGT
TACAACAACAGTCAGCAACATGGCGGAGGTAAGATCCTACTGCTATGAGGCATCAATATCAGACA
TGGCTTCGGACAGCCGCTGCCAACACAAGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAA
TATGTCTGCAAAAGAACGTTAGTGGACAGAGGCTGGGGAAATGGATGTGGACTTTTTGGCAAAGG
30 GAGCCTGGTGACATGCGCTAAGTTTGCATGCTCCAAGAAAAATGACCGGAAGAGCATCCAGCCAG
AGAATCTGGAGTACCGGATAATGCTGTGATGCTTCCAGTCCAGCACAGTGGGATGATCGTTAATG
ACACAGGACATGAAACTGATGAGAATAGAGCGAAGGTTGAGATAACGCCCAATTCACCAAGAGC
CGAAGCCACCCTGGGGGGTTTTGGAAGCCTAGGACTTGATTGTGAACCGAGGACAGGCCTTGACT
TTTCAGATTTGTATTACTTGACTATGAATAACAAGCACTGGTTGGTCCACAAGGAGTGGTTCCACG
35 ACATTCCATTACCTTGGCACGCTGGGGCAGACACCGGAATCCACACTGGAACAACAAAGAAGCA
CTGGTAGAGTTCAAGGACGCACATGCCAAAAGGCAAACTGTCGTGGTTCTAGGGAGTCAAGAAGG
AGCAGTTCACACGGCCCTTGCTGGAGCTCTGGAGGCTGAGATGGATGGTGCAAAGGGAAGGCTGT
CCTCTGGCCACTTGAAATGTGCGCTGAAAATGGATAAACTTAGATTGAAGGGCGTGTCTACTCCT
TGTGTACCGCAGCGTTCACATTACCAAGATCCCGGCTGAAACACTGCACGGGACAGTCACAGTG
40 GAGGTACAGTACGCAGGGACAGATGGACCTTGCAAGGTTCCAGCTCAGATGGCGGTGGACATGCA
AACTCTGACCCAGTTGGGAGGTTGATAACCGCTAACCCCGTAATCACTGAAAGCACTGAGAATC
CTAAGATGATGCTGGAACCTTGATCCACCATTGTTGGGACTCTTACATTGTCATAGGAGTCGGGGAGA
AGAAGATCACCCACCACTGGCACAGGAGTGGCAGCACCATTGGAAAAGCATTGTAAGCCACTGTG
AGAGGTGCCAAGAGAATGGCAGTCTTGGGAGACACAGCCTGGGACTTTGGATCAGTTGGAGGCGC
45 TCTCAACTCATTGGGCAAGGGCATCCATCAAATTTTTGGAGCAGCTTCAAATCATTGTTGGAGG
AATGTCCTGGTTCTCACAAATCCTCATTGGAACGTTGCTGATGTGGTTGGGTCTGAACACAAAGAA
TGGATCTATTTCCCTTATGTGCTTGGCCTTAGGGGGAGTGTGATCTTCTATCCACAGCCGTCTCT
GCTGATGTGGGGTGTCTCGGTGGACTTCTCAAAGAAGGAGACGAGATGCGGTACAGGGGTGTTCTG
CTATAACGACGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCCTGACTCCCCCGTAGATTGG
50 CAGCAGCAGTCAAGCAAGCCTGGGAAGATGGTATCTGCGGGATCTCCTCTGTTTCAAGAATGGAG
AACATCATGTGGAGATCAGTAGAAGGGGAGCTCAACGCAATCTTGGAAAGAGAATGGAGTTCAACT
GACGGTCTGTGGGATCTGTAAAAAACCCCATGTGGAGAGGTCCACAGAGATTGCCCGTGCCTG
TGAACGAGCTGCCCCACGGCTGGAAGGCTTGGGGGAAATCGTACTTCTGTCAGAGCAGCAAAAGACA
AATAACAGCTTTGTGCTGGATGGTGACACACTGAAGGAATGCCCACTCGAACATAGAGCATGGAA
55 CAGCTTTCTGTGGAGGATCATGGGTTCGGGGTATTTCACACTAGTGTCTGGCTCAAGGTTAGAGA

AGATTATTCATTAGAGTGTGATCCAGCCGTTATTGGAACAGCTGTTAAGGGGAAGGAGGCTGTAC
 ACAGTGATCTAGGCTACTGGATTGAGAGTGAGAAGAATGACACATGGAGGCTGAAGAGGGCCCAT
 CTAATCGAGATGAAAAACATGTGAATGGCCAAAGTCCCACACATTGTGGGCAGATGGAATAGAAGA
 GAGTGATCTGATCATTCCCAAGTCTTTAGCTGGGCCACTCAGCCATCACAATACCAGAGAGGGCTA
 5 CAGGACCCAAATGAAAGGGCCATGGCACAGTGAAGAGCTTGAAATTCGGTTTGAGGAATGCCCGG
 GCACTAAGGTCCACGTGGAGGAAACATGTGGAACAAGAGGACCATCTCTGAGATCAACCACTGCA
 AGCGGAAGGGTGATCGAGGAATGGTGCTGCAGGGAGTGCACAATGCCCCCACTGTCTGTTCCGGGC
 TAAAGATGGCTGTTGGTATGGAATGGAGATAAGGCCCAGGAAAGAACCAGAAAGCAACTTAGTA
 AGGTCACTGGTGACTGCAGGATCAACTGATCAGATGGATCACTTCTCCCTTGGAGTGCTTGTGATT
 10 CTGCTCATGGTGCAGGAAGGGCTGAAGAAGAGAATGACCACAAAGATCATCATAAGCACATCAAT
 GGCAGTGCTGGTAGCTATGATCCTGGGAGGATTTTCAATGAGTGACCTGGCTAAGCTTGCAATTTT
 GATGGGCGCCACCTTCGCGGAAATGAACACTGGAGGAGATGTAGCTCATCTGGCGCTGATAGCGG
 CATTCAAAGTCAGACCAGCGTTGCTGGTATCTTTCATCTTCAGAGCTAATTGGACACCCCGTGAAA
 GCATGCTGTGGCCTTGGCCTCGTGTCTTTTGCAAACTGCGATCTCCGCCTTGAAGGCGACCTGA
 15 TGGTTCTCATCAATGGTTTTGCTTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCACGCACTGA
 TAACATCACCTTGGCAATCCTGGCTGCTCTGACACCACTGGCCCCGGGCACACTGCTTGTGGCGTG
 GAGAGCAGGCCCTTGCTACTTGCAGGGGGGTTTATGCTCCTCTCTCTGAAGGGAAAAGGCAGTGTGA
 AGAAGAAGTTACCATTTGTCATGGCCCTGGGACTAACCGCTGTGAGGCTGGTCGACCCCATCAACG
 TGGTGGGACTGCTGTTGCTCACAAGGAGTGGGAAGCGGAGCTGGCCCCCTAGCGAAGTACTCACA
 20 GCTGTTGGCCTGATATGCGCATTGGCTGGAGGGTTCGCCAAGGCAGATATAGAGATGGCTGGGCC
 CATGGCCGCGGTGCGTCTGCTAATTGTCAGTTACGTGGTCTCAGGAAAGAGTGTGGACATGTACAT
 TGAAAGAGCAGGTGACATCAGATGGGAAAAAGATGCGGAAGTCACTGGAAACAGTCCCCGGCTC
 GATGTGGCGCTAGATGAGAGTGGTGATTTCTCCCTGGTGGAGGATGACGGTCCCCCATGAGAGA
 GATCATACTCAAGGTGGTCTGATGACCATCTGTGGCATGAACCAATAGCCATACCCCTTTCAGC
 25 TGGAGCGTGGTACGTATACGTGAAGACTGGAAAAAGGAGTGGTGCTCTATGGGATGTGCCTGCTC
 CCAAGGAAGTAAAAAGGGGGAGACCACAGATGGAGTGTACAGAGTAATGACTCGTAGACTGCT
 AGGTTCAACACAAGTTGGAGTGGGAGTTATGCAAGAGGGGGTCTTTCACACTATGTGGCACGTCA
 CAAAAGGATCCGCGCTGAGAAGCGGTGAAGGGAGACTTGATCCATACTGGGGAGATGTCAAGCA
 GGATCTGGTGTCATACTGTGGTCCATGGAAGCTAGATGCCGCTGGGACGGGCACAGCGAGGTGC
 30 AGCTCTTGGCCGTGCCCCCGGAGAGAGAGCGAAGAACATCCAGACTCTGCCCGGAATATTTAAG
 ACAAAGGATGGGGACATTGGAGCGGTTGCGCTGGATTACCCAGCAGGAAGTTCAGGATCTCCAAT
 CCTAGACAAGTGTGGGAGAGTGATAGGACTTTATGGCAATGGGGTCTGTGATCAAAAATGGGAGTT
 ATGTTAGTGCCATCACCCAAGGGAGGAGGGAGGAAGAGACTCCTGTTGAGTGCTTCGAGCCTTCG
 ATGCTGAAGAAGAAGCAGCTAACTGTCTTAGACTTGCATCCTGGAGCTGGGAAAACAGGAGAGT
 35 TCTTCTGAAATAGTCCGTGAAGCCATAAAAAACAAGACTCCGTAAGTGTGATCTTAGCTCCAACAG
 GGTGTCGCTGCTGAAATGGAGGAAGCCCTTAGAGGGCTTCCAGTGCCTTATATGACAACAGCAG
 TCAATGTACCCACTCTGGAACAGAAATCGTCGACTTAATGTCCATGCCACCTTCACTTCACGTC
 TACTACGCCAATCAGAGTCCCCAATAATCTGTATATTATGGATGAGGCCCCACTTCACAGATC
 CCTCAAGTATAGCAGCAAGAGGATACATTTCAACAAGGGTTGAGATGGGCGAGGCGGCTGCCATC
 40 TTCATGACCGCCACGCCACCAGGAACCCGTGACGCATTTCCGGACTCCAACCTACCAATTATGGAC
 ACCGAAGTGGAAGTCCCAGAGAGAGCCTGGAGCTCAGGCTTTGATTGGGTGACGGATCATTCTGG
 AAAAAACAGTTTGGTTTGTTCAGCGTGAGGAACGGCAATGAGATCGCAGCTTGTCTGACAAAAGG
 CTGGAAAACGGGTCATACAGCTCAGCAGAAAAGACTTTTGAGACAGAGTTCCAGAAAACAAAACAT
 CAAGAGTGGGACTTTGTCTGTGACAACTGACATTTAGAGATGGGCGCCAACCTTTAAAGCTGACCGT
 45 GTCATAGATTCCAGGAGATGCCTAAAGCCGGTCATCTTATGATGGCGAGAGAGTCAATTTGGCTGGA
 CCCATGCCTGTACACATGCCAGCGCTGCCAGGAGGAGGGGGCGCATAGGCAGGAATCCCAACAA
 ACCTGGAGATGAGTATCTGTATGGAGGTGGGTGCGCAGAGACTGACGAAGACCATGCACACTGGC
 TTGAAGCAAGAATGCTCCTTGACAATATTTACCTCCAAGATGGCCTCATAGCCTCGCTCTATCGAC
 CTGAGGCGGACAAAGTAGCAGCCATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAAGGAAGAC
 50 CTTTGTGGAAGTCAATGAAAAAGAGGAGATCTTCTGTTTGGCTGGCCTATCAGGTTGCATCTGCCGG
 AATAACCTACACAGATAGAAGATGGTGCTTTGATGGCACGACCAACAACACCATAATGGAAGACA
 GTGTGCCGGCAGAGGTGTGGACCAGACACGGAGAGAAAAAGAGTGCTCAAACCGAGGTGGATGGA
 CGCCAGAGTTTGTTCAGATCATGCGGCCCTGAAGTCAATTCAAGGAGTTTGCCGCTGGGAAAAGAG
 GAGCGGCTTTTGGAGTGATGGAAGCCCTGGGAACACTGCCAGGACACATGACAGAGAGATTCCAG
 55 GAAGCCATTGACAACCTCGCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCTTACAAAGCCGC
 GGCGGCCCAATTGCCGAGACCCTAGAGACCATTATGCTTTTGGGGTTGCTGGGAACAGTCTCGCT
 GGGAATCTTTTTCTGCTTGTGATGAGGAACAAGGGCATAGGGAAGATGGGCTTTGGAATGGTGACTCT

TGGGGCCAGCGCATGGCTCATGTGGCTCTCGGAAATTGAGCCAGCCAGAATTGCATGTGTCCTCAT
 TGTGTGTTCCTATTGCTGGTGGTGCTCATACCTGAGCCAGAAAAGCAAAGATCTCCCCAGGACAA
 CCAAATGGCAATCATCATCATGGTAGCAGTAGGTCTTCTGGGCTTGATTACCGCCAATGAACTCGG
 5 ATGGTTGGAGAGAAACAAAGAGTGACCTAAGCCATCTAATGGGAAGGAGAGAGGAGGGAGCAACC
 ATAGGATTCTCAATGGACATTGACCTGCGGCCAGCCTCAGCTTGGGCCATCTATGCTGCCTTGACA
 ACTTTCATTACCCAGCCGTCCAACATGCAGTGACCACTTCATACAACAACACTACTCCTTAATGGCG
 ATGGCCACGCAAGCTGGAGTGTTGTTTGGTATGGGCAAAGGGATGCCATTCTACGCATGGGACTTT
 GGAGTCCCGCTGCTAATGATAGGTTGCTACTCACAATTAACACCCCTGACCCTAATAGTGGCCATC
 ATTTTGCTCGTGGCGCACTACATGTACTTGATCCCAGGGCTGCAGGCAGCAGCTGCGCGTGCTGCC
 10 CAGAAGAGAACGGCAGCTGGCATCATGAAGAACCCTGTTGTGGATGGAATAGTGGTGACTGACAT
 TGACACAATGACAATTGACCCCCAAGTGGAGAAAAAGATGGGACAGGTGCTACTCATAGCAGTAG
 CAGTCTCCAGCGCCATACTGTGCGGACCGCCTGGGGGTGGGGGGAGGCTGGGGCCCTGATCACA
 GCCGCAACTTCCACTTTGTGGGAAGGCTCTCCGAACAAGTACTGGAACCTCTACAGCCACTTCA
 CTGTGTAACATTTTAGGGGAAGTTACTTGGCTGGAGCTTCTCTAATCTACATAGTAACAAGAAAC
 15 GCTGGCTTGGTCAAGAGACGTGGGGGTGGAACAGGAGAGACCCTGGGAGAGAAATGGAAGGCC
 GCTTGAACCAGATGTGCGCCCTGGAGTTCTACTCCTACAAAAAGTCAGGCATCACCGAGGTGTGCA
 GAGAAGAGGGCCCGCCGCGCCCTCAAGGATGGTGTGGCAACGGGAGGCCATGCTGTGTCCCAGGA
 AGTGCAAAGCTGAGATGGTTGGTGGAGCGGGGATACCTGCAGCCCTATGGAAGGTCATTGATCT
 TGGATGTGGCAGAGGGGGCTGGAGTTACTACGCCGCCACCATCCGCAAGTTCAAGAAGTGAAAG
 20 GATACACAAAAGGAGGCCCTGGTCATGAAGAACCCTGTTGGTGCAAGCTATGGGTGGAACATA
 GTCCGTCTTAAGAGTGGGGTGGACGTCTTTCATATGGCGGCTGAGCCGTGTGACACGTTGCTGTGT
 GACATAGGTGAGTCATCATCTAGTCCTGAAGTGGAAGAAGCACGACGCTCAGAGTCTCTCCAT
 GGTGGGGGATTGGCTTGAAAAAGACCAGGAGCCTTTTGTATAAAAGTGTGTGCCCATACACCA
 GCACTATGATGGAAACCCTGGAGCGACTGCAGCGTAGGTATGGGGGAGGACTGGTCAGAGTGCCA
 25 CTCTCCCGCAACTCTACACATGAGATGTACTGGGTCTCTGGAGCGAAAAGCAACACCATAAAAAG
 TGTGTCCACCACGAGCCAGCTCCTCTTGGGGCGCATGGACGGGCCTAGGAGGCCAGTGAATATG
 AGGAGGATGTGAATCTCGGCTCTGGCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATG
 AAGATCATTGGTAACCGCATTGAAAGGATCCGCAGTGAGCACGCGGAAACGTGGTTCTTTGACGA
 GAACCAACCATATAGGACATGGGCTTACCATGGAAGCTATGAGGCCCCACACAAGGGTCAGCGT
 30 CCTCTTAATAAACGGGGTTGTCAAGGTCCTGTGCAAAACCCTGGGATGTGGTGACTGGAGTCACAG
 GAATAGCCATGACCGACACCACACCGTATGGTCAGCAAAAGAGTTTTCAAGGAAAAAGTGGACACT
 AGGGTGCCAGACCCCCAAGAAGGCACTCGTCAGGTTATGAGCATGGTCTCTTCTGGTTGTGGAAA
 GAGCTAGGCAAAACACAAACGGCCACGAGTCTGTACCAAGAAGAGTTCATCAACAAGGTTCTGTAG
 CAATGCAGCATTAGGGGCAATATTTGAAGAGGAAAAAGAGTGGAAGACTGCAGTGGAAGCTGTG
 35 AACGATCCAAGTTCTGGGCTCTAGTGGACAAGGAAAGAGAGCACCACTGAGAGGAGAGTGCC
 AGAGTTGTGTGTACAACATGATGGGAAAAAGAGAAAAAGAAACAAGGGGAATTTGGAAGGCCAA
 GGGCAGCCGCGCCATCTGGTATATGTGGCTAGGGCTAGATTCTAGAGTTCTGAAGCCCTTGGATT
 CTGGAAGGAGATCACTGGATGGGGAGAGAGAACTCAGGAGGTGGTGTGAAGGCTGGGATTAC
 AAAGACTCGGATATGTCCTAGAAGAGATGAGTCGCATACCAGGAGGAAGGATGTATGCAGATGAC
 40 ACTGCTGGCTGGGACACCCGCATCAGCAGGTTGATCTGGAGAATGAAGCTCTAATCACCAACCA
 AATGGAGAAAGGGCATAGGGCCTTGGCATTGGCCATAATCAAGTACACATACCAAAAACAAAGTGG
 TAAAGGTCTTAGACCAGCTGAAAAAGGGAAAAACAGTTATGGACATTATTCGAGACAAAGACCA
 AGGGGGAGCGGACAAGTTGTCACTTACGCTCTTAACACATTTACCAACCTAGTGGTGCAACTCATT
 CGGAATATGGAGGCTGAGGAAGTTCTAGAGATGCAAGACTTGTGGCTGCTGCGGAGGTGAGAGAA
 45 AGTGACCAACTGGTTGCAGAGCAACGGATGGGATAGGCTCAAACGAATGGCAGTCAGTGGAGATG
 ATTGCGTTGTGAAGCCAATTGATGATAGGTTTGCACATGCCCTCAGGTTCTTGAATGATATGGGAA
 AAGTTAGGAAGGACACACAAGAGTGGAACCCCTCAACTGGATGGGACAACCTGGGAAGAAGTTCC
 GTTTTGCTCCCACTTCAACAAGCTCCATCTCAAGGACGGGAGGTCCATTGTGGTTCCCTGCCG
 CCACCAAGATGAACTGATTGGCCGGGCCCCGCTCTCTCCAGGGGCGGGATGGAGCATCCGGGAGA
 50 CTGCTTGCCCTAGCAAAATCATATGCGCAATGTGGCAGCTCCTTTATTTCCACAGAAGGGACCTCC
 GACTGATGGCCAATGCCATTTGTTTCATCTGTGCCAGTTGACTGGGTTCCAACCTGGGAGAACTACCT
 GGTCAATCCATGGAAGGGGAGAATGGATGACCACTGAAGACATGCTTGTGGTGTGGAACAGAGTG
 TGGATTGAGGAGAACGACCACATGGAAGACAAGACCCAGTTACGAAATGGACAGACATTCCTTA
 TTTGGAAAAAAGGGAAGACTTGTGGTGTGGATCTCTCATAGGGCACAGACCCGCGCACCACTGGG
 55 CTGAGAACATTAAAAACACAGTCAACATGGTGCAGGATCATAGGTGATGAAGAAAAAGTACATG
 GACTACCTATCCACCCAAGTTCGCTACTTGGGTGAAGAAGGGTCTACACCTGGAGTGCTGTAAGCA
 CCAATCTTAATGTTGTCAGGCCTGCTAGTCAGCCACAGCTTGGGGAAAGCTGTGCAGCCTGTGACC

PAT018/EP/PR3

CCCCAGGAGAAGCTGGGAAACCAAGCCTATAGTCAGGCCGAGAACGCCATGGCACGGAAGAAG
CCATGCTGCCTGTGAGCCCCTCAGAGGACACTGAGTCAAAAAACCCCATGCGCTTGGAGGCGCAG
GATGGGAAAAAGAGGTGGCGACCTTCCCCACCTTCAATCTGGGGCCTGAACTGGAGATCAGCTG
TGGATCTCCAGAAGAGGGACTAGTGGTTAGAGGAGACCCCCGGAAAAACGCAAAACAGCATATTG
5 ACGCTGGGAAAGACCAGAGACTCCATGAGTTTCCACCACGCTGGCCGCCAGGCACAGATCGCCGA
ATAGCGGCGGCCGGTGTGGGGAATCCATGGGTCTT

KU681081.3 Zika virus isolate Zika virus/H.sapiens-tc/THA/2014/SV0127- 14, Thailand,
complete genome (SEQ ID NO: 7)

10 AGTTGTTGATCTGTGTGAATCAGACTGCGACAGTTTCGAGTTTGAAGCGAAAGCTAGCAACAGTATC
AACAGGTTTTATTTTGGATTGGAAACGAGAGTTTCTGGTCATGAAAAACCCAAAAAAGAAATCC
GGAGGATTCCGGATTGTCAATATGCTAAAACGCGGAGTAGCCCGTGTGAGCCCCCTTTGGGGGCTTG
AAGAGGCTGCCAGCCGGACTTCTGCTGGGTCTATGGGCCCATCAGGATGGTCTTGGCGATTCTAGCC
TTTTTGAGATTACGGCAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTCAGTGGGAAAA
15 AAAGAGGCTATGGAAATAATAAAGAAGTTCAAGAAAGATCTGGCTGCCATGCTGAGAATAATCAA
TGCTAGGAAGGAGAAGAAGAGACGAGGCACAGATACTAGTGTGGAATTGTTGGCCTCCTGCTGA
CCACAGCTATGGCAGCGGAGGTCACTAGACGTGGGAGTGCATACTATATGTACTTGGACAGAAGC
GATGCTGGGGAGGCCATATCTTTCCAACCACACTGGGGATGAATAAGTGTTATATACAGATCATG
GATCTTGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTATGCTGGATGAGGGGGTAGA
20 ACCAGATGACGTCGATTGTTGGTGCAACACGACGTCAACTTGGGTTGTGTACGGAACCTGCCATCA
CAAAAAAGGTGAAGCACGGAGATCCAGAAGAGCTGTGACGCTCCCCTCCCATTCCACTAGGAAGC
TGCAACGCGGTGCGACACCTGGTTGGAATCAAGAGAATACACAAAGCACTTGATTAGAGTCGAA
AATTGGATATTACAGGAACCTGGCTTCGCGTTAGCAGCAGCTGCCATCGCTTGGCTTTTGGGAAGC
TCAACGAGCCAAAAAGTCATATACTTGGTCATGATACTGCTGATTGCCCCGGCATAACAGCATCAGG
25 TGCATAGGAGTCAGTAATAGGGACTTTGTGGAAGGTATGTCAGGTGGGACTTGGGTTGATGTTGTC
TTGGAACATGGAGTTGTGTACCGTAATGGCACAGGACAAACCGACTGTGACATAGAGCTGGT
TACAACAACAGTCAGCAACATGGCGGAGGTAAGATCCTACTGCTATGAGGCATCAATATCGGACA
TGGCTTCGGACAGCCGCTGCCAACACAAGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAA
TATGTCTGCAAAAGAACGTTAGTGGACAGAGGCTGGGGAATGGATGTGGACTTTTTGGCAAAGG
30 GAGCCTGGTGACATGCGCTAAGTTTGCATGCTCCAAGAAAAATGACCGGAAGAGCATCCAGCCAG
AGAATCTGGAGTACCGGATAATGTGTGCTGATGGCTCCAGCACAGTGGGATGATCGTTAATG
ACACAGGACATGAAACTGATGAGAATAGAGCGAAGGTTGAGATAACGCCCAATTCACCAAGAGC
CGAAGCCACCCTGGGGGGTTTTGGAAGCCTAGGACTTGATTGTGAACCGAGGACAGGCCTTGACT
TTTCAGATTTGTATTACTTGACTATGAACAACAAGCACTGGTTGGTTCACAAGGAGTGGTTCACG
35 ACATTCCATTACCTTGGCACACTGGGGCAGACACCGGAATCCACACTGGAACAACAAAGAAGCA
CTGGTAGAGTTCAAGGACGCACATGCCAAAAGGCAAACTGTCGTGGTTCTAGGGAGTCAAGAAGG
AGCAGTTCACACGGCCCTTGCTGGAGCTCTGGAGGCTGAGATGGATGGTGCAAAGGGAAGGCTGT
CCTCTGGCCACTTGAAATGTGCGCTGAAAATGGATAAACTTAGATTGAAGGGCGTGTCTACTCCT
TGTGTACCGCAGCGTTCACATTACCAAGATCCCGGCTGAAACACTGCACGGGACAGTCACAGTG
40 GAGGTACAGTACGCAGGGACAGATGGACCTTGCAAGGTTCCAGCTCAGATGGCGGTGGACATGCA
AACTCTGACCCAGTTGGGAGGTTGATAACCGCTAACCCCGTAATCACTGAAGGCACTGAGAAT
CTAAGATGATGCTGGAACCTTGATCCACCATTGGGGACTCTTACATTGTCATAGGAGTCGGGGAGA
AGAAGATCACCCACCACTGGCACAGGAGTGGCAGCACCATTGGAAAAGCATTGGAAGCCACTGTG
AGAGGTGCCAAGAGAATGGCAGTCTTGGGAGACACAGCCTGGGACTTTGGATCAGTTGGAGGCGT
45 TCTTAACCTCATTGGGCAAGGGCATCCATCAAATTTTTGGAGCAGCTTCAAATCATGTTTGGAGG
AATGTCCTGGTTCTCACAAATTCTCATTGGAACGTTGCTGATGTGGTTGGGTCTGAATACAAAGAA
TGGATCTATTTCCCTTATGTGCTTGGCCTTAGGGGGAGTGTTGATCTTCTTATCCACAGCCGTCTCC
GCTGATGTGGGGTGCTCGGTGGACTTCTCAAAGAAGGAAACGAGATGCGGTACAGGGGTGTTCTGT
CTATAACGACGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCCTGACTCCCCTCGTAGATTGGC
50 AGCAGTAGTCAAAGCAAGCCTGGGAAGATGGTATCTGTGGGATCTCCTCTGTTTCAAAGAATGGA
ACATCATGTGGAGATCAGTAGAAGGGGAGCTCAACGCAATCCTGGAAGAGAATGGAGTTCAACTG
ACGGTCGTTGTGGGATCTGTAAAAAACCCCATGTGGAGAGGTCCACAGAGATTGCCCCGTGCCTGT
GAACGAGCTGCCCCACGGCTGGAAGGCTTGGGGGAAATCGTACTTCGTCAGAGCAGCAAGACAA
ATAACAGCTTTGTGCTGGATGGTGACACACTGAAGGAATGCCCACTCAAACATAGAGCATGGAAC
55 AGCTTCTTGTGGAGGATCATGGGTTTCGGGTATTTCACACTAGTGTCTGGCTCAAGGTTAGAGAA

GATTATTCACTAGAGTGTGATCCAGCCGTCATTGGAACAGCTGTTAAGGGAAAGGAGGCTGTACA
 CAGTGATCTAGGCTACTGGATTGAGAGTGAGAAGAACGACACATGGAGGCTGAGGAGGGCCCACC
 TGATCGAGATGAAAAATGTGAATGGCCAAAGTCCCACACATTGTGGACAGATGGAATAGAAGAG
 AGTGATCTGATCATACCCAAGTCTTTAGCTGGGCCACTCAGCCATCACAACACCAGAGAGGGCTAC
 5 AGGACCCAAATGAAAGGGCCATGGCACAGTGAAGAGCTTGAAATTCGGTTTGAGGAATGCCCAGG
 CACTAAGGTCCACGTGGAGGAAACATGTGGAACAAGAGGACCATCTCTGAGATCAACCACTGCAA
 GCGGAAGGGTGATCGAGGAATGGTGCTGCAGGGAGTGACAATGCCCCACTGTCGTTCCGGGCT
 AAAGATGGCTGTTGGTATGGAATGGAGATAAGGCCAGGAAAGAACAGAAAGTAACCTTAGTAA
 GGTCATGGTGACTGCAGGATCAACTGATCACATGGATCACTTTTCCCTTGAGTGTCTGTGATTTC
 10 TGCTCATGGTGAGGAAGGGCTGAAGAAGAGAATGACCACAAAGATCATCATAAGCACATCAATG
 GCAGTGCTGGTAGCTATGATCCTGGGAGGATTTTCAATGAGTGATCTGGCTAAGCTTGCAATTTTG
 ATGGGTGCCACCTTTGCGGAAATGAACACTGGAGGAGATGTAGCTCATCTGGCGCTGGTAGCGGC
 ATTCAAAGTCAGACCAGCGTTGCTGGTATCTTTTCACTTTCAGAGCTAATTGGACACCCCGTGAAAG
 CATGCTGCTGGCCTTGGCCTCGTGTCTTTTGCAAACTGCGATCTCCGCCTTGGGAAGGCGACCTGAT
 15 GGTCTCATCAATGGTTTTGCTTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCACGCACTGAC
 AATATCACCTTGGCAATCCTGGCTGCTCTGACACCCTGGCCCGGGGCACACTGCTTGTGGCGTGG
 AGAGCAGGCCTTGCTACTTGCGGGGGGTTTATGCTCCTCTCTCTGAAGGGGAAAGGCAGTGTGAA
 GAAGAAGTACCATTGTGTCATGGCCCTGGGACTAACCCTGCTGTGAGGCTGGTCGACCCCATCAACGT
 GGTGGGACTGCTGTTGCTCACAAGGAGTGGGAAGCGGAGCTGGCCCCCTAGCGAAGTACTCACAG
 20 CTGTTGGCCTGATATGCGCATTGGCTGGAGGGTTCGCCAAGGCAGATATAGAGATGGCTGGGCCC
 ATGGCCCGGTCGGTCTGCTAATTGTCAGTTACGTGGTCTCAGGAAAGAGTGTGGACATGTACATT
 GAAAGAGCAGGTGACATCACATGGGAAAAAGATGCGGAAGTTACTGGAAACAGTCCCCGGCTCG
 ATGTGGCACTAGATGAGAGTGGTGATTCTCCCTGGTGAGGATGACGGTCCCCCATGAGAGAG
 ATCATACTCAAAGTGGTCTGATGACCATCTGTGGCATGAACCAATAGCCATACCCCTTTCAGCT
 25 GGAGCGTGGTACGTATACGTGAAAAGTGGAAAAAGGAGTGGTGCTCTATGGGATGTGCCTGCTCC
 CAAGGAAGTAAAAAGGGGGAGACCACAGATGGAGTGTACAGAGTAATGACTCGTAGACTGCTA
 GGTTCACACAAGTTGGAGTGGGAGTTATGCAAGAGGGGGTCTTTTCACTATGTGGCATGTCCAC
 AAAAGGATCCGCGCTGAGAAGCGGTGAAGGGAGACTTGATCCATACTGGGGAGATGTCAAGCAG
 GATCTGGTGTACATACTGTGGTCCATGGAAGCTAGATGCCGCTGGGACGGGCACAGCGAGGTGCA
 30 GCTCTTGGCCGTGCCCCCGGAGAGAGAGCGAGGAACATCCAGACTCTGCCCGGAATATTTAAGA
 CAAAGGATGGGGACATTGGAGCGGTTGCGCTGGACTATCCAGCAGGAACCTCAGGATCTCCAATC
 CTAGACAAGTGTGGGAGAGTGATAGGACTCTATGGCAATGGGGTCTGATCAAGAATGGGAGTTA
 TGTCAGTGCCATCACCAAGGGAGGAGGGAGGAAGAGACTCCTGTTGAGTGCTTCGAGCCTTCGA
 TGCTGAAGAAGAAGCAGCTAACTGTCTTAGACTTGTCATCCTGGAGCTGGGAAAACAGGAGAGTT
 35 CTTCTGAAATAGTCCGTGAAGCCATAAAAACGAGACTCCGTACTGTGATCTTAGCTCCAACCAAGG
 GTTGTGCTGCTGAAATGGAGGAAGCCCTTAGAGGGCTTCCAGTGCGTTATATGACAACAGCAGTGC
 AATGTACCCATTCTGGGACAGAAATCGTTGACTTAATGTGCCATGCCACCTTCACTACAGTCTA
 CTACAGCCAACTCAGAGTCCCCAACTATAATCTGTATATTATGGATGAGGCCCACTTCACAGATCCC
 TCAAGTATAGCAGCAAGAGGATACATTTCAACAAGGGTTGAGATGGGCGAGGCAGCTGCCATCTT
 40 CATGACCGCCACGCCACCAGGAACCCGTGACGCATTCCCGGACTCCAACCTACCAATTATGGACA
 CCGAAGTGGAAGTCCCAGAGAGAGCCTGGAGCTCAGGCTTTGATTGGGTGACGGATCATTCTGGA
 AAAACAGTTTGGTTTGTCCAAAGCGTGAGGAACGGCAATGAGATCGCAGCTTGTCTGACAAAGGC
 TGGAAAACGGGTCATACAGCTCAGCAGAAAAGACTTTTGAGACAGAGTTCCAGAAAACAAAACATC
 AAGAGTGGGACTTCGTCTGTGACAACTGACATTTTCAAGATGGGCGCAACTTTAAAGCTGACCGT
 45 GTCATAGATTCCAGGAGATGCCTAAAGCCGCTCATACTTGATGGCGAGAGAGTCATTCTGGCTGG
 ACCCATGCCTGTACACATGCCAGCGCTGCCAGAGGAGGGGGCGCATAGGCAAGGAATCCCAACA
 AACCTGGAGATGAGTATCTGTATGGAGGTGGGTGCGCAGAGACTGATGAAGACCATGCACACTGG
 CTTGAAGCAAGAATGCTCCTTGACAATATTTACCTCCAAGATGGCCTCATAGCCTCGCTCTATCGA
 CCTGAGGCCGACAAAGTAGCAGCCATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAAGGAAGA
 50 CCTTTGTGGAACCTCATGAAAAAGAGGAGATCTTCTGTTTGGCTGGCCTATCAGGTTGCATCTGCCG
 GAATAACCTACACAGATAGAAGATGGTGCTTTGATGGCATGACCAACAACACCATAATGGAAGAC
 AGTGTGCCGGCAGAGGTGTGGACCAGACCGGAGAGAAAAGAGTGCTCAAACCGAGGTGGATGG
 ACGCCAGAGTTTGTTCAGATCATGCGGCCCTGAAGTCATTCAAGGAGTTTGGCCGTGGGAAAAGA
 GGAGCGGCTTTTGGAGTGATGGAAGCCCTGGGAACACTGCCAGGACACATGACGGAGAGATTCCA
 55 GGAAGCCATTGACAACCTCGCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAGCCG
 CGGCGGCCCAATTGCCGGAGACCCTAGAGACCATTATGCTTTTGGGGTTGCTGGGAACAGTCTCGC
 TGGGAATCTTTTTCGTCTTGATGCGGAACAAGGGCATAGGGAAGATGGGCTTTGGAATGGTGACTC

TTGGGGCCAGCGCATGGCTCATGTGGCTCTCGGAAATTGAGCCAGCCAGAATTGCATGCGTCCTCA
 TTGTTGTGTTCTTATTGCTGGTGGTGGTGCATACCTGAGCCAGAAAAGCAAAGATCCCCCAGGACA
 ACCAAATGGCAATCATCATCATGGTAGCAGTAGGTCTTCTGGGCTTGATTACCGCCAATGAACTCG
 5 GATGGTTGGAGAGAAACAAAGAGTGACCTAAGCCATCTAATGGGAAGGAGAGAGGAGGGGGCAAC
 CATAGGATTCTCAATGGACATTGACCTGCGGCCAGCCTCGGCCTGGGCCATCTATGCTGCCCTGAC
 AACTTTCATTACCCCAGCCGTCCAACATGCAGTGACCACTTCATACAACAACACTACTCCTTAATGGC
 GATGGCCACGCAAGCTGGAGTGTGTTGTTGGTATGGGCAAAAGGGATGCCATTCTACGCATGGGACTT
 TGGAGTCCCCTGCTAATGATAGGTTGCTACTCACAATTAACACCCCTGACCCTAATAGTGGCTAT
 10 CATTTTGTCTGTGGCGCACTACATGTACTTGTATCCCAGGGCTGCAGGCAGCAGCTGCGCGTGCTGC
 CCAGAAGAGAACGGCAGCTGGCATCATGAAGAACCCTGTTGTGGATGGAATAGTGGTGACTGACA
 TTGACACAATGACTATTGACCCCCAAGTGGAGAAAAAGATGGGACAGGTGCTACTCATAGCAGTA
 GCCGTCTCCAGCGCCATACTGTGCGGACCGCCTGGGGGTGGGGGAAGCTGGGGCCCTGATCAC
 AGCTGCAACTTCCACTTTTGTGGGAAGGCTCTCCGAACAAGTACTGGAACCTCTACAGCCACTTC
 15 ACTGTGCAACATTTTATAGGGGAAGTTACTTGGCTGGAGCTTCTCTAATCTACACAGTAACAAGAAA
 CGCTGGCTTGGTCAAGAGACGTGGGGGTGGAACAGGAGAGACCCTGGGAGAGAAATGGAAGGCC
 CGCTTGAACCAGATGTGCGCCCTGGAGTTCTACTCTACAAAAAGTCAGGCATCACCGAGGTGTGC
 AGAGAAGAGGCCCCGCCGCCCTCAAGGACGGTGTGGCAACGGGAGGCCATGCTGTGTCCCGAGG
 AAGTGCAAAGCTGAGATGGTTGGTGGAGCGGGGATACCTGCAGCCCTATGGAAGGTCATTGATC
 20 TTGGATGTGGCAGAGGGGGCTGGAGTTACTACGCCGCCACCATCCGCAAAAGTTCAAGAAGTGAAA
 GGATACACAAAAGGAGGCCCTGGTCATGAAGAACCCTATGTTGGTGCAAGCTATGGGTGGAACAT
 AGTCCGTCTTAAGAGTGGGGTGGACGTCTTTCATATGGCGGCTGAGCCGTGTGACACGTTGCTGTG
 TGACATAGGTGAGTCATCATCTAGTCCTGAAGTGGAAGAAGCACGGACGCTCAGAGTCTCTCCAT
 GGTGGGGGATTGGCTTGAAAAAAGACCAGGAGCCTTTTGTGTAAAAGTGTGTGCCCATACACCA
 25 GCACTATGATGGAAACCCTGGAGCGACTGCAGCGTAGGTATGGGGGAGGACTGGTCAGAGTGCCA
 CTCTCCCGCAACTCTACACATGAGATGTACTGGGTCTCTGGAGCGAAAAGCAACACCATAAAAAG
 TGTGTCCACCACGAGCCAGCTCCTCTTGGGGCGCATGGACGGGCCAGGAGGCCAGTGAATATG
 AGGAGGATGTGAATCTCGGCTCTGGCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATG
 AAGATCATTGGTAACCGCATTGAAAGGATCCGCAGTGAGCACGCGGAAACGTGGTTCTTTGACGA
 GAACCAACCATATAGGACATGGGCTTACCATGGAAGCTATGAGGCCCTACACAAGGGTCAGCGT
 30 CCTCTTAATAAACGGGGTTGTGACGGTCTCTGCAAAAACCCTGGGATGTGGTGACTGGAGTCACAG
 GAATAGCCATGACCGACACCACACCGTATGGTCAGCAAAAGAGTTTTCAAGGAAAAAGTGGACACC
 AGGGTGCCAGACCCCCAAGAAGGCACTCGTCAGGTTATGAGCATGGTCTCTTCTGGTTGTGGAAA
 GAGCTAGGCAAAACACAAACGGCCACGAGTCTGTACCAAGAAGAGTTCATCAACAAGGTTCTGTAG
 CAATGCAGCATTAGGGGCAATATTTGAAGAGGAAAAAGAGTGGAAGACCGCAGTGGAAGCTGTG
 35 AACGATCCAAGTTCTGGGCTCTAGTGGACAAGGAAAGAGAGCACCACTGAGAGGAGAGTGCC
 AGAGCTGTGTGTACAACATGATGGGAAAAAGAGAAAAAGAAACAAGGGGAATTTGGAAGGCCAA
 GGGCAGCCGCGCCATCTGGTATATGTGGCTAGGGCTAGATTCTAGAGTTCTGAAGCCCTTGGATT
 CTAAATGAGGATCACTGGATGGGGAGAGAGAACTCAGGAGGTGGTGTGGAAGGCTGGGATTAC
 AAAGACTCGGATATGTCCTAGAAGAGATGAGTCGCATACCAGGAGGAAGGATGTATGCAGATGAC
 40 ACTGCTGGCTGGGACACCCGCATCAGCAGGTTTGATCTGGAGAATGAAGCTTTAATCACCAACCA
 AATGGAGAAAGGGCACAGGGCCTTAGCATTGGCCATAATCAAGTACACATACCAAAAACAAAGTGG
 TAAAGGTCTTAGACCAAGCTGAAAAAGGGAAGACAGTTATGGACATTATTTCAAGACAAAGACCAA
 AGGGGGAGCGGACAAGTTGTCACTTACGCTCTTAACACATTACCAACCTAGTGGTGCAACTCATT
 CGGAATATGGAGGCTGAGGAAGTTCTAGAGATGCAAGACTTGTGGCTGCTGCGGAGGTGAGAGAA
 45 AGTGACCAACTGGTTGCAGAGCAACGGATGGGATAGGCTCAAACGAATGGCAGTCAGTGGAGATG
 ATTGCGTTGTGAAGCCAATTGATGATAGGTTTGACATGCCCTCAGGTTCTTGAATGATATGGGAA
 AAGTTAGGAAGGACACACAAGAGTGGAAACCCTCAACTGGATGGGACAACCTGGGAAGAAGTTCC
 GTTTTGTTCACCACCTTCAACAAGCTCCATCTCAAGGACGGGAGGTCCATTGTGGTTCCCTGCCG
 CCACCAAGATGAACTGATTGGCCGGGCCCCGTGTCTCTCCAGGGGCGGGATGGAGCATCCGGGAGA
 50 CTGCTTGCCCTAGCAAAAGTCATATGCGCAATGTGGCAGCTCCTTTATTTCCACAGAAGGGACCTCC
 GACTGATGGCCAATGCCATCTGTTTCATCTGTGCCAGTTGACTGGGTTCCAACCTGGGAGAACTACCT
 GGTCAATCCATGGAAAGGGAGAATGGATGACCACTGAAGACATGCTTGTGGTGTGGAACAGAGTG
 TGGATTGAGGAGAACGACCACATGGAAGACAAGACCCAGTTACGAAATGGACAGACATTCCTTA
 TCTGGGAAAAAGGGAAAGACTTGTGGTGTGGATCTCTCATAGGGCACAGACCCGCGCACCCAGTGG
 55 CTGAGAACATTAAAAACACAGTCAACATGGTGCAGGATCATAGGTGATGAAGAAAAAGTACATG
 GACTACCTATCCACCCAAGTTCGCTACTTGGGTGAAGAAGGGTCTACACCTGGAGTGCTATAAGCA
 CCAATCTTAGTGTTGTCAGGCCTGCTAGTCAGCCACAGCTTGGGGAAAGCTGTGCAGCCTGTGACC

PAT018/EP/PR3

CCCCAGGAGAGGCTGGGAAACCAAGCCCATAGTCAGGCCGAGAACGCCATGGCACGGAAGAAG
CCATGCTGCCTGTGAGCCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAGGCGCAG
GATGGGAAAAAGAGGTGGCGACCTTCCCCACCCTTCAATCTGGGGCCTGAACTGGAGATCAGCTG
TGGATCTCCAGAAGAGGGACTAGTGGTTAGAGGAGACCCCCGGAAAAACGCAAAACAGCATATTG
5 ACGCTGGGAAAGACCAGAGACTCCATGAGTTTCCACCACGCTGGCCGCCAGGCACAGATCGCCGA
ATAGCGGCGGCCGGTGTGGGGAAATCCATGGGTCT

KU681082.3 Zika virus isolate Zika virus/H.sapiens-tc/PHL/2012/CPC-0740, Philippines,
complete genome (SEQ ID NO: 8)

10 AGTTGTTGATCTGTGTGAATCAGACTGCGACAGTTTCGAGTTTGAAGCGAAAGCTAGCAACAGTATC
AACAGGTTTTATTTTGGATTGGAAACGAGAGTTTCTGGTCATGAAAAACCCAAAAAGAAATCC
GGAGGATTCCGGATTGTCAATATGCTAAAACGCGGAGTAGCCCGTGTGAGCCCCCTTTGGGGGCTTG
AAGAGGCTGCCAGCCGACTTCTGCTGGGCCATGGGCCCATCAGGATGGTCTTGGCGATACTAGC
CTTTTGTAGATTACGGCAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTCAGTGGGGAA
15 AAAAGAGGCTATGGAAATAATAAAGAAAGTTCAAGAAAGATCTGGCTGCCATGCTGAGAATAATCA
ATGCTAGGAAGGAGAAGAAGAGACGAGGCGCAGATACTAGCGTCGGAATTGTTGGCCTCTCTCTG
ACCACAGCCATGGCAGTAGAGGTCACTAGACGTGGGAGTGCATACTATATGTACTTGGACAGAAG
CGATGCTGGGGAGGCCATATCTTTCCAACCACACTGGGGATGAATAAGTGTTACATACAAATCAT
GGATCTTGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTATGTTGGATGAGGGGGTAG
20 AACCAGATGACGTCGATTGCTGGTGCAACACGACATCAACTTGGGTTGTGTATGGAACCTGCCACC
ACAAAAAAGGTGAAGCACGGAGATCTAGAAGAGCTGTGACGCTCCCTCCCATTTCCACTAGGAAG
CTGCAAACGCGGTCGACAGACCTGGTTGGAATCAAGAGAATACACAAAGCACCTGATTAGAGTTGA
AAATTGGATATTACAGGAACCCCTGGCTTCGCGTTAGCAGCAGCTGTCATCGCTTGGCTTTTGGGAAG
TTCAACGAGCCAAAAAGTCATATATCTGGTCATGATACTGCTGATTGCCCCGGCATAACAGCATCAG
25 GTGCATAGGAGTCAGCAATAGGGACTTTGTGGAAGGTATGTCAGGTGGGACTTGGGTTGATGTTGT
CTTGAACATGGAGGTTGTGTTACCGTAATGGCACAGGACAAACCGACTGTCGACATAGAGCTGG
TTACAACAACAGTCAGCAACATGGCGGAGGTAAGATCCTACTGCTATGAGGCATCAATATCGGAT
ATGGCTTCGGACAGCCGCTGCCCAACACAAGGTGAGGCCTACCTTGACAAGCAGTCAGACACTCA
ATATGTCTGCAAAAGAACGTTAGTGGACAGAGGCTGGGGAAATGGATGTGGACTTTTGGCAAAG
30 GGAGCCTGGTGACATGCGCTAAGTTTCATGCTCCAAGAAAATGACCGGGAAGAGCATCCAGCCA
GAGAATCTGGAGTACCGGATAATGCTGTCAGTTTCATGGCTCCAGCACAGTGGGATGATCGTTAAT
GACACAGGACATGAACTGATGAGAATAGAGCGAAGGTTGAGATAACGCCCAATTCACCAAGAG
CCGAAGCCACCCTGGGGGGTTTTGGGAGCCTAGGACTTGATTGTGAACCGAGGACAGGCCTTGAC
TTTTAGATTGTATTACCTGACTATGAATAACAAGCACTGGTTGGTTCACAAGGAGTGGTTCCAC
35 GACATTCCATTACCTTGGCATGCTGGGGCAGACACTGGAACCTCCACATTGGAACAACAAAGAAGC
ACTGGTAGAGTTCAAGGACGCACATGCAAAAAGGCAAACCTGTCGTGGTTCTAGGGAGTCAAGAAG
GAGCAGTTCACACGGCCCTTGCTGGAGCTCTGGAGGCTGAGATGGATGGAGCCAAGGGAAGGCTG
TCCTCTGGCCACTTGAAATGTGCGCTGAAAATGGATAAACTTAGATTGAAGGGCGTGTCACTACTC
TTGTGCACTGCAGCGTTACATTACCAAGATCCCGGCTGAAACACTGCACGGGACAGTCACAGTG
40 GAGGTACAGTACGCAGGGACAGATGGACCTTGCAAGGTTCCAGCTCAGATGGCGGTGGATATGCA
AACTCTGACCCAGTTGGGAGGTTGATAACCGCTAACCTGTAATCACTGAAAGCACCGAGAATCT
CTAAGATGATGCTGGAACCTTGATCCACCATTGGGGACTCTTACATTGTCATAGGAGTCGGGGAGA
AGAAGATCACCCATCACTGGCACAGGAGTGGCAGCACCATTGGAAGAGCATTGGAAGCCACTGTG
AGAGGTGCCAAGAGAATGGCAGTCTTGGGAGACACAGCCTGGGACTTTGGATCAGTTGGGGGTGC
45 TCTCAACTCATTGGGCAAGGGCATCCATCAAATTTTTGGAGCAGCTTCAAATCATTGTTTCGGAGG
AATGTCCTGGTTCTCACAAATTCTCATTGGAACGTTGCTGGTGTGGTTGGGTCTGAATACAAAGAA
TGGATCTATTTCCCTTACGTGCTTGGCCTTAGGGGGAGTGTTGATCTTCTTATCCACAGCCGTTCT
GCTGATGTGGGGTGCTCGGTGGACTTCTCAAAGAAGGAAACGAGATGCGGTACAGGGGTGTTCTG
CTATAACGACGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCCTGACTCCCTCGTAGATTGGC
50 AGCAGCAGTCAAAGCAAGCCTGGGAAGATGGGATCTGTGGGATCTCCTCTGTCTCAAAGAAATGGAAA
ACATCATGTGGAGATCAGTAGAAGGGGAGCTCAACGCAATCCTGGAAGAGAATGGAGTTCAACTG
ACGGTCGTTGTGGGATCTGTAAAAAACCCCATGTGGAGAGGTCCACAGAGATTGCCCCGTGCCTGT
GAACGAGCTGCCCCACGGCTGGAAGGCTTGGGGGAAATCGTACTTCGTCAGAGCAGCAAGACAA
ATAACAGCTTTGTCTGTGGATGGTGACACACTGAAGGAATGCCCACTCAAACATAGAGCATGGAAC
55 AGCTTCTTGTGGAGGATCATGGGTTTGGGGTATTTCACACTAGTGTCTGGCTCAAGGTTAGAGAA

GATTATTCATTAGAGTGTGATCCAGCCGTCATTGGAACAGCTGCTAAGGGAAAGGAGGCTGTGCA
 CAGCGATCTAGGCTACTGGATTGAGAGTGAGAAGAACGACACATGGAGGCTGAAGAGGGCCAC
 CTGATCGAGATGAAAAACATGTGAATGGCCAAAGTCCCACACATTGTGGACAGATGGAGTAGAAGA
 AAGTGATCTGATCATACCCAAGTCTTTAGCTGGGCCACTCAGCCATCACAACACCAGAGAGGGCT
 5 ACAGGACTCAAATGAAAGGGCCATGGCACAGTGAAGAGCTTGAAATTCGGTTTGAGGAATGCCCA
 GGCACATAAGGTCCACGTGGAGGAAACATGTGGGACAAGAGGACCATCCCTGAGATCAACCACTGC
 AAGCGGAAGGGTGATCGAGGAATGGTGTCTGCAGGGAATGCACAATGCCCCCACTGTCTGTTCCGAG
 CTAAAGATGGCTGTTGGTATGGAATGGAGATAAGGCCCAGGAAAGAACAGAAAGTAACCTTAGTA
 AGGTCAATGGTGACTGCAGGATCAACTGATCACATGGATCACTTCTCTCTTGGAGTGCTTGTGATT
 10 TTGCTCATGGTGCAGGAAGGGCTGAAGAAGAGAATGACCACAAAGATCATCATAAGCACATCAAT
 GGCAGTGCTGGTAGCCATGATCCTGGGAGGATTTTCAATGAGTGACCTGGCTAAGCTTGCAATTTT
 GATGGGTGCCACCTTCGCGGAAATGAACACTGGAGGAGATGTAGCTCATTTGGCGCTGATAGCGG
 CATTCAAAGTCAGACCTGCGTTGCTGGTATCTTTCATCTTCAGAGCTAATTGGACACCCCGTGAGA
 GCATGTGCTGGCCTTGGCCTCGTGTCTTCTGCAAACTGCGATCTCCGCCTTGGAAGGCGACCTGA
 15 TGTTTCTCATCAATGGTTTTGCTTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCACGCACTGA
 CAACATCACCTTGGCAATCCTGGCTGTCTGACACCACTGGCCCCGGGACACTGCTTGTGGCGTG
 GAGAGCAGGCCCTTGCTACTTGCAGGGGGGTTTATGCTCCTCTCTCTGAAGGGGAAAGGCAGTGTGA
 AGAAGAACCTACCATTTGTCATGGCCTTGGGACTAAGTGTGTGAGGCTGGTTCGACCCCATCAACG
 TGGTGGGACTGCTGTTGCTCACAAGGAGTGGGAAGCGGAGCTGGCCCCCTAGTGAAGTACTCACA
 20 GCTGTTGGCCTGATATGCGCATTGGCTGGAGGGTTTCGCCAAGGCGGATATAGAGATGGCTGGGCC
 CATGGCCGCGGTGCGTCTGCTAATTGTCAGTTACGTGGTCTCAGGAAAGAGTGTGGACATGTACAT
 TGAAAGAGCAGGTGACATCACATGGGAAAAAGATGCGGAAATCACTGGAAACAGTCCCCGGCTC
 GATGTGGCACTAGATGAGAGTGGTGATTTCTCCCTAGTGGAGGATGATGGTCCACCCATGAGAGA
 GATCATACTCAAAGTGGTCCTGATGACCATCTGCGGCATGAACCCAATAGCCATACCCCTTTCAGC
 25 TGGAGCGTGGTACGTGTATGTGAAGACTGGAAAAAGGAGTGGTGTCTATGGGATGTGCCTGCTC
 CCAAGGAAGTAAAAAGGGGGAGACCACAGATGGAGTGTACAGAGTAATGACTCGTAGACTGCT
 TGGTTCAACACAAGTTGGAGTGGGAGTCAATGCAAGAGGGGGTCTTCCACACTATGTGGCACGTCA
 CAAAAGGATCCGCGCTGAGAAGCGGTGAAGGGAGACTTGATCCATACTGGGGAGATGTCAAGCA
 GGATCTGGTGTCTACTGTGGTCCGTGGAAGCTAGACGCCGCTGGGACGGGCACAGCGAGGTGC
 30 AGCTCTTGGCCGTGCCCCCGGAGAGAGAGAGCGGAACATCCAGACTCTGCCCGGAACATTTAAG
 ACAAAGGATGGGGACATTGGAGCAGTTGCGCTGGACTACCCAGCAGGAACCTTCAGGATCTCCAAT
 CCTAGACAAGTGTGGGAGAGTGATAGGACTCTATGGTAATGGGGTCTGTGATAAAAAATGGGAGTT
 ATGTTAGTGCCATCACCCAAGGGAGGAGGGAGGAAGAGACTCCTGTTGAGTGCTTCGAGCCTTCG
 ATGCTGAAGAAGAAGCAGCTAACTGTCTTAGACCTGCATCCTGGAGCCGGGAAAACCAGGAGAGT
 35 TCTTCTGAAATAGTCCGTGAAGCCATAAAAAACAAGACTCCGTAAGTGTGATCTTAGCTCCAACCA
 GGTGCTGCTGTGAAATGGAGGAAGCCCTTAGAGGGCTTCCAGTTTCTTATATGACAACAGCAGT
 CAATGTCACCCATTCTGGGACAGAAATCGTTGACTTAATGTGCCATGCTACCTTCACTTACAGCCT
 ACTACAACCAATCAGAGTCCCCAACTATAATTTGTATATTATGATGATGAGGCCCACTTACAGATCC
 CTCAAGTATAGCAGCAAGAGGATACATTTCAACAAGGGTTGAGATGGGCGAGGCGGCTGCCATCT
 40 TCATGACCGCCACGCCACCAGGAACCCGTGACGCATTCCCGGACTCCAACCTACCAATTATGGACA
 CCGAGGTGGAAGTCCCAGAGAGAGCCTGGAGCACAGGCTTTGATTGGGTGACGGATCATTCTGGG
 AAAACAGTCTGGTTTGTTCGAAGCGTGAGGAACGGCAATGAGATCGCAGCTTGTCTGACAAAGGC
 TGGAAAACGGGTCATACAGCTCAGCAGAAAAGACTTTTGAGACAGAGTTCCAGAAAACGAAAAATC
 AAGAGTGGGACTTCGTCTGTGACAACCGACATTTTCAAGAGATGGGCGCAACTTTAAAGCTGACCGT
 45 GTCATAGATTCCAGGAGATGCTTAAAGCCGCTCATACTTGTATGGCGAGAGAGTCATTTTGGCTGGA
 CCCATGCCTGTACACATGCCAGCGCTGCTCAGAGGAGGGGGCGCATAGGCAGGAATCCCAACAA
 ACCTGGAGATGAGTATCTGTATGGAGGTGGGTGCGCAGAGACTGATGAAGATCACGCACACTGGC
 TTGAAGCAAGAATGCTTCTTGACAACATTTACCTCCAAGATGGCCTCATAGCTTCGCTCTATCGAC
 CTGAGGCCGACAAAGTAGCAGCTATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAAGGAAGAC
 50 CTTTGTGGAACCTCATGAAAAAGAGGAGATCTTCCGGTTTGGTTGGCCTATCAGGTTGCATCTGCCGG
 AATAACCTACACAGATAGAAGATGGTGCTTTGATGGCATGACCAACAACACCATAATGGAAGACA
 GTGTGCCGGCAGAGGTGTGGACCAGATACGGAGAGAAAAAGAGTGTCAAACCGAGGTGGATGGA
 CGCCAGAGTTTGTTCAGATCATGCGGCCCTGAAGTCATTCAAAGAGTTTGGCGCTGGGAAAAGAG
 GAGCGGCCTTTGGAGTGATAGAAGCCCTGGGAACACTGCCAGGACACATGACAGAGAGATTCCAG
 55 GAAGCCATTGACAACCTCGCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCTTACAAAGCCGC
 GGCGGCCCAATTGCCGAGACCCTAGAGACCATTATGCTTTTGGGGTTGCTGGGAACAGTCTCGCT
 GGGAATCTTTTTCTGCTTGTATGCGGAACAAGGGCATGGGGAAGATGGGCTTTGGAATGGTGACTCT

TGGGGCCAGCGCATGGCTTATGTGGCTCTCGGAAATTGAGCCAGCCAGAATTGCATGTGTCCTCAT
 TGTCGTGTTCTTATGCTGGTGGTGCTCATACCTGAGCCAGAAAAGCAAAGATCTCCTCAGGACAA
 CCAAATGGCAATCATCATCATGGTAGCAGTGGGTCTTCTGGGCTTGATTACCGCCAATGAACTCGG
 5 ATGGTTGGAGAGAAACAAAAAGTGACCTAAGCCATCTAATGGGAAGGAGAGAGGAGGGGGCAACC
 ACAGGATTCTCAATGGACATTGACCTGCGGCCAGCCTCAGCTTGGGCTATCTATGCTGCTCTGACA
 ACTTTCATCACCCAGCCGTCCAACATGCGGTGACCACTTCATACAACAACACTACTCCTTAATGGCG
 ATGGCCACGCAAGCTGGGGTGTGTTTGGTATGGGCAAAAGGGATGCCATTCTACGCATGGGACTTT
 GGAGTCCCGCTGCTAATGATGGGTGCTACTCACAATTAACACCTCTGACCTAATAGTGGCCATC
 ATTTTGTCTGTGGCGCACTACATGTACTTGATCCCAGGGCTGCAGGCAGCAGCTGCGCGGGCTGCC
 10 CAGAAGAGAACGGCAGCTGGCATCATGAAGAACCCTGTTGTGGATGGAATAGTGGTGACTGACAT
 TGACACAATGACAATTGACCCCCAAGTGGAAAAAAGATGGGGCAGGTGCTACTCATAGCAGTAG
 CCGTCTCCAGCGCCATACTGTGCGGACCGCCTGGGGGTGGGGGGAGGCTGGGGCCCTGATCACA
 GCTGCAACTTCCACCTTGTGGGAAGGCTCTCCGAACAAGTACTGGAACCTCCACAGCCACTTCA
 CTGTGTAACATTTTTAGGGGAAGTTACTTGGCTGGAGCTTCTCTAATCTACACAGTAACAAGAAAC
 15 GCTGGCTTGGTCAAGAGACGTGGGGGTGGAACGGGAGAGACCCTGGGAGAGAAATGGAAGGCC
 GCCTGAACCAGATGTGCGCCCTGGAGTCTACTCCTACAAAAAGTCAGGCATCACCGAGGTGTGC
 AGAGAAGAGGCCCGCCGTGCCCTCAAGGACGGTGTGGCAACAGGAGGCCATGCTGTGTCCCGAGG
 AAGTGCAAAGCTTAGATGGCTGGTGGAGAGAGGATACCTGCAGCCCTATGGAAGGTCATTGATC
 TTGGATGTGGCAGAGGGGGCTGGAGTTACTATGCCGCCACCATCCGCAAAGTTCAGGAAGTGAAA
 20 GGATACACAAAAGGAGGCCCTGGTCATGAAGAACCCTGTTGGTGCAAAGCTATGGGTGGAACAT
 AGTCCGTCTTAAGAGTGGGGTGGACGTCTTTCACATGGCGGCTGAGCCGTGTGACACTTTGCTGTG
 TGATATAGGTGAGTCATCATCTAGTCTGAAAGTGAAGAAGCACGGACGCTCAGAGTCTCTCCAT
 GGTGGGGGATTGGCTTGAAAAAAGACCAGGAGCCTTTTGTATAAAAGTGTGTGCCCATACACCA
 GCACTATGATGGAAACCCTGGAGCGACTGCAGCGTAGGTATGGGGGAGGACTGGTCAGGGTGCCA
 25 CTCTCCCGCAACTCTACACATGAGATGTACTGGGTCTCTGGAGCGAAAAGCAACACCATAAAAAG
 TGTGTCCACCACGAGCCAGCTCCTCTTGGGGCGCATGGACGGGCCAGGAGGCCAGTGAATATG
 AGGAGGATGTGAATCTCGGCTCTGGCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATG
 AAGATCATTGGTAACCGCATTGAGAGGATCCGCAGTGAGCACGCGGAAACGTGGTCTTTGACGA
 GAACCAACCATATAGGACATGGGCTTACCATGGAAGCTATGAGGCCCTACACAAGGGTCAGCGT
 30 CCTCTTAATAAACGGGGTGTGTCAGGCTCCTGTAACAAACCCTGGGATGTGGTGACTGGAGTCAAG
 GAATAGCCATGACTGACACCACACCGTATGGTCAGCAAAGAGTTTTCAAGGAAAAAGTGGACACT
 AGGGTGCCAGACCCCCAAGAAGGCACTCGTCAGGTTATGAGCATGGTCTCTTCTGGTTATGGAAG
 GAGCTAGGCAAAACACAAACGGCCACGAGTCTGTACCAAGAAGAGTTCATCAACAAGGTTCTGTAG
 CAATGCAGCATTAGGGGCAATATTTGAAGAGGAAAAAGAGTGGAAAGACTGCAGTGGAAAGCTGTG
 35 AATGATCCAAGGTTCTGGGCTCTAGTGGACAAGGAAAGAGAGCATCACCTGAGAGGAGAGTGTC
 GAGCTGTGTGTACAACATGATGGGAAAAAGAGAAAAAGAAACAAAGGGGAATTTGGAAGGCCAAG
 GGCAGCCGCCCATCTGGTATATGTGGCTAGGGGCTAGATTCTAGAGTTCGAAGCCCTTGGATTCT
 TTGAATGAGGATCATTTGGATGGGGAGAGAGAATTCAAGGAGGTGGTGTGGAAGGACTCGGATTACA
 AAGACTCGGATATGTCTAGAAGAGATGAGTCGCATACCAGGAGGAAGGATGTATGCAGATGATA
 40 CTGCTGGCTGGGACACCCGCATCAGCAGGTTTGATCTGGAGAATGAAGCTCTAATCACCAACCAA
 ATGGAGAAAGGGCACAGGGCCTTGGCATTGGCCATAATCAAGTACACATACCAAAACAAAGTGGT
 AAAGGTCCTTAGACCAGCTGAAAAAGGGAAGACAGTTATGGACATTATTTCAAGACAAGACCAAA
 GGGGGAGCGGACAAGTTGTCACTTACGCTCTTAATACATTACCAACCTGGTGGTGCAGCTCATTC
 GGAATATGGAGGCTGAGGAAGTTCTAGAGATGCAAGACTTGTGGCTGCTGCGGAGGCCAGAGAAA
 45 GTGACCAACTGGTTGCAAAGCAACGGATGGGATAGGCTCAAAGAATGGCAGTCAGTGGAGATG
 ATTGCGTTGTGAAACCAATTGATGATAGGTTTGACATGCCCTCAGGTTCTTGAATGATATGGGAA
 AAGTTAGGAAGGACACACAAGAGTGGAAACCCTCAACTGGATGGGACAACCTGGGAAGAAGTTCC
 GTTTTGTCTCCACCACTTCAACAAACTCCATCTTAAGGACGGGAGGTCCATTGTGGTTCCCTGCCG
 CCACCAAGATGAACTGATTGGCCGAGCCCGGTATCACCAGGGGCGGGATGGAGCATCCGGGAGA
 50 CTGCTTGCCCTAGCAAAATCATATGCGCAAATGTGGCAGCTCCTTTATTTCCACAGAAGGGACCTCC
 GACTGATGGCCAATGCCATTTGTTTCATCTGTGCCAGTTGATTGGGTTCCAACCTGGGAGAACTACCT
 GGTCAATCCATGGAAAGGGAGAATGGATGACCACTGAAGACATGCTTGTGGTATGGAACAGAGTG
 TGGATTGAGGAAAACGACCACATGGAAGACAAGACCCAGTTACAAAATGGACAGACATTCCCTA
 TTTGGGAAAAAGAGAAGACTTGTGGTGTGGATCTCTCATAGGGCACAGACCCGCTACTACCTGGG
 55 CTGAGAACATCAAAAATACAGTCAACATGATGCGCAGGATCATAGGTGATGAAGAAAAGTACATG
 GACTACCTATCCACCCAGGTTCTGCTACTTGGGTGAAGAAGGGTCCACACCTGGAGTGCTGTAAGCA
 CCAATCTTAGTGTTGTCAGGCCTGCTAGTCAGCCACAGCTTGGGGAAAGCTGTGCAGCCTGTGACC

PAT018/EP/PR3

CCCCAGGAGAAGCTGGGAAACCAAGCCTATAGTCAGGCCGAGAACGCCATGGCACGGAAGAAG
CCATGCTGCCTGTGAGCCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAGGCGCAG
GATGGGAAAAAGAGGTGGCGACCTTCCCCACCTTCAATCTGGGGCCTGAACTGGAGATCAGCTG
5 TGGATCTCCAGAAGAGGGACTAGTGGTTAGAGGAGACCCCCGGAAAAACGCAAAACAGCATATTG
ACGCTGGGAAAGACCAGAGACTCCATGAGTTTCCACCACGCTGGCCGCCAGGCACAGATCGCCGA
ATAGCGGCGGCCGGTGTGGGGAAATCCATGGGTCT

KU707826.1 Zika virus isolate SSABR1, Brazil, complete genome (SEQ ID NO: 9)

10 GACAGTTCGAGTTTGAAGCGAAAGCTAGCAACAGTATCAACAGGTTTTATTTGGATTGGAACG
AGAGTTTCTGGTCATGAAAAACCAAAAAAGAAATCCGGAGGATTCCGGATTGTCAATATGCTAA
AACGCGGAGTAGCCCGTGTGAGCCCCTTTGGGGGCTTGAAGAGGCTGCCAGCCGGACTTCTGCTG
GGTCATGGGCCCATCAGGATGGTCTTGGCGATTCTAGCCTTTTTGAGATTACGGAATCAAGCCA
TCACTGGGTCTCATCAATAGATGGGGTTCAGTGGGGAAAAAGAGGCTATGGAAATAATAAGAA
15 GTTCAAGAAAGATCTGGCTGCCATGCTGAGAATAATCAATGCTAGGAAGGAGAAGAAGAGACGA
GGCGCAGATACTAGTGTGCGAATTGTTGGCCTCCTGCTGACCACAGCTATGGCAGCGGAGGTCCT
AGACGTGGGAGTGCATACTATATGTACTTGGACAGAAACGATGCTGGGGAGGCCATACTTTTTCCA
ACCATTTGGGGATGAATAAGTGTATATACAGATCATGGATCTTGGACACATGTGTGATGCCACC
ATGAGCTATGAATGCCCTATGCTGGATGAGGGGTGGAACCAGATGACGTCGATTGTTGGTGCAA
20 CACGACGTCAACTTGGGTGTGTACGGAACCTGCCATCAGAAAAAGGTGAAGCACGGAGATCTA
GAAGAGCTGTGACGCTCCCTCCCTTCCACTAGGAAGCTGCAAACGCGGTGCAAACCTGGTTG
GAATCAAGAGAATACACAAAGCACTTGATTAGAGTCGAAAATTGGATATTCAGGAACCTGGCTT
CGCGTTAGCAGCAGCTGCCATCGCTTGGCTTTTGGGAAGCTCAACGAGCCAAAAAGTCATATACTT
GGTCATGATACTGCTGATTGCCCGGCATACAGCATCAGGTGCATAGGAGTCAGCAATAGGGACT
25 TTGTGGAAGGTATGTGAGGTGGGACCTGGGTTGATGTTGTCTTGGAAACATGGAGGTTGTGTACCG
TAATGGCAGAGCAAAACCGACTGTCGACATAGAGCTGGTTACAACAACAGTCAGCAACATGGCG
GAGGTAAGATCCTACTGCTATGAGGCATCAATATCAGACATGGCTTCGGACAGCCGCTGCCAAC
ACAAGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAATATGTCTGCAAAAAGACGTTAGTGG
ACAGAGGCTGGGGAAATGGATGTGGACTTTTTGGCAAAGGGAGCCTGGTGACATGCGCTAAGTTT
30 GCATGCTCCAAGAAAATGACCGGGAAGAGCATCCAGCCAGAGAATCTGGAGTACCGGATAATGCT
GTCAGTTCATGGCTCCCAGCACAGTGGGATGATTGTTAATGACACAGGACATGAAACTGATGAGA
ATAGAGCGAAAGTTGAGATAACGCCCAATTCACCAAGAGCCGAAGCCACCTGGGGGGTTTTGGA
AGCCTAGGACTTGATTGTGAACCGAGGACAGGCTTGACTTTTTCAGATTTGTATTACTTGACTATG
AATAACAAGCACTGGTTGGTTCACAAGGAGTGGTTCCACGACATTCCATTACCTTGGCAGCTGGG
35 GCAGACACCGGAACTCCACACTGGAACAAACAAGCACTGGTAGAGTTCAAGGACGCACATG
CCAAAAGGCAAACTGTCGTGGTTCTAGGGAGTCAAGAAGGAGCAGTTCACACGGCCCTTGCTGGA
GCTCTGGAGGCTGAGATGGATGGTGCAAAGGGAAGGCTGTCTCTGGCCACTTGAAATGTCGCCT
GAAAATGGATAAACTTAGATTGAAGGGCGTGTCACTCCTTGTGTACTGCAGCGTTCACATTCAC
CAAGATCCCGGCTGAAACACTGCACGGGACAGTCACAGTGGAGGTACAGTACGCAGGGACAGAT
40 GGACCTTGCAAGGTTCCAGCTCAGATGGCGGTGGACATGCAAACTCTGACCCCACTTGGGAGGTT
GATAACCGCTAACCCCGTAATCACTGAAAGCACTGAGAACTTAAGATGATGCTGGAACCTTGATC
CACCATTGGGGACTCTTACATTGTATAGGAGTCGGGGAGAAGAAGATCACCCACCACTGGCAC
AGGAGTGGCAGCACCATTTGGAAGGCAATTTGAAGCCACTGTGAGAGGTGCCAAGAGAATGGCAGT
CTTGGGAGACACAGCCTGGGACTTTGGATCAGTTGGAGGCGCTCTCAACTCATTGGGCAAGGGCA
45 TCCATCAAATTTTTGGAGCAGCTTTCAAATCATTGTTGGAGGAATGTCTGGTTCTCAGAAATTTCT
CATTGGAACGTTGCTGATGTGGTTGGGTCTGAACACAAAGAATGGATCTATTTCCCTTATGTGCTT
GGCCTTAGGGGGAGTGTGATCTTCTTATCCACAGCCGTCTCTGCTGATGTGGGGTGCTCGGTGGA
CTTCTCAAAGAAGGAGACGAGATGCGGTACAGGGGTGTTCTGCTATAACGACGTTGAAGCCTGGA
GGGACAGGTACAAGTACCATCCTGACTCCCCCGTAGATTGGCAGCAGCAGTCAAGCAAGCCTGG
50 GAAGATGGTATCTGCGGGATCTCCTCTGTTTCAAGAATGGAAACATCATGTGGAGATCAGTAGA
AGGGGAGCTCAACGCAATCCTGGAAGAGAATGGAGTTCAACTGACGGTCGTTGTGGGATCTGTAA
AAAACCCCATGTGGAGAGGTCCACAGAGATTGCCCCTGCCTGTGAACGAGCTGCCCCACGGCTGG
AAGGCTTGGGGGAAATCGTACTTCGTGAGAGCAGCAAAGACAAATAACAGCTTTGTCTGTGGATGG
TGACACACTGAAGGAATGCCCACTCAACATAGAGCATGGAACAGCTTCTTGTGGAGGATCATG
55 GGTTCGGGGTATTTCACTAGTGTCTGGCTCAAGGTTAGAGAAAGATTATTCATTAGAGTGTGATC
CAGCCGTTATTGGAACAGCTGTTAAGGGAAAGGAGGCTGTACACAGTGATCTAGGCTACTGGATT

GAGAGTGAGAAGAATGACACATGGAGGCTGAAGAGGGCCCATCTGATCGAGATGAAAACATGTG
 AATGGCCAAAGTCCACACATTGTGGACAGATGGAATAGAAGAGAGTGATCTGATCATACCCAAG
 TCTTTAGCTGGGCCACTCAGCCATCACAATACCAGAGAGGGCTACAGGACCCAAATGAAAGGGCC
 5 ATGGCACAGTGAAGAGCTTGAATTCGGTTTGAGGAATGCCCAGGCACTAAGGTCCACGTGGAGG
 AAACATGTGGAACAAGAGGACCATCTCTGAGATCAACCACTGCAAGCGGAAGGGTGATCGAGGA
 ATGGTGCTGCAGGGAGTGCACAATGCCCCACTGTCGTTCCGGGCTAAAGATGGCTGTTGGTATGG
 AATGGAGATAAGGCCAGGAAAGAACCAGAAAGCAACTTAGTAAGGTCAATGGTGAAGTGCAGGA
 TCAACTGATCAGATGGACCACTTCTCCCTTGGAGTGTCTGTGATTCTGCTCATGGTGCAGGAAGGG
 10 CTGAAGAAGAGAATGACCACAAAGATCATCATAAGCACATCAATGGCAGTGCTGGTAGCTATGAT
 CCTGGGAGGATTTTCAATGAGTGACCTGGCTAAGCTTGCAATTTTGATGGGTGCCACCTTCGCGGA
 AATGAACACTGGAGGAGATGTAGCTCATCTGGCGCTGATAGCGGCATTCAAAGTCAGACCAGCGT
 TGCTGGTATCTTTCATCTTCAGAGCTAATTGGACACCCCGTGAAAGCATGCTGCTGGCCCTTGGCCCT
 GTGTCTTTTGCAAACTGCGATCTCCGCCTTGAAGGCGACCTGATGGTTCTCATCAATGGTTTTGCT
 TTGGCCTGGTTGGCAATACGAGCGATGGTTGTCCACGCACTGATAACATCACCTTGGCAATCCTG
 15 GCTGCTCTGACACCACTGGCCCGGGGCACACTGCTTGTGGCGTGGAGAGCAGGCCCTTGCTACTTGC
 GGGGGGTTTATGCTCCTCTCTCTGAAGGGAAGGACAGTGTGAAGAAGAACTTACCATTGTGCATG
 GCCCTGGGACTAACCGCTGTGAGGCTGGTCGACCCCATCAACGTGGTGGGACTGCTGTTGCTCACA
 AGGAGTGGGAAGCGGAGCTGGCCCCCTAGCGAAGTACTCACAGCTGTTGGCCTGATATGCGCATT
 GGCTGGAGGGTTTCGCAAGGCAGATATAGAGATGGCTGGGCCCATGGCCGCGGTGCGTCTGCTAA
 20 TTGTCAGTTACGTGGTCTCAGGAAAGAGTGTGGACATGTACATTGAAAGAGCAGGTGACATCACA
 TGGGAAAAAGATGCGGAAGTCACTGGAACAGTCCCCGGCTCGATGTGGCGCTAGATGAGAGTGG
 TGATTTCTCCCTGGTGGAGGATGACGCTCCCCCATGAGAGAGATCATACTCAAGGTGGTCTGAT
 GACCATCTGTGGCATGAACCAATAGCCATACCCTTTGCAGCTGGAGCGTGGTACGTATACGTGAA
 GACTGGAAAAAGGAGTGGTGTCTATGGGATGTGCCTGCTCCCAAGGAAGTAAAAAAGGGGGAG
 25 ACCACAGATGGAGTGTACAGAGTAATGACTCGTAGACTGCTAGGTTCAACACAAGTTGGAGTGGG
 AGTTATGCAAGAGGGGGTCTTTCACACTATGTGGCACGTCACAAAAGGATCCGCGCTGAGAAGCG
 GTGAAGGGGAGACTTGATCCATACTGGGGAGATGTCAAGCAGGATCTGGTGTCACTGTGGTCCA
 TGGAAGCTAGATGCCGCTGGGACGGGCACAGCGAGGTGCAGCTCTTGGCCGTGCCCCCGGAGA
 GAGAGCGAGGAACATCCAGACTCTGCCCGGAATATTTAAGACAAAGGATGGGGACATTGGAGCG
 30 GTTGGCTGGATTACCCAGCAGGAACCTTCAGGATCTCCAATCCTAGACAAGTGTGGGAGAGTGAT
 AGGACTTTATGGCAATGGGGTCTGTATCAAAAATGGGAGTTATGTTAGTGCCATCACCCAAGGGA
 GGAGGGAGGAAGAGACTCCTGTTGAGTGCTTCGAGCCTTCGATGCTGAAGAAGAAGCAGCTAACT
 GTCTTAGACTTGCATCCTGGAGCTGGGAAAACAGGAGAGTTCTTCTGAAATAGTCCGTGAAGCC
 ATAAAAACAAGACTCCGTACTGTGATCTTAGCTCCAACAGGGTTGTCGCTGCTGAAATGGAGGA
 35 GGCCCTTAGAGGGCTTCCAGTGCGTTATATGACAACAGCAGTCAATGTCACCCACTCTGGAACAGA
 AATCGTCGACTTAATGTGCCATGCCACCTTCACTTCACGTCTACTACAGCCAATCAGAGTCCCCAA
 CTATAATCTGTATATTATGGATGAGGCCCATCTCACAGATCCCTCAAGTATAGCAGCAAGAGGATA
 CATTATCAACAAGGGTTGAGATGGGCGAGGCGGCTGCCATCTTCATGACCGCCAGCCACAGGAA
 CCGTGACGCATTTCCGGACTCCAACCTACCAATTATGGACACCGAAGTGGAAGTCCAGAGAGA
 40 GCCTGGAGCTCAGGCTTTGATTGGGTGACGGATCATTCTGAAAAACAGTTTGGTTTGTTCGAAGC
 GTGAGGAACGGCAATGAGATCGCAGCTTGTCTGACAAAGGCTGGAAAAACGGGTGCATACAGCTCAG
 CAGAAAAGACTTTTGAGACAGAGTTCCAGAAAACAAAACATCAAGAGTGGGACTTTGTCTGTACAA
 CTGACATTTACAGAGATGGGCGCCAACTTTAAAGCTGACCGTGTGCATAGATTCCAGGAGATGCCTAA
 AGCCGGTGCATCTTGATGGCGAGAGAGTCACTTCTGGCTGGACCCATGCCTGTACACATGCCAGCG
 45 CTGCCCAGAGGAGGGGGCGCATAGGCAGGAATCCCAACAAACCTGGAGATGAGTATCTGTATGGA
 GGTGGGTGCGAGAGACTGACGAAGACCATGCACACTGGCTTGAAGCAAGAATGCTCCTTGACAA
 TATTTACCTCCAAGATGGCCTCATAGCCTCGCTCTATCGACCTGAGGCGGACAAAGTAGCAGCCAT
 TGAGGGAGAGTTCAAGCTTAGGACGGAGCAAAGGAAGACCTTTGTGGAAGTCAAGAAAAGAGGA
 GATCTTCTGTTTGGCTGGCCTATCAGGTTGCATCTGCCGGAATAACCTACACAGATAGAAGATGG
 50 TGCTTTGATGGCACGACCAACAACACCATAATGGAAGACAGTGTGCCGGCAGAGGTGTGGACCAG
 ACACGGAGAGAAAAGAGTGCTCAAACCGAGGTGGATGGACGCCAGAGTTTGTTCAGATCATGCGG
 CCCTGAAGTCATTCAAGGAGTTTGGCGCTGGGAAAAGAGGAGCGGCTTTTGGAGTGATGGAAGCC
 CTGGGAACACTGCCAGGACACATGACAGAGAGATTCCAGGAAGCCATTGACAACCTCGCTGTGCT
 CATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAGCCGCGGCGGCCCAATTGCCGGAGACCCATAG
 55 AGACCATTATGCTTTTGGGGTTGCTGGGAACAGTCTCGCTGGGAATCTTCTTCGTCTTGATGAGGA
 ACAAGGGCATAGGGAAGATGGGCTTTGGAATGGTGAAGTCTTGGGGCCAGCGCATGGCTCATGTGG
 CTCTCGGAAATTGAGCCAGCCAGAATTGCATGTGTCTCATTGTTGTGTTCTATTGCTGGTGGTGC

TCATACCTGAGCCAGAAAAAGCAAAGATCTCCCCAGGACAACCAAATGGCAATCATCATCATGGTA
 GCAGTAGGTCTTCTGGGCTTGATTACCGCCAATGAACTCGGATGGTTGGAGAGAAACAAAGAGTGA
 CCTAAGCCATCTAATGGGAAGGAGAGAGGAGGGGGCAACCATAGGATTCTCAATGGACATTGACC
 5 TCGGGCCAGCCTCAGCTTGGGCCATCTATGCTGCCTTGACAACTTTCATTACCCAGCCGTCCAAC
 ATGCAGTGACCACTTCATACAACAACACTACTCCTTAATGGCGATGGCCACGCAAGCTGGAGTGTGT
 TTGGTATGGGCAAAGGGATGCCATTCTACGCATGGGACTTTGGAGTCCCGCTGCTAATGATAGGTT
 GCTACTCACAATTAACACCCCTGACCCTAATAGTGGCCATCATTTTGTCTGTGGCGCACTACATGT
 ACTTGATCCCAGGGCTGCAGGCAGCAGCTGCGCGTGTGCCCAGAAGAGAACGGCAGCTGGCATC
 10 ATGAAGAACCCTGTTGTGGATGGAATAGTGGTGACTGACATTGACACAATGACAATTGACCCCCA
 AGTGGAGAAAAAGATGGGACAGGTGCTACTCATAGCAGTAGCCGTCTCCAGCGCCATACTGTCTGC
 GGACCGCCTGGGGGTGGGGGGAGGCTGGGGCCCTGATCACAGCCGCAACTTCCACTTTGTGGGAA
 GGCTCTCCGAACAAGTACTGGAACCTCTACAGCCACTTCACTGTGTAACATTTTTAGGGGAAGT
 TACTTGGCTGGAGCTTCTCTAATCTACACAGTAACAAGAAACGCTGGCTTGGTCAAGAGACGTGGG
 15 GGTGGAACAGGAGAGACCCTGGGAGAGAAATGGAAGGCCCGCTTGAACCAGATGTCGGCCCTGG
 AGTTCTACTCCTACAAAAAGTCAAGGCATCACCGAGGTGTGCAGAGAAGAGGCCCGCCGCGCCCTC
 AAGGACGGTGTGGCAACGGGAGGCCATGCTGTGTCCCCGAGGAAGTGCAAAGCTGAGATGGTTGGT
 GGAGCGGGGATACCTGCAGCCCTATGGAAAGGTCATTGATCTTGGATGTGGCAGAGGGGGCTGGA
 GTTACTACGCCGCCACCATCCGCAAAGTTCAAGAAGTGAAAGGATACACAAAAGGAGGCCCTGGT
 20 CATGAAGAACCCTGTTGTGTGCAAAGCTATGGGTGGAACATAGTCCGTCTTAAGAGTGGGGTGG
 CGTCTTTCATATGGCGGCTGAGCCGTGTGACACGTTGCTGTGTGACATAGGTGAGTCATCATCTAG
 TCCTGAAGTGAAGAAGCACGGACGCTCAGAGTCTCTCCATGGTGGGGGATTTGGCTTGAAAAA
 GACCAGGAGCCTTTTGTATAAAAGGTGTTGTGCCCATACACCAGCACTATGATGGAAACCCTGGAGC
 GACTGCAGCGTAGGTATGGGGGAGGACTGGTCAGAGTGCCACTCTCCCGCAACTCTACACATGAG
 25 ATGTATTGGGTCTCTGGAGCGAAAAAGCAACACCATAAAAAAGTGTGTCCACCACGAGCCAGCTCCT
 CTTGGGGCGCATGGACGGGCCTAGGAGGCCAGTGAAATATGAGGAGGATGTGAATCTCGGCTCTG
 GCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATGAAGATCATTGGTAACCGCATTGAA
 AGGATCCGCAGTGAGCACGCGGAAACGTGGTTCTTTGACGAGAACCACCCATATAGGACATGGGC
 TTACCATGGAAGCTATGAGGCCCCACACAAGGGTCAGCGTCTCTCTAATAAACGGGTTGTCAAG
 30 GCTCCTGTCAAAACCCTGGGATGTGGTGACTGGAGTCACAGGAATAGCCATGACCGACACCACAC
 CGTATGGTCAGCAAAAGAGTTTCAAGGAAAAAGTGGACACTAGGGTGCCAGACCCCAAGAAGGC
 ACTCGTCAGGTTATGAGCATGGTCTCTTCTGTTGTGGAAAGAGCTAGGCACAAACACAAACGGCC
 ACGAGTCTGTACCAAAGAAGAGTTCATCAACAAGGTTCTGTAGCAATGCAGCATTAGGGGCAATAT
 TTGAAGAGGAAAAAGAGTGAAGACTGCAGTGGAAGCTGTGAACGATCCAAGGTTCTGGGCTCTA
 35 GTGGATAAGGAAAGAGAGCACCACCTGAGAGGAGAGTGCCAGAGTTGTGTGTACAACATGATGG
 GAAAAAGAGAAAAAGAAACAAGGGGAATTTGGAAGGCCAAGGGCAGCCGCGCCATCTGGTATAT
 GTGGCTAGGGGCTAGATTTCTAGAGTTCGAAGCCCTTGGATTCTTGAACGAGGATCACTGGATGGG
 GAGAGAGAACTCAGGAGGTGGTGTGAAGGGCTGGGATTACAAAGACTCGGATATGTCTAGAAG
 AGTAGAGTCGTATACAGGAGGAAGGATGTATGCAGATGACACTGCTGGCTGGGACACCCGCATC
 40 AGCAGGTTTGTATCTGGAGAATGAAGCTCTAATCACCAACCAAATGGAAGGACAGGGCCTT
 GGCATTGGCCATAATCAAGTACACATACCAAAACAAAGTGGTAAAGGTCCTTAGACCAGCTGAAA
 AAGGGAAAAACAGTTATGGACATTATTTTCAGACAAAGACCAAAGGGGGAGCGGACAAGTTGTCACT
 TACGCTCTTAACACATTTACCAACCTAGTGGTGCAACTCATTCGGAATATGGAGGCTGAGGAAGTT
 CTAGAGATGCAAGACTTGTGGCTGCTGCGGAGGTCAGAGAAAGTGACCAACTGGTTGCAGAGCAA
 45 CGGATGGGATAGGCTCAAACGAATGGCAGTCAGTGGAGATGATTGCGTTGTGAAGCCAATTGATG
 ATAGGTTTGCACATGCCCTCAGGTTCTTGAATGATATGGGAAAAAGTTAGGAAGGACACACAAGAG
 TGGAAACCCTCAACTGGATGGGACAACTGGGAAGAAGTTCCGTTTTGCTCCCACCACCTTCAACAAG
 CTCCATCTCAAGGACGGGAGGTCCATTGTGGTTCCCTGCCGCCACCAAGATGAACTGATTGGCCGG
 GCCCCGCTCTCTCCAGGGGCGGGATGGAGCATCCGGGAGACTGCTTGCTAGCAAAATCATATGC
 50 GCAAATGTGGCAGCTCCTTTATTTCCACAGAAGGGACCTCCGACTGATGGCCAATGCCATTTGTTT
 ATCTGTGCCAGTTGACTGGGTTCCAACCTGGGAGAACTACCTGGTCAATCCATGGAAAAGGAGAAT
 GGATGACCACTGAAGACATGCTTGTGGTGTGGAACAGAGTGTGGATTGAGGAGAACGACCACATG
 GAAGACAAGACCCAGTTACGAAATGGACAGACATCCCCTATTTGGGAAAAAGGGAAGACTTGTG
 GTGTGGATCTCTCATAGGGCAGAGACCGCGCACCACTGGGCTGAGAACATTAAAAACACAGTCA
 55 ACATGGTCCGAGGATCATAGGTGATGAAGAAAAGTACATGGACTACCTATCCACCCAAAGTTTCG
 TACTTGGGTGAAGAAGGGTCTACACCTGGAGTGCTGTGAAGCACCAAGTCTTAATGTTGTGAGGCCTG
 CTAGTCAGCCACAGCTTGGGGAAAGCTGTGCAGCCTGTGACCCCCCAGGAGAAAGCTGGGAAACC
 AAGCCTATAGTCAGGCCGAGAACGCCATGGCACGGAAGAAGCCATGCTGCCTGTGAGCCCCCTCAG

PAT018/EP/PR3

AGGACACTGAGTCAAAAAACCCACGCGCTTGGAGGCGCAGGATGGGAAAAGAAGGTGGCGACC
TTCCCCACCCTTCAATCTGGGGCCTGAACTGGAGATCAGCTGTGGATCTCCAGAAGAGGGACTAGT
GGTTAGAGGAG

- 5 KU744693.1 Zika virus isolate VE_Ganxian, China, complete genome (SEQ ID NO: 10)
- GTGTTACTGTTGCTGACTCAGACTGCGACAGTTTCGAGTTTGAAGCGAAAAGCTAGCAACAGTATCA
ACAGGTTTTATTTGGATTGGAACGAGAGTTTCTGGTCATGAAAAACCCAAAAAGAAATCCGG
AGGATTCGGATTGTCAATATGCTAAAACGCGGAGTAGCCCGTGTGAGCCCCCTTTGGGGGCTTGAA
GAGGCTGCCAGCCGACTTCTGCTGGGTCATGGGCCCATCAGGATGGTCTTGGCAATTCTAGCCTT
10 TTTGAGATTACCGCAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTCAGTGGGAAAAA
AAGATGCTATGGAATAATAAAGAAGTTCAAGAAAGATCTGGCTGCCATGCTGAGAATAATCAAT
GCTAGGAAGGAGAAGAAGAGACGAGGCGCAGATACTAGTGTGGAATTGTTGGCCTCTGCTGAC
CACAGCTATGGCAGCGGAGGTCACTAGACGTGGGAGTGCATACTATATGTACTTGGACAGAAACG
ATGCTGGGGAGGCCATATCTTTTCCAACCACATTGGGGATGAATAAGTGTATATACAGATCATGG
15 ATCTTGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTATGCTGGATGAGGGGGTGGAA
CCAGATGACGTCGATTGTTGGTGCAACACGACGTCAACTTGGGTTGTGTACGGAACCTGCCATCAC
AAAAAAGGTGAAGCACGGAGATCTAGAAGAGCTGTGACGCTCCCTTCCCATTCCTACTAGGAAGT
GCAAACGCGGTCGCAAACCTGGTTGGAATCAAGAGAATACACAAAGCACTTGATTAGAGTCGAAA
ATTGGATATTCAGGAACCTGGCTTCGCGTTAGCAGCAGCTGCCATCGCTTGGCTTTTGGGAAGCT
20 CAACGAGCCAAAAAGTCATATACTTGGTCATGATACTGCTGATTGCCCCGGCATACAGCATCAGGT
GCATAGGAGTCAGCAATAGGGACTTTGTGGAAGGTATGTCAGGTGGGACTTGGGTTGATGTTGTCT
TGGAACATGGAGGTTGTGTCAACGCAATGGCACAGGACAAACCGACTGTGACATAGAGCTGGTT
ACAACAACAGTCAGCAACATGGCGGAGGTAAGATCCTACTGCTATGAGGCATCAATATCAGACAT
GGCTTCGACAGCCGCTGCCAACACAAGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAAT
25 ATGTTTGCAAAAGAACGTTAGTGGACAGAGGCTGGGGAAATGGATGTGGACTTTTGGCAAAGGG
AGTCTGGTGACATGCGCTAAGTTTGCATGCTCCAAGAAAATGACCGGGAAGAGCATCCAGCCAGA
GAATCTGGAGTACCGGATAATGCTGTGCTGCTCCAGCACAGTGGGATGCTCGTTAATGA
CACAGGACATGAAACTGATGAGAATAGAGCGAAGGTTGAGATAACGCCCAATTCACCAAGAGCC
GAAGCCACCCTGGGGGGTTTTGGAAGCCTAGGACTTGATTGTGAACCGAGGACAGGCCTTGACTTT
30 TCAGATTTGTATTACTTGACTATGAATAACAAGCACTGGTTGGCTCACAAGGAGTGGTTCCACGAC
ATTCCATTACCTTGGCAGCTGGGGCAGCCACCGGAATCCACACTGGAACAACAAAGAAGCACT
GGTAGAGTTCAAGGACGACATGCCAAAAGGCAAACTGTCTGTTCTAGGGAGTCAAGAAGGAG
CAGTTACACGCGCCCTTGTGGAGCTCTGGAGGCTGAGATGGATGGTGCAGGAAAGGAGGCTGTCC
TCTGGCCACTTGAAATGTGCGCTGAAAATGGATAAACTTAGATTGAAGGGCGTGTACTACTCTTG
35 TGTACCGCAGCGTTACATTACCAAGATCCCGGCTGAAACAGTGGACGGGACAGTCACAGTGGG
GGGACAGTACGGAGGGACAGATGGACCTTGCAAGGTTCCAGCTCAGATGGCGGTGGACATGCAGA
CTCTGACCCAGTTGGGAGGTTGATAACCGCTAACCCCGTAATCACTGAAAGCACTGAGAACTCTA
AGATGATGCTGGAACCTTGATCCACCATTGGGGACTCTTACATTGTCATAGGAGTCGGGGGAGAAG
AAGATCACCCACCACTGGCACAGGAGTGGCAGCACCATTGGAAGGCAATTTGAAGCCACTGTGAG
40 AGGTGCCAAGAGAATGGCAGTCTTGGGAGACACAGCCTGGGACTTTGGATCAGTTGGAGGCGCTC
TCAACTCATTGGGCAAGGGCATCCATCAAATTATTGGAGCAGCTTCAAATCATTGTTTGGAGGAA
TGTCTGTTCTCACAAATTCTCATTGGGACGTTGCTGATGTGGTTGGGTCTGAACACAAAGAATG
GATCTATTTCCCTTATGTGCTTGGCCTTAGGGGGAGTGTGATCTTCTTATCCACAGCCGTCTCAGG
TGGTGTGGGGTGTCTCGGTGGACTTCTCAAAGAAGGAGACGAGATGCGGTACAGGGGTGTTCTGTCT
45 ATAACGATGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCCTGACTCCCCCGTAGATTGGCA
GCAGCAGTCAAGCAAGCCTGGGAAGATGGTATCTGCGGGATCTCCTCTGTTTCAAGGAATGGA
CATCATGTGGAGATCAGTAGAAGGGGAGCTCAACGCAATCCTGGAAGAGAATGGAGTTCAACTGA
CGGTCTGTTGTGGGATCTGTAAAAAACCCATGTGGAGAGGTCCACAGAGATTGCCCGTGCCTGTG
AACGAGCTGCCCCAGCGCTGGAAGGCTTGGGGGAAATCGTACTTCTGTCAGAGCAGCAAAAGACAAA
50 TAACAGCTTTGTGCTGGATGGTGACACACTGAAGGAATGCCCACTCAAACATAGAGCATGGAACA
GCTTTCTTGTGGAGGATCATGGGTTCTGGGTATTTACACTAGTGTCTGGCTCAAGGTTAGAGAAG
ACTATTGGTTAGAGTGTGATCCAGCCGTTATTGGAACAGCTGTAAAGGGAAGGAGGCTGTACAC
AGTGATCTAGGCTACTGGATTGAGAGTGAGAAGAATGACACATGGTGGCTGAAGAGGGCCCATCT
GATCGAGATGAAAAATGTGAATGGCCAAAAGTCCCAACACATTGTGGACAGATGGAATAGAAAGAG
55 AGTGATCTGATCATACCAAGTCTTTAGCTGGGCCACTCAGCCATCACAATGCCAGAGAGGGCTAC

AGGACCCAAATGAAAGGGCCATGGCACAGTGAAGAGCTTGAAATTCGGTTTGAGGAATGCCCAGG
 CACTAAGGTCCACGTGGAGGAAACATGTGGAACAAGAGGACCATCTCTGAGATCAACCACTGCAA
 GCGGAAGGGTGATCGAGGAATGGTGCTCCAGGGAGTGACAATGCCCCACTGTCCTTCCAGGCT
 5 AAAGATGGCTGTTGGTATGGAATGGAGATAAGGCCCAGGAAAGAACCAGAAAGCAACTTAGTAA
 GGTCAATGGTGACTGCAGGATCAACTGATCACATGGATCACTTCTCCCTTGGAGTGCTTGTGATT
 TGCTCATGGTGACAGGAAGGGCTGAAGAAGAGAATGACCACAAAGATCATCATAAGCACATCAATG
 GCAGTGCTGGTAGCTATGATCCTGGGAGGATTTTCAATGAGTGACCTGGCTAAGCTTGCAATTTTG
 ATGGGTGCCACCTTCGCGGAAATGAACACTGGAGGAGATGTAGCTCATCTGGCGCTGATAGCGGC
 ATTCAAAGTCAGACCAGCGTTGCTGGTATCTTTCATCTTCAGAGCTAATTGGACACCCCGTGAAAG
 10 CATGCTGCTGGCCTTGGCCTCGTGTCTTTTGCAAACCTGCGATCTCCGCCTTGAAGGCGACCTGAT
 GGTCTCATCAATGGTTTGTCTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCACGCACTGAT
 AACATCACCTTAGCAATCCTGGCTGCTCTGACACCACTGGCCCCGGGCGCACACTGCTTGTGGCGTGG
 AGAGCAGGCCTTGCTACTTGCGGGGGGTTTATGCTCCTCTCTCTGAAGGAAAAGGCAGTGTGAA
 GAAGAAGTTACCATTTGTCATGGCCCTGGGACTAACCCTGTGAGGCTGGTCGACCCCATCAACTG
 15 GGTGGGACTGCTGTTGCTCACAAGGAGTGGGAAGCGGAGCTGGCCCCCTAGCGAAGTACTCACAG
 CTGTTGGCCTGATATGCGCATTGGCTGGAGGGTTCGCCAAGGCAGATATAGAGATGGCTGGGCCC
 ATGGCCGCGGTCTGCTAATTGTCAGTTACGTGGTCTCAGGAAAGAGTGTGGACATGTACATT
 GAAAGAGCAGGTGACATCACATGGGAAAAAGATGCGGAAGTCACTGGAAACAGTCCCCGCTCG
 ATGTGGCGCTAGATGAGAGTGGTGATTTCTCCCTGGTGGAGGATGACGGTCCCCCATGAGAGAG
 20 ATCATACTCAAGGTGGTCTGATGACCATCTGTGGCATGAACCAATAGCCATACCCCTTTCAGCT
 GGAGCGTGGTACGTATACGTGAAGACTGGAAAAAGGAGTGGTGCTCTATGGGATGTGCCTGCTCC
 CAAGGAAGTAAAAAAGGGGGAGACCACAGATGGAGTGTACAGAGTAATGACTCGCAGACTGCTA
 GGTTCACACAAGTTGGAGTGGGAGTTATGCAAGAGGGGGTCTTTCACACTATGTGGCACGTAC
 AAAAGGATCCGCGCTGAGAAGCGGTGAAGGGAGACTTGATCCATACTGGGGAGATGTCAAGCAG
 25 GATCTGGTGTCACTGTGGTCCATGGAAGCTAGATGCCGCTGGGACGGGCACAGCGAGGTGCA
 GCTCTTGGCCGTGCCCCCGGAGAGAGAGCGAGGAACATCCAGACTCTGCCCGGAATATTTAAGA
 CAAAGGATGGGGACATTGGAGCGGTTGCACTGGATTACCCAGCAGGAACCTCAGGATCTCCAATC
 CTAGACAAGTGTGGGAGAGTGATAGGACTTTATGGCAATGGGGTCTGTGATCAAAAATGGGAGTTA
 TGTTAGTGCCATACCCAAGGGAGGAGGAGGAAGAGACTCCTGTTGAGTGCTTCGAGCCTTCGA
 30 TGCTGAAGAAGAAGCAGCTAACTGTCTTAGACTTGCACTCTGGAGCTGGGAAAACAGGAGAGTT
 CTTCTGAAATAGTCCGTGAAGCCATAAAAAACAAGACTCCGTACTGTGATCTTGGCTCCAACCAGG
 GTTGTGCTGCTGAAATGGAGGAGGCCCTTAGAGGGCTTCCAGTGCGTTATATGACAACAGCAGTC
 AATGTCACCCACTCTGGAACAGAAATCGTCGACTTAATGTGCCATGCCACCTTCACCTCACGTCTA
 CTACAGCCAATTAGAGTCCCCAACTATAATCTGTATATTATGGATGAGGCCACTTCACAGATCCC
 35 TCAAGTATAGCAGCAAGAGGATACATTTCAACAAGGGTTGAGATGGGCGAGGCGGCTGCCATCTT
 CATGACCGCCACGCCACCAGGAACCCGTGACGCATTTCCGGACTCCAACCTACCAATTATGGACAC
 CGAAGTGGAAAGTCCCAGAGAGAGCCTGGAGCTCAGGCTTTGATTGGGTGACGGAGTATTCTGGAA
 AAACAGTTTGGTTTGTCCACGCTGAGGAACGCGAATGAGATCGCAGCTTGTCTGACAAAGGCT
 GGAAAACGGGTCATACAGCTCAGCAGAAAAGACTTTTGAGACAGAGTTCCAGAAAAACAAAACATCA
 40 AGAGTGGGACTTTGTCTGACAACTGACATTTTCAGAGATGGGCGCCAACCTTTAAAGCTGACCGTGT
 CATAGATTCCAGGAGATGCCTAAAGCCGGTCATACTTGGTGGCGAGAGAGTCATTCTGGCTGGAC
 CCATGCCTGTCACACATGCCAGCGCTGCCAGAGGAGGGGCGCATAGGCAGGAATCCCAACAAA
 CCTGGAGATGAGTATCTGTATGGAGGTGGGTGCGCAGAGACTGACGAAGACCATGCACACTGGCT
 TGAAGCAAGAATGCTCCTTGACAATATTTACCTCCAAGATGGCCTCATAGCCTCGCTCTATCGACC
 45 TGAGGCCGACAAAGTAGCAGCCATTGAGGAGAGGTTCAAGCTTAGGACGGAGCAAAGGAAGAAC
 TTTGTGGAATCATGAAAAAGAGGAGATCTTCTGTTTGGCTGGCCTATCAGGTTGCATCTGCGGGA
 ATAACCTACACAGATAGAAGATGGTGCTTTGATGGCACGACCAACAACACCATAATGGAAGACAG
 TGTGCCGGCAGAGGTGTGGACCAGACACGGAGAGAAAAGAGTGCTCAAACCGAGGTGGATGGAC
 GCCAGAGTTTGTTCAGATCATGCGGCCCTGAAGTCATTCAAGGAGTTTGGCGCTGGGAAAAGAGG
 50 AGCGGCTTTTGGAGTGATGGAAGCCCTGGGAACACTGCCAGGACACATGACAGAGAGATTCCAGG
 AAGCCATTGACAACCTCGCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAGCCGCG
 GCGGCCCAATTGCCGGAGACCCTAGAGACCATTATGCTTTTGGGGTTGCTGGGAACAGTCTCGCTG
 GGAATCTTTTTCTGCTTTGATGAGGAACAAGGCATAGGGAAGATGGGCTTTGGAATGGTGACTCTT
 55 GGGGCCAGCGCATGGCTCATGTGGCTCTCGGAAATTGAGCCAGCCAGAATTGCATGTGTCTCTATT
 GTTGTGTTCTATTGCTGGTGGTGCTCATACTGAGCCAGAAAAGCAAAGATCTCCCCAGGACAAC
 CAAATGGCCATCATCATCATGGTAGCAGTAGGTCTTCTGGGCTTGATTACCGCCAATGAACTCGGA
 TGGTTGGAGAGAACAAAGAGTGACCTAAGCCATCTAATGGGAAGGAGAGAGGAGGGGGCAACCA

TGGGATTCTCAATGGACATTGACCTGCGGCCAGCCTCAGCTTGGGCCATCTATCCTGCCTTGACAT
 CTTTCATTACCCAGCCGTCCAACATGCAGTGACCACTTCATACAACAACACTACTCCTTAATGGCGA
 TGGCCACGCAAGCTGGAGTGTGTTGTTGGTATGGGCAAAAGGATGCCATTCTACGCATGGGACTTTG
 5 GAGTCCCCTGCTAATGATAGTTGCTACTCACAATTAACGCCCTGACCCTAATAGTGGCCATCA
 TTTTGCTCGTGGCGCACTACATGTACTTGATCCCAGGGCTGCAGGCAGCAGCTGCGCGTGTGCCC
 AGAAGAGAACGGCAGCTGGCATCATGAAGAACCCTGTTGTGGAGGGAATAGTGGTGACTGACATT
 GACACAATGACAATTGACCCCCAAGTGGAGAAAAAGATGGGACAGGTGCTACTCATGGCAGTAGC
 CGTCTCCAGCGCCATACTGTGAGGACCGCCTGGGGGTGGGGGGAGGCTGGGGCCCTGATCACAG
 10 CCGCAACTTCCACTTTGTGGGAAGGCTCTCCGAACAAGTACTGGAACCTCTACAGCCACCTCAC
 TGTGTAACATTTTATAGGGGAAGTTACTTGGCTGGAGCTTCTCTAATCTACACAGTAACAAGAAACG
 CTGGCTTGGTCAAGAGACGTGGGGGTGGAACAGGAGAGACCTTGGGAGAGAAATGGAAGGCCCG
 CTTGAACCAGATGTGCGCCCTGGAGTTCTACTCCTACAAAAAGTCAGGCATCACCGAGGTGTGCGA
 AGAAGAGGCCCCGCGCGCCCTCAAGGACGGTGTGGCAACGGGAGGCCATGCTGTGTCCCGAGGAA
 GTGTCCACCACGAGCCAGCTCCTCTTGGGGCGCATGGACGGGCCTAGGAGGCCAGTGAAATATGA
 15 GGATGTGGCAGAGGGGGCTGGAGTTACTACGCCGCCACCATCCGCAAAAGTTCAAGAAGTGAAAGG
 ATACACAAAAGGAGGGCCCTGGTTCATGAAGAACCCGTGTTGGTGCAAAGCTATGGGTGGAACATAG
 TCCGTCTTAAGAGTGGGGTGGACGTCTTTCATATGGCGGCTGAGCCGTGTGACACGTTGCTGTGTG
 ACATAGGTGAGTCATCATCTAGTCTGAAGTGAAGAAGCACGACGCTCAGAGTCCTCTCCATG
 GTGGGGGATTGGCTTGAAAAAGACCAGGAGCCTTTTGTATAAAAGTGTTGTGCCCATACACCAG
 20 CACTATGATGGAACCCCTGGAGCGACTGCAGCGTAGGTATGGGGGAGGACTGGTCAGAGTGCCAC
 TCTCCCGCAACTCTACACATGAGATGTACTGGGTCTCTGGAGCGAAAAAGCAACACCATAAAAAAGT
 GTGTCCACCACGAGCCAGCTCCTCTTGGGGCGCATGGACGGGCCTAGGAGGCCAGTGAAATATGA
 GGAGGATGTGAATCTCGGCTCTGGCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATGA
 AGATCATTTGGTAACCGCATTGAAAGGATCCGCGCTGAGAAAGCGGAAACGTGGTTCTTTGACGAG
 25 AACCACCCATATAGGACATGGGCTTACCATGGAAGCTATGATGCCGCCACACAAGGGTCAGCGTC
 CTCTCTAATAAACGGGGTGTGAGGCTCCTGTCAAACCCCTGGGATGTGGTGACTGGAGTCACAGG
 AATAGCCATGACCGACACCACACCGTATGGTCAGCAAAGAGTTTTCAAGGAAAAAGTGGACACTA
 GGGTGCCAGACCCCCAAGAAGGCACCTCGTCAGGTTATGAGCATGGTCTCTTCTGGTTGTGGAAG
 AGCTAGGCAAAACACAAACGGCCACGAGTCTGTACCAAAAGAGAGTTCATCAACAAGGTTCTGATG
 30 AATGCAGCATTAGGGGCAATATTTGAAGAGGAAAAAGAGTGGAAAGACTGCAGTGGAAAGCTGTGA
 ACGATCCAAGGTTCTGGGCTCTAGTGGACAAGGAAAAGAGAGCACCACCTGAGAGGAGAGTGCCA
 GAGTTGTGTGTACATCACAATGGGAAAAAGAGAAAAAGAAACAAGGGGAATTTGGAAAGGCCAAG
 GGCAGCCGCGCCATCTGGTATATGTGGCTAGGGGCTAGATTCTAGAGTTCTGAAGCCCTTGGATTCT
 TTGAACGAGGATCACTGGATGGGGAGAGAGAACTCAGGAGGTGGTGTGAAGGGCTGGGATTACA
 35 AAGACTCGGATATGTCCTAGAAGAGATGAGTCGCATACCAGGAGGAAGGATGTATGCAGATGACA
 CTGCTGGCTGGGACACCCGCATCAGCAGGTTTGATCTGGAGAATGAAGCTCTAATCACCAACCAA
 ATGGAGAAAGGGCACAGGGCCTTGGCATTTGGCCATAATCAAGTACACATACCAAAACAAAGTGGT
 AAAGGTCCTTAGACCAAGCTGAAAAAGGGAAGACAGTTATGGACATTATTCGAGACAAGACCAAA
 GGGGGAGCGGACAAGTTGTCACTTACGCTCTCAACACATTACCAACCTAGTGGTGCAACTCATTC
 40 GGAATATGGAGGCTGAGGAAGTTCTAGAGATGCAAGACTTGTGGCTGCTGCGGAGGTGAGAGAAA
 GTGACCAACTGGTTGCAGAGCAACGGATGGGATAGGCTCAAACGAATGGCGGTGAGTGGAGATGA
 TTGCGTTGTGAAACCAATTGATGATAGGTTTGCACATGCCCTCAGGTTCTTGAATGATATGGGAAA
 AGTTAGGAAGGACACACAAGAGTGGAAACCCTCAACTGGATGGGACAACCTGGGAAGAAGTTCCTT
 TCTGCTCCCAACCTTCAACAAGCTCCATCTCAAGGACGGGAGGTCCATTGTGGTTCCCTGCCGCC
 45 ACCAAGATGAAGTATTGGCCGGGCCCCGCTCTCTCCAGGGGCGGGATGGAGCATCCGGGAGACT
 GCTTGCCATGCAAAAATCATATGCGCAAAATGTGCAAGCTCCTTTATTTCCACAGAAGGGACCTCCGA
 CTGATGGCCAATGCCATTTGTTTCATCTGTGCCAGTTGACTGGGTTCCAACCTGGGAGAACTACCTGG
 TCAATCCATGGAAGGGGAGAATGGATGACCACTGAAGACATGCTTGTGGCGTGGAACAGAGTGTG
 GATTGAGGAGAACGACCACATGGAAGACAAGACCCAGTCACGAAATGGACAGACATTCCCTATT
 50 TGGGAAAAAGGGAAGACTTGTGGTGTGGATCTCTCATAGGGCACAGACCGCGCACCCACCTGGGCT
 GAGAACATTAAAAACACAGTCAACATGGTGCAGGATCATAGGTGATGAAGAAAAAGTACATGG
 ACTACCTATCCACCAAGTTTCGCTACTTGGGTGAAGAAGGGTCTACACCTGGAGTGCTGTAAGCAC
 CAATCTTAATGTTGTCAGGCCTGCTAGTCAGCCACAGCTTGGGGAAGCTGTGCAGCCTGTGACCC
 CCCCAGGAGAAAGCTGGGAAACCAAGCCTATAGTCAGGCCGAGAAGCCATGGCACGGAAGAAGC
 55 CATGCTGCCTGTGAGCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAGGCGCAGG
 ATGGGAAAAAGAAGGTGGCGACCTTCCCCACCTTCAATCTGGGGCCTGAACTGGAGATCAGCTGT
 GGATCTCCAGAAGAGGGACTAGTGGTTAGAGGAGA

PAT018/EP/PR3

LC002520.1 Zika virus genomic RNA, strain: MR766-NIID, Uganda, complete genome
(SEQ ID NO: 11)

```
5  AGTTGTTGATCTGTGTGAGTCAGACTGCGACAGTTCGAGTCTGAAGCGAGAGCTAACAACAGTATC
AACAGGTTTAATTTGGATTTGGAAACGAGAGTTTCTGGTTCATGAAAAACCCAAAGAAGAAATCCG
GAGGATTCGGATTGTCAATATGCTAAAACGCGGAGTAGCCCGTGTAACCCCTTGGGAGGTTTG
AAGAGGTTGCCAGCCGGACTTCTGCTGGGTCATGGACCCATCAGAATGGTTTTGGCGATACTAGCC
TTTTTGAGATTTACAGCAATCAAGCCATCACTGGGCCCTTATCAACAGATGGGGTTCCGTGGGGA
AAAGAGGCTATGGAAATAATAAAGAAGTTCAAGAAAGATCTTGCTGCCATGTTGAGAATAATCAA
10 TGCTAGGAAAGAGAGGAAGAGACGTGGCGCAGACACCAGCATCGGAATCATTGGCCTCCTGCTGA
CTACAGCCATGGCAGCAGAGATCACTAGACGCGGGAGTGCATACTACATGTACTTGGATAGGAGC
GATGCCGGGAAGGCCATTTCTGTTTGTACCATTTGGGAGTGAACAAGTGCCACGTACAGATCAT
GGACCTCGGGCACATGTGTGACGCCACCATGAGTTATGAGTGCCCTATGCTGGATGAGGGAGTGG
AACCAGATGATGTCGATTGCTGGTGCAACACGACATCAACTTGGGTTGTGTACGGAACCTGTCATC
15 ACAAAAAAGGTGAGGCACGGCGATCTAGAAGAGCCGTGACGCTCCCTTCTCACTCTACAAGGAAG
TTGCAAACGCGGTGCGAGACCTGGTTAGAAATCAAGAGAATACACGAAGCACTTGATCAAGGTTGA
AACTGGATATTCAGGAACCCCGGGTTTGCCTAGTGGCCGTTGCCATTGCCTGGCTTTTGGGAAG
CTCGACGAGCCAAAAAGTCATATACTTGGTCATGATACTGCTGATTGCCCCGGCATACAGTATCAG
GTGCATTGGAGTCAGCAATAGAGACTTCGTGGAGGGCATGTCAGGTGGGACCTGGGTTGATGTTG
20 TCTTGGAACATGGAGGCTGCGTTACCGTGATGGCACAGGACAAGCCAACAGTTGACATAGAGTTG
GTCACGACGACGGTTAGTAACATGGCCGAGGTAAGATCCTATTGCTACGAGGCATCGATATCGGA
CATGGCTTCGGACAGTCGTTGCCCAACACAAGGTGAAGCCTACCTTGACAAGCAATCAGACACTC
AATATGTCTGCAAAAAGAACATTAGTGGACAGAGGTTGGGGAAACGGTTGTGGACTTTTTGGCAAA
GGGAGCTTGGTGACATGTGCCAAGTTTACGTGTTCTAAGAAGATGACCGGGAAGAGCATTCAACC
25 GGAAAATCTGGAGTATCGGATAATGCTATCAGTGCATGGCTCCCAGCATAGCGGGATGACTGTCA
ATGATATAGGATATGAAACTGACGAAAATAGAGCGAAAGTCGAGGTTACGCCTAATTCACCAAGA
GCGGAAGCAACCTTGGGAGGCTTTGGAAGCTTAGGACTTGACTGTGAACCAAGGACAGGCCTTGA
CTTTTCAGATCTGTATTACCTGACCATGAACAATAAGCATTGGTTGGTGACAAAAGAGTGGTTTCA
TGACATCCCATTGCCTTGGCATGCTGGGGCAGACACTGGAACCTCCACACTGGAACAACAAAGAGG
30 CATTGGTAGAATTCAAGGATGCCCACGCCAAGAGGCAAACCGTCGTCGTTCTGGGGAGCCAGGAA
GGAGCCGTTTCACACGGCTCTCGCTGGAGCTCTAGAGGCTGAGATGGATGGTGCAAAGGGAAAGCT
GTTCTCTGGCCATTTGAAATGCCGCCTAAAAATGGACAAGCTTAGATTGAAGGGCGTGTATATTC
CTTGTGCACTGCGGCATTACATTACCAAGGTCCCAGCTGAAACACTGCATGGAACAGTCACAGT
GGAGGTGCAGTATGCAGGGACAGATGGACCCTGCAAGATCCCAGTCCAGATGGCGGTGGACATGC
35 AGACCCTGACCCAGTTGGAAGGCTGATAACCGCCAACCCCGTGATTACTGAAAGCACTGAGAAC
TCAAAGATGATGTTGGAGCTTGACCCACCATTTGGGGATTCTTACATTGTCATAGGAGTTGGGGAC
AAGAAAATCACCCACCACTGGCATAGGAGTGGTAGCACCATCGGAAAGGCATTTGAGGCCACTGT
GAGAGGCGCCAAGAGAATGGCAGTCCTGGGGGATACAGCCTGGGACTTCGGATCAGTCGGGGGTG
TGTTCAACTCACTGGGTAAGGGCATTCACCAGATTTTGGAGCAGCCTTCAAATCACTGTTTGGAG
40 GAATGTCTGTTCTCACAGATCCTCATAGGCACGCTGCTAGTGTGGTTAGGTTTGAACACAAAGA
ATGGATCTATCTCCCTCACATGCTTGGCCCTGGGGGGAGTGATGATCTTCTCTCCACGGCTGTTTC
TGCTGACGTGGGGTGCTCAGTGGACTTCTCAAAAAAGGAAACGAGATGTGGCACGGGGGTATTCA
TCTATAATGATGTTGAAGCCTGGAGGGACCGGTACAAGTACCATCCTGACTCCCCCGCAGATTGG
CAGCAGCAGTCAAGCAGGCCTGGGAAGAGGGGATCTGTGGGATCTCATCCGTTTCAAGAATGGAA
45 AACATCATGTGGAATCAGTAGAAGGGGAGCTCAATGCTATCCTAGAGGAGAATGGAGTTCAACT
GACAGTTGTTGTGGGATCTGTAAAAAACCCTATGTGGAGAGGTCCACAAAAGATTGCCAGTGCCTG
TGAATGAGCTGCCCCATGGCTGGAAAGCCTGGGGGAAATCGTATTTTGTAGGGCGGCAAAGACC
AACAACAGTTTTGTTGTGACGGTGACACACTGAAGGAATGTCCGCTTGAGCACAGAGCATGGAA
TAGTTTTCTTGTGGAGGATCACGGGTTTGGAGTCTTCCACACCAGTGTCTGGCTTAAGGTCAGAGA
50 AGATTACTCATTAGAATGTGACCCAGCCGTCATAGGAACAGCTGTTAAGGGAAGGGAGGCCGCGC
ACAGTGATCTGGGCTATTGGATTGAAAGTGAAAGAATGACACATGGAGGCTGAAGAGGGCCAC
CTGATTGAGATGAAAACATGTGAATGGCCAAAGTCTCACACATTGTGGACAGATGGAGTAGAAGA
AAGTGATCTTATCATACCAAGTCTTTAGCTGGTCCACTCAGCCACCACAACACCAGAGAGGGTTA
CAGAACCCAAAGTGAAAGGGCCATGGCACAGTGAAGAGCTTGAATCCGGTTTGAGGAATGTCCAG
55 GCACCAAGGTTTACGTGGAGGAGACATGCGGAACTAGAGGACCATCTCTGAGATCAACTACTGCA
```

AGTGGAAAGGGTCATTGAGGAATGGTGCTGTAGGGAATGCACAATGCCCCACTATCGTTTCGAGC
 AAAAGACGGCTGCTGGTATGGAATGGAGATAAGGCCAGGAAAGAACCAGAGAGCAACTTAGTG
 AGGTCAATGGTGACAGCGGGGTCAACCGATCATATGGACCACTTCTCTCTTGGAGTGCTTGTGATT
 5 CTAATCATGGTGCAGGAGGGGTTGAAGAAGAGAATGACCACAAAGATCATCATGAGCACATCAAT
 GGCAGTGCTGGTAGTCATGATCTTGGGAGGATTTTCAATGAGTGACCTGGCCAAGCTTGTGATCCT
 GATGGGTGCTACTTTTCGCAGAAATGAACACTGGAGGAGATGTAGCTCACTTGGCATTGGTAGCGG
 CATTAAAGTCAGACCAGCCTTGCTGGTCTCCTTCATTTTCAGAGCCAATTGGACACCCCGTGAGA
 GCATGCTGCTAGCCCTGGCTTCGTGTCTTCTGCAAACTGCGATCTCTGCTCTTGAAGGTGACTTGAT
 10 GGTCTCATTAATGGATTTGCTTTGGCCTGGTTGGCAATTCGAGCAATGGCCGTGCCACGCACTGA
 CAACATCGCTCTACCAATCTTGGCTGCTCTAACACCACTAGCTCGAGGCACACTGCTCGTGGCATG
 GAGAGCGGGCTGGCTACTTGTGGAGGGATCATGCTCCTCTCCCTGAAAGGGAAAGGTAGTGTGA
 AGAAGAACCTGCCATTTGTCATGGCCCTGGGATTGACAGCTGTGAGGGTAGTAGACCCTATTAATG
 TGGTAGGACTACTGTTACTCACAAGGAGTGGGAAGCGGAGCTGGCCCCCTAGTGAAGTTCTCACA
 15 GCGGTTGGCCTGATATGTGCACTGGCCGGAGGGTTTCCAAAGGCAGACATTGAGATGGCTGGACC
 CATGGCTGCAGTAGGCTTGCTAATTGTCAGCTATGTGGTCTCGGGAAAGAGTGTGGACATGTACAT
 TGAAAGAGCAGGTGACATCAGATGGGAAAAGGACGCGGAAGTCACTGGAAACAGTCTCTGGCTTG
 ACGTGGCACTGGATGAGAGTGGTGATTTCTCCTTGGTAGAGGAAGATGGTCCACCCATGAGAGAG
 ATCATACTTAAGGTGGTCTGATGGCCATCTGTGGCATGAACCCAATAGCTATACCTTTTGCTGCA
 20 GGAGCGTGGTATGTGTATGTGAAGACTGGGAAAAGGAGTGGCGCCCTCTGGGACGTGCCTGCTCC
 CAAAGAAGTGAAGAAAGGAGAGACCACAGATGGAGTGTACAGAGTGATGACTCGCAGACTGCTA
 GGTTCACACAGGTTGGAGTGGGAGTCATGCAAGAGGGAGTCTTCCACACCATGTGGCACGTTAC
 AAAAGGAGCCGCACTGAGGAGCGGTGAGGGAAGACTTGATCCATACTGGGGGGATGTCAAGCAG
 GACTTGGTGTCACTGTGGGCCTTGGAAGTTGGATGCAGCTTGGGATGGACTCAGCGAGGTACA
 25 GCTTTTGCCGTACCTCCCGGAGAGAGGGCCAGAAACATTGAGACCCTGCCTGGAATATTCAAGA
 CAAAGGACGGGGACATCGGAGCAGTTGCTCTGGACTACCCTGCAGGGACCTCAGGATCTCCGATC
 CTAGACAAATGTGGAAGAGTGATAGGACTCTATGGCAATGGGGTTGTGATCAAGAATGGAAGCTA
 TGTTAGTGCTATAACCCAGGGAAAGAGGGAGGAGGAGACTCCGGTTGAATGTTTCGAACCCCTCGA
 TGCTGAAGAAGAAGCAGCTAACTGTCTTGGATCTGCATCCAGGAGCCGGAAGAAACCAGGAGAGTT
 30 CTTCTGAAATAGTCCGTGAAGCCATAAAAAAGAGACTCCGGACAGTGATCTTGGCACCAACTAG
 GGTGTGCTGCTGAGATGGAGGAGGCCCTTGAGAGGACTTCCGGTGCGTTACATGACAACAGCAG
 TCAACGTCACCCATTCTGGGACAGAAATCGTTGATTTGATGTGCCATGCCACTTTCACTTCACGCTT
 ACTACAACCCATCAGAGTCCCTAATTACAATCTCTACATCATGGATGAAGCCCACTTCACAGACCC
 CTCAAGTATAGCTGCAAGAGGATATATATCAACAAGGGTTGAAATGGGCGAGGCGGCTGCCATTT
 35 TTATGACTGCCACACCACAGGAACCCGTGATGCGTTTCTGACTCTAACTACCAATCATGGACA
 CAGAAGTGGAAGTCCCAGAGAGAGCCTGGAGCTCAGGCTTTGATTGGGTGACAGACCATTCTGGG
 AAAACAGTTTGGTTGTTCCAAGCGTGAGAAACGGAAATGAAATCGCAGCCTGTCTGACAAAGGC
 TGGAAAGCGGGTATACAGCTCAGCAGGAAGACTTTTGGAGACAGAATTTCAAGAAACAAAAATC
 AAGATGGGACTTTGTGATAACAACTGACATCTCAGAGATGGGCGCCAACCTCAAGGACACCGG
 40 GTCATAGACTCTAGGAGATGCCATAAACAGTCATACTTGATGGTGAGAGAGTCATCTTGGCTGGG
 CCCATGCCTGTCACGCATGCTAGTGCTGCTCAGAGGAGAGGACGTATAGGCAGGAACCCATAACA
 ACCTGGAGATGAGTACATGTATGGAGGTGGGTGTGCAGAGACTGATGAAGGCCATGCACACTGGC
 TTGAAGCAAGAATGCTTCTTGACAACATCTACCTCCAGGATGGCCTCATAGCCTCGCTCTATCGGC
 CTGAGGCCGATAAGGTAGCCGCCATTGAGGGAGAGTTTAAGCTGAGGACAGAGCAAAGGAAGAC
 45 CTTCTGTTGAACCTCATGAAGAGAGGAGACCTTCCCGTCTGGCTAGCCTATCAGGTTGCATCTGCCG
 AATAACTTACACAGACAGAAGATGGTGCTTTGATGGCACAACCAACAACACCATAATGGAAGACA
 GCGTACCAGCAGAGGTGTGGACAAAGTATGGAGAGAAAGAGAGTGCTCAAACCGAGATGGATGGA
 TGCTAGGGTCTGTTTCAGACCATGCGGCCCTGAAGTCTGTTCAAAGAATTCGCCGCTGGAAAAAGAG
 GAGCGGCTTTGGGAGTAATGGAGGCCCTGGGAACACTGCCAGGACACATGACAGAGAGGTTTCAG
 50 GAAGCCATTGACAACCTCGCCGTGCTCATGCGAGCAGAGACTGGAAGCAGGCTTATAAGGCAGC
 GGCAGCCCAACTGCCGAGACCCTAGAGACCATATGCTCTTAGGTTTGCTGGGAACAGTTTCACT
 GGGGATCTTCTTCTGCTTGTATGCGGAATAAGGGCATCGGGAAGATGGGCTTTGGAATGGTAACCT
 TGGGGCCAGTGATGGCTCATGTGGCTTTTCGGAATTTGAACCAGCCAGAATTGCATGTGTCTCAT
 TGTGTGTTTTTATTACTGGTGGTGCTCATACCCGAGCCAGAGAAGCAAAGATCTCCCCAAGATAA
 55 CCAGATGGCAATTATCATCATGGTGGCAGTGGGCCTTCTAGGTTTGATAAAGTCAAAACGAACTTGG
 ATGGCTGGAAAGAACAAAAATGACATAGCTCATCTAATGGGAAGGAGAGAAGAAGGAGCAACC
 ATGGGATTCTCAATGGACATTGATCTGCGGCCAGCCTCCGCTGGGCTATCTATGCCGCATTGACA
 ACTCTCATACCCAGCTGTCCAACATGCGGTAACCACTTCATACAACAACACTCTCTTAATGGCG

ATGGCCACACAAGCTGGAGTGCTGTTTGGCATGGGCAAAGGGATGCCATTTTATGCATGGGACCTT
 GGAGTCCCGCTGCTAATGATGGGTTGCTATTACAAATTAACACCCCTGACTCTGATAGTAGCTATC
 ATTCTGCTTGTGGCGCACTACATGTACTTGATCCCAGGCCTACAAGCGGCAGCAGCGCTGCTGCC
 CAGAAAAGGACAGCAGCTGGCATCATGAAGAATCCCGTTGTGGATGGAATAGTGGTAACTGACAT
 5 TGACACAATGACAATAGACCCCCAGGTGGAGAAGAAGATGGGACAAGTGTTACTCATAGCAGTAG
 CCATCTCCAGTGCTGTGCTGCTGCGGACCGCTGGGGATGGGGGGAGGCTGGAGCTCTGATCACA
 GCAGCGACCTCCACCTTGTGGGAAGGCTCTCCAAACAAATACTGGAACCTCTCTACAGCCACCTCA
 CTGTGCAACATCTTCAGAGGAAGCTATCTGGCAGGAGCTTCCCTTATCTATACAGTGACGAGAAAC
 GCTGGCCTGGTTAAGAGACGTGGAGGTGGGACGGGAGAGACTCTGGGAGAGAAGTGGAAGCTC
 10 GTCTGAATCAGATGTCGGCCCTGGAGTTCTACTCTTATAAAAAGTCAGGTATCACTGAAGTGTGTA
 GAGAGGAGGCTCGCCGTGCCCTCAAGGATGGAGTGGCCACAGGAGGACATGCCGTATCCCGGGGA
 AGTGCAAAGCTCAGATGGTTGGTGGAGAGAGGATATCTGCAGCCCTATGGGAAGGTTGTTGACCT
 CGGATGTGGCAGAGGGGGCTGGAGCTATTATGCCGCCACCATCCGCAAAGTGCCAGGAGGTGAGAG
 GATACACAAAAGGAGGTCCCGGTATGAAGAACCCATGCTGGTGCAAAGCTATGGGTGGAACATA
 15 GTTCGTCTCAAGAGTGGAGTGGACGTCTTCCACATGGCGGCTGAGCCGTGTGACACTCTGCTGTGT
 GACATAGGTGAGTCATCATCTAGTCCTGAAGTGAAGAGACACGAACACTCAGAGTGCTCTCTAT
 GGTGGGGGACTGGCTTGAAAAAAGACCAGGGGCCTTCTGTATAAAGGTGCTGTGCCCATACACCA
 GCACTATGATGGAACCATGGAGCGACTGCAACGTAGGCATGGGGGAGGATTAGTCAGAGTGCCA
 TTGTCTCGCAACTCCACACATGAGATGTAAGTGGTCTCTGGGGCAAAGAGCAACATCATAAAAAG
 20 TGTGTCCACCACAAGTCAGTCCTCCTGGGACGCATGGATGGCCCCAGGAGGCCAGTGAAATATG
 AGGAGGATGTGAACCTCGGCTCGGGTACACGAGCTGTGGCAAGCTGTGCTGAGGCTCCTAACATG
 AAAATCATCGGCAGGCGCATTGAGAGAATCCGCAATGAACATGCAGAAACATGGTTTCTTGATGA
 AAACCACCCATACAGGACATGGGCCTACCATGGGAGCTACGAAGCCCCCACGCAAGGATCAGCGT
 CTTCCCTCGTGAACGGGGTTGTTAGACTCCTGTCAAAGCCTTGGGACGTGGTGACTGGAGTTACAG
 25 GAATAGCCATGACTGACACCACACCATACGGCCAACAAAGAGTCTTCAAAGAAAAAGTGGACACC
 AGGGTGCCAGATCCCCAAGAAGGCACTCGCCAGGTAATGAACATAGTCTCTTCTGCTGTGGAA
 GGAGCTGGGGAAACGCAAGCGGCCACGCGTCTGCACCAAAGAAGAGTTTATCAACAAGGTGCGC
 AGCAATGCAGCACTGGGAGCAATATTTGAAGAGGAAAAAGAATGGAAGACGGCTGTGGAAGCTG
 TGAATGATCCAAGGTTTTGGGCCCTAGTGGATAGGGAGAGAGAACCACCTGAGAGGAGAGTGT
 30 CACAGCTGTGTGTACAACATGATGGGAAAAAGAGAAAAAGAAGCAAGGAGAGTTCGGGAAAGCAA
 AAGGTAGCCGCGCCATCTGGTACATGTGGTTGGGAGCCAGATTCTTGGAGTTTGAAGCCCTTGGAT
 TCTTGAACGAGGACCATTGGATGGGAAGAGAAAACTCAGGAGGTGGAGTCAAGGGTTAGGATTG
 CAAAGACTTGGATACATTCTAGAAGAAATGAATCGGGCACCAGGAGGAAAGATGTACGCAGATG
 AACTGCTGGCTGGGACACCCGCATTAGTAAGTTTGATCTGGAGAATGAAGCTCTGATTACCAACC
 35 AAATGGAGGAAGGGCACAGAACTCTGGCGTTGGCCGTGATTAAATACACATACCAAAACAAAGTG
 GTGAAGGTTCTCAGACCAGCTGAAGGAGGAAAAACAGTTATGGACATCATTTCAGACAAGACCA
 GAGAGGGAGTGGACAAGTTGTCACTTATGCTCTCAACACATTCACCAACTTGGTGGTGCACTTAT
 CCGGAACATGGAAGCTGAGGAAGTGTAGGATGACCAAGACTTATGGTTGTGGGAAGCCAGAGA
 AAGTGACCAGATGGTTGCAGAGCAATGGATGGGATAGACTCAAACGAATGGCGGTGAGTGGAGAT
 40 GACTGCGTTGTGAAGCCAATCGATGATAGGTTTGCACATGCCCTCAGGTTCTTGAATGACATGGGA
 AAAGTTAGGAAAGACACACAGGAGTGGAACCCCTCGACTGGATGGAGCAATTGGGAAGAAGTCC
 CGTTCTGCTCCCACCACTTCAACAAAGCTGTACCTCAAGGATGGGAGATCCATTGTGGTCCCTTGCC
 GCCACCAAGATGAACTGATTGGCCGAGCTCGCGTCTCACCAGGGGCAGGATGGAGCATCCGGGAG
 ACTGCCGTGCTTGCAAAATCATATGCGCAGATGTGGCAGCTCCTTTATTTCCACAGAAGAGACCTT
 45 CGACTGATGGCTAATGCCATTTGCTCGGCTGTGCCAGTTGACTGGGTACCAACTGGGAGAACCACC
 TGGTCAATCCATGGAAAAGGAGAAATGGATGCCACTGAGGACATGCTCATGGTGTGGAATAGAGT
 GTGGATTGAGGAGAACGACCATATGGAGGACAAGACTCCTGTAACAAAATGGACAGACATTCCCT
 ATCTAGGAAAAAGGGAGGACTTATGGTGTGGATCCCTTATAGGGCACAGACCCCGCACCACCTTGG
 GCTGAAAACATCAAAGACACAGTCAACATGGTGCAGGATCATAGGTGATGAAGAAAAGTACAT
 50 GGAATATCTATCCACCCAAAGTCCGCTACTTGGGTGAGGAAGGGTCCACACCCGGAGTGTGTAAAGC
 ACCAATTTTAGTGTGTGTCAGGCCTGCTAGTCAGCCACAGTTTGGGGAAAGCTGTGCAGCCTGTAAC
 CCCCCAGGAGAAGCTGGGAAACCAAGCTCATAGTCAGGCCGAGAACGCCATGGCACGGAAGAA
 GCCATGTGCCTGTGAGCCCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAAGCGCA
 GGATGGGAAAAAGAGGTGGCGACCTTCCCCACCCTTCAATCTGGGGCTGAACCTGGAGACTAGCT
 55 GTGAATCTCCAGCAGAGGGACTAGTGGTTAGAGGAGACCCCCCGGAAAAACGCAAAACAGCATATT
 GACGCTGGGAAAGACCAGAGACTCCATGAGTTTCCACCACGCTGGCCGCCAGGCACAGATCGCCG
 AACAGCGGCGGCCGGTGTGGGGAATCCATGGTTTCT

AY632535.2 NC_012532.1 Zika virus strain MR 766, Uganda, complete genome (SEQ ID NO: 12)

```

5  AGTTGTTGATCTGTGTGAGTCAGACTGCGACAGTTCGAGTCTGAAGCGAGAGCTAACAACAGTATC
AACAGGTTTAATTTGGATTTGGAAACGAGAGTTTCTGGTCATGAAAAACCCCAAAGAAGAAATCC
GGAGGATCCGGATTGTCAATATGCTAAAACGCGGAGTAGCCCGTGTAACCCCTTGGGAGGTTTG
AAGAGGTTGCCAGCCGACTTCTGCTGGGTCATGGACCCATCAGAATGGTTTTGGCGATACTAGCC
TTTTTGAGATTACAGCAATCAAGCCATCACTGGGCTTATCAACAGATGGGGTTCCTGGGGAAA
AAAGAGGCTATGGAAATAATAAAGAAGTTCAAGAAAGATCTTGCTGCCATGTTGAGAATAATCAA
10 TGCTAGGAAAGAGAGGAAGAGACGTGGCGCAGACACCAGCATCGGAATCATTGGCCTCCTGCTGA
CTACAGCCATGGCAGCAGAGATCACTAGACGCGGAGTGCATACTACATGTACTTGGATAGGAGC
GATGCCGGGAAGGCCATTTCTGTTGCTACCACATTGGGAGTGAACAAGTGCCACGTACAGATCAT
GGACCTCGGGCACATGTGTGACGCCACCATGAGTTATGAGTGGCCTATGCTGGATGAGGGAGTGG
AACCAGATGATGTCGATTGCTGGTGCAACACGACATCAACTTGGGTTGTGTACGGAACCTGTCATC
15 ACAAAAAAGGTGAGGCACGGCGATCTAGAAGAGCCGTGACGCTCCCTTCTCACTCTACAAGGAAG
TTGCAAACGCGGTGCGAGACCTGGTTAGAATCAAGAGAATACACGAAGCACTTGATCAAGGTTGA
AACTGGATATTACAGGAACCCCGGGTTTGCCTAGTGGCCGTTGCCATTGCCTGGCTTTTGGGAAG
CTCGACGAGCCAAAAAGTCATATACTTGGTCATGATACTGCTGATTGCCCCGGCATACAGTATCAG
GTGCATTGGAGTCAGCAATAGAGACTTCGTGGAGGGCATGTCAGGTGGGACCTGGGTTGATGTTG
20 TCTTGGAACATGGAGGCTGCGTTACCGTGATGGCACAGGACAAGCCAACAGTCGACATAGAGTTG
GTCACGACGACGGTTAGTAACATGGCCGAGGTAAGATCCTATTGCTACGAGGCATCGATATCGGA
CATGGCTTCGGACAGTCGTTGCCAACACAAGGTGAAGCCTACCTTGACAAGCAATCAGACACTC
AATATGTCTGCAAAAAGAACATTAGTGGACAGAGGTTGGGGAAACGGTTGTGGACTTTTTGGCAAA
GGGAGCTTGGTGACATGTGCCAAGTTTACGTGTTCTAAGAAGATGACCGGGAAGAGCATTCAACC
25 GGAAAATCTGGAGTATCGGATAATGCTATCAGTGCATGGCTCCCAGCATAGCGGGATGATTGGAT
ATGAAACTGACGAAGATAGAGCGAAAGTCGAGGTTACGCCTAATTCACCAAGAGCGGAAGCAAC
CTTGGGAGGCTTTGGAAGCTTAGGACTTGACTGTGAACCAAGGACAGGCCTTGACTTTTCAGATCT
GTATTACCTGACCATGAACAATAAGCATTGGTTGGTGCACAAAGAGTGGTTTCATGACATCCCATT
GCCTTGGCATGCTGGGGCAGACACCGGAACCTCCACACTGGAACAACAAAGAGGCATTGGTAGAAT
30 TCAAGGATGCCCACGCCAAGAGGCAACCGTCGTCGTTCTGGGGAGCCAGGAAGGAGCCGTTCCAC
ACGGCTCTCGCTGGAGCTCTAGAGGCTGAGATGGATGGTGCAAGGGAAGGCTGTTCTCTGGCCA
TTTGAAATGCCGCCTAAAAATGGACAAGCTTAGATTGAAGGGCGTGTATATTCTTGTGCACTGC
GGCATTACATTACCAAGGTCCAGCTGAAACACTGCATGGAACAGTCACAGTGGAGGTGCAGT
ATGCAGGGACAGATGGACCCTGCAAGATCCAGTCCAGATGGCGGTGGACATGCAGACCCTGACC
35 CCAGTTGGAAGGCTGATAACCGCCAACCCCGTGATTACTGAAAGCACTGAGAACTCAAAGATGAT
GTTGGAGCTTGACCCACCATTTGGGGATTCTTACATTGTCATAGGAGTTGGGGACAAGAAAATCAC
CCACCACTGGCATAGGAGTGGTAGCACCATCGGAAAGGCATTTGAGGGCACTGTGAGAGGCGCCA
AGAGAATGGCAGTCTTGGGGGATACAGCCTGGGACTTCGGATCAGTCGGGGGTGTGTTCAACTCA
CTGGGTAAGGGCATTACACAGATTTTGGAGCAGCCTTCAAATCACTGTTTGGAGGAATGTCTGG
40 TTCTCACAGATCCTCATAGGCACGCTGCTAGTGTGGTTAGGTTTGAACACAAAGAATGGATCTATC
TCCCTCACATGCTTGGCCCTGGGGGGAGTGATGATCTTCTCTCCACGGCTGTTTCTGCTGACGTGG
GGTGCTCAGTGGACTTCTCAAAAAAGGAAACGAGATGTGGCACGGGGGTATTCATCTATAATGAT
GTTGAAGCCTGGAGGGACCGGTACAAGTACCATCCTGACTCCCCCGCAGATTGGCAGCAGCAGT
CAAGCAGGCCTGGGAAGAGGGGATCTGTGGGATCTCATCCGTTTCAAGAATGGAAAACATCATGT
45 GGAAATCAGTAGAAGGGGAGCTCAATGCTATCCTAGAGGAGAATGGAGTTCAACTGACAGTTGTT
GTGGGATCTGTAAAAAACCCCATGTGGAGAGGTCCACAAAAGATTGCCAGTGCTGTGAATGAGCT
GCCCCATGGCTGGAAAGCCTGGGGGAAATCGTATTTTGTAGGGCGGCAAGACCAACAACAGTT
TTGTTGTCGACGGTGACACACTGAAGGAATGTCCGCTTGAGCACAGAGCATGGAATAGTTTCTTG
TGGAGGATCACGGGTTTGGAGTCTTCCACACCAGTGTCTGGCTTAAGGTCAGAGAAGATTACTCAT
50 TAGAATGTGACCCAGCCGTCATAGGAACAGCTGTTAAGGGAAAGGGAGGCCGCGCACAGTGATCTG
GGCTATTGGATTGAAAGTGAAAAGAATGACACATGGAGGCTGAAGAGGGCCACCTGATTGAGAT
GAAAACATGTGAATGGCCAAAGTCTCACACATTGTGGACAGATGGAGTAGAAGAAAGTGATCTTA
TCATACCCAAGTCTTTAGCTGGTCCACTCAGCCACCACAACACCAGAGAGGGTTACAGAACCCAA
GTGAAAAGGGCCATGGCACAGTGAAGAGCTTGAATCCGGTTTGAGGAATGTCCAGGCACCAAGGT
55 TTACGTGGAGGAGACATGCGGAACTAGAGGACCATCTCTGAGATCAACTACTGCAAGTGGAAGGG

```

TCATTGAGGAATGGTGTCTGTAGGGAATGCACAATGCCCCACTATCGTTTCGAGCAAAAAGACGGC
 TGCTGGTATGGAATGGAGATAAGGCCAGGAAAGAACCAGAGAGCAACTTAGTGAGGTCAATGGT
 GACAGCGGGGTCAACCGATCATATGGACCACTTCTCTTTGGAGTGCTTGTGATTCTACTCATGGT
 5 GCAGGAGGGGTTGAAGAAGAGAATGACCACAAAGATCATCATGAGCACATCAATGGCAGTGCTG
 GTAGTCATGATCTTGGGAGGATTTTCAATGAGTGACCTGGCCAAGCTTGTGATCCTGATGGGTGCT
 ACTTTCGCAGAAATGAACACTGGAGGAGATGTAGCTCACTTGGCATTGGTAGCGGCATTAAAGTC
 AGACCAGCCTTGCTGGTCTCCTTCATTTTCAGAGCCAATTGGACACCCCGTGAGAGCATGCTGCTA
 GCCCTGGCTTCGTGTCTTCTGCAAACCTGCGATCTCTGCTCTTGAAGGTGACTTGATGGTCCTCATTA
 10 ATGGATTTGCTTTGGCCTGGTTGGCAATTCGAGCAATGGCCGTGCCACGCACTGACAACATCGCTC
 TACCAATCTTGGCTGCTCTAACACCACTAGCTCGAGGCACACTGCTCGTGGCATGGAGAGCGGGCC
 TGGCTACTTGTGGAGGGATCATGCTCCTCTCCCTGAAAGGGAAAAGGTAGTGTGAAGAAGAACCTG
 CCATTGTGTCATGGCCCTGGGATTGACAGCTGTGAGGGTAGTAGACCCTATTAATGTGGTAGGACTA
 CTGTTACTCACAAGGAGTGGGAAGCGGAGCTGGCCCCCTAGTGAAGTTCTCACAGCCGTTGGCCTG
 15 ATATGTGCACTGGCCGGAGGGTTTGCCAAGGCAGACATTGAGATGGCTGGACCCATGGCTGCAGT
 AGGCTTGCTAATTGTGCTATGTGGTCTCGGGAAAGAGTGTGGACATGTACATTGAAAAGAGCAG
 GTGACATCACATGGGAAAAGGACGCGGAAGTCACTGGAACAGTCCTCGGCTTGACGTGGCACTG
 GATGAGAGTGGTGACTTCTCCTTGGTAGAGGAAGATGGTCCACCCATGAGAGAGATCATACTCAA
 GGTGGTCCTGATGGCCATCTGTGGCATGAACCAATAGCTATACCTTTTGCTGCAGGAGCGTGGTA
 20 TGTGTATGTGAAGACTGGGAAAAGGAGTGGCGCCCTCTGGGACGTGCCTGCTCCCAAAGAAGTGA
 AGAAAGGAGAGACCACAGATGGAGTGTACAGAGTGATGACTCGCAGACTGCTAGGTTCAACACA
 GGTGGAGTGGGAGTCATGCAAGAGGGAGTCTTCCACACCATGTGGCACGTTACAAAAGGAGCCG
 CACTGAGGAGCGGTGAGGGAAGACTTGATCCATACTGGGGGGATGTCAAGCAGGACTTGGTGCTCA
 TACTGTGGGCCCTTGAAGTTGGATGCAGCTTGGGATGGACTCAGCGAGGTACAGCTTTTGCCGTA
 25 CCTCCCGGAGAGAGGGCCAGAAACATTACAGCCCTGCCTGGAATATTCAAGACAAAGGACGGGGA
 CATCGGAGCAGTTGCTCTGGACTACCCTGCAGGGACCTCAGGATCTCCGATCCTAGACAAATGTGG
 AAGAGTGATAGGACTCTATGGCAATGGGGTTGTGATCAAGAATGGAAGCTATGTTAGTGCTATAA
 CCCAGGGAAGAGGGAGGAGGAGACTCCGTTGAATGTTTGAACCCCTCGATGCTGAAGAAGAA
 GCAGCTAACTGTCTTGGATCTGCATCCAGGAGCCGGAACCAAGGAGAGTTCTTCTGAAATAG
 TCCGTGAAGCCATAAAAAAGAGACTCCGGACAGTGATCTTGGCACCAACTAGGGTTGTCGCTGCT
 30 GAGATGGAGGAGGCCTTGAGAGGACTTCCGTTGCGTTACATGACAACAGCAGTCAACGTCAACCA
 TTCTGGGACAGAAATCGTTGATTTGATGTGCCATGCCACTTTCACCTTACGCTTACTACAACCCATC
 AGAGTCCCTAATTACAATCTCAACATCATGGATGAAGCCCACTTCACAGACCCCTCAAGTATAGCT
 GCAAGAGGATACATATCAACAAGGGTTGAAATGGGCGAGGCGGCTGCCATTTTTATGACTGCCAC
 ACCACCAGGAACCCGTGATGCGTTTCTGACTCTAACTCACCATCATGGACACAGAAGTGGAAG
 35 TCCCAGAGAGAGCCTGGAGCTCAGGCTTTGATTGGGTGACAGACCATTCTGGGAAAACAGTTTGG
 TTCGTTCCAAGCGTGAGAAACGGAAATGAAATCGCAGCCTGTCTGACAAAGGCTGGAAGCGGGT
 CACACAGCTCAGCAGGAAGACTTTTGAGACAGAATTCAGAAAAACAAAAATCAAGAGTGGGACT
 TTGTCATAACAACTGACATCTCAGAGATGGGGCCCAACTTCAAGGCTGACCGGCTGAGGACTCTA
 GGAGATGCCTAAAACAGTCATACTTGATGGTGAGAGAGTCATCTTGGCTGGGCCCATGCCTGTCA
 40 CGCATGCTAGTGCTGCTCAGAGGAGAGGACGTATAGGCAGGAACCCCTAACAAACCTGGAGATGAG
 TACATGTATGGAGGTGGGTGTGCAGAGACTGATGAAGGCCATGCACACTGGCTTGAAGCAAGAAT
 GCTTCTTGACAAACATCTACCTCCAGGATGGCCTCATAGCCTCGCTCTATCGGCCTGAGGCCGATAA
 GGTAGCCGCCATTGAGGGAGAGTTTAAAGCTGAGGACAGAGCAAAGGAAGACCTTCGTGGAACCTA
 TGAAGAGAGGAGACCTTCCCGTCTGGCTAGCCTATCAGGTTGCATCTGCCGGAATAACTTACACAG
 45 ACAGAAGATGGTGCTTTGATGGCACAACCAACACCATTAATGGAAGACAGTGTACCAGCAGAG
 GTTTGGACAAAAGTATGGAGAGAAGAGAGTGTCTCAAACCGAGATGGATGGATGCTAGGGTCTGTTT
 AGACCATGCGGCCCTGAAGTCGTTCAAAGAATTCGCCGCTGGAAAAAGAGGAGCGGCTTTGGGAG
 TAATGGAGGCCCTGGGAACACTGCCAGGACACATGACAGAGAGGTTTCAGGAAGCCATTGACAAAC
 CTCGCCGTGCTCATGCGAGCAGAGACTGGAAGCAGGCCTTATAAGGCAGCGGCAGCCCAACTGCC
 50 GGAGACCCTAGAGACCATTATGCTCTTAGGTTTGCTGGGAACAGTTTCACTGGGGATCTTCTTCGT
 CTTGATGCGGAATAAGGGCATCGGGAAGATGGGCTTTGGAATGGTAACCCCTTGGGGCCAGTGCAT
 GGCTCATGTGGCTTTTCGGAAATTGAACCAGCCAGAATTGCATGTGTCCTCATTGTTGTGTTTTATT
 ACTGGTGGTGCTCATACCCGAGCCAGAGAAGCAAAAGATCTCCCCAAGATAACCAGATGGCAATTA
 TCATCATGGTGGCAGTGGGCCTTCTAGGTTTGATAAAGTGAACGAACTGGATGGCTGGAAAGA
 55 ACAAAAAATGACATAGCTCATCTAATGGGAAGGAGAGAAGAAGGAGCAACCATGGGATTCTCAA
 TGGACATTGATCTGCGGCCAGCCTCCGCCTGGGCTATCTATGCCGCATTGACAACTCTCATCCCC
 CAGCTGTCCAACATGCGGTAACCACTTCATACAACAACACTCTCTTAATGGCGATGGCCACACAAG

CTGGAGTGTCTTTGGCATGGGCAAAGGGATGCCATTTATGCATGGGGACCTTGGAGTCCCGCTGC
 TAATGATGGGTTGCTATTACAAATTAACACCCCTGACTCTGATAGTAGCTATCATTCTGCTTGTGGC
 GCACTACATGTACTTGATCCCAGGCCTACAAGCGGCAGCAGCGCGTGTGCCAGAAAAGGACAG
 CAGCTGGCATCATGAAGAATCCCGTTGTGGATGGAATAGTGGTAACTGACATTGACACAATGACA
 5 ATAGACCCCCAGGTGGAGAAGAAGATGGGACAAGTGTTACTCATAGCAGTAGCCATCTCCAGTGC
 TGTGTGCTGCGGACCGCTGGGGATGGGGGGAGGCTGGAGCTCTGATCACAGCAGCGACCTCCA
 CTTGTGGGAAGGCTCTCCAAACAAATACTGGAACCTCTCTACAGCCACCTCACTGTGCAACATCT
 TCAGAGGAAGCTATCTGGCAGGAGCTTCCCTTATCTATACAGTGACGAGAAACGCTGGCCTGGTTA
 AGAGACGTGGAGGTGGGACGGGAGAGACTCTGGGAGAGAAGTGGAAAGCTCGTCTGAATCAGAT
 10 GTCGGCCCTGGAGTTCTACTCTTATAAAAAAGTCAGGTATCACTGAAAGTGTGTAGAGAGGAGGCTCG
 CCGTGGCCCTCAAGGATGGAGTGGCCACAGGAGGACATGCCGTATCCCGGGGAAGTGCAAAAGATCA
 GATGGTTGGAGGAGAGAGGATATCTGCAGCCCTATGGGAAGGTTGTTGACCTCGGATGTGGCAGA
 GGGGGCTGGAGCTATTATGCCGCCACCATCCGCAAAGTGCAGGAGGTGAGAGGATACACAAAGG
 GAGGTCCCGGTATGAAGAACCCTGCTGGTGCAAAGCTATGGGTGGAACATAGTTCGTCTCAAG
 15 AGTGGAGTGGACGTCTTCCACATGGCGGCTGAGCCGTGTGACACTCTGCTGTGTGACATAGGTGAG
 TCATCATCTAGTCCTGAAGTGGAAAGAGACACGAACACTCAGAGTGTCTCTATGGTGGGGGACTG
 GCTTGAaaaaAGACCAGGGGCCCTTCTGTATAAAAGGTGCTGTGCCCATACACCAGCACTATGATGG
 AAACCATGGAGCGACTGCAACGTAGGCATGGGGGAGGATTAGTCAGAGTGCCATTGTGTGCGAAC
 TCCACACATGAGATGTACTGGGTCTCTGGGGCAAAGAGCAACATCATAAAAAAGTGTGTCCACCAC
 20 AAGTCAGCTCCTCCTGGGACGCATGGATGGCCCCAGGAGGCCAGTGAAATATGAGGAGGATGTGA
 ACCTCGGCTCGGGTACACGAGCTGTGGCAAGCTGTGCTGAGGCTCCTAACATGAAAATCATCGGC
 AGGCGCATTGAGAGAATCCGCAATGAACATGCAGAAACATGGTTTCTTGATGAAAACACCACCAT
 CAGGACATGGGCCTACCATGGGAGCTACGAAGCCCCACGCAAGGATCAGCGTCTTCCCTCGTGA
 ACGGGGTTGTTAGACTCCTGTCAAAGCCTTGGGACGTGGTGACTGGAGTTACAGGAATAGCCATG
 25 ACTGACACCACACCATACGGCCAACAAAGAGTCTTCAAAGAAAAAGTGGACACCAGGGTGCCAG
 ATCCCCAAGAAGGCACTCGCCAGGTAATGAACATAGTCTCTTCCCTGGCTGTGGAAGGAGCTGGGG
 AAACGCAAGCGGCCACGCGTCTGCACCAAGAAGAGTTTATCAACAAGGTGCGCAGCAATGCAGC
 ACTGGGAGCAATATTTGAAGAGGAAAAAGAATGGAAGACGGCTGTGGAAGCTGTGAATGATCCA
 AGGTTTTGGGCCCTAGTGGATAGGGAGAGAGAACACCACCTGAGAGGAGAGTGTACAGCTGTGT
 30 GTACAACATGATGGGAAAAAGAGAAAAAGCAAGGAGAGTTTCGGGAAAGCAAAAGGTAGCCGC
 GCCATCTGGTACATGTGGTTGGGAGCCAGATTCTTGAGTTTGAAGCCCTTGGATTCTTGAACGAG
 GACCATTGGATGGGAAGAGAAAACTCAGGAGGTGGAGTCGAAGGGTTAGGATTGCAAAAGACTTG
 GATACATTCTAGAAGAAATGAATCGGGCACCAGGAGGAAAGATGTACGCAGATGACACTGCTGGC
 TGGGACACCCGCATTAGTAAGTTGATCTGGAGAATGAAGCTCTGATTACCAACCAAAATGGAGGA
 35 AGGGCACAGAACTCTGGCGTTGGCCGTGATTAAATACACATACCAAAACAAAGTGGTGAAGGTTT
 TCAGACCAGCTGAAGGAGGAAAAACAGTTATGGACATCATTTCAAGACAAGACCAGAGAGGGAG
 TGGACAAGTTGTCACTTATGCTCTCAACACATTACCAACTTGGTGGTGCAGCTTATCCGGAACAT
 GGAAGCTGAGGAAGTGTTAGAGATGCAAGACTTATGGTTGTTGAGGAAGCCAGAGAAAGTGACCA
 GATGGTTGCAGAGCAATGGATGGGATAGACTCAAACGAATGGCGGTCAGTGGAGATGACTGCGTT
 40 GTGAAGCCAATCGATGATAGTTTGCACATGCCCTCAGGTTCTTGAATGACATGGGAAAAAGTTAG
 GAAAGACACACAGGAGTGGAAACCCCTGACTGGATGGAGCAATTGGGAAGAAAGTCCCGTTCTGCT
 CCCACCCTTCAACAAAGCTGTACCTCAAGGATGGGAGATCCATTGTGGTCCCTTGCCGCCACCAAG
 ATGAACTGATTGGCCGAGCTCGCGTCTCACCAGGGGCAGGATGGAGCATCCGGGAGACTGCCTGT
 CTTGCAAAATCATATGCGCAGATGTGGCAGCTCCTTTATTTCCACAGAAGAGACCTTCGACTGATG
 45 GCTAATGCCATTTGCTCGGCTGTGCCAGTTGACTGGGTACCAACTGGGAGAACCACTGGTCAATC
 CATGGAAAAGGGAGAAATGGATGACCACTGAGGACATGCTCATGGTGTGGAATAGAGTGTGGATTGA
 GGAGAACGACCATATGGAGGACAAGACTCCTGTAACAAAATGGACAGACATTCCCTATCTAGGAA
 AAAGGGAGGACTTATGGTGTGGATCCCTTATAGGGCACAGACCCCGCACCCTTGGGCTGAAAAC
 ATCAAAGACACAGTCAACATGGTGCAGGATCATAGGTGATGAAGAAAAGTACATGGACTATCT
 50 ATCCACCCAAAGTCCGCTACTTGGGTGAGGAAGGGTCCACACCCGGAGTGTTGTAAGCACCAATTTT
 AGTGTGTGTCAGGCCTGCTAGTCAGCCACAGTTTGGGGAAAAGCTGTGCAGCCTGTAACCCCCCAGG
 AGAAGCTGGGAAACCAAGCTCATAGTCAGGCCGAGAACGCCATGGCACGGAAGAAGCCATGCTG
 CCTGTGAGCCCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAAAGCGCAGGATGGGAA
 AAGAAGGTGGCGACCTTCCCCACCCTTCAATCTGGGGCCTGAACTGGAGACTAGCTGTGAATCTCC
 55 AGCAGAGGGACTAGTGGTTAGAGGAGACCCCCCGGAAAAACGCAAAACAGCATATTGACGTGGGA
 AAGACCAGAGACTCCATGAGTTTCCACCACGCTGGCCGCCAGGCACAGATCGCCGAACCTTCGGCG
 GCCGCTGTGGGGAAATCCATGGTTTCT

>Chimeric Asian ZIKV Sequence H/PF/2013 polyprotein flanked with consensus sequence from other strains (SEQ ID NO: 13)

```

5  GTTGTGTGATCTGTGTGAATCAGACTGCGACAGTTCGAGTTTGAAGCGAAAGCTAGCAACAGTATCA
   ACAGGTTTTATTTTGGATTTGGAAACGAGAGTTTCTGGTTCATGAAAAACCCAAAAAAGAAATCCG
   GAGGATTCCGGATTGTCAATATGCTAAAACGCGGAGTAGCCCGTGTGAGCCCCCTTTGGGGGCTTGA
   AGAGGCTGCCAGCCGACTTCTGCTGGGTCATGGGCCCATCAGGATGGTCTTGGCGATTCTAGCCT
   TTTTGAGATTACGGCAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTCAGTGGGGAAAA
   AAGAGGCTATGGAAATAATAAAGAAGTTCAAGAAAGATCTGGCTGCCATGCTGAGAATAATCAAT
10  GCTAGGAAGGAGAAGAAGAGACGAGGCGCAGATACTAGTGTGCGAATTGTTGGCCTCCTGCTGAC
   CACAGCTATGGCAGCGGAGGTCACTAGACGTGGGAGTGCATACTATATGTACTTGGACAGAAACG
   ACGCTGGGGAGGCCATATCTTTTCCAACCACATTGGGGATGAATAAGTGTATATACAGATCATGG
   ATCTTGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTATGCTGGATGAGGGGGTGGAA
   CCAGATGACGTCGATTGTTGGTGCAACACGACGTCAACTTGGGTTGTGTACGGAACCTGCCATCAC
15  AAAAAAGGTGAAGCACGAGATCTAGAAGAGCTGTGACGCTCCCCCTCCCATTCCTACTAGGAAGCT
   GCAAACGCGGTGCAAAACCTGGTTGGAATCAAGAGAATACACAAAGCACTTGATTAGAGTCGAAA
   ATTGGATATTCAGGAACCTGGCTTCGCGTTAGCAGCAGCTGCCATCGCTTGGCTTTTGGGAAGCT
   CAACGAGCCAAAAAGTCATATACTTGGTCATGATACTGCTGATTGCCCCGGCATACAGCATCAGGT
   GCATAGGAGTCAGCAATAGGGACTTTGTGGAAGGTATGTCAGGTGGGACTTGGGTTGATGTTGTCT
20  TGGAACATGGAGGTTGTGTCAACGTAATGGCACAGGACAAACCGACTGTCGACATAGAGCTGGTT
   ACAACAACAGTCAGCAACATGGCGGAGGTAAGATCCTACTGCTATGAGGCATCAATATCGGACAT
   GGCTTCGACAGCCGCTGCCCAACACAAGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAAT
   ATGTCGCAAAAAGAACGTTAGTGGACAGAGGCTGGGGAAATGGATGTGGACTTTTGGCAAAGGG
   AGCCTGGTGACATGCGCTAAGTTTGCATGCTCCAAGAAAAATGACCGGGAAGAGCATCCAGCCAGA
25  GAATCTGGAGTACCGGATAATGCTGTGCTAGTTTCATGGCTCCAGCACAGTGGGATGATCGTTAATGA
   CACAGGACATGAAACTGATGAGAATAGAGCGAAGGTTGAGATAACGCCCAATTCACCAAGAGCC
   GAAGCCACCCTGGGGGGTTTTGGAAGCCTAGGACTTGATTGTGAACCGAGGACAGGCCTTGACTTT
   TCAGATTTGTATTACTTGACTATGAATAACAAGCACTGGTTGGTTTACAAGGAGTGGTTCCACGAC
   ATTCCATTACCTTGGCAGCTGGGGCAGACACCGGAACCTCCACACTGGAACAACAAAGAAGCACT
30  GGTAGAGTTCAAGGACGCACATGCCAAAAGGCAAACTGTCGTGGTTCTAGGGAGTCAAGAAGGAG
   CAGTTCACACGGCCCTTGTGGAGCTCTGGAGGCTGAGATGGATGGTGCAAAGGGAAGGCTGTCC
   TCTGGCCACTTGAAATGTGCTGCTGAAAATGGATAAACTTAGATTGAAGGGCGTGTCACTACTCTTG
   TGTACCGCAGCGTTTCACATTCACCAAGATCCCGGCTGAAACACTGCACGGGACAGTCACAGTGG
   GGTACAGTACGCAGGGACAGATGGACCTTGCAAGGTTCCAGCTCAGATGGCGGTGGACATGCAAA
35  CTCTGACCCCAAGTTGGGAGGTTGATAACCGCTAACCCCGTAATCACTGAAAGCACTGAGAACTCTA
   AGATGATGCTGGAACCTTGATCCACCATTTGGGGACTCTTACATTGTCATAGGAGTCGGGGGAGAAG
   AAGATCACCCACCACTGGCACAGGAGTGGCAGCACCATTGGAAAAGCATTGGAAGCCACTGTGAG
   AGGTGCCAAGAGAATGGCAGTCTTGGGAGACACAGCCCTGGGACTTTGGATCAGTTGGAGGCGCTC
   TCAACTCATTGGGCAAGGGCATCCATCAAATTTTGGAGCAGCTTTCAAATCATTGTTTGGAGGAA
40  TGTCTTGGTTCTCACAAATTCTCATTGGAACGTTGCTGATGTGGTTGGGTCTGAACACAAAGAATG
   GATCTATTTCCCTTATGTGCTTGGCCTTAGGGGGAGTGTGATCTTCTTATCCACAGCTGTCTCTGC
   TGATGTGGGGTGTCTCGGTGGACTTCTCAAAGAAGGAGACGAGATGCGGTACAGGGGTGTTCTGTCT
   ATAACGACGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCCTGACTCCCCCGTAGATTGGCA
   GCAGCAGTCAAGCAAGCCTGGGAAGATGGTATCTGTGGGATCTCCTCTGTTTCAAGAATGGAAAA
45  CATCATGTGGAGATCAGTAGAAGGGGAGCTCAACGCAATCCTGGAAGAGAATGGAGTTCAACTGA
   CGGTGTTGTGGGATCTGTAAAAAACCCCATGTGGAGAGGTCCACAGAGATTGCCCGTGCCTGTG
   AACGAGCTGCCCCACGGCTGGAAGGCTTGGGGGAAATCGTACTTCTGTAGAGCAGCAAAAGACAAA
   TAACAGCTTTGTGCTGGATGGTGACACACTGAAGGAATGCCCACTCAAACATAGAGCATGGAACA
   GCTTTCTTGTGGAGGATCATGGGTTCTGGGGTATTTACACTAGTGTCTGGCTCAAGGTTAGAGAAG
50  ATTATTCATTAGAGTGTGATCCAGCCGTTATTGGAACAGCTGTTAAGGGAAAGGAGGCTGTACACA
   GTGATCTAGGCTACTGGATTGAGAGTGAGAAGAATGACACATGGAGGCTGAAGAGGGGCCATCTG
   ATCGAGATGAAAACATGTGAATGGCCAAAGTCCCACACATTGTGGACAGATGGAATAGAAGAGA
   GTGATCTGATCATACCAAGTCTTTAGCTGGGCCACTCAGCCATCACAATACCAGAGAGGGGCTACA
   GGACCCAAATGAAAAGGGCCATGGCACAGTGAAGAGCTTGAATTCGGTTTGAGGAATGCCAGGC
55  ACTAAGGTCCACGTGGAGGAAACATGTGGAACAAGAGGACCATCTCTGAGATCAACCACTGCAAG

```

CGGAAGGGTGATCGAGGAATGGTGCTGCAGGGAGTGCACAATGCCCCACTGTTCGTTCCGGGCTA
 AAGATGGCTGTTGGTATGGAATGGAGATAAGGCCAGGAAAGAACAGAAAGTAACTTAGTAAG
 GTCAATGGTGACTGCAGGATCAACTGATCAGATGGATCACTTCTCCCTTGGAGTGCTTGTGATTCT
 5 GCTCATGGTGCAGGAAGGGCTGAAGAAGAGAATGACCACAAAGATCATCATAAGCACATCGATG
 GCAGTGCTGGTAGCTATGATCCTGGGAGGATTTTCAATGAGTGACCTGGCTAAGCTTGCAATTTTG
 ATGGGTGCCACCTTCGCGGAAATGAACACTGGAGGAGATGTAGCTCATCTGGCGCTGATAGCGGC
 ATTCAAAGTCAGACCAGCGTTGCTGGTATCTTTCATCTTCAGAGCTAATTGGACACCCCGTGAAAG
 CATGCTGCTGGCCTTGGCCTCGTGTCTTTTGCAAACTGCGATCTCCGCCTTGGAAAGGCGACCTGAT
 10 GGTTCATCAATGGTTTTGCTTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCACGCACTGAT
 AACATCACCTTGGCAATCCTGGCTGCTCTGACACCACTGGCCCGGGGCACACTGCTTGTGGCGTGG
 AGAGCAGGCCTTGCTACTTGCAGGGGGTTTATGCTCCTCTCTCTGAAGGGAAAAGGCAGTGTGAA
 GAAGAACTTACCATTTGTCATGGCCCTGGGACTAACCCTGTGAGGCTGGTCGACCCCATCAACGT
 GGTGGGACTGCTGTTGCTCACAAGGAGTGGGAAGCGGAGCTGGCCCCCTAGCGAAGTACTCACAG
 CTGTTGGCCTGATATGCGCATTTGGCTGGAGGGTTCGCCAAGGCAGATATAGAGATGGCTGGGCCC
 15 ATGGCCGCGGTGCGTCTGCTAATTGTCAGTTACGTGGTCTCAGGAAAAGAGTGTGGACATGTACATT
 GAAAGAGCAGGTGACATCACATGGGAAAAAGATGCGGAAGTCACTGGAAACAGTCCCCGGCTCG
 ATGTGGCGCTAGATGAGAGTGGTGATTTCTCCCTGGTGGAGGATGACGGTCCCCCATGAGAGAG
 ATCATACTCAAGGTGGTCTGATGACCATCTGTGGCATGAACCCAATAGCCATACCCTTTGCAGCT
 GGAGCGTGGTACGTATACGTGAAGACTGGAAAAAGGAGTGGTGCTCTATGGGATGTGCCTGCTCC
 20 CAAGGAAGTAAAAAAGGGGGAGACCACAGATGGAGTGTACAGAGTAATGACTCGTAGACTGCTA
 GGTTCACACAAGTTGGAGTGGGAGTTATGCAAGAGGGGGTCTTTCACACTATGTGGCACGTAC
 AAAAGGATCCGCGCTGAGAAGCGGTGAAGGGAGACTTGATCCATACTGGGGAGATGTCAAGCAG
 GATCTGGTGTACTACTGTGGTCCATGGAAGCTAGATGCCGCTGGGACGGGCACAGCGAGGTGCA
 GCTCTTGGCCGTGCCCCCGGAGAGAGAGCGAGGAACATCCAGACTCTGCCCGGAATATTTAAGA
 25 CAAAGGATGGGGACATTGGAGCGGTTGCGCTGGATTACCCAGCAGGAACCTCAGGATCTCCAATC
 CTAGACAAGTGTGGGAGAGTGATAGGACTTTATGGCAATGGGGTCTGATCAAAAATGGGAGTTA
 TGTTAGTGCCATCACCCAAGGGAGGAGGGAGGAAGAGACTCCTGTTGAGTGCTTCGAGCCTTCGA
 TGCTGAAGAAGAAGCAGCTAACTGTCTTAGACTTGCATCCTGGAGCTGGGAAAACAGGAGAGTT
 CTTCTGAAATAGTCCGTGAAGCCATAAAAAACAAGACTCCGTACTGTGATCTTAGCTCCAACCAGG
 30 GTTGTGCTGCTGAAATGGAGGAAGCCCTTAGAGGGCTTCCAGTGCGTTATATGACAACAGCAGTC
 AATGTCACCCACTCTGGAACAGAAATCGTCGACTTAATGTGCCATGCCACCTTCACCTCACGTCTA
 CTACAGCCAATCAGAGTCCCCAACTATAATCTGTATATTATGGATGAGGCCCACTTCACAGATCCC
 TCAAGTATAGCAGCAAGAGGATACATTTCAACAAGGGTTGAGATGGGCGAGGCGGCTGCCATCTT
 CATGACCGCCACGCCACCAGGAACCCGTGACGCATTTCCGGACTCCAACCTACCAATTATGGACAC
 35 CGAAGTGGAAGTCCCAGAGAGAGCCTGGAGCTCAGGCTTTGATTGGGTGACGGATCATTCTGGAA
 AAACAGTTTGGTTTGTTCGAAGCGTGAGGAACGGCAATGAGATCGCAGCTTGTCTGACAAAGGCT
 GGAAAACGGGTACATACAGCTCAGCAGAAAAGACTTTTGAGACAGAGTCCAGAAAACAAACATCA
 AGAGTGGGACTTTGTCTGACAACTGACATTTACAGAGATGGGCGCCAACCTTAAAGACACCTGT
 CATAGATTCCAGGAGATGCCTAAAGCCGGTCATACTTGATGGCGAGAGAGTCATTCTGGCTGGAC
 40 CCATGCCTGTCACACATGCCAGCGCTGCCAGAGGAGGGGGCGCATAGGCAGGAATCCCAACAAA
 CCTGGAGATGAGTATCTGTATGGAGGTGGGTGCGCAGAGACTGACGAAGACCATGCACACTGGCT
 TGAAGCAAGAATGCTCCTTGACAATATTTACCTCCAAGATGGCCTCATAGCCTCGCTCTATCGACC
 TGAGGCCGACAAAAGTAGCAGCCATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAAGGAAGACC
 TTTGTGGAATCATGAAAAGAGGAGATCTTCTGTTTGGCTGGCCTATCAGGTTGCATCTGCCGGA
 45 ATAACCTACACAGATAGAAGATGGTGCTTGTAGTGGCAGCACCAACAACACCATAATGGAAGACAG
 TGTGCCGGCAGAGGTGTGGACCAGACACGGAGAGAAAAGAGTGCTCAAACCGAGGTGGATGGAC
 GCCAGAGTTTGTTCAGATCATGCGGCCCTGAAGTCATTCAAGGAGTTTGCCGCTGGGAAAAGAGG
 AGCGGCTTTTGGAGTGATGGAAGCCCTGGGAACACTGCCAGGACACATGACAGAGAGATTCCAGG
 AAGCCATTGACAACCTCGCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAGCCGCG
 50 GCGGCCCAATTGCCGGAGACCCTAGAGACCATTATGCTTTTGGGGTTGCTGGGAACAGTCTCGCTG
 GGAATCTTTTTCGTCTTGATGAGGAACAAGGGCATAGGGAAGATGGGCTTTGGAATGGTGACTCTT
 GGGGCCAGCGCATGGCTCATGTGGCTCTCGGAAATTGAGCCAGCCAGAATTGCATGTGTCCTCATT
 GTTGTGTTCTATTGCTGGTGGTGCTCATACCTGAGCCAGAAAAGCAAAGATCTCCCCAGGACAAC
 CAAATGGCAATCATCATGTTAGCAGTAGGTCTTCTGGGCTTGATTACCGCAATGAACTCGGA
 55 TGGTTGGAGAGAAACAAGAGTGACCTAAGCCATCTAATGGGAAGGAGAGAGGAGGGGGCAACCA
 TAGGATTCTCAATGGACATTGACCTGCGGCCAGCCTCAGCTTGGGCCATCTATGCTGCCTTGACAA
 CTTTCATTACCCAGCCGTCCAACATGCAGTGACCACCTTCATACAACAACACTACTCTTAATGGCGA

TGGCCACGCAAGCTGGAGTGTGTTGTTTGGTATGGGCAAAGGGATGCCATTCTACGCATGGGACTTTG
 GAGTCCCGCTGCTAATGATAGGTTGCTACTCACAATTAACACCCCTGACCCTAATAGTGGCCATCA
 TTTTGCTCGTGGCGCACTACATGTACTTGATCCAGGGCTGCAGGCAGCAGCTGCGCGTGCTGCCC
 5 AGAAGAGAACGGCAGCTGGCATCATGAAGAACCCTGTTGTGGATGGAATAGTGGTGACTGACATT
 GACACAATGACAATTGACCCCAAGTGGAGAAAAAGATGGGACAGGTGCTACTCATAGCAGTAGC
 CGTCTCCAGCGCCATACTGTCGCGGACCGCCTGGGGGTGGGGGGAGGCTGGGGCCCTGATCACAG
 CGGCAACTTCCACTTTGTGGGAAGGCTCTCCGAACAAGTACTGGAACCTCTACAGCCACTTCAC
 TGTGTAACATTTTTAGGGGAAGTTACTTGGCTGGAGCTTCTCTAATCTACACAGTAACAAGAAACG
 CTGGCTTGGTCAAGAGACGTGGGGGTGGAACAGGAGAGACCCTGGGAGAGAAATGGAAGGCCCG
 10 CTGAACCAGATGTCGGCCCTGGAGTTCTACTCCTACAAAAAGTCAGGCATCACCGAGGTGTGCAG
 AGAAGAGGCCCCGCCGCGCCCTCAAGGACGGTGTGGCAACGGGAGGCCATGCTGTGTCCCGAGGAA
 GTGCAAAGCTGAGATGGTTGGTGGAGCGGGGATACCTGCAGCCCTATGGAAAGGTCATTGATCTT
 GGATGTGGCAGAGGGGGCTGGAGTTACTACGCCGCCACCATCCGCAAAGTTCAAGAAGTGAAAGG
 ATACACAAAAGGAGGCCCTGGTTCATGAAGAACCCTATGTTGGTGCAAAGCTATGGGTGGAACATAG
 15 TCCGTCTTAAGAGTGGGGTGGACGTCTTTCATATGGCGGCTGAGCCGTGTGACACGTTGCTGTGTG
 ACATAGGTGAGTCATCATCTAGTCTGAAGTGAAGAAGCACGGACGCTCAGAGTCCTCTCCATG
 GTGGGGGATTGGCTTGAAAAAGACCAGGAGCCTTTTGTATAAAAGTGTGTGCCCATACACCAG
 CACTATGATGGAACCCCTGGAGCGACTGCAGCGTAGGTATGGGGGAGGACTGGTCAGAGTGCCAC
 TCTCCCGCAACTCTACACATGAGATGTAAGTGGTCTCTGGAGCGAAAAGCAACACCATAAAAAAGT
 20 GTGTCCACCACGAGCCAGCTCCTCTTGGGGCGCATGGACGGGGCCAGGAGGCCAGTGAAATATGA
 GGAGGATGTGAATCTCGGCTCTGGCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATGA
 AGATCATTGGTAACCGCATTGAAAGGATCCGCAGTGAGCACGCGGAAACGTGGTTCTTTGACGAG
 AACCACCCATATAGGACATGGGCTTACCATGGAAGCTATGAGGCCCCACACAAGGGTCAGCGTC
 CTCTCTAATAAACGGGGTTGTGAGGCTCCTGTCAAAACCCTGGGATGTGGTGACTGGAGTCACAGG
 25 AATAGCCATGACCGACACCACACCGTATGGTCAGCAAAGAGTTTTCAAGGAAAAAGTGGACACTA
 GGGTGCCAGACCCCCAAGAAGGCACTCGTCAGGTTATGAGCATGGTCTCTTCTGTTGTGGAAAG
 AGCTAGGCAAAACAAACGGCCACGAGTCTGTACCAAAGAAGAGTTTCATCAACAAGGTTTCGTAGC
 AATGCAGCATTAGGGGCAATATTTGAAGAGGAAAAAGAGTGGAAAGCTGCAGTGGAAGCTGTGA
 ACGATCCAAGGTTCTGGGCTCTAGTGGACAAGGAAAGAGAGCACCACCTGAGAGGAGAGTGCCA
 30 GAGTTGTGTGTACAACATGATGGGAAAAAGAGAAAAAGAAACAAAGGGGAATTTGGAAAGGCCAAG
 GGCAGCCGCGCCATCTGGTATATGTGGCTAGGGGCTAGATTTCTAGAGTTCGAAGCCCTTGGATTCT
 TTGAACGAGGATCACTGGATGGGGAGAGAGAACTCAGGAGGTGGTGTGTAAGGGCTGGGATTACA
 AAGACTCGGATATGTCCTAGAAGAGATGAGTCGCATACCAGGAGGAAGGATGTATGCAGATGACA
 CTGCTGGCTGGGACACCCGCATCAGCAGGTTTGTATCTGGAGAATGAAGCTCTAATCACCACCAA
 35 ATGGAGAAAGGGCACAGGGCCTTGGCATTGGCCATAATCAAGTACACATAACCAAAACAAAGTGGT
 AAAGGTCCTTAGACCAGCTGAAAAAGGGAAGACAGTTATGGACATTATTTTCGAGACAAGACCAAA
 GGGGGAGCGGACAAGTTGTCACTTACGCTCTTAACACATTTACCAACCTAGTGGTGCAACTCATTC
 GGAATATGAGGCTGAGGAAGTTCTAGAGATGCAAGACTTGTGGCTGCTGCGGAGGTGAGAGAAA
 GTGACCAACTGGTTGCAGAGCAACGGATGGGATAGGCTCAAACGAATGGCAGTCAGTGAGATGA
 40 TTGCGTTGTGAAGCCAATTGATGATAGGTTTGCACATGCCCTCAGGTTCTTGAATGATATGGGAAA
 AGTTAGGAAGGACACACAAGAGTGGAAACCCTCAACTGGATGGGACAACCTGGGAAGAAGTTCCG
 TTTTGCTCCCACTTCAACAAGCTCCATCTCAAGGACGGGAGGTCCATTGTGGTTCCCTGCCGC
 CACCAAGATGAACTGATTGGCCGGGCGCGCTCTCTCAGGGGCGGGATGGAGCATCCGGGAGAC
 TGCTTGCTAGCAAAATCATATGCGCAAATGTGGCAGCTCCTTTATTTCCACAGAAGGGACCTCCG
 45 ACTGATGGCCAATGCCATTTGTTTCATCTGTGCCAGTTGACTGGGTTCCAACTGGGAGAACCTACCTG
 GTCAATCCATGGAAAAGGAGAATGGATGACCATTGAAGACATGCTTGTGGTGTGGAACAGAGTGT
 GGATTGAGGAGAACGACCACATGGAAGACAAGACCCAGTTACGAAATGGACAGACATTCCCTAT
 TTGGGAAAAAGGGAAGACTTGTGGTGTGGATCTCTCATAGGGCACAGACCGCGCACCACCTGGGC
 TGAGAACATTAAAAACACAGTCAACATGGTGCGCAGGATCATAGGTGATGAAGAAAAGTACATGG
 50 ACTACCTATCCACCCAAGTTTCGCTACTTGGGTGAAGAAGGGTCTACACCTGGAGTGCTGTAAGCAC
 CAATCTTAGTGTGTGTCAGGCCTGCTAGTCAGCCACAGCTTGGGGAAAGCTGTGCAGCCTGTGACCC
 CCCCAGGAGAAGCTGGGAAACCAAGCCTATAGTCAGGCCGAGAACGCCATGGCACGGAAGAAGC
 CATGCTGCCTGTGAGCCCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAGGCGCAGG
 ATGGGAAAAAGAGGTGGCGACCTTCCCCACCTTCAATCTGGGGCTGAACTGGAGATCAGCTGT
 55 GGATCTCCAGAAGAGGGACTAGTGGTTAGAGGAGACCCCCGGAACGCAAAACAGCATATTG
 ACGCTGGGAAAGACCAGAGACTCCATGAGTTTCCACCACGCTGGCCGCCAGGCACAGATCGCCGA
 ATAGCGGCGCGCGGTGTGGGGAAATCC

In some embodiments, the Zika virus has a RNA genome corresponding to the DNA sequence provided by the nucleic acid sequence of any one of SEQ ID NOs: 2-13. In some
 5 embodiments, the Zika virus has a variant genome that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% identical to any one of SEQ ID NOs: 2-13.

10 Provided below are amino acid sequences of the E-proteins of Zika strains that may be used in the methods, compositions, and/or vaccines described herein.

isol-ARB15076.AHF49784.1.Central_African_Republic/291-788 Flavivirus envelope glycoprotein E. (SEQ ID NO: 14)

15 IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDRGWGNCGFLFGKGS�VTCAKFTCSKKMTGKSIQPEN
 LEYRIMLSVHGSQHSGMIVNDENRAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYYLTMMN
 KHWLVHKEWFHDIPLPHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHTALAGAL
 EAEMDGAKGRLFSGHLKCRLLKMDKRLRLKGVSYSLCTAAFTFTKVPAETLHGTVTVEVQYAGTDGPCK
 20 VPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGDKKITHHWHRSSTIGK
 AFEATVRGAKRMAVLGDTAWDFGSVGGVFNSLKGKIHQIFGAFAFKSLFGGMSWFSQILIGTLLVWLGL
 NTKNGSISLTCLALGGVMIFLSTAVSA

isol-IbH_30656.AEN75265.1.Nigeria/291-788 Flavivirus envelope glycoprotein E. (SEQ ID NO: 15)

25 IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDRGWGNCGFLFGKGS�VTCAKFTCSKKMTGKSIQPEN
 LEYRIMLSVHGSQHSGMIVNDENRAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYYLTMMN
 KHWLVHKEWFHDIPLPHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHTALAGAL
 EAEMDGAKGRLSSGHLKCRLLKMDKRLRLKGVSYSLCTAAFTFTKVPAETLHGTVTVEVQYAGRDGPCK
 30 VPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGDKKITHHWHRSSTIGK
 AFEATVRGAKRMAVLGDTAWDFGSVGGVFNSLKGKIHQIFGAFAFKSLFGGMSWFSQILIGTLLVWLGL
 NTKNGSISLTCLALGGVMIFLSTAVSA

ArB1362.AHL43500.1.-/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO: 16)

35 IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDRGWGNCGFLFGKGS�VTCAKFTCSKKMTGKSIQPEN
 LEYRIMLSVIIGSQHSGMIVNDXXXXXXXXNRAEVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 YLTMMNKHVLVHKEWFHDIPLPHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
 ALAGALEAEMDGAKGRLFSGHLKCRLLKMDKRLRLKGVSYSLCTAAFTFTKVPAETLHGTVTVEVQYA
 GTDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGDKKITHHWH
 40 RSGSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGVFNSLKGKIHQIFGAFAFKSLFGGMSWFSQILIG
 TLLVWLGLNTKNGSISLTCLALGGVMIFLSTAVSA

ArD128000.AHL43502.1.-/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO: 17)

45 IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDRGWGNCGFLFGKGS�VTCAKFTCSKKMTGKSIQPEN
 LEYRIMLSVHGSQHSGMXXXXXGHETDENRAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 YLTMMNKHRLVRKEWFHDIPLPHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
 ALAGALEAEMDGAKGRLFSGHLKCRLLKMDKRLRLKGVSYSLCTAAFTFTKVPAETLHGTVTVEVQYA
 GTDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGDKKITHHWH

PAT018/EP/PR3

KKGSSIGKAFEATVRGAKRMAVLGDTAWDFGSVGGVFNSLKGKVHQIFGAAFKSLFGGMSWFSQILIG
TLLVWLGLNTKNGSISLTCLALGGVMIFLSTAVSA

ArD158095.AHL43505.1.-/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO: 18)

5 IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDRGWNGCGLFGKGSVTCAKFTCSKKMTGKSIQPEN
LEYRIMLSVHGSQHSGMIVNDIGHETDENRAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYY
LTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHTA
LAGALEAEMDGAAGRLFSGHLKCRLLKMDKLRLKGVSYSLCTAAFTFTKVPAETLHGTVTVEVQYAGT
10 DGPKCVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGDKKITHHWHRS
GSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGVFNSLKGKVHQIFGAAFKSLFGGMSWFSQILIGTL
LVWLGLNTKNGSISLTCLALGGVMIFLSTAVSA

ArD158084.AHL43504.1.-/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO: 19)

15 IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDRGWNGCGLFGKGSVTCAKFTCSKKMTGKSIQPEN
LEYRIMLSVHGSQHSGMIVNDIGHETDENRAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYY
LTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHTA
LAGALEAEMDGAAGRLFSGHLKCRLLKMDKLRLKGVSYSLCTAAFTFTKVPAETLHGTVTVEVQYAGT
DGPKCVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGDKKITHHWHRS
20 GSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGVFNSLKGKVHQIFGAAFKSLFGGMSWFSQILIGTL
LVWLGLNTKNGSISLTCLALGGVMIFLSTAVSA

isol-ARB13565.AHF49783.1.Central_African_Republic/291-794 Flavivirus envelope glycoprotein
E. (SEQ ID NO: 20)

25 IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDRGWNGCGLFGKGSVTCAKFTCSKKMTGKSIQPEN
LEYRIMLSVHGSQHSGMIVNDIGHETDENRAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYY
LTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHTA
LAGALEAEMDGAAGRLFSGHLKCRLLKMDKLRLKGVSYSLCTAAFTFTKVPAETLHGTVTVEVQYAGT
DGPKCVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGDKKITHHWHRS
30 GSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGVFNSLKGKVHQIFGAAFKSLFGGMSWFSQILIGTL
LVWLGLNTKNGSISLTCLALGGVMIFLSTAVSA

isol-ARB7701.AHF49785.1.Central_African_Republic/291-794 Flavivirus envelope glycoprotein
E. (SEQ ID NO: 21)

35 IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDRGWNGCGLFGKGSVTCAKFTCSKKMTGKSIQPEN
LEYRIMLSVHGSQHSGMIVNDIGHETDENRAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYY
LTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHTA
LAGALEAEMDGAAGRLFSGHLKCRLLKMDKLRLKGVSYSLCTAAFTFTKVPAETLHGTVTVEVQYAGT
40 DGPKCVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGDKKITHHWHRS
GSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGVFNSLKGKVHQIFGAAFKSLFGGMSWFSQILIGTL
LVWLGLNTKNGSISLTCLALGGVMIFLSTAVSA

isol-ArD_41519.AEN75266.1.Senegal/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO:
22)

45 IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDRGWNGCGLFGKGSVTCAKFTCSKKMTGKSIQPEN
LEYRIMLSVHGSQHSGMIVNDIGHETDENRAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYY
YLTMMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHTA
LAGALEAEMDGAAGRLFSGHLKCRLLKMDKLRLKGVSYSLCTAAFTFTKVPAETLHGTVTVEVQYAGT
50 GTDGPKCVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGDKKITHHWH
RSGSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGVFNSLKGKVHQIFGAAFKSLFGGMSWFSQILIG
TLLVWLGLNTKNGSISLTCLALGGVMIFLSTAVSA

MR766-NIID.BAP47441.1.Uganda/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO:
23)

- IRCIGVSNRDFVEGMSGGTWVDVVLHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFTCSKKMTGKSIQPEN
 LEYRIMLSVHGSQHSGMTVNDIGYETDENRAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 YLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
 5 ALAGALEAEMDGAAGKLFSGHLKCRKMDKRLKGVSYSLCTAAFTFTKVPÄETLHGTVTVEVQYA
 GTDGPCKIPVQMAVDMQTLTPVGRITANPVITESTENSKMMELEDPFPGDSYIVIGVGDKKITHHWHR
 SGSTIGKAFEATVRGAKRMAVLGDTAWDFGSGGVFNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTL
 LVWLGLNTKNGSISLTCLALGGVMIFLSTAVSA
 LC002520.1/326-829 Zika virus genomic RNA, strain: MR766-NIID, Uganda, Flavivirus
- 10 envelope glycoprotein E. (SEQ ID NO: 24)
 IRCIGVSNRDFVEGMSGGTWVDVVLHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFTCSKKMTGKSIQPEN
 LEYRIMLSVHGSQHSGMTVNDIGYETDENRAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 YLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
 15 ALAGALEAEMDGAAGKLFSGHLKCRKMDKRLKGVSYSLCTAAFTFTKVPÄETLHGTVTVEVQYA
 GTDGPCKIPVQMAVDMQTLTPVGRITANPVITESTENSKMMELEDPFPGDSYIVIGVGDKKITHHWHR
 SGSTIGKAFEATVRGAKRMAVLGDTAWDFGSGGVFNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTL
 LVWLGLNTKNGSISLTCLALGGVMIFLSTAVSA
- 20 isol-MR_766.AEN75263.1.Uganda/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO: 25)
 IRCIGVSNRDFVEGMSGGTWVDVVLHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFTCSKKMTGKSIQPEN
 LEYRIMLSVHGSQHSGMIVNDTG YETDENRAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 YLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
 25 ALAGALEAEMDGAAGKLFSGHLKCRKMDKRLKGVSYSLCTAAFTFTKVPÄETLHGTVTVEVQYA
 GTDGPCKIPVQMAVDMQTLTPVGRITANPVITESTENSKMMELEDPFPGDSYIVIGVGDKKITHHWHR
 SGSTIGKAFEATVRGAKRMAVLGDTAWDFGSGGVFNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTL
 LVWLGLNTKNGSISLTCLALGGVMIFLSTAVSA
- 30 ArD7117.AHL43501.1.-/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO: 26)
 IRCIGVSNRDFVEGMSGGTWVDVVLHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFTCSKKMTGKSIQPEN
 LEYRIMLSVHGSQHSGMIVNDIGHETDENRAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 YLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHTA
 LAGALEAEMDGAAGKLFSGHLKCRKMDKRLKGVSYSLCTAAFTFTKVPÄETLHGTVTVEVQYAG
 TDGPCKIPVQMAVDMQTLTPVGRITANPVITESTENSKMMELEDPFPGDSYIVIGVGDKKITHHWHR
 35 SGSTIGKAFEATVRGAKRMAVLGDTAWDFGSGGVFNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTL
 LVWLGLNTKNGSISLTCLALGGVMIFLSTAVSA
- AY632535.2/326-825 NC_012532.1 Zika virus strain MR 766, Uganda, Flavivirus envelope
 glycoprotein E. (SEQ ID NO: 27)
 IRCIGVSNRDFVEGMSGGTWVDVVLHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
 40 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFTCSKKMTGKSIQPEN
 LEYRIMLSVHGSQHSGMIGYETDEDRAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 YLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHTA
 LAGALEAEMDGAAGKLFSGHLKCRKMDKRLKGVSYSLCTAAFTFTKVPÄETLHGTVTVEVQYAG
 TDGPCKIPVQMAVDMQTLTPVGRITANPVITESTENSKMMELEDPFPGDSYIVIGVGDKKITHHWHR
 45 SGSTIGKAFEATVRGAKRMAVLGDTAWDFGSGGVFNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTL
 LVWLGLNTKNGSISLTCLALGGVMIFLSTAVSA
- MR_766.AAV34151.1.Uganda/291-790 Flavivirus envelope glycoprotein E.
 [Q32ZE1|Q32ZE1_9FL (SEQ ID NO: 28)
 IRCIGVSNRDFVEGMSGGTWVDVVLHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
 50 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFTCSKKMTGKSIQPEN
 LEYRIMLSVHGSQHSGMIGYETDEDRAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 YLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHTA
 LAGALEAEMDGAAGKLFSGHLKCRKMDKRLKGVSYSLCTAAFTFTKVPÄETLHGTVTVEVQYAG
 TDGPCKIPVQMAVDMQTLTPVGRITANPVITESTENSKMMELEDPFPGDSYIVIGVGDKKITHHWHR
 SGSTIGKAFEATVRGAKRMAVLGDTAWDFGSGGVFNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTL

- GKAFEATVRGAKRMAVLGDTAWDFGSGGVFNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLVW
LGLNTKNGSISLTCLALGGVMIFLSTAVSA
MR_766.YP_009227198.1.Uganda/1-500 envelope protein E [Zika virus] (SEQ ID NO: 29)
5 IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVTCAKFTCSKKMTGKSIQPEN
LEYRIMLSVHGSQHSQMIGYETDEDRAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTM
NNKHVLVHKEWFHDIPLPHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHTALAG
ALEAEMDGAAGKRLFSGLKCRLLKMDKRLKGVSYSLCTAAFTFTKIPAEHLHGTVTVEVQYAGTDGP
10 CKIPVQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFGDSYIVIGVGDKKITHHWHRSSTI
GKAFEATVRGAKRMAVLGDTAWDFGSGGVFNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLVW
LGLNTKNGSISLTCLALGGVMIFLSTAVSA
KU681081.3/308-811 Zika virus isolate Zika virus/H.sapiens-tc/THA/2014/SV0127- 14,
Thailand, Flavivirus envelope glycoprotein E. (SEQ ID NO: 30)
15 IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVTCAKFACSKKMTGKSIQPE
NLEYRIMLSVHGSQHSQMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
YLTMMNNKHVLVHKEWFHDIPLPHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
ALAGALEAEMDGAAGKRLSSGHLKCRLLKMDKRLKGVSYSLCTAAFTFTKIPAEHLHGTVTVEVQYAG
TDGPCKVPAQMAVDMQTLTPVGRITANPVITEGTENSKMMLELDPFGDSYIVIGVGEKKITHHWHR
20 SGSTIGKAFEATVRGAKRMAVLGDTAWDFGSGGVFNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGT
LLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA
isol-Zika_virus%*H.sapiens-tc*%THA%2014%SV0127-_14.AMD61710.1.Thailand/291-794
Flavivirus envelope glycoprotein E. (SEQ ID NO: 31)
25 IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVTCAKFACSKKMTGKSIQPE
NLEYRIMLSVHGSQHSQMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
YLTMMNNKHVLVHKEWFHDIPLPHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
ALAGALEAEMDGAAGKRLSSGHLKCRLLKMDKRLKGVSYSLCTAAFTFTKIPAEHLHGTVTVEVQYAG
TDGPCKVPAQMAVDMQTLTPVGRITANPVITEGTENSKMMLELDPFGDSYIVIGVGEKKITHHWHR
30 SGSTIGKAFEATVRGAKRMAVLGDTAWDFGSGGVFNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGT
LLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA
CK-ISL_2014.AIC06934.1.Cook_Islands/1-504 Flavivirus envelope glycoprotein E. (Fragment)
OS=Zika virus GN=E PE=4 SV=1 (SEQ ID NO: 32)
35 IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVTCAKFACSKKMTGKSIQPE
NLEYRIMLSVHGSQHSQMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
YLTMMNNKHVLVHKEWFHDIPLPHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
ALAGALEAEMDGAAGKRLSSGHLKCRLLKMDKRLKGVSYSLCTAAFTFTKIPAEHLHGTVTVEVQYAG
TDGPCKVPAQMAVDMQTLTPVGRITANPVITEGTENSKMMLELDPFGDSYIVIGVGEKKITHHWHR
40 GSTIGKAFEATVRGAKRMAVLGDTAWDFGSGGVFNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGT
LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA
Natal_RGN.AMB18850.1.Brazil:_Rio_Grande_do_Norte,_Natal/291-794 Flavivirus envelope
glycoprotein E.] (SEQ ID NO: 33)
45 IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVTCAKFACSKKMTGKSIQPE
NLEYRIMLSVHGSQHSQMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
YLTMMNNKHVLVHKEWFHDIPLPHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
ALAGALEAEMDGAAGKRLSSGHLKCRLLKMDKRLKGVSYSLCTAAFTFTKIPAEHLHGTVTVEVQYAG
TDGPCKVPAQMAVDMQTLTPVGRITANPVITEGTENSKMMLELDPFGDSYIVIGVGEKKITHHWHR
50 GSTIGKAFEATVRGAKRMAVLGDTAWDFGSGGVFNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGT
LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA
isol-Si323.AMC37200.1.Colombia/1-504 Flavivirus envelope glycoprotein E. (SEQ ID NO: 34)
IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVTCAKFACSKKMTGKSIQPE
55 NLEYRIMLSVHGSQHSQMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY

- YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
ALAGALEAEMDGAKGRLSSGHLKCRCLKMDKRLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAG
TDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRS
GSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTL
5 LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA
KU707826.1/317-820 Zika virus isolate SSABR1, Brazil, Flavivirus envelope glycoprotein E.
(SEQ ID NO: 35)
IRCIGVSNRDFVEGMSGGTWVDVVLHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFACSKKMTGKSIQPE
10 NLEYRIMLSVHGSQHSQMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
ALAGALEAEMDGAKGRLSSGHLKCRCLKMDKRLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAG
TDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRS
GSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTL
15 LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA
KU509998.1/326-829 Zika virus strain Haiti/1225/2014, Haiti, Flavivirus envelope glycoprotein E.
(SEQ ID NO: 36)
IRCIGVSNRDFVEGMSGGTWVDVVLHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFACSKKMTGKSIQPE
20 NLEYRIMLSVHGSQHSQMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
ALAGALEAEMDGAKGRLSSGHLKCRCLKMDKRLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAG
TDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRS
GSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTL
25 LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA
isol-GDZ16001.AML82110.1.China/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO:
37)
IRCIGVSNRDFVEGMSGGTWVDVVLHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFACSKKMTGKSIQPE
30 NLEYRIMLSVHGSQHSQMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
ALAGALEAEMDGAKGRLSSGHLKCRCLKMDKRLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAG
TDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRS
GSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTL
35 LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA
BeH819015.AMA12085.1.Brazil/291-794 Flavivirus envelope glycoprotein E.] (SEQ ID NO: 38)
IRCIGVSNRDFVEGMSGGTWVDVVLHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFACSKKMTGKSIQPE
40 NLEYRIMLSVHGSQHSQMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
ALAGALEAEMDGAKGRLSSGHLKCRCLKMDKRLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAG
TDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRS
GSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTL
45 LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA
MRS_OPY_Martinique_PaRi_2015.AMC33116.1.Martinique/291-794 Flavivirus envelope
glycoprotein E. (SEQ ID NO: 39)
IRCIGVSNRDFVEGMSGGTWVDVVLHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFACSKKMTGKSIQPE
50 NLEYRIMLSVHGSQHSQMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
ALAGALEAEMDGAKGRLSSGHLKCRCLKMDKRLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAG
TDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRS
GSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTL
LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

- KU501215.1/308-811 Zika virus strain PRVABC59, Puerto Rico, Flavivirus envelope glycoprotein E. (SEQ ID NO: 40)
- 5 IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFACSKKMTGKSIQPE
NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGLDCEPRTGLDFSDLY
YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
ALAGALEAEMDGAKGRLSSGHLKCRKMDKRLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAG
TDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRS
GSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLKGKGIHQIFGAAFKSLFGGMSWFSQILIGTL
10 LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA
Haiti%1225%2014.AMB37295.1.Haiti/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO: 41)
- 15 IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFACSKKMTGKSIQPE
NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGLDCEPRTGLDFSDLY
YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
ALAGALEAEMDGAKGRLSSGHLKCRKMDKRLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAG
TDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRS
GSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLKGKGIHQIFGAAFKSLFGGMSWFSQILIGTL
20 LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA
KU527068.1/308-811 Zika virus strain Natal RGN, Brazil: Rio Grande do Norte, Natal, Flavivirus envelope glycoprotein E. (SEQ ID NO: 42)
- 25 IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFACSKKMTGKSIQPE
NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGLDCEPRTGLDFSDLY
YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
ALAGALEAEMDGAKGRLSSGHLKCRKMDKRLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAG
TDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRS
GSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLKGKGIHQIFGAAFKSLFGGMSWFSQILIGTL
30 LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA
isol-Z1106027.ALX35662.1.Suriname/5-508 Flavivirus envelope glycoprotein E. (SEQ ID NO: 43)
- 35 IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFACSKKMTGKSIQPE
NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGLDCEPRTGLDFSDLY
YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
ALAGALEAEMDGAKGRLSSGHLKCRKMDKRLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAG
TDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRS
GSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLKGKGIHQIFGAAFKSLFGGMSWFSQILIGTL
40 LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA
isol-FLR.AMM39804.1.Colombia: _Barranquilla/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO: 44)
- 45 IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFACSKKMTGKSIQPE
NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGLDCEPRTGLDFSDLY
YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
ALAGALEAEMDGAKGRLSSGHLKCRKMDKRLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAG
TDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRS
GSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLKGKGIHQIFGAAFKSLFGGMSWFSQILIGTL
50 LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA
PLCal_ZV_isol-From_Vero_E6_cells.AHL37808.1.Canada/254-757 Flavivirus envelope glycoprotein E. (SEQ ID NO: 45)
- 55 IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFACSKKMTGKSIQPE
NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGLDCEPRTGLDFSDLY
YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNKEALVEFKDAHAKRQTVVVLGSQEGAVHT

- ALAGALEAEMDGA KRLSSGHLK CRLKMDKLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAG
 TDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRS
 GSTIGKA FEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGA AFKSLFGGMSWFSQILIGTL
 LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA
- 5 BeH818995.AMA12084.1.Brazil/291-794 Flavivirus envelope glycoprotein E. [Zika virus].
 IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDRGWNGCGLFGKGS LVTCAKFACSKKMTGKSIQPE
 NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 YLTMNNKH WL VHKEWFHDIP LPHAGADTGTPHWNKEALVEFKDAHAKRQT VVVLGSQEGAVHT
- 10 ALAGALEAEMDGA KRLSSGHLK CRLKMDKLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAG
 TDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRS
 GSTIGKA FEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGA AFKSLFGGMSWFSQILIGTL
 LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA
- 15 H/PP/2013.AHZ13508.1.French_Polynesia/291-794 Flavivirus envelope glycoprotein E. (SEQ ID
 NO: 47)
 IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDRGWNGCGLFGKGS LVTCAKFACSKKMTGKSIQPE
 NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 YLTMNNKH WL VHKEWFHDIP LPHAGADTGTPHWNKEALVEFKDAHAKRQT VVVLGSQEGAVHT
- 20 ALAGALEAEMDGA KRLSSGHLK CRLKMDKLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAG
 TDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRS
 GSTIGKA FEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGA AFKSLFGGMSWFSQILIGTL
 LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA
- 25 PRVABC59.AMC13911.1.Puerto_Rico/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO:
 48)
 IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDRGWNGCGLFGKGS LVTCAKFACSKKMTGKSIQPE
 NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 YLTMNNKH WL VHKEWFHDIP LPHAGADTGTPHWNKEALVEFKDAHAKRQT VVVLGSQEGAVHT
- 30 ALAGALEAEMDGA KRLSSGHLK CRLKMDKLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAG
 TDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRS
 GSTIGKA FEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGA AFKSLFGGMSWFSQILIGTL
 LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA
- 35 KU321639.1/326-829 Zika virus strain ZikaSPH2015, Brazil, Flavivirus envelope glycoprotein E.
 (SEQ ID NO: 49)
 IRCIGVSNRDFVEGMSGGTWVDIVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDM
 ASDSRCPTQGEAYLDKQSDTQYVCKRTLVDRGWNGCGLFGKGS LVTCAKFACSKKMTGKSIQPENL
 EYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYYL
 TMNNKH WL VHKEWFHDIP LPHAGADTGTPHWNKEALVEFKDAHAKRQT VVVLGSQEGAVHTAL
- 40 AGALEAEMDGA KRLSSGHLK CRLKMDKLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAGTD
 GPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRS
 TIGKA FEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGA AFKSLFGGMSWFSQILIGTLLM
 WLGLNTKNGSISLMCLALGGVLIFLSTAVSA
- 45 ZikaSPH2015.ALU33341.1.Brazil/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO: 50)
 IRCIGVSNRDFVEGMSGGTWVDIVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDM
 ASDSRCPTQGEAYLDKQSDTQYVCKRTLVDRGWNGCGLFGKGS LVTCAKFACSKKMTGKSIQPENL
 EYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYYL
 TMNNKH WL VHKEWFHDIP LPHAGADTGTPHWNKEALVEFKDAHAKRQT VVVLGSQEGAVHTAL
- 50 AGALEAEMDGA KRLSSGHLK CRLKMDKLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAGTD
 GPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRS
 TIGKA FEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGA AFKSLFGGMSWFSQILIGTLLM
 WLGLNTKNGSISLMCLALGGVLIFLSTAVSA
- 103344.AMC13912.1.Guatemala/291-794 polyprotein [Zika virus].
 103344.AMC13912.1.Guatemala Flavivirus envelope glycoprotein E. (SEQ ID NO: 51)

IRCIGVSNRDFVEGMSGGTWVDVVLHGGCVTVMAQDKPTVDIELVTTTVSNMAEIRSYCYEASISDM
 ASDSRCPTQGEAYLDKQSDTQYVCKRTLVDRGWNGCGLFGKGS�VTCAKFACSKKMTGKSIQPENL
 EYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYL
 5 TMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHTAL
 AGALEAEMDGAKEGRLSSGHLKCRKMDKRLRLKGVSYSLCTAAFTFTKIPAEHLHGTVTVEVQYAGTD
 GPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMELEDPFGDSYIVIGVGEKKITHHWHRS
 TIGKAFAEATVRGAKRMAVLGDTAWDFGSVGGALNSLKGKIHQIFGAFAKSLFGGMSWFSQILIGTLLM
 WLGLNTKNGSISLMCLALGGVLIFLSTAVSA
 isol-Brazil-ZKV2015.AMD16557.1.Brazil/291-794 Flavivirus envelope glycoprotein E. (SEQ ID
 10 NO: 52)
 IRCIGVSNRDFVEGMSGGTWVDVVLHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDRGWNGCGLFGKGS�VTCAKFACSKKMTGKSIQPE
 NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGTQEGAVHT
 15 ALAGALEAEMDGAKEGRLSSGHLKCRKMDKRLRLKGVSYSLCTAAFTFTKIPAEHLHGTVTVEVQYAG
 TDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMELEDPFGDSYIVIGVGEKKITHHWHRS
 GSTIGKAFAEATVRGAKRMAVLGDTAWDFGSVGGALNSLKGKIHQIFGAFAKSLFGGMSWFSQILIGTL
 LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA
 KU497555.1/308-811 Zika virus isolate Brazil-ZKV2015, Flavivirus envelope glycoprotein E.
 20 (SEQ ID NO: 53)
 IRCIGVSNRDFVEGMSGGTWVDVVLHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDRGWNGCGLFGKGS�VTCAKFACSKKMTGKSIQPE
 NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGTQEGAVHT
 25 ALAGALEAEMDGAKEGRLSSGHLKCRKMDKRLRLKGVSYSLCTAAFTFTKIPAEHLHGTVTVEVQYAG
 TDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMELEDPFGDSYIVIGVGEKKITHHWHRS
 GSTIGKAFAEATVRGAKRMAVLGDTAWDFGSVGGALNSLKGKIHQIFGAFAKSLFGGMSWFSQILIGTL
 LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA
 isol-ZJ03.AMM39806.1.China/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO: 54)
 30 IRCIGVSNRDFVEGMSGGTWVDVVLHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDRGWNGCGLFGKGS�VTCAKFACSKKMTGKSIQPE
 NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
 ALAGALEAEMDGAKEGRLSSGHLKCRKMDKRLRLKGVSYSLCTAAFTFTKIPAEHLHGTVTVEVQYAG
 35 TDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMELEDPFGDSYIVIGVGEKKITHHWHRS
 GSTIGKAFAEATVRGARRMAVLGDTAWDFGSVGGALNSLKGKIHQIFGAFAKSLFGGMSWFSQILIGTL
 LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA
 isol-FSS13025.AFD30972.1.Cambodia/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO:
 40 55)
 IRCIGVSNRDFVEGMSGGTWVDVVLHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDRGWNGCGLFGKGS�VTCAKFACSKKMTGKSIQPE
 NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
 ALAGALEAEMDGAKEGRLSSGHLKCRKMDKRLRLKGVSYSLCTAAFTFTKIPAEHLHGTVTVEVQYAG
 45 TDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMELEDPFGDSYIVIGVGEKKITHHWHRS
 GSTIGKAFAEATVRGAKRMAVLGDTAWDFGSVGGALNSLKGKIHQIFGAFAKSLFGGMSWFSQILIGTL
 LVWLGLNTKNGSISLMCLALGGVLIFLSTAVSA
 isol-Z1106032.ALX35660.1.Suriname/291-794 Flavivirus envelope glycoprotein E. [Zika virus]
 (SEQ ID NO: 56)
 50 IRCIGVSNRDFVEGMSGGTWVDVVLHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDRGWNGCGLFGKGS�VTCAKFACSKKMTGKSIQPE
 NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
 ALAGALEAEMDGAKEGRLSSGHLKCRKMDKRLRLKGVSYSLCTAAFTFTKIPAEHLHGTVTVEVQYAG
 55 TDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMELEDPFGDSYIVIGVGEKKITHHWHRS

GSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLKGKGIHQIFGAAFKSLFGGMSWFSQILIGTL
LMWLGLNAKNGSISLMCLALGGVLIFLSTAVSA

isol-Z1106033.ALX35659.1.Suriname/291-794 Flavivirus envelope glycoprotein E. [Zika virus]
(SEQ ID NO: 57)

5 IRCIGVSNRDFVEGMSGGTWVDVVLHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFACSKKMTGKSIQPE
NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
ALAGALEAEMDGAAGRLSSGHLKCRKMDKRLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAG
10 TDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRS
GSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLKGKGIHQIFGAAFKSLFGGMSWFSQILIGTL
LMWLGLNAKNGSISLMCLALGGVLIFLSTAVSA

isol-BeH828305.AMK49165.1.Brazil/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO:
58)

15 IRCIGVSNRDFVEGMSGGTWVDVVLHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFACSKKMTGKSIQPE
NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
ALAGALEAEMDGAAGRLSSGHLKCRKMDKRLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAG
20 TDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRS
GSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLKGKGIHQIFGAAFKSLFGGMSWFSQILIGTL
LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

isol-GD01.AMK79468.1.China/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO: 59)

25 IRCIGVSNRDFVEGMSGGTWVDVVLHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFACSKKMTGKSIQPE
NLEYRIMLSVHGSQHSGMIVNGTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
ALAGALEAEMDGAAGRLSSGHLKCRKMDKRLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAG
TDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRS
30 GSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLKGKGIHQIFGAAFKSLFGGMSWFSQILIGTL
LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

isol-Z1106031.ALX35661.1.Suriname/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO:
60)

35 IRCIGVSNRDFVEGMSGGTWVDVVLHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFACSKKMTGKSIQPE
NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
ALAGALEAEMDGAAGRLSSGHLKCRKMDKRLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAG
TDGPCKVLAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHR
40 SGSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLKGKGIHQIFGAAFKSLFGGMSWFSQILIGT
LLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

ACD75819.1.Micronesia/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO: 61)

45 IRCIGVSNRDFVEGMSGGTWVDVVLHGGCVTVMAQDKPAVDIELVTTTTSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFACSKKMTGKSIQPE
NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
ALAGALEAEMDGAAGRLSSGHLKCRKMDKRLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAG
TDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRS
GSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLKGKGIHQIFGAAFKSLFGGMSWFSQILIGTL
50 LVWLGLNTKNGSISLTCLALGGVLIFLSTAVSA

KU681082.3/308-811 Zika virus isolate Zika virus/H.sapiens-tc/PHL/2012/CPC-0740,
Philippines, Flavivirus envelope glycoprotein E. (SEQ ID NO: 62)

IRCIGVSNRDFVEGMSGGTWVDVVLHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFACSKKMTGKSIQPE
55 NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY

YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
 ALAGALEAEMDGAKGRLSSGHLKCRCLKMDKLRLLKGVSYSLCTAAFTFTKIPAE TLHGT V TVEVQYAG
 TDGPCKVPAQMAVDMQTLTPVGR LITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRS
 GSTIGKA FEATVRGAKRMAVLGDTAWDFG SVGGALNSLGKGIHQIFGA AFKSLFGGMSWFSQILIGTL
 5 LVWLGLNTKNGSISLTCLALGGVLIFLSTAVSA
 isol-Zika_virus%*H.sapiens-tc*%PHL%2012%CPC-0740.AMD61711.1.Philippines/291-794
 Flavivirus envelope glycoprotein E. (SEQ ID NO: 63)
 IRCIGVSNRDFVEGMSGGTWVDVVLHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVD RGWGNGCGLFGKGS LVTCAKFACSKKMTGKSIQPE
 10 NLEYRIMLSVHGSQHS GMI VNDTG HETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYL
 YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
 ALAGALEAEMDGAKGRLSSGHLKCRCLKMDKLRLLKGVSYSLCTAAFTFTKIPAE TLHGT V TVEVQYAG
 TDGPCKVPAQMAVDMQTLTPVGR LITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRS
 GSTIGKA FEATVRGAKRMAVLGDTAWDFG SVGGALNSLGKGIHQIFGA AFKSLFGGMSWFSQILIGTL
 15 LVWLGLNTKNGSISLTCLALGGVLIFLSTAVSA
 isol-BeH823339.AMK49164.2.Brazil/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO:
 64)
 IRCIGVSNRDFVEGMSGGTWVDVVLHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEATISDI
 ASDSRCPTQGEAYLDKQSDTQYVCKRTLVD RGWGNGCGLFGKGS LVTCAKFACSKKMTGKSIQPE
 20 EYRIMLSVHGSQHS GMI VNDTG HETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYL
 TMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTA VVVLGSQEGAVHTAL
 AGALEAEMDGAKGRLSSGHLKCRCLKMDKLRLLKGVSYSLCTAAFTFTKIPAE TLHGT V TVEVQYAGTD
 GPCKVPAQMAVDMQTLTPVGR LITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRS
 TIGKA FEATVRGAKRMAVLGDTAWDFG SVGGALNSLGKGIHQIFGA AFKSLFGGMSWFSQILIGTLLM
 25 WLGLNTKNGSISLMCLALGGVLIFLSTAVSA
 isol-P6-740.AEN75264.1.Malaysia/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO: 65)
 IRCIGVSNRDFVEGMSGGTWVDVVLHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVD RGWGNGCGLFGKGS LVTCAKFACSKKMTGKSIQPE
 NLEYRIMLSVHGSQHS GMI VNDXGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 30 YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
 ALAGALEAEMDGAKGRLSSGHLKCRCLKMDKLRLLKGVSYSLCTAAFTFTKIPAE TLHGT V TVEVQYAG
 TDGPCKVPAQMAVDMQTLTPVGR LITANPVITESTENSKMMLELDPPFGDSYIVIGVGD K KITHHWHXR
 SGSTIGKA FEATVRGAKRMAVLGDTAWDFG SVGGALNSLGKGIHQIFGA AFKSLFGGMSWFSQILIGT
 LLVWLGLNTKNGSISLTCLALGGVLIFLSTAVSA
 35 KU744693.1/326-829 Zika virus isolate VE_Ganxian, China, Flavivirus envelope glycoprotein E.
 (SEQ ID NO: 66)
 IRCIGVSNRDFVEGMSGGTWVDVVLHGGCVTAMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVD RGWGNGCGLFGKGS LVTCAKFACSKKMTGKSIQPE
 NLEYRIMLSVHGSQHS GML VNDTG HETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 40 YYLTMNNKHWLAHKEWFHDIPLPWHAGAATGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVH
 TALAGALEAEMDGAKGRLSSGHLKCRCLKMDKLRLLKGVSYSLCTAAFTFTKIPAE TVDGT V TVEGQYG
 GTDGPCKVPAQMAVDMQTLTPVGR LITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWH
 RSGSTIGKA FEATVRGAKRMAVLGDTAWDFG SVGGALNSLGKGIHQIIGA AFKSLFGGMSWFSQILIGT
 LLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSG
 45 isol-VE_Ganxian.AMK79469.1.China/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO:
 67)
 IRCIGVSNRDFVEGMSGGTWVDVVLHGGCVTAMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVD RGWGNGCGLFGKGS LVTCAKFACSKKMTGKSIQPE
 NLEYRIMLSVHGSQHS GML VNDTG HETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 50 YYLTMNNKHWLAHKEWFHDIPLPWHAGAATGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVH
 TALAGALEAEMDGAKGRLSSGHLKCRCLKMDKLRLLKGVSYSLCTAAFTFTKIPAE TVDGT V TVEGQYG
 GTDGPCKVPAQMAVDMQTLTPVGR LITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWH
 RSGSTIGKA FEATVRGAKRMAVLGDTAWDFG SVGGALNSLGKGIHQIIGA AFKSLFGGMSWFSQILIGT
 LLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSG
 55

PAT018/EP/PR3

ArD157995.AHL43503.1.-/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO: 68)
ISCIGVSNRDLVEGMSGGTWVDVLEHGGCVTEMAQDKPTVDIELVTMTVSNMAEVRSYCYEASLSD
MASASRCPTQGEPSLDKQSDTQSVCKRTLGDGRWGNGCGIFGKGS�VTCSKFTCKKMPGKSIQPENL
EYRIMLPVHGSQHSGMIVNDIGHETDENRAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYYL
5 TMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHTAL
AGALEAEMDGAKGRLFSGHLKCRKMDKRLKGVSYSLCTAAFTFTKVPAETLHGTVTVEVQSAGTD
GPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGDKKITHHWHRSG
STIGKAFEATVRGAKRMAVLGDTAWDFGSGGVFNSLKGKGIHQIFGAAFKSLFGGMSWFSQILIGTLL
10 VWLGLNTKNGSISLTCLALGGVMIFLSTAVSA

MR_766.ABI54475.1.Uganda/291-788 Flavivirus envelope glycoprotein E. (SEQ ID NO: 69)
IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFTCSKKMTGKSIQPEN
15 LEYRIMLSVHGSQHSGMIVNDENRAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYYLTMMN
KHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHTALAGAL
EAEMDGAKGRLFSGHLKCRKMDKRLKGVSYSLCTAAFTFTKVPAETLHGTVTVEVQYAGTDGPCK
VPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGDKKITHHWHRSGSTIGK
AFEATVRGAKRMAVLGDTAWDFGSGGVFNSLKGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLVWLGL
20 NTKNGSISLTCLALGGVMIFLSTAVSA

In some embodiments, the Zika virus has polyprotein, including an envelope (E) protein, with an amino acid sequence provided by any one of SEQ ID NO: 14-69. In some embodiments, the polyprotein or E protein sequence is at least 80%, 81%, 82%, 83%, 84%,
25 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% identical to any one of SEQ ID NOs: 2-69.

The terms "identical" or percent "identity" in the context of two or more nucleic acids or amino acid sequences refer to two or more sequences or subsequences that are the same.

30 Two sequences are "substantially identical" if two sequences have a specified percentage of amino acid residues or nucleotides that are the same (*e.g.*, at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity) over a specified region or over the entire sequence, when compared and aligned for maximum correspondence over a comparison window, or designated region as measured using one of the following sequence comparison algorithms or
35 by manual alignment and visual inspection. Optionally, the identity exists over a region that is at least about 50 nucleotides (or 10 amino acids) in length, or more preferably over a region that is 100 to 500 or 1000 or more nucleotides (or 20, 50, 200 or more amino acids) in length. In some embodiments, the identity exists over the length of a protein, such as the E protein.

For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. Methods of alignment of sequences for comparison are well known in the art. See, *e.g.*, by the local homology algorithm of Smith and Waterman (1970) Adv. Appl. Math. 2:482c, by the homology alignment algorithm of Needleman and Wunsch, J. Mol. Biol. 48:443, 1970, by the search for similarity method of Pearson and Lipman. Proc. Natl. Acad. Sci. USA 85:2444, 1988, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, Jalview and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group. 575 Science Or., Madison. WI), by multi sequence alignment implementation using *e.g.* CLUSTALW (Larkin et al., (2007). Bioinformatics, 23, 2947-2948.) or MAFFT (Katoh & Toh 2008 Briefings in Bioinformatics 9:286-298), or by manual alignment and visual inspection (see. *e.g.*, Brent et al., Current Protocols in Molecular Biology, John Wiley & Sons, Inc. (Ringbou ed., 2003)). Two examples of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., Nuc. Acids Res. 25:3389-3402, 1977; and Altschul et al., J. Mol. Biol. 215:403-410, 1990, respectively.

EXAMPLES

20 Example 1: Production of a Zika drug substance suitable for application as a vaccine in humans and animals

Materials and Methods:

For the production of ZikaV the JEV process platform (Srivastava et al., Vaccine 19 (2001) 4557-4565; US 6,309,650B1) was used as a basis. Small changes of certain process steps were applied to adapt on ZikaV properties and to improve purity. A short summary of the process steps is outlined below (see also Figure 8a+b).

Upstream:

- Roller Bottle based Vero cell expansion (25x850cm² CellBind):
- 30 • 5% CO₂, 35°C, MEM+2mM L-Glutamine+10% FBS
- Infection with ZikaV research Master Seed Bank (rMSB) at MOI 0.01
- Virus Production without serum

PAT018/EP/PR3

- 5% CO₂, 35°C, MEM+2mM L-Glutamine
- Multiple harvests (days 2, 3, 5 and 7) with re-feed
- Sterile filtration of harvests and storage at 2-8°C until further processing

5 Downstream:

- Pooling of harvests and concentration by ultrafiltration (100kDa)
- Stabilization of concentrated harvest (Tris/10% sucrose) for storage if required (-80°C)
- Removal of hcDNA by Protamine Sulphate (2 mg/mL)
- 10 • Sucrose Gradient Purification (optimized three layered gradient)
- Formaldehyde Inactivation (0.02%, 22°C, 10 days), neutralization with Na-metabisulfite
- Dilution to DS antigen target content and formulation with Aluminium hydroxide (0.5mg Al/mL)

15

Definitions & Abbreviations

BSA Bovine serum albumin

HPLC High performance liquid chromatography

JEV Japanese Encephalitis Virus

20 MALS Multi angle light scattering

NIV Neutralized inactivated virus

PBS Phosphate buffered saline

rms radius Root mean square radius

RSD Relative standard deviation

25 SEC Size exclusion chromatography

SGP Sucrose gradient purified

ZikaV Zika Virus

rMSB research master seed bank

p.i. Post infection

30 SGC Sucrose gradient chromatography

PS Protamine sulfate

PAT018/EP/PR3

Zika Virus Strain H/PF/2013 was originally isolated from a 51-year-old woman (SEQ ID NO: 13). A sample was obtained from European Virus Archive EVAg. Based on this material, a research master seed bank (rMSB) was prepared on vero cells as the cell substrate.

5 Virus growth on Vero Cells

Vero cells were grown in Eagle's minimal essential medium (EMEM) containing 10% fetal bovine serum (FBS). Roller bottle cultures of Vero cell monolayers were infected with Zika Virus Strain H/PF/2013 at a multiplicity of infection (moi) of 0.01 plaque forming units (pfu) per cell. After 2 hours of virus adsorption, the cultures were washed 3 times with PBS
10 and fed with EMEM without FBS and incubated at +35°C with 5% CO₂. Infected Vero cell cultures were incubated until the virus titer reaches a desired level.

The culture medium was harvested at days 2, 3, 5 and 7 and were pooled from those harvest days and then centrifuged in standard centrifuge. The supernatants were then filtered. Virus culture supernatants were concentrated by TFF ultrafiltration to remove cell culture
15 media components and reduce batch volume.

Evaluation of harvest Procedure

The current JEV harvest process has scheduled harvests on days 3, 5, 7 and 9 post infection. To mimic the JEV process roller bottles infected with ZIKV bank P4-FBS at an
20 MOI of 0.01 in infection medium (MEM with 2% FBS + 2mM L-glutamine) for 2 hours. After removing the inoculum the cells were washed twice with PBS and 200mL production medium (MEM+ 2mM L-glutamine) was added.

After taking a sample on day 2 the first virus harvest was conducted on day 3 after infection. At this point significant higher CPE could be observed compared to cells where
25 virus was removed on day 2. Plaque assay analysis showed that the viral titers on day 2 were in the same range as for the standard harvesting schedule. However, starting with day 3 harvest the observed titers were significantly lower correlating with the increased CPE observed compared to the standard harvest schedule. On day 5 post infection no more living cells could be observed at all and the experiment was terminated with a final day 5 harvest.
30 The calculated titers per plaque assay are summarized in the list below:

Log 10 PFU/mL
sample day2 7.02

PAT018/EP/PR3

harvest day 3 6.66

harvest day 5 6.26

This finding led to an optimized harvest schedule to better control of CPE and allow additional harvest day 5 and 7, see Figure 19. For both harvest days the optimized ZikaV protocol yield significant higher virus titers compared to the modified protocol showing that the time of the first harvest is crucial for production yields. Additionally first harvesting at day 3 results in maximum 2 harvest points whereas first harvesting at day 2 allows for 4 harvest points further increasing the yield gain.

Downstream Purification of Zika virus

The purification process was carried out at room temperature (18-22 °C) unless stated otherwise. Virus purification started with concentration of filtered combined harvest using 100 kDa cut-off TFF ultrafiltration modules to remove cell culture media components and reduce batch volume. After concentration, the pooled filtered harvest material was adjusted to a final concentration of 25 mM Tris pH 7.5 and 10% sucrose (w/w) using stock solution of both components (see Figure 9 for SEC_HPLC of different harvests prior to PS treatment). This allowed for freezing the concentrated harvest at <-65°C if required.

Host cell DNA and protein reduction as well reduction of non-infectious virus aggregates in the concentrated material was achieved by precipitation with protamine sulphate (2 mg/mL) followed by sucrose density centrifugation (2-8°C) as final polishing step (see Figure 10 for SEC_HPLC of different harvests post PS treatment). The purification process was designed to be completed within 2 working days with SGC starting on end of day 1 followed by fractionation and SDS-PAGE analysis on day 2. The sucrose gradient fractions were stored at 2-8 °C during the SDS-PAGE analysis (Silver staining) to identify the pure fractions containing ZikaV (see Figure 12). After pooling the relevant fractions, the pool was diluted and inactivated by Formalin. After pooling the relevant fractions of sucrose gradient centrifugation, the pool was diluted 1:3 in PBS and inactivated by Formalin (0.02% v/v, 200ppm). Fractions were subjected to analysis by SDS-PAGE.

Effect of PS treatment on virus recovery

Samples of individual 30x concentrated harvests day 2, 3, 5 and 7 were analysed before and after PS treatment by SEC-HPLC and plaque assay. SEC-HPLC was used for determination of relative total ZikaV content (active + inactive) expressed as peak area, whereas the rel. ZikaV peak purity is given as relative content of virus monomer population to total virus peak. Plaque assay states the content of total active virus particles in each sample. Experimental results are summarized in Table 1. The virus peak recovery by SEC-HPLC was only between 12 to 36% with peak purity after PS treatment in the range of >90% (no virus aggregates detected). The recovery of active virus particles by plaque assay was all > 100% (130-700%, range within the variability of the assay) showing that no active virus particles were lost during PS treatment. These results show that during PS treatment only non-infective (immature and/or aggregated virus) particles were removed.

Table 1: ZikaV Recovery by SEC-HPLC and Plaque assay before and after PS treatment.

SEC-HPLC

	Peak area mAU*min			
Harvest day	30x conc	30x +PS	SEC Recovery (%)	rel. virus monomer content after PS (%)
Day 2	101.36	18.63	18	89%
Day 3	144.51	17.48	12	90%
Day 5	19.97	5.92	30	96%
Day 7	68.80	24.43	36	99%

Plaque Assay

	PFU/mL		
Harvest day	30x conc	30x +PS	Plaque Recovery (%)
Day 2	3E+08	5E+08	179
Day 3	2E+08	4E+08	193
Day 5	1E+08	9E+08	700
Day 7	3E+08	4E+08	132

Sucrose gradient centrifugation

The PS treated harvest was split in two parts and loaded on two centrifuge bottles.

Sucrose density gradient centrifugation (SGC) was used for final concentration and polishing of the ZikaV material. The ZikaV PS treated concentrated harvest was loaded on top of a solution consisting of three layers of sucrose with different density. The three sucrose layers were selected based on a preliminary study which showed the formation of a linear sucrose gradient and complete separation of the virus particles from residual contaminants as demonstrated for ChikV, see Figure 13. The optimal volumes of the sucrose solutions were determined empirically. The volumes of individual layers for a centrifugation in 100 mL bottle scale are shown in Table 2.

10	Table 2: Individual layers/volumes for a centrifugation in bottle
	~40 mL PS treated harvest load Load
	15 mL 15 % Sucrose solution J
	15 mL 35 % Sucrose solution I
	20 mL 50 % Sucrose solution H
15	90 mL total volume

The sucrose gradient bottles were prepared by stratifying the individual sucrose layers. A plastic tube was attached to peristaltic pump tubing. The plastic tube was mounted on a laboratory stand using a clamp and placed into the centrifuge bottle. The nozzle of the plastic tube was touching the bottom of the bottle (see Figure 11). Using a peristaltic pump the ZikaV material and the sucrose solutions were pumped into the cylinder. A measuring cylinder was used as feed vessel. The first solution pumped was the ZikaV material as it represented the solution of lowest density (10 % sucrose (w/w)). After the ZikaV material the sucrose solutions were pumped in ascending order starting with the 15 % (w/w) solution J, followed by 35 % sucrose solution I and finishing with the highest density sucrose solution H (50 % (w/w)). The described setup is shown in Figure 11. After all sucrose solutions were transferred the plastic tubing was carefully removed in order not to disturb the layers.

Prior to centrifugation the centrifuge was pre-cooled to 4 °C. The prepared SG bottles were carefully transferred into the pre-cooled rotor (Note: Sudden movement of the bottles during transfer to the rotor must be avoided in order not to disturb the sucrose layers). The bottles were centrifuged at ~11.000 RCF max at 4 °C for at least 20 hours, no break/deceleration activated. In case a different centrifuge system with a different rotor is

used the necessary speed and centrifugation times need to be calculated based on the k-factor in order to achieve comparable centrifugation efficiency.

Harvesting of the sucrose gradient was done manually using a peristaltic pump. A plastic tube attached to peristaltic pump tubing was used for harvesting the sucrose gradient. The bottle containing the gradient was mounted onto a laboratory stand in a tilted position ($\sim 12^\circ$) using a clamp. The plastic tubing was then placed into the bottle touching the bottom edge of the bottle and was fastened in position using a clamp. This resulted in a small gap of 1-2 mm between the tubing inlet and the bottom of the bottle.

Using a peristaltic pump set to a flow rate of 30 mL per minute the gradient was harvested and manually split into 2 mL fractions. A total number of 32 fractions per bottle were harvested (~ 64 mL) and the remaining volume was discarded. The fractions were immediately tested by SDS-PAGE / silver stain to identify the virus containing fractions with sufficient high purity. Representative SDS-PAGE is shown in Figure 12. Fraction 10-14 were pooled and further processed.

The purified viral solution was inactivated by incubation with 0.02% formaldehyde over a period of ten days in a 22°C controlled-temperature incubator. The formaldehyde is neutralized by addition of sodium metabisulphite on the tenth day.

The sucrose gradient pool (~ 17 mL after sampling) was further diluted 3-fold with PBS to a final volume of 51 mL in a PETG container. A volume of 1% formaldehyde (10,000 ppm) solution equivalent to 1/50 of the final volume of the pre-formaldehyde pool was added to this pool resulting in an effective concentration of 200 ppm. The formaldehyde-treated solution was mixed on a magnetic stirrer for 10 minutes. After sampling, the formaldehyde-treated viral solution was placed within a cooled incubator at $22^\circ\text{C} \pm 2^\circ\text{C}$. On Day 5 post addition of formaldehyde, the formaldehyde-treated viral solution was filtered through a $0.2 \mu\text{m}$ filter and then placed in the incubator at $22^\circ\text{C} \pm 2^\circ\text{C}$ again. On Day 10, after removing the 10-Day inactivation final sample, a volume of 1 % (of the weight of the final formaldehyde-treated viral solution) of 200 mM-sodium metabisulphite solution (2 mM final concentration) was aseptically transferred into the PETG container containing the formaldehyde-treated viral solution. After mixing for 5 minutes on a magnetic stirrer, the neutralized inactivated viral solution is held at room temperature (20 to 25°C) for a minimum

PAT018/EP/PR3

of 30 minutes. After sampling, the neutralized inactivated viral solution is stored at $5^{\circ}\text{C} \pm 3^{\circ}\text{C}$ until further processing.

Inactivation by formaldehyde

5 Critical parameters for this step are final formalin concentration, temperature, mixing and transfer into a new container. A preliminary acceptance criteria for maximum pfu/mL (determined by plaque assay) has been set on the diluted pool pre formaldehyde treatment.

The quality of the neutralized inactivated viral solution is monitored by the following parameters: Plaque assay on Day 10, SEC-HPLC, SDS-PAGE/Western Blot.

10 Interestingly, SEC-HPLC analysis of samples taken during the inactivation period followed by neutralization with bisulfite showed more or less constant peak area throughout the inactivation period. This is in contrast to JEV where losses of viral particles up to 60% are observed using the process disclosed by Srivastava et al. Vaccine 19 (2001) 4557-4565. In a scale-down model the viral losses were even much higher due to surface/area ratio at smaller
15 scale and high losses due to unspecific adsorption. Differences of the ZikaV inactivation experiment and JEV inactivation were noticed as follows:

A) Much higher purity of ZikaV SGP pool with regard to residual PS ($<2\mu\text{g/mL}$) compared to JEV. The 3-fold ZikaV inactivated sample contained therefore $<<1\mu\text{g/mL}$ of
20 residual PS. Commercial JEV SGP pool contains on average $\sim 120\mu\text{g/mL}$ (up to $152\mu\text{g/mL}$ possible). The average dilution to inactivation solution of ~ 14 -fold results in a residual PS content up to $\sim 11\mu\text{g/mL}$. It may be that higher amount of residual PS could cause virus precipitation due to cross-linking / reaction with formalin.

25 B) ZikaV inactivation sample contained $\sim 10\%$ sucrose (3-fold dilution of SGP pool containing ~ 30 - 35% sucrose). Sucrose might have stabilizing effect of viral ZikaV particles during treatment with formalin.

Dilution to DS and Formulation with Aluminium hydroxide (DP)

30 For preparation of ZikaV drug substance used in mouse potency assay an antigen content (expressed as total viral particles or SEC peak area) of 5 times higher compared to Ixiaro was targeted. The basis for determination of antigen content was SEC-HPLC. In short,

PAT018/EP/PR3

a Superose 6 10/300 Increase column (GE Healthcare) equilibrated with PBS + 250 mM NaCl, pH 7.4 at 1 ml/min and 25 °C, is used to detect ZikaV at 214 nm detection wavelength in harvest samples and throughout the downstream process. In the current JEV process the antigen content in NIV is determined by a specific ELISA. A good correlation was observed between antigen content determined by ELISA and SEC-HPLC. On average, the antigen content in commercial NIV samples is in the range of 33 AU/mL corresponding to ~5.2mAU JEV peak area, see Figure 14.

ZikaV NIV day10 (Zika peak ~36 mAU, analysed on Waters HPLC/Superose6 Increase column) was diluted with PBS to a target of 6.3 (~5.7x dilution). Aluminium hydroxide was added to a final concentration of 0.5 mg/mL Aluminium (1/20 v/v Alum 2% stock solution added) to prepare ZikaV Drug Product (DP). The DP was gently mixed for 5 min. An aliquot of the DP was removed, Alum sedimented by centrifugation and the clear supernatant analysed by SEC-HPLC. No ZikaV peak was detected in the supernatant indicating complete adsorption (estimated as >95%) of viral particles on the mineral adjuvant. Formulated ZikaV DP was stored at 2-8°C.

The impurity profile of the inactivated Zika virus DS is comparable to the profile of JEV DS with the exception of a lower PS content (Table 3).

Table 3: Determination of impurity profile in Zika and JEV DS samples:

	Specification (JEV DS)	JEV	Zika
HCP (ng/mL)	<100 LOQ 12 ng/mL	<LOQ	<LOQ
DNA (pg/mL)	<200 LOQ 40 pg/mL	<40	<40
Aggregates by SEC-MALLS (%)	Not specified, part of characterization LOQ 5%	<LOQ	<LOQ
PS (µg/mL)	Specification only at SGP pool to demonstrate consistent process performance (19-152µg/mL), *PS content in DS calculated based on PS content in SGP pool (~100 µg/mL) and average dilution factor (~28x) to DS; LOQ 2µg/mL	~4*	<<LOQ

PAT018/EP/PR3

*Typical PS impurity in a JEV sample produced in accordance with protocol disclosed in Srivastava et al. Vaccine 19 (2001) 4557-4565

SEC-MALLS Results

5 A representative SEC-HPLC elution profile of ZikaV NIV at 214 nm detection wavelength is shown in Figure 20. Note that BSA (50µg/mL) was added to the sample to minimize losses in HPLC glass vial due to unspecific surface adsorption. ZikaV monomer content was estimated as ~98% with a multimer content of ~2%.

SEC-MALLS analysis (Figure 21) of the sample confirmed the radius R_z of the
10 monomer ZikaV population peak 1 as 21.6nm and ~49nm for the multimer peak 2. Cumulative particle size distribution showed that 89% of all viral particles are within a radius range between 18 to 25nm (Figure 22).

Results confirm purity and homogeneity of ZikaV NIV.

15 Viral titer by plaque assay

Active ZikaV was analyzed by plaque assay throughout the process.

Sample	Pfu/mL
Harvest day 2 (filtered)	6.4×10^7
Harvest day 3 (filtered)	1.0×10^8
Harvest day 5 (filtered)	1.5×10^8
Harvest day 7 (filtered)	1.1×10^8
PS treated harvest 300x concentrate (=SGP load)	9.0×10^8
SGP pool	8.9×10^8
Inactivation start (SGP pool 1:3 diluted)	3.4×10^8
Inactivation day 5	<LOD
Inactivation day 10	<LOD

20

Comparison of PS and Benzonase on process performance

A direct comparison of DNA removal method of concentrated ZikaV harvest pool was done. One aliquot was treated with PS (2mg/mL, 15min at room temperature), the other aliquot was treated with Benzonase (50 U/mL, 2 mM MgCl₂, 4h RT, 48h 2-8°C). Both
25 samples were further purified by sucrose gradient as described in this report. Interestingly,

the Benzonase treated samples did not sure any pure fractions after sucrose gradient centrifugation of the treated ZikaV harvest. In those fractions where the specific virus bands were detected, a high amount of host cell proteins was detected throughout the collected fractions. The PS treated material resulted in pure ZikaV containing fractions as expected.

5 This finding may suggest that PS is not only effective for DNA removal by precipitation; in addition it improves the recovery of virus particles in the gradient by disrupting interaction of DNA (fragments) and virus particles. Benzonase treatment does not remove DNA, it only results in its fragmentation. Residual DNA fragments might still interact with virus particles and residual HCPs resulting in cross-contamination and co-purification in the sucrose
10 gradient. Pooled SGP fractions were also analysed by SEC-HPLC. Although a large peak was detected, SDS-PAGE confirmed that this sample was highly contaminated with HCPs. A large peak might be detected at UV214 and 280nm after SEC-HPLC analysis due to possible interaction of HCPs with large virus particles, changing the UV absorbance.

15 Immunogenicity of Vero grown Zika virus

Immunization of mice

Prior to immunization, groups of ten 6-week-old female CD1 mice were bled via vena facialis and pre-immune sera were prepared. One intraperitoneal immunizations of 200 µL were administered. A dose titration (12 µg, 3 µg, 1 µg, 0.33 µg, 0.11 µg, 0.037 µg and 0.012
20 µg, equivalent to the protein amount in IXIARO) of inactivated Zika virus formulated with aluminium hydroxide (Al(OH)₃) at a final concentration of 0.7%. Three weeks after immunization, blood was collected and immune sera were prepared. All animal experiments were conducted in accordance with Austrian law (BGB1 Nr. 501/1989) and approved by “Magistratsabteilung 58”.

25 *Plaque reduction neutralization test (PRNT)*

Twelve well plates were used for PRNT. Each well were seeded with 1 mL medium containing 4x10⁵ Vero cells and incubated 35°C with 5%CO₂ overnight. Pools of heat inactivated sera from each dose group were tested in triplicates. The target virus (H/PF/2013 (SEQ ID NO: 13) or MR766 (SEQ ID NO: 11)) were dilute to 100 pfu/165 µL. Equal
30 volumes of target virus and serum dilution were incubated at 35°C with 5%CO₂ for 1 hour. The cell culture medium were aspirated from the Vero cells and 330 µL of the mixture target virus/serum dilution were added to each well and the plated were rocked back and forth 5

PAT018/EP/PR3

times before incubated for 2 hours at 35°C with 5%CO₂. To each well 1 mL of a 2% methylcellulose solution containing EMEM and nutrients was added, the plates were then incubated for 5 days at 35°C with 5%CO₂ before staining the cells for 1 hour with crystal violet/5% formaldehyde and subsequently washed 3 times with deionized water. The plates
5 were air dried and the numbers of plaques in each well were manually counted.

Results

Neutralization was observed with serum pools from mice immunized with inactivated Zika virus vaccine (H/PF/2013) down to 37 ng (dosing equivalent to the amount protein in IXIARO®) against Zika viruses of both the Asian (H/PF/2013) and African (MR766)
10 lineages (Figures 23 and 24). Complete inhibition was seen at the 1:20 serum dilution with an immunization dose down to 110 ng (dosing equivalent to the amount protein in IXIARO®). The neutralization of both the Asian (H/PF/2013) and African (MR766) lineages of the Zika virus was equivalent, which indicates high cross-neutralization between different Zika virus strains of the inactivated Zika virus vaccine (H/PF/2013).

Further methods: The immunogenicity of inactivated Zika virus preparations is assessed using a mouse model of Zika infection. Groups of adult mice are immunized subcutaneously (s.c.) with 500, 50, or 5 ng of inactivated Zika virus with adjuvant (*e.g.* aluminium hydroxide with or without IC31®), or without adjuvant. An additional group of mice receive PBS as a negative control. Each group is administered the indicated inoculum
20 at t=0 and in some cases also at three to four weeks later (t=3/4). Beginning approximately three weeks after administration of the last immunization, serum samples are obtained from each of the mice at regular intervals. The serum samples are tested for the presence of neutralizing antibodies using PRNT.

The *in vivo* protective efficacy of the inactivated Zika virus preparations is also
25 assessed using a mouse model of Zika infection, *i.e.* IFN-alpha/beta receptor knock-out mice (A129) (see *e.g.* Dowall et al., 4. March 2016, <http://dx.doi.org/10.1101/042358>) or blocking of the IFN-alpha/beta receptor by administration of anti-IFN-alpha/beta receptor monoclonal antibodies to C57BL/6 or BALB/c mice (see *e.g.* Pinto et al., 7. December 2011, DOI: 10.1371/journal.ppat.1002407). For protection assays, groups of 10 three- to eight-weeks-old
30 A129, C57BL/6 or BALB/c mice are inoculated subcutaneously in the hindquarters with inactivated Zika virus with adjuvant (aluminium hydroxide) or without adjuvant at t=0. Age-matched controls are inoculated with PBS or non-specific antigens in alum. Mice are

PAT018/EP/PR3

optionally boosted with a second administration of the indicated inoculation three to four weeks later. The mice are then challenged subcutaneously at three to eight weeks post immunization by inoculation with a deadly dose of live Zika virus. One day prior to challenge of C57BL/6 and BALB/c mice, they are passively administered (intraperitoneally) with anti-
5 IFN-alpha/beta receptor monoclonal antibodies. Challenged mice are monitored daily for morbidity and mortality for up to twenty-one days. Another alternative is to challenge intracranially adult vaccinated/non-vaccinated adult mice and observe protection.

It is expected that the Zika virus produced by the process of the invention will provide very similar functional read-outs in *in vitro*, *in vivo* and finally human trials as the
10 currently licensed JEV vaccine in the EU and US and elsewhere, IXIARO®. The dosage may alter but due to the very similar impurity profile and almost identical manufacture, a very similar efficacy and safety result will be expected as was determined for the currently licensed JEV vaccine (licensed in the EU and US and elsewhere).

Discussion & Conclusion

15 The existing manufacturing platform for production of inactivated JEV vaccine IXIARO® was used as a basis for a manufacturing feasibility study of inactivated ZikaV vaccine candidate (Asian strain H/PF/2013). The virus was produced on vero cells cultivated in roller bottles. The virus was purified by PS treatment followed by an optimized sucrose gradient. Inactivation was done by formalin treat (0.02 %, 10 days at 22 °C). For exploratory
20 immunization studies in mice, a DP formulated with Alum was prepared with an estimated 5-fold higher virus particle content compared to IXIARO®, the commercial JEV Vaccine. The impurity profile of the DS met all criteria as defined in the specification for IXIARO®, the commercial JEV Vaccine. The neutralization of both the Asian (H/PF/2013) and African (MR766) lineages of the Zika virus was equivalent, which indicates high cross-neutralization
25 between different Zika virus strains of the inactivated Zika virus vaccine (H/PF/2013).

Example 2: Development of a purification process for live attenuated Chikungunya virus vaccine produced in Vero cells

A downstream process was developed for the purification of infectious Chikungunya virus particles whereby non-infectious virus particles and aggregates are removed by the addition of protamine sulphate. The unexpected and novel purification properties of protamine sulphate (PS) were evaluated in purification processes for Chikungunya Virus (ChikV) as follows:

A downstream purification process for the attenuated Chikungunya virus mutant “Δ5nsP3” (as described by Hallengård et al., 2014, supra) produced under standard cell culture conditions in Vero cells was developed. Briefly, the downstream process consists of crude harvest filtration followed by concentration and diafiltration on a tangential flow filtration (TFF) system. DNA and host cell proteins were reduced by precipitation with protamine sulphate and by batch adsorption, respectively. Sucrose density gradient centrifugation was done as a final polishing step. Out of 16 roller bottles 1 x 10¹² total PFU were purified with an overall DSP process yield of 10 - 15 % (~1 log₁₀ TCID₅₀ loss). Sucrose gradient pool samples were characterized with regard to product-related impurities, such as hcDNA, HCP and endotoxins and met safety criteria.

Harvest of Vero cell culture medium containing ChikV Δ5nsP3

ChikV Δ5nsP3 was grown on Vero cells in roller bottles. A first harvest was performed after 24 hours post infection (hpi; day 1 harvest) and stored at 2-8°C until further processing. After the first harvest, fresh medium was added and the roller bottles were returned to the incubator. A second harvest was done after 48 hours post infection (day 2 harvest) and stored at 2-8 °C.

Filtration of crude cell culture harvest

At both harvest timepoints the crude harvest was immediately filtered using a 0.2 µm filter capsule (GE ULTA™ CG, 2 inch). The filtered harvest after 48 hpi was pooled together with the 24 hpi harvest and the pooled filtered harvest material was immediately further processed by ultrafiltration.

Purification of ChikV Δ5nsP3 by tangential flow filtration (TFF)

The pooled filtered harvest material was further processed by tangential flow filtration (TFF) in order to concentrate the harvest, reduce host cell proteins and replace the depleted cell

PAT018/EP/PR3

culture medium with a defined buffer system (buffer exchange). A Millipore TFF system (Millipore Pellicon II mini membrane holder) equipped with a 100 kDa cutoff PES membrane module (Pellicon2 Biomax, 1000 cm²) was used for concentration and buffer exchange. A Pellicon2 Biomax membrane module was mounted on the Pellicon II mini filter holder and the device was connected to a peristaltic pump. The system was first rinsed with ultra-pure water and then sanitized by recirculation of 0.1 M NaOH for 60 min. In case the system was not used immediately, it was stored in 0.1 M NaOH until use. Prior to use the system was rinsed with 1 L of RO-water followed by buffer A until the permeate pH value was constant at pH 7.4 ± 0.2.

Adjustment of the ChikV Δ5nsP3 harvest (pH, salt)

The pooled filtered harvest material was adjusted to a final concentration of 25 mM Tris and 150 mM NaCl using stock solutions of both components (see Table 1). This adjustment was done to increase buffering capacity and to reduce unspecific adsorption to the membrane. The necessary volumes of stock solutions D (1 M Tris, pH 7.4) and E (4.5 M NaCl) were calculated as follows:

Volume of stock solution D (1 M Tris, pH 7.4) added to pooled harvest = Volume of pooled filtered harvest / 40

Volume of stock solution E (4.5 M NaCl) added to pooled harvest = Volume of pooled filtered harvest / 30

4 L harvest obtained from 20 RB (850cm²) would require addition of 100 mL stock solution D (1 M Tris, pH 7.4) and 133 mL stock solution E (4.5 M NaCl).

The calculated volumes of stock solution D and Buffer E were added to the pooled filtered harvest under gentle stirring. The adjusted harvest was then stirred using a magnetic stirrer for 5 minutes at room temperature.

Concentration and diafiltration of the ChikV Δ5nsP3 harvest by TFF

In a first step the adjusted harvest material was concentrated approximately 10 fold. The feed flowrate was approximately 220 mL/min. The transmembrane flux at a transmembrane pressure of approximately 0.6 bar was in the range of 90 ± 5 mL/min per 1000 cm² membrane. After concentration, the cell culture medium was exchanged against 25

PAT018/EP/PR3

mM Tris, 150 mM NaCl, pH 7.5 by continuous diafiltration with 6 volume exchanges. The diafiltration buffer was supplied to the feed vessel from a measuring cylinder by a second peristaltic pump set to a flowrate of approximately 90 mL/min. Minor flowrate adjustments of the second peristaltic pump in the range of ± 10 mL/min were done manually to ensure a constant volume of harvest in the feed vessel. After 6 volume exchanges, diafiltration was stopped. The liquid remaining in the membrane module was recovered by pumping the module empty with air.

Sucrose addition to diafiltrated ChikV $\Delta 5nsP3$ material

After diafiltration, sucrose stock solution H (50% (w/w) sucrose solution) was added to the diafiltrated material to achieve a final sucrose concentration of 10% (w/w). The volume of buffer H was calculated as follows:

Volume of stock solution H added (mL) = Volume (mL) of diafiltrated ChikV material $\times 0.25$ (dilution factor = 1:4) (i.e., final sucrose concentration is 10%)

Example: 400mL diafiltrated ChikV solution would require addition of 100mL stock solution H (50% sucrose).

The calculated volume of solution H was added to the diafiltrated ChikV $\Delta 5nsP3$ material under gentle stirring and the solution was then stirred using a magnetic stirrer for a further 5 minutes at room temperature. (At this stage of the process the material can be either immediately further processed or stored frozen ($< -65^{\circ}\text{C}$, hold step).)

DNA reduction by protamine sulphate precipitation

A DNA precipitation step using protamine sulphate (PS) was performed to reduce hcDNA. Protamine sulphate stock solution L (50 mg/mL PS in PBS) was added to the diafiltrated ChikV $\Delta 5nsP3$ material to a final nominal concentration of ~ 1.6 mg/mL. The necessary volume of stock solution L was calculated as follows:

Volume of stock solution L (50 mg/mL PS) added = Volume of diafiltrated ChikV $\Delta 5nsP3$ material in 10% sucrose / 31

Example: 500 mL diafiltrated ChikV $\Delta 5nsP3$ solution in 10% sucrose would require addition of 16 mL stock solution L (50 mg/mL PS in PBS).

The protamine sulphate stock solution was added while stirring the ChikV Δ5nsP3 material using a magnetic stirrer followed by incubation at 2-8°C for 30 minutes. After incubation, the DNA precipitate was not removed. The material was immediately further processed by batch adsorption with Capto™ Core 700 chromatography media.

5 Batch adsorption with Capto™ Core 700

To reduce HCPs, a batch adsorption step with Capto™ Core 700 (CC700) chromatography medium was performed after DNA precipitation. CC700 slurry (50% slurry in buffer A) was added directly to the protamine sulphate treated material. The required slurry volume was determined based on the volume of ChikV harvest material (d1+d2) and
10 was calculated as follows:

Volume of CC700 slurry added to PS-treated concentrated harvest (mL) = Volume of ChikV Δ5nsP3 harvest material (mL) x 0.02 (dilution factor = 1:50) (i.e., final concentration of CC700 is 1%)

After slurry addition, the material was incubated at 4°C for 15 minutes under constant
15 agitation using a magnetic stirrer. After incubation, the CC700 solid matter was allowed to settle by gravity for 10 minutes. The ChikV Δ5nsP3 material was then removed from the top of the solution in order to avoid blocking of the filter by the CaptoCore particles. The remaining CaptoCore particles and the DNA precipitate were then removed from the solution by filtration using a 0.2 µm Mini Kleenpak EKV filter capsule (Pall). The resulting filtrate
20 was further processed by sucrose density gradient centrifugation.

Sucrose density gradient centrifugation

Sucrose density gradient centrifugation (SGC) was used for final concentration and polishing of the ChikV Δ5nsP3 material. The ChikV material was loaded on top of a solution
25 consisting of three layers of sucrose with different densities. The three sucrose layers were selected based on a preliminary study which showed the formation of a linear sucrose gradient and good separation of the virus particles from residual contaminants. The optimal volumes of the sucrose solutions were determined empirically. The volumes of individual layers for a centrifugation at 500 mL scale are shown in Table 3.

30

Table 3. Sucrose concentrations and volumes (500 mL scale).

Solution	Volume (mL)
----------	-------------

PAT018/EP/PR3

Harvest with 10% sucrose 360

15% sucrose 40

35% sucrose 40

50% sucrose 60

5 Total volume 500

Preparation of the sucrose gradient

The sucrose gradient bottles (500 mL) were prepared by underlaying the individual sucrose layers. A 3.5 mm ID plastic tube was attached to 60 cm of peristaltic pump tubing.

10 The plastic tube was mounted on a laboratory stand using a clamp and placed into the centrifuge bottle. The nozzle of the plastic tube was touching the bottom of the bottle. Using a peristaltic pump set to a flow rate of 25 mL per minute, the ChikV Δ5nsP3 material and the sucrose solutions were pumped into the cylinder. A measuring cylinder was used as a feed vessel. The first solution pumped was the ChikV Δ5nsP3 material as it had the lowest density

15 (10% sucrose (w/w)). Following the addition of the ChikV Δ5nsP3 material, the sucrose solutions were pumped in ascending order starting with the lowest (15%), followed by the 35% sucrose solution and finishing with the highest density sucrose solution (50%). After all sucrose solutions were transferred, the plastic tubing was carefully removed in order not to disturb the layers.

20

Centrifugation

Prior to centrifugation a Beckman Avanti JXN-26 centrifuge equipped with rotor Beckman 10.500 was pre-cooled to 4°C. The prepared SG bottles were carefully transferred into the pre-cooled (4°C) rotor so as to not to disturb the sucrose layers. The bottles were

25 centrifuged at 10,000 rpm (~18,500 rcf) at 4°C for 17-20 hours. (In case a different centrifuge system with a different rotor would be used, the necessary speed and centrifugation times would need to be calculated based on the k-factor in order to achieve comparable centrifugation efficiency.)

Sucrose gradient harvest

30 Harvesting of the sucrose gradient was done manually using a peristaltic pump. A 3.5 mm ID plastic tube attached to 60 cm of peristaltic pump tubing was used for harvesting the

PAT018/EP/PR3

sucrose gradient. The 500 mL bottle containing the centrifuged gradient was mounted onto a laboratory stand in a tilted position ($\sim 12^\circ$) using a clamp. The plastic tubing was then placed into the bottle touching the bottom edge of the bottle and was fastened in position using a clamp. This resulted in a small gap of 1-2 mm between the tubing inlet and the bottom of the bottle. Using a peristaltic pump set to a flow rate of 60 mL per minute, the gradient was harvested and manually split into 5 mL fractions. A third of the bottle volume was harvested and the rest was discarded. The fractions were immediately tested by measuring UV absorbance in a plate reader as described below.

10 Analysis of fractions by UV absorbance and SEC-HPLC

UV absorbance measurement was used as primary method for analysis of the sucrose gradient fractions. Absorbance at 214, 280 and 260 nm was tested immediately after fractionation was completed. Briefly, a 100 μ L sample of each fraction was transferred into a 96 well plate and absorbance at 214, 260 and 280 nm was measured using a plate reader. The absorbance values were plotted against the fraction number. The presence of impurities was indicated by an increase of the UV214 signal after the main peak. The fractions comprising the main peak were pooled from the peak start to the valley of the 214 nm curve. This method can be used as single method for pooling ChikV $\Delta 5\text{nsP3}$ fractions.

After identification of the virus containing fractions, the respective fractions were pooled. Pooling criteria for SGC fractions were based on UV 260 nm data, e.g. start of pooling at $\sim 10\%$ of peak maximum, end of pooling at $\sim 30\%$ of peak maximum. (Final pooling criteria at a manufacturing scale may need to be determined empirically.) The sucrose gradient pool was either stored at $< -65^\circ\text{C}$ or immediately further formulated to drug substance (DS).

25

Size exclusion chromatography

The final pooled SGC fractions containing purified infectious ChikV $\Delta 5\text{nsP3}$ virus particles were analyzed for purity by SEC-HPLC. In brief, SEC was performed as follows: a Superose 6 10/300 Increase column (GE Healthcare) equilibrated with PBS + 250 mM NaCl, pH 7.4 at 1 ml/min and 25°C , was used to detect ChikV particles at 214 nm detection wavelength in the pooled samples. SEC-HPLC is a semi-quantitative (relative yield) and qualitative (purity) method that separates intact virus particles from virus aggregates and host

PAT018/EP/PR3

cell proteins (HCPs). The method cannot distinguish between infectious and non-infectious virus particles due to their identical retention time.

Two defined peaks were identified by SEC: the ChikV $\Delta 5nsP3$ peak and a peak corresponding to buffer components. The SGC step yield based on SEC-HPLC data for pooled fractions F6-F11 was estimated at ~70 %. The final purity of the ChikV $\Delta 5nsP3$ SGC pool, based on SEC-HPLC analysis, was estimated at >95%.

SDS-PAGE and silver stain

SDS-PAGE silver stain was performed in order to qualitatively assess sample purity throughout the purification process from the first crude harvest through SGC. Briefly, ChikV process samples analyzed by SDS-PAGE/silver stain were diluted 1:1.33 with LDS buffer and were heated to 70°C for 5 minutes. The samples were loaded onto 4-12 % Bis-Tris Gels (NuPAGE). Silver staining was done using the Silver Express staining kit (Invitrogen).

A silver-stained gel of a representative ChikV $\Delta 5nsP3$ purification is shown in Figure 15. The viral proteins E1, E2 and C are marked on the right-hand side of the gel. The final SGC pool (fraction 7-fraction 11) is shown in lane 12. Note that a defined HCP band migrating between ChikV protein E2 and C still appears after CaptoCore700 treatment that has been identified as a single band in SDS-PAGE. This impurity is removed by sucrose gradient centrifugation, but can still be seen in fractions 13 and 14 (corresponding to lanes 14 and 15 of Figure 15).

Enrichment of infectious ChikV $\Delta 5nsP3$ particles by PS treatment

Although generally used as a method of removing contaminating hcDNA, it was observed in the course of the present invention that PS treatment also removes virus aggregates and HCPs. Size exclusion chromatography (SEC-HPLC, as described above) was used to throughout the purification process to determine the purity of the ChikV virus relative to impurities which also generate UV absorption.

As can be seen in Figure 16a, treatment with PS reduces not only host cell proteins and low molecular weight contaminants of the ChikV $\Delta 5nsP3$ preparation, but also reduces the SEC area corresponding to virus products, including aggregates as indicated. A surprising finding, however, was that even a reduction of the total SEC area by 86% (in a representative experiment shown in Fig. 16B, grey portion of bars) did not result in a

PAT018/EP/PR3

concomitant reduction in infectious virus particles as measured by TCID₅₀ (left axis). Instead, even though a large percentage of virus particles were removed by PS treatment, the infectious particles were not. This observation indicates that PS treatment selectively enriches infectious virus particles from a larger pool of total virus particles present in the crude harvest.

TCID₅₀ was performed to quantify infectious virus particles during the course of the purification process and to assign an active virus titer to final drug substance and drug product samples. Briefly, Vero cells were seeded at 2×10^4 cells per well in 100 μ L medium (EMEM with 2 mM L-Glutamine + 5 % FBS (+ 1 % antibiotic/antimycotic) in 96-well TC-treated flat-bottom plates and incubated overnight at 35°C / 5% CO₂. On day two, Vero cell monolayers were infected by adding 100 μ L of 1:10 serial dilutions of test samples to each of quintuplicate wells seeded with Vero cells and incubated at 35°C / 5% CO₂. On day seven, plaques were counted by visualization under a microscope. The TCID₅₀ was calculated according to the Reed & Munch endpoint calculation method (Reed, L.J.; Muench, H. (1938) A simple method of estimating fifty percent endpoints" The American Journal of Hygiene 27: 493–497).

Furthermore, electron microscopy of ChikV samples before and after PS treatment showed that not only large aggregates but also smaller non-infectious virus-like particles (basically not fully assembled particles without RNA genome) are effectively removed by PS.

Furthermore, this enrichment of infectious virus particles could also be observed when analyzing day one and day two crude harvests separately. As presented in Table 4, the SEC area (total virus particles) of the day 1 harvest remains roughly the same after PS treatment; whereas a large decrease in virus peak area is seen for the day 2 harvest. This observation was confirmed by MALLS analysis of the virus preparation, wherein it was seen that a higher percentage of virus particles were of the correct size following PS treatment. Similarly to the results shown in Fig. 16, day 1 and day 2 harvests showed no reduction in infectious particles as measured by TCID₅₀ following PS treatment, indicating that mainly non-infectious, immature and/or aggregated virus particles are removed during the PS treatment and infectious particles are enriched in the preparation.

Table 4. Overview of the process of ChikV Δ5nsP3 purification as described in Example 1.

5 SEC-MALLS analysis of harvests before and after PS treatment shows the removal of larger virus particles (aggregates), an effect that is particularly pronounced for day 2 harvests.

	SEC	MALLS	Infectious particles		
	Area [mAU*min]		Total particles/mL	% correct size	
	(20-40 nm)	TCID50 log 10			
10	Harvest 1 (H1)	57	1.17E+11	49%	10.2
	Harvest 1 + PS	53	1.33E+11	81%	10.0
	Harvest 2 (H2)	36	4.60E+09	3%	7.9
	H2 + protamine sulphate	2	8.80E+09	59%	7.9
15	Combined Harvests (C)	67	2.60E+10	14%	9.9
	C + protamine sulphate	24	8.00E+10	72%	10.1

20 Finally, an overview of the relative amounts of ChikV particles and other components as measured by SEC-HPLC at various steps throughout the entire virus purification process from crude harvest (a) to the final SGC purified pool can be seen in Figure 17. In sum, not only are the vast majority of contaminants and undesired products removed by the process, ChikV particles are highly purified. As shown by the previously presented data, the final preparation is a highly enriched preparation of infectious ChikV particles.

25

Drug Substance (DS) Formulation

The pooled SGC fractions are diluted with DS formulation buffer M (10 mM Tris, 5% Sucrose, 1% (10 mg/mL) rHSA, pH 7.4 ± 0.2). The final target volume of DS should be in the range of approximately 2 L. Based on current data the estimated range of the dilution factor might be 1:20 to 1:50.

30

Final DS sterile filtration

The final DS was filtered under aseptic conditions in a laminar flow hood using a sterility grade 0.2 µm syringe filter (e.g. 0.2 µm Mini Kleenpak EKV filter capsule with 220
5 cm² filter surface, Pall).

Quantification of host cell DNA (hcDNA) host cell protein (HCP) and endotoxin
The residual host cell DNA content of the sucrose gradient pool samples was determined by using the qPCR based assay. The DNA content in SGC pool was determined to be ≤ 0.002
10 ng/mL. The presence of residual host cell protein (HCP) from Vero cells was determined by ELISA. Residual host cell proteins present in the sucrose gradient pool samples were quantified using the Vero Cell HCP ELISA kit (Cygnus, F500). The residual host cell protein content in SGC pool was determined to be ≤ 200 ng/mL.

Endotoxin content of the SGC pool and DS was measured by Endosafe®-PTSTM
15 system (Charles River). The system uses LAL reagents by a kinetic chromogenic methodology to measure color intensity directly related to the endotoxin content in a sample. Each cartridge contains precise amounts of a licensed LAL reagent, chromogenic substrate and an endotoxin control standard. Samples were diluted 1:100 in WFI. The SGC Pool F7-F11 was determined to be < 5.00 EU/mL; likewise, the Drug Substance was also determined
20 to have < 5.00 EU/mL.

The following specifications for impurities in final Drug product were proposed:
hcDNA < 10 ng/dose; Endotoxins < 50 EU/dose; HCP < 200 ng/dose. These residual specifications would already be met in the highly concentrated SGC pool (~10 log
TCID₅₀/mL), which provides a high margin of safety considering the high dilution factor of
25 SGC pool to final DP of > 1:1000.

Further more detailed aspects of the invention:

5 A1. A Zika virus vaccine comprising an optimally inactivated Zika virus particle, wherein the Zika virus particle is able to seroconvert a subject that is administered the Zika virus vaccine with at least a 70% probability.

A2. The Zika virus vaccine of claim A1, wherein the Zika virus particle is able to seroconvert the subject that is administered the Zika virus vaccine with at least a 80%, 85%, 90%, or 95% probability.

10

A3. The vaccine of claim A1 or A2, wherein the Zika virus particle has a RNA genome corresponding to the DNA sequence provided by any one of the nucleic acid sequences of SEQ ID NOs: 1-13, or a variant nucleic acid sequence that is at least 88% identical to any one of SEQ ID NOs: 1-13 and able to pack a virulent Zika virus.

15

A4. The vaccine of any one of claims A1-A3, wherein the Zika virus particle has an E protein selected from the amino acid sequences provided by any one of SEQ ID NOs: 14-69, or a variant amino acid sequence that is at least 95% identical to any one of SEQ ID NOs: 14-69 and able to pack a virulent Zika virus.

20

A5. The vaccine of any one of claims A1-A4, wherein the Zika virus is inactivated by chemical inactivation, thermal inactivation, pH inactivation, or UV inactivation.

25 A6. The vaccine of claim A5, wherein the chemical inactivation comprises contacting the Zika virus with a chemical inactivation agent to completely inactivate the Zika virus as measured by plaque assay.

A7. The vaccine of claim A6, wherein the chemical inactivation comprises contacting the Zika virus with formaldehyde.

30

A8. The vaccine of claim A7, wherein the formaldehyde inactivation comprises contacting the Zika virus with formaldehyde for between 2-10 days.

A9. The vaccine of any one of claims A5-A8, wherein the chemical activation is performed at about +4°C or about +22°C.

5 A10. The vaccine of any one of claims A1-A9, further comprising an adjuvant.

A11. The vaccine of claim A10, wherein the adjuvant is an aluminum salt adjuvant.

10 A12. The vaccine of claim A11, wherein the aluminum salt adjuvant is aluminium hydroxide or aluminium phosphate salt.

A13. The vaccine of any one of A10-A12, wherein the vaccine comprises or further comprises an adjuvant comprising a peptide and a deoxyinosine-containing immunostimulatory oligodeoxynucleic acid molecule (I-ODN).

15

A14. The vaccine of claim A13, wherein the peptide comprises the sequence KLKL5KLK (SEQ ID NO: 70) and the I-ODN comprises oligo-d(IC)13 (SEQ ID NO: 71).

20 A15. The vaccine of any one of claims A1-A14, further comprising one or more pharmaceutically acceptable excipient.

B1. A kit comprising a Zika virus vaccine of any one of claims A1-A15.

25 B2. The kit of claim B1, further comprising a second vaccine.

B3. The kit of claim B2, wherein the second vaccine is a West Nile virus vaccine, a Japanese Encephalitis virus vaccine, a Yellow Fever virus vaccine, a Dengue virus vaccine or a Chikungunya virus vaccine.

30

C1. A method, comprising

administering a first dose of a therapeutically effective amount of the Zika virus vaccine of any one of claims A1-A15 to a subject in need thereof.

5 C2. The method of claim C1, further comprising administering a second dose of a therapeutically effective amount of the Zika virus vaccine.

C3. The method of claim C1 or C2, wherein the second dose of the Zika virus vaccine is administered about 7 days after the first dose of the Zika virus vaccine.

10 C4. The method of claim C1 or C2, wherein the second dose of the Zika virus vaccine is administered about 14 days after the first dose of the Zika virus vaccine.

C5. The method of claim C1 or C2, wherein the second dose of the Zika virus vaccine is administered about 28 days after the first dose of the Zika virus vaccine.
15

C6. The method of any one of claims C1-C5, wherein the administering results in production of Zika virus neutralizing antibodies.

20 D1. A method of producing a Zika virus vaccine, comprising
(i) passaging a Zika virus on Vero cells, thereby producing a culture supernatant comprising the Zika virus;
(ii) harvesting the culture medium of (i);
(iii) precipitating the harvested culture medium of (ii), thereby producing a Zika virus
25 supernatant; and
(iv) optimally inactivating the Zika virus in the Zika virus supernatant of (iii) thereby producing an inactivated Zika virus.

D2. The method of claim D1, further comprising concentrating the culture medium of (ii)
30 prior to step (iii).

PAT018/EP/PR3

D3. The method of claim D1 or D2, wherein the precipitating of (iii) comprises contacting the culture medium of (ii) with protamine sulfate or benzoate.

D4. The method of any one of claims D1-D3, further comprising (v) dialyzing the
5 inactivated Zika virus of (iv), thereby producing a dialyzed Zika virus.

D5. The method of claim D4, further comprising (vi) filtering the dialyzed Zika virus of (v).

10 D6. The method of any one of claims D1-D5, wherein the inactivating is by chemical inactivation, thermal inactivation, pH inactivation, or UV inactivation.

D7. The method of claim D6, wherein the chemical inactivation comprises contacting the Zika virus with a chemical inactivation agent for at least 4 days.

15 D8. The method of claim D6 or D7, wherein the chemical inactivation agent comprises formaldehyde.

D9. The method of any one of claims D6-D8, wherein the chemical activation is
20 performed at about +4°C or about +22°C.

D10. The method of claim D8 or D9, further comprising neutralizing the formaldehyde.

D11. The method of claim D10, wherein the neutralizing is performed with sodium
25 metabisulfite.

E1. The use of the optimally inactivated Zika virus vaccine of any one of claims A1-A15 for the treatment and prevention of a Zika virus infection.

30 E2. The use of claim E1, wherein the inactivated Zika virus vaccine is administered in a first dose of a therapeutically effective amount to a subject in need thereof.

E3. The use of claim E2, wherein the inactivated Zika virus vaccine is administered in a second dose of a therapeutically effective amount to the subject.

5 E4. The use of claim E3, wherein the second dose of the inactivated Zika virus vaccine is administered about 7 days after the first dose of the Zika virus vaccine.

E5. The use of claim E3, wherein the second dose of the Zika virus vaccine is administered about 14 days after the first dose of the Zika virus vaccine.

10

E6. The use of claim E3, wherein the second dose of the Zika virus vaccine is administered about 28 days after the first dose of the Zika virus vaccine.

15 E7. The use of any one of claims E1-E6, wherein the vaccine administration results in production of Zika virus neutralizing antibodies.

F1. A pharmaceutical composition for use in the treatment and prevention of a Zika virus infection, wherein said pharmaceutical composition comprises the optimally inactivated Zika virus vaccine of any one of claims A1-A15.

20

F2. The pharmaceutical composition of claim F1, wherein the inactivated Zika virus vaccine is administered in a first dose of a therapeutically effective amount to a subject in need thereof.

25

F3. The use of claim F2, wherein the inactivated Zika virus vaccine is administered in a second dose of a therapeutically effective amount to the subject.

30 F4. The use of claim F3, wherein the second dose of the inactivated Zika virus vaccine is administered about 7 days after the first dose of the Zika virus vaccine.

PAT018/EP/PR3

F5. The use of claim F3, wherein the second dose of the Zika virus vaccine is administered about 14 days after the first dose of the Zika virus vaccine.

F6. The use of claim F3, wherein the second dose of the Zika virus vaccine is
5 administered about 28 days after the first dose of the Zika virus vaccine.

F7. The use of any one of claims F1-F6, wherein the vaccine administration results in production of Zika virus neutralizing antibodies.

CLAIMS

What is claimed is:

1. A process of purification of infectious virus particles, comprising the steps of:
 - 5 (a) providing a crude harvest (a) comprising virus particles and impurities, wherein the impurities are generated from growing said virus particles on a cell substrate;
 - (b) reducing impurities from the crude harvest (a) by precipitation with an agent comprising protamine, preferably a protamine salt, more preferably a protamine sulphate, even more preferably a recombinant protamine sulphate, to obtain a virus preparation (b);
 - 10 (c) further purifying the virus preparation (b) by an optimized sucrose density gradient centrifugation, wherein the optimized sucrose gradient is provided such that the protamine can be completely or almost completely separated from the virus fraction; and wherein the protamine concentration is reduced by this step to the extent that the protamine concentration in the final drug substance is below 1 µg/ml, preferably below 0.5 µg/mL, more preferably
 - 15 below 0.1 µg/mL, most preferably below 0.05µg/mL.
2. The process of claim 2, wherein the virus particles are selected from the group consisting of flaviviruses, e.g. yellow fever virus or Zika virus and alphaviruses, e.g. Chikungunya.
- 20 3. The process of claim 1 or claim 2, additionally comprising the step of:
 - (d) a solid-phase matrix packed in a column comprising a ligand-activated core and an inactive shell comprising pores, wherein the molecular weight cut off of the pores excludes the virus particles from entering the ligand-activated core, and wherein a molecule smaller
 - 25 than the molecular weight cutoff of the pores can enter the ligand-activated core and collecting the virus particles.
4. The process of any of claims 1 to 3, wherein the residual host cell DNA of the virus preparation (c) is less than 10 ng/mL and the residual host cell protein of the final virus
- 30 preparation (c) is less than 100 ng/mL.

5. The process of any of claims 1 to 4, wherein the crude harvest (a) comprising virus particles and impurities is subjected to one or more pre-purification step(s) prior to step (b).
6. The process of claim 5, wherein the one or more pre-purification step(s) comprises
- 5 (a) filtration using a filter having a pore size equal to or less than 0.2 μm ; and/or
- (b) digestion of host cell genomic DNA by enzymatic treatment; and/or
- (c) ultra/diafiltration using a hollow fiber membrane having a pore size equal to or greater than 300 kDa, preferably equal to or greater than 100 kDa.
- 10 7. The process of any one of claims 1 to 6, wherein the concentration of protamine sulphate is 0.5 to 3 mg/ml, more preferably 1 to 2 mg/ml, more preferably 1.2 to 1.8 mg/ml, more preferably 1.4 to 1.6 mg/ml, most preferably 1.6 mg/ml or 2 mg/ml.
8. The process of any one of claims 1 to 7, wherein the enrichment of infectious virus
- 15 particles in the virus preparation (c) or any final virus preparation relative to total virus products in the crude harvest (a) is in the range from at least 50% to 95%, preferably at least 80%.
9. The process of any one of claims 5 to 8, wherein the one or more pre-purification
- 20 step(s) prior to step (b) of any of claims 5 to 8 is performed using a filter having a pore size equal to or less than 1 μm , preferably 0.2 μm .
10. The process of any one of claims 1 to 9, wherein the residual impurity of the virus preparation (c) is less than 10%.
- 25 11. The process of any one of claims 1 to 10, wherein the virus is propagated in a cell line selected from the group consisting of an EB66 cell line, a Vero cell line, a Vero- αHis cell line, a HeLa cell line, a HeLa-S3 cell line, a 293 cell line, a PC12 cell line, a CHO cell line, a 3T3 cell line, a PerC6 cell line, a MDSK cell line, a chicken embryonic fibroblast cell line, a
- 30 duck cell line, and a diploid avian cell line.
12. The process of claim 11, wherein said cell line is a Vero cell line.

13. The process of any one of claims 1 to 12, wherein the infectious virus particles is an infectious Zika virus particle that is a live virus, an attenuated live virus, a chimeric virus, a modified live virus, or a recombinant live virus.
- 5
14. The process of any one of claims 1 to 13, wherein the Zika virus is a Zika virus strain of the Asian lineage or an immunogenic variant thereof.
15. The process of any one of claims 1 to 14, wherein said process resulting in final virus preparation (c) or (d) is followed by an inactivation step, wherein the virus is inactivated preferably by formaldehyde.
- 10
16. Use of the process according to any one of claims 1 to 15 for manufacturing a composition for immunization against a virus infection.
- 15
17. The use according to claim 16, wherein the composition for immunization against a virus infection is an infection caused by a group of viruses consisting of yellow fever virus, Chikungunya virus and Zika virus.
- 20
18. A composition comprising the virus particles obtainable or obtained by the process of any one of claims 1 to 17 for treating and/or preventing an infection, such as e.g. a Zika virus infection.
- 25
19. A Zika virus vaccine comprising an inactivated Zika virus particle grown on vero cells, wherein the Zika virus particle is able to seroconvert a subject that is administered the Zika virus vaccine with at least a 70% probability and comprises minor amounts of protamine sulphate, preferably below the detection limit.
- 30
20. The Zika virus vaccine of claim 19, wherein the Zika virus particle is able to seroconvert the subject that is administered the Zika virus vaccine with at least a 80%, 85%, 90%, or 95% probability, preferably a 80% probability.

21. The vaccine of claim 19 or 20, wherein the Zika virus particle has a RNA genome corresponding to the DNA sequence provided by any one of the nucleic acid sequences of SEQ ID NOs: 2-13, or a variant nucleic acid sequence that is at least 88% identical to any one of SEQ ID NOs: 2-13 and able to pack a virulent Zika virus.

5

22. The vaccine of any one of claims 19, 20 and 21, wherein the Zika virus particle has an E protein selected from the amino acid sequences provided by any one of SEQ ID NOs: 14-69, or a variant amino acid sequence that is at least 95% identical to any one of SEQ ID NOs: 14-69 and able to pack a virulent Zika virus.

10

23. The vaccine of any one of claims 19, 20 to 22, wherein the Zika virus obtained by culturing on Vero cells is purified by protamine sulfate precipitation and sucrose gradient centrifugation.

15

24. The vaccine of claim 23, wherein the sucrose gradient centrifugation is an optimized sucrose gradient centrifugation.

20

25. The vaccine of claim 24, wherein the optimized sucrose gradient centrifugation comprises a virus comprising fraction in a 10% (w/w) sucrose solution and three layers of sucrose with different densities, i.e. a first sucrose solution with 15% (w/w) sucrose solution, a second sucrose solution with 35% (w/w) sucrose solution, and a third sucrose solution with a 50% (w/w) sucrose solution.

25

26. The vaccine of any one of claims 19, 20 to 25, wherein the Zika virus is inactivated by chemical inactivation, thermal inactivation, pH inactivation, or UV inactivation.

30

27. The vaccine of claim 26, wherein the chemical inactivation comprises contacting the Zika virus with a chemical inactivation agent for longer than is required to completely inactivate the Zika virus as measured by plaque assay.

28. The vaccine of claim 27, wherein the chemical inactivation comprises contacting the Zika virus with formaldehyde.

29. The vaccine of claim 28, wherein the formaldehyde inactivation comprises contacting the Zika virus with formaldehyde for between 2-10 days.
- 5 30. The vaccine of any one of claims 27-29, wherein the chemical activation is performed at about +4°C or about +22°C.
31. The vaccine of any one of claims 19 to 30, further comprising an adjuvant.
- 10 32. The vaccine of claim 31, wherein the adjuvant is an aluminum salt adjuvant.
33. The vaccine of claim 32, wherein the aluminum salt adjuvant is aluminium hydroxide or aluminium phosphate salt.
- 15 34. The vaccine of claim 32, wherein the aluminum salt adjuvant is aluminium hydroxide with less than 1.25ppb Cu based on the final pharmaceutical composition comprising the Zika virus, preferably the inactivated Zika virus.
35. The vaccine of any one of claims 19 to 34, further comprising one or more
20 pharmaceutically acceptable excipient.

PAT018/EP/PR3

ABSTRACT

Described herein are improved purification methods for virus vaccines and compositions. Also described are Zika vaccines and methods of producing and administering
5 said vaccines to subjects in need thereof.

Figure 1




Figure 2




Figure 3

	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
DVV_1 NC_001477.1	0	100.0	70.1	73.0	67.8	60.5	60.4	60.5	60.5	60.7	55.8	60.6	60.3	60.6	58.0	57.9	57.9	62.3	62.3	62.3	61.3
DVV_16681 NC_001474.2	1	70.1	100.0	70.8	68.6	60.5	60.5	60.5	60.6	60.7	54.9	60.9	60.3	60.4	58.3	58.3	58.3	62.7	62.8	62.8	62.2
DVV_3 NC_001475.2	2	73.0	70.8	100.0	68.9	60.2	60.1	60.1	60.1	60.1	55.8	60.3	60.3	60.1	57.5	57.6	57.5	62.6	62.7	62.7	62.5
DVV_4 NC_002640.1	3	67.8	58.6	68.9	100.0	60.5	60.6	60.6	60.4	55.4	60.8	60.3	60.5	60.5	58.0	57.9	57.9	62.1	62.0	62.0	62.1
JEV_SA14-14-2 AF315119.1	4	60.5	60.5	60.2	60.5	100.0	99.8	99.4	99.5	98.1	56.5	70.6	70.3	70.3	57.9	58.0	58.0	61.9	61.8	61.8	61.4
JEV_SA14-14-2 D90195.1	5	60.4	60.5	60.1	60.6	99.8	100.0	99.4	99.5	98.2	56.6	70.6	70.4	70.3	57.9	58.0	57.9	61.9	61.8	61.8	61.5
JEV_SA14.D90194.1	6	60.5	60.5	60.1	60.6	99.4	99.4	100.0	99.8	98.6	56.6	70.8	70.5	70.4	58.0	58.0	58.0	61.9	61.8	61.8	61.6
JEV_virus.M55506.1	7	60.5	60.6	60.1	60.6	99.5	99.5	99.8	100.0	98.6	56.7	70.8	70.4	70.3	58.0	58.1	58.0	61.9	61.8	61.8	61.6
JEV_virus NC_001437.1	8	60.7	60.7	60.1	60.4	98.1	98.2	98.6	98.6	100.0	56.6	70.6	70.5	70.6	58.3	58.3	58.4	62.1	62.0	62.0	61.7
TEV_virus NC_001672.1	9	55.8	54.9	55.8	55.4	56.5	56.6	56.6	56.7	56.6	56.6	56.2	56.7	56.6	56.9	57.0	57.0	56.6	56.7	56.7	56.7
WNV_956 NC_001563.2	10	60.6	60.9	60.3	60.8	70.6	70.6	70.8	70.8	70.6	56.2	100.0	79.6	79.6	58.1	58.0	58.1	62.3	62.3	62.3	62.2
WNV_Chin-01.AY490240.2	11	60.3	60.3	60.0	60.3	70.3	70.4	70.5	70.4	70.5	56.7	79.6	100.0	95.3	58.2	58.2	58.2	62.0	62.1	62.1	62.7
WNV_NY99_isol-385-99 NC_009942.1	12	60.6	60.4	60.1	60.5	70.3	70.3	70.4	70.3	70.6	56.6	79.6	95.3	100.0	57.8	57.8	57.8	62.0	62.0	62.0	62.4
YFV_17D_vaccine_strain_NC_002031.1	13	58.0	58.3	57.5	58.0	57.9	57.9	58.0	58.0	58.3	56.9	58.1	58.2	57.8	100.0	99.4	99.9	58.5	58.5	58.5	58.2
YFV_ASIBI.AY640589.1	14	57.9	58.3	57.6	57.9	58.0	58.0	58.0	58.1	58.3	57.0	58.0	58.2	57.8	99.4	100.0	99.4	58.4	58.4	58.4	58.1
YFV_Pasteur_17D-204.X15062.1	15	57.9	58.3	57.5	57.9	58.0	57.9	58.0	58.0	58.4	57.0	58.1	58.2	57.8	99.9	99.4	100.0	58.4	58.4	58.4	58.2
YFV_vaccine_strain_17D-213.U17067.1	16	58.0	58.3	57.5	57.9	58.0	58.0	58.0	58.1	58.3	57.0	58.2	58.2	57.8	99.9	99.4	99.9	58.4	58.4	58.4	58.1
ZVV_MR766.NIID.LC002520.1	17	62.3	62.7	62.6	62.1	61.9	61.9	61.9	61.9	62.1	56.6	62.4	62.0	62.0	58.5	58.4	58.4	100.0	99.7	99.7	88.9
ZVV_MR_766.AY632535.2	18	62.3	62.8	62.7	62.0	61.8	61.8	61.8	61.8	62.0	56.7	62.3	62.1	62.0	58.5	58.4	58.4	99.7	100.0	100.0	88.8
ZVV_MR_766 NC_012532.1	19	62.3	62.8	62.7	62.0	61.8	61.8	61.8	61.8	62.0	56.7	62.3	62.1	62.0	58.5	58.4	58.4	99.7	100.0	100.0	88.8
ZVV_ZikaSPH2015.KU321639.1	20	61.3	62.2	62.5	62.1	61.4	61.5	61.6	61.6	61.7	56.7	62.2	62.7	62.4	58.2	58.1	58.2	88.9	88.9	88.8	100.0

60 % Identity and higher

70 % Identity and higher

80 % Identity and higher

Figure 4




Figure 5




Figure 6

	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	
DVV_1_NC_001477.1	0	100.0	68.7	77.4	63.8	49.7	49.7	50.1	49.9	50.5	38.3	51.5	50.5	50.9	43.0	43.8	43.0	43.2	57.3	57.9	58.4	58.4	57.1
DVV_16881_NC_001474.2	1	68.7	100.0	68.7	64.0	46.7	46.7	47.1	46.9	47.5	38.9	48.4	47.6	47.6	43.6	44.4	43.6	43.6	53.6	53.8	54.2	54.2	53.8
DVV_3_NC_001475.2	2	77.4	68.7	100.0	62.8	48.0	48.0	48.2	48.2	48.6	38.2	48.8	46.7	46.3	41.6	42.2	41.6	41.7	57.3	57.7	58.2	58.2	57.1
DVV_4_NC_002640.1	3	63.8	64.0	62.8	100.0	47.5	47.5	47.7	47.5	48.1	39.7	49.6	49.6	49.8	40.0	40.6	40.0	40.0	55.8	56.4	56.4	56.4	55.8
JEV_SA14-14-2_AF315119.1	4	49.7	46.7	48.0	47.5	100.0	99.8	98.0	98.6	97.8	39.6	76.1	76.5	76.7	43.1	42.9	43.1	43.1	54.0	54.8	54.8	54.8	54.0
JEV_SA14-D90194.1	5	49.7	46.7	48.0	47.5	99.8	100.0	98.2	98.8	98.0	39.8	76.3	76.7	76.9	43.1	42.9	43.1	43.1	54.0	54.8	54.8	54.8	54.0
JEV_virus_M55506.1	6	50.1	47.1	48.2	47.7	96.0	98.2	100.0	99.4	99.4	40.0	77.5	77.8	78.0	43.3	43.3	43.3	43.3	54.4	55.4	55.2	55.2	54.4
JEV_virus_NC_001437.1	7	49.9	46.9	48.2	47.5	98.6	98.8	99.4	100.0	99.2	40.0	77.3	77.6	77.8	43.3	43.3	43.3	43.3	54.2	55.2	55.0	55.0	54.2
TEV_virus_NC_001672.1	8	50.5	47.5	48.6	48.1	97.8	98.0	98.4	99.2	100.0	40.4	78.0	78.4	79.6	43.5	43.5	43.5	43.5	54.8	55.4	55.2	55.2	54.8
WNV_956_NC_001563.2	9	38.3	38.9	38.2	39.7	39.6	39.8	40.0	40.0	40.4	100.0	41.3	41.6	41.0	42.3	41.9	42.3	42.3	39.9	39.9	39.6	39.6	39.9
WNV_Chin-01_AY490240.2	10	51.5	48.4	46.8	49.6	76.1	76.3	77.5	77.3	78.0	41.3	100.0	94.6	94.0	43.8	43.6	43.8	43.8	55.0	55.0	54.8	54.8	55.0
WNV_NY99_Isol-385-99_NC_009942.1	11	50.5	47.6	46.7	49.6	76.5	76.7	77.8	77.6	78.4	41.6	94.6	100.0	93.8	43.9	43.5	43.9	43.9	54.4	54.2	54.0	54.0	54.4
YFV_17D_vaccine_strain_NC_002031.1	12	50.9	47.6	46.3	49.8	76.7	76.9	78.0	77.8	78.6	41.0	94.0	98.8	100.0	43.9	43.5	43.9	43.9	54.0	53.8	53.8	53.8	54.0
YFV_ASIBI_AY640589.1	13	43.0	43.6	41.6	40.0	43.1	43.1	43.3	43.3	43.5	42.3	43.8	43.9	43.9	100.0	97.6	100.0	99.8	42.0	43.4	43.5	43.5	42.0
YFV_Isol-Pasteur_17D-204_XJ5062.1	14	43.8	44.4	42.2	40.6	42.9	42.9	43.3	43.3	43.5	41.9	43.6	43.5	43.5	97.6	100.0	97.6	97.4	42.4	43.8	43.9	43.9	42.4
YFV_vaccine_strain_17D-213_U17067.1	15	43.0	43.6	41.6	40.0	43.1	43.1	43.3	43.3	43.5	42.3	43.8	43.9	43.9	100.0	97.6	100.0	99.8	42.0	43.4	43.5	43.5	42.0
ZVV_BeH818995_KU365777.1	16	43.2	43.6	41.7	40.0	43.1	43.1	43.3	43.3	43.5	42.3	43.8	43.9	43.9	99.8	97.4	99.8	100.0	42.0	43.4	43.5	43.5	42.0
ZVV_MR766-NIID_LC002520.1	17	57.3	53.6	57.3	55.8	54.0	54.0	54.4	54.2	54.8	39.9	55.0	54.4	54.0	42.0	42.4	42.0	42.0	100.0	96.8	96.4	96.4	99.8
ZVV_MR_766_AY632535.2	18	57.9	53.8	57.7	56.4	54.8	54.8	55.4	55.2	55.4	39.9	55.0	54.2	53.8	43.4	43.8	43.4	43.4	96.8	100.0	98.8	98.8	96.6
ZVV_MR_766_NC_012532.1	19	58.4	54.2	58.2	56.4	54.8	54.8	55.2	55.0	55.2	39.6	54.8	54.0	53.8	43.5	43.9	43.5	43.5	96.4	98.8	100.0	100.0	96.2
ZVV_ZikaSPH2015_KU321639.1	20	58.4	54.2	58.2	56.4	54.8	54.8	55.2	55.0	55.2	39.6	54.8	54.0	53.8	43.5	43.9	43.5	43.5	96.4	98.8	100.0	100.0	96.2
	21	57.1	53.8	57.1	55.8	54.0	54.0	54.4	54.2	54.8	39.9	55.0	54.4	54.0	42.0	42.4	42.0	42.0	99.8	96.6	96.2	96.2	100.0

50

% Identity and higher

60

% Identity and higher

70

% Identity and higher

Figure 7 (a)

[illegible][illegible]

Figure 7 (b)

[illegible]

747	748	749	750	751	752	753	754	755	756	757	758	759	760	761	762	763	764	765	766	767	768	769	770	771	772	773	774	775	776	777	778	779	780	781	782	783	784	785	786	787	788	789	790	791	792	793	794	795	796	797	798	799	800	801	802	803	804	805	806	807	808	809	810	811	812	813	814	815	816	817	818	819	820	821	822	823	824	825	826	827	828	829	830	831	832	833	834	835	836	837	838	839	840	841	842	843	844	845	846	847	848	849	850	851	852	853	854	855	856	857	858	859	860	861	862	863	864	865	866	867	868	869	870	871	872	873	874	875	876	877	878	879	880	881	882	883	884	885	886	887	888	889	890	891	892	893	894	895	896	897	898	899	900	901	902	903	904	905	906	907	908	909	910	911	912	913	914	915	916	917	918	919	920	921	922	923	924	925	926	927	928	929	930	931	932	933	934	935	936	937	938	939	940	941	942	943	944	945	946	947	948	949	950	951	952	953	954	955	956	957	958	959	960	961	962	963	964	965	966	967	968	969	970	971	972	973	974	975	976	977	978	979	980	981	982	983	984	985	986	987	988	989	990	991	992	993	994	995	996	997	998	999	1000
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	------

Figure 8a




Figure 8b






Figure 9



- + Similar virus concentration in harvests Day 2, Day 3, Day 7; lower virus concentration in harvest Day 5
- + Day 2 and Day 3 harvests contain more HCP than Day 5 / 7 (correlates with observed CPE)
- + Minor amount of virus multimers observed

Figure 10



- + Protamine Sulfate removes virus aggregates and partially HCP
- + Infectious virus titer is not affected by PS treatment
- + Strong CPE on day 3, drop in productivity
- + Remaining cells seem to recover well and increase in Zika productivity

Figure 11





Figure 12



Pooled fractions F10-F14
(10mL total volume per bottle)

Lane	Sample
1	Molecular weight Marker
2	JEV Sucrose Gradient Pool(Reference)
3	Zika Harvest pool (day 2,3,5,7)
4	Zika Harvest pool (day 2,3,5,7) concentrated 300x
5	Zika Harvest pool (day 2,3,5,7) concentrated 300x + Protamine sulfate
6	Ultrafiltration Permeate
7	SGC Bottle1, Fraction 4
8	SGC Bottle1, Fraction 5
9	SGC Bottle1, Fraction 6
10	SGC Bottle1, Fraction 7
11	SGC Bottle1, Fraction 8
12	SGC Bottle1, Fraction 9
13	SGC Bottle1, Fraction 10
14	SGC Bottle1, Fraction 11
15	SGC Bottle1, Fraction 12
16	SGC Bottle1, Fraction 13
17	SGC Bottle1, Fraction 14
18	SGC Bottle1, Fraction 15
19	SGC Bottle1, Fraction 16
20	SGC Bottle1, Fraction 17
21	SGC Bottle1, Fraction 18
22	SGC Bottle1, Fraction 19
23	SGC Bottle1, Fraction 20
24	SGC Bottle1, Fraction 21
25	SGC Bottle1, Fraction 22
26	SGC Bottle1, Fraction 23

Figure 13

Baseline separation of Virus and PS/HCP




Figure 14





Figure 15



Lane	Sample
1	Marker Seebblueplus2
2	CHIKV/lot20150812_WV82015-01_Filtered harvest 0.2μ_24hpi
3	CHIKV/lot20150812_WV82015-01_Filtered harvest 0.2μ_48hpi
4	20150813_CHIKV_DSP_UF/DF_Load
5	20150813_CHIKV_DSP_UF/DF_conc. 10x
6	20150813_CHIKV_DSP_UF/DF_conc.&dia. 11x
7	20150813_CHIKV_DSP_PStreatment
8	20150813_CHIKV_DSP_PS&CC700treatment
9	20150813_CHIKV_DSP_SGCFrac F5
10	20150813_CHIKV_DSP_SGCFrac F6
11	20150813_CHIKV_DSP_SGCPool F7-F10
12	20150813_CHIKV_DSP_SGCPool F7-F11 (final pool)
13	20150813_CHIKV_DSP_SGCPool F7-F12
14	20150813_CHIKV_DSP_SGCFrac F13
15	20150813_CHIKV_DSP_SGCFrac F14

Figure 16a




Figure 16b




Figure 17




Figure 18a




Figure 18b




Figure 18c




Figure 18d




Figure 19




Figure 20





Figure 21




Figure 22




Figure 23




Figure 24

